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Abstract 
 
Metastasis is a multistep process which involves the tumour cells invasion through 
extracellular matrix (ECM) barriers and finding new spaces for colonization and proliferation. 
Focal adhesions (FAs) are important structures in facilitating cell migration and invasion. FAs 
can be modified through post-translational modifications (PTMs) and one of them is 
SUMOylation. In this study, MDA-MB-231 breast carcinoma and U2OS osteosarcoma cells 
have been used to study the regulation of FAs in the cancer cells and a regulatory 
mechanism of SUMOylation has been proposed. Later, the platelets and a megakaryocyte-
like cell line (CMK11-5 cells) were used.  
 
Firstly, a SUMOylation inhibitor ginkgolic acid (GA) was used in MDA-MB-231 cells, which 
significantly increased the mean number, size and turnover time of FAs; GA at 25, 50 and 
100µM significantly decreased the speed of cell migration in MDA-MB-231 cells after 24 
hours. Ubc9 (SUMO-conjugating enzyme) siRNA was used in MDA-MB-231 cells to knock 
down Ubc9, which also significantly increased the mean number and size of FAs; the 
combination of GA and Ubc9 siRNA did not further increase the mean number and size of 
FAs. 25nM Ubc9 siRNA reduced the speed of cell migration after 25 and 48 hours. All 
SUMOylation inhibitors including ginkgolic acid, 2-D08 and gossypetin significantly increased 
the FAs mean number or size in U2OS cells and in MDA-MB-231 cells.  
 
Bioinformatics software, such as SUMOplot and GPS SUMO predicted that talin and vinculin 
were SUMOylated. Three different immunoprecipitation methods (IP) have been developed 
as endogenous IP, HA-tagged SUMO-2 IP and using a SUMO-VIVATM binding assay. The IP 
and western blotting showed that talin could be SUMOylated in both MDA-MB-231 and 
U2OS cells; vinculin SUMOylation was determined in MDA-MB-231 cells and in the co-
immunoprecipitation experiments (co-IP). The effects of inhibiting SUMOylation on FA 
cleavage were further investigated in the IP and co-IP experiments in both cancer cells. For 
example, in the IP and co-IP experiments, talin appeared at the intact molecular weight 
250kDa (230kDa using different antibodies) as well as 47kDa and other molecular weights 
(such as 220kDa and 100kDa) during inhibitor treatments, suggesting that talin could be 
cleaved and the inhibitor treatment either inhibited the intact talin protein or the cleaved 
products of talin. A Mass Spectrometry study was conducted to identify and confirm the 
previously SUMOylated proteins in all three cell lines: MDA-MB-231, CMK11-5 and platelets; 
talin SUMOylation was identified in all three cell lines. Furthermore, fila.min-1 was identified 
and confirmed in the experimental conditions.  
 
14 
Finally, the regulatory mechanism of SUMOylation in talin was studied in CMK11-5 cells and 
platelets. GA significantly increased the mean number and size of talin containing FAs in 
CMK11-5 cells and the effects of talin cleavage in platelets were further investigated.  
 
In summary, SUMOylation plays an important role in the regulation of focal adhesions and 
cell migration. 
 
Key words: focal adhesions, focal adhesion number, size & turnover, SUMOylation, cancer 
cell migration, talin, vinculin, filamin-1, focal adhesion cleavage, ginkgolic acid, 2-D08, 
gossypetin, Ubc9 siRNA, MDA-MB-231, U2OS, CMK11-5, platelets 
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Chapter 1 – Introduction 
 
1.1 Cancer Cell Metastasis  
The six hallmarks of cancer have been summarised as the ‘acquired capabilities of cancer’ 
firstly in 2000 and revised in 2011 (Hanahan and Weinberg, 2011) in Figure 1, which are 
categorised as sustained proliferative signalling, resistance to cell death, induced 
angiogenesis, replicative immortality, evading growth suppressors and activated invasion 
and metastasis. In addition to the six hallmarks of cancer pathogenesis there are two 
emerging hallmarks, deregulation of cellular energetics, which is the capability to modify or 
reprogram cellular metabolism to support neoplastic proliferation, the other is avoiding 
immune destruction i.e. the cancer cells can escape and evade immunological destructions 
by T and B lymphocytes, macrophages and natural killer cells. Two enabling characteristics 
have also been proposed as genome instability and mutation, which could provide cancer 
cells with genomic instability and mutability driving neoplasia; the other is tumour-promoting 
inflammation.  
 
Therapeutic targets have been developed and introduced into the clinic; these include VEGF 
signalling inhibitors targeting angiogenesis; PARP inhibitors, which target genome instability 
and mutations; EGFR inhibitors, which target the sustained proliferative signalling; HGF/c-
Met inhibitors targeting invasion and metastasis; cyclin-dependent kinase inhibitors, 
proapoptotic BH3 mimetics, telomerase inhibitors, selective anti-inflammatory drugs, small 
molecule monoclonal antibodies i.e. immune activating anti-CTLA4 mAb (Hanahan and 
Weinberg, 2011). 
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Figure 1. The rationalized and favoured six hallmarks described by Hanahan and Weinberg, taken 
from (Hanahan and Weinberg, 2011) describing: 1. Chronic proliferation signalling maintenance 2. 
Evasion of the tumour growth suppressors, i.e. circumvention of the tumour suppressor genes 
encoding the proteins RB (retinoblastoma-associated) and TP53 also known as p53 proteins, 
corruption of the TGF-β pathway etc 3. Attenuation of the natural barrier of programmed cell death by 
apoptosis 4. Permission of replicative immortality 5. Inducing angiogenesis 6. activation of invasion 
and metastasis – metastasis will be the main focus for this study  
 
 
Tumour cell invasion and metastasis is thought to be responsible for 90% of cancer-
associated deaths, which remains one of the most perplexing aspects of this disease, more 
specifically, the secondary tumours but not the primary neoplasia are the main threat to 
cancer mortality (Leber and Efferth, 2009b, Chaffer and Weinberg, 2011).  
 
Metastasis is a multistep process where the tumour cells disseminate, invade local or 
adjacent tissues, intravasate at the primary site, proliferate and survive in the blood or 
lymphatic circulation, extravasate and colonize to the distant parts of the body (Friedl, 2011).  
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Figure 2. Epithelial-mesenchymal transition (EMT) is a mechanism important for promoting primary 
tumour cell invasion, where the tumour cells proliferate and supplied with oxygen and nutrients 
through angiogenesis; when a group of cancer cells detached from the primary tumours and could 
breach through the blood vessel wall, various signalling factors and multiple complicated signalling 
cascades are involved, the cancer cells could switch back through mesenchymal-epithelial transition 
(MET) after extravasation finding a space to colonize and form macro-metastases in the distant parts 
of the body, modified from Robert A. Weinberg, 2007, The Biology of Cancer, Chapter 14: Invasion 
and Metastasis, Figure 14.17b. Focal adhesions play an important role in the cancer cell metastasis 
 
In Figure 2, EMT has been shown to be one of the main mechanisms for cancer cell 
migration and metastasis. Several modes of cell migration have been noted; single cell 
migration includes the mesenchymal  amoeboid transition for both directions; 
multicellular cell migration includes the mesenchymal  multicellular streaming/collective 
transition on both directions or collective-to-amoeboid transition (Friedl, 2010). Focal 
adhesions (FAs) are an important functional group of proteins that play an important role in 
the transition of cell migration. These adhesions include talin, vinculin, paxillin, focal 
adhesion kinase (FAK), zyxin, VASP (vasodilator-stimulated phosphoprotein), α-actinin and 
over 100 FA specific proteins have been identified (Kim et al., 2012). 
 
The tumour local microenvironment or the extracellular matrix (ECM) is essential in tumour 
cell migration and metastasis, where in the primary tumour niche, ECM can stimulate and 
enable micro- and macro-metastasis and promote cancer progression (Ram, 2005). 
Aberrant ECM remodelling activities and metabolism can lead to changes in the 
organization, composition, topography and biochemical properties of the ECM (Lu, 2012). 
There are several main promoters/contributors involved in metastasis such as ECM 
Progression: 
Genetic & sporadic 
Primary tumour: 
Carcinoma in situ 
Basement membrane 
Invasive carcinoma 
EMT 
Single-cell 
migration &  
Collective cell 
migration: 
Adhesion  
Intravasation and transportation 
through system circulation 
Adhesion on the 
blood vessel wall 
Extravasation 
Distant 
metastases and 
colonisation: 
Adhesion 
MET 
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degrading enzymes matrix metalloproteinases (MMPs), stromal cells, immune cells, cancer-
associated fibroblasts, cytokines, growth factors, epithelial cells and mesenchymal stem 
cells etc (Lu, 2012, Friedl, 2011, Ngoc, 2012). The ECM is crucial in establishing and 
maintaining tissue polarity and architecture, where the cells in the epithelial or solid organs 
have distinct polarity that are vital in distinguishing tissue or organ formation and function; 
this ECM-maintained tissue architecture prevents tumour cell invasion (Lu, 2012).  
 
One of the two mechanisms in tumour single-cell migration has been demonstrated as the 
EMT in vivo in Figure 2 (Grunert et al., 2003, Friedl, 2011, Wolf, 2003). Abnormal or 
deregulated ECM dynamics can promote EMT, which facilitates the primary polarised 
epithelial tumour cells to invade through the basement membrane, undergo multiple 
biochemical changes resulting in mesenchymal transition leading to invasion and metastasis 
(Lu, 2012, Wirtz et al., 2011). The tumours are often surrounded by highly concentrated 
collagen-containing matrices, which the surrounding tissue is more rigid or isotropic (Lu, 
2012, Geiger, 2011). Therefore, EMT type of cell migration plays an important role in tumour 
cell migration. 
 
The EMT epithelial-mesenchymal transition has been proposed and classified into three 
types and markers have been denoted for the epithelial or the mesenchymal phenotype; 
specifically, type 3 EMT occurs in neoplastic cells which have undergone genetic and 
epigenetic changes previously and these mesenchymal cells express markers such as 
vimentin, desmin, N-cadherin, fibronectin, β-catenin, syndecan-1, α5β1 integrin and so on; 
moreover, the full spectrum of signalling events which contribute to EMT in carcinoma 
development is complex and the signal is likely originated from the tumour-ECM associated 
stroma notably HGF, EGF, PDGF and TGF-β (Kalluri and Weinberg, 2009). The metastatic 
capacity of the tumours might be inherent; therefore, the understanding of the molecular 
mechanisms of the metastatic processes is essential (Weigelt et al., 2005). The phenotypic 
and biochemical alterations during the metastasis are concerned with various aspects 
including cell-cell adhesion, growth factor signalling, gene expression, motility and so on 
(Leber and Efferth, 2009a). Focal adhesions have been studied in this study. 
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1.2 SUMOylation and its Post-Translational Protein Modification Cycle 
SUMOylation has been known for the last 30 years as a type of protein post-translational 
modifications (PTMs). SUMO (small ubiquitin-related modifier) families are ubiquitin-related 
small proteins, which are 10~18kDa and can be conjugated to cellular substrates in the 
same way as ubiquitin, but the SUMO proteins share less than 20% amino acid sequence 
identity with ubiquitin; SUMOylation is regulated through a controlled cycle by E1, E2 and E3 
enzymes (Geiss-Friedlander and Melchior, 2007). SUMO is covalently conjugated to a 
variety of proteins and de-conjugated by SUMO-specific proteases; SUMO modifications of 
proteins regulates crucial cell signalling, factors and functional parameters of proteins; 
specifically, like ubiquitin, SUMO has been found to be covalently attached to certain lysine 
residues of specific proteins (Hilgarth et al., 2004, Hay, 2005). SUMO is critically important in 
early embryonic development whilst SUMO is also present throughout development (Nie et 
al., 2009). More proteins have been identified to be SUMO modified through protein-protein 
interactions, genetic networks and proteomics; more than 1000 proteins have been identified 
as potential SUMO-conjugation (SUMOylation) targets (Makhnevych et al., 2009, Wang and 
Dasso, 2009). 
 
Four SUMO homologues have been described. SUMO-1 is found mainly in the nucleus; 
SUMO-2/-3 are predominantly present in the cytosol, where SUMO-2 and -3 are 95% similar 
to each other and SUMO-1 is more distinct, being only ~45% similar to SUMO-2/3 (Azuma et 
al., 2003); the important distinctions between SUMO-2/3 and SUMO-1 conjugation pathways 
have been quantitatively and qualitatively characterized (Saitoh and Hinchey, 2000). SUMO-
1 and SUMO-2 protein conjugates can be distinct but also overlapping as some proteins can 
only be modified by SUMO-1 or SUMO-2 only and some proteins can be modified by both 
SUMO-1 and SUMO-2 (Vertegaal et al., 2006). SUMO-4 has been described with restrict 
pattern of expression with the highest in the kidney reported (Gill, 2004, Bohren et al., 2004). 
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Figure 3. The SUMOylation pathway in studying the SUMOylation of protein substrates: the ~100 
amino acid SUMO has to be cleaved by a carboxyterminal hydrolase, Ulp or a SUMO protease to 
expose the carboxy-terminal glycine SUMO-GG. Then, a thioester conjugation is formed between the 
SUMO-GG and the E1 activating enzyme via cysteine (Aos1/Uba2) in the presence of ATP. This 
pathway is continuously processed where a thioester intermediate conjugation is formed between 
active SUMO-GG and the E2 conjugating enzyme Ubc9 via active cysteine. This modification is 
ligated through E3 ligases such as PIAS or RanBP2 acting as an adaptor between the Ubc9 and the 
target protein. The isopeptidase SENPs are active in protein deSUMOylation, therefore SUMOylation 
or de-SUMOylation could happen in balance within the SUMO cycle, modified from (Seeler and 
Dejean, 2003) 
 
In Figure 3, the covalent SUMO conjugation involves three enzymatic reactions: firstly, 
SUMO family proteins must be post-translationally modified by SUMO proteases to expose 
the COOH-terminal diglycine motif in a ATP-dependent manner; and with the catalytic 
cysteine of E1 activating enzyme which forms a thioester bond between SUMO family 
proteins and their substrate targets; the E1 enzyme known as the SUMO-activating enzyme 
SAE1/SAE2 heterodimer, also as Aos1 and Uba2 in yeast; secondly, this is followed by the 
activated SUMO conjugation to the E2-conjugating enzyme Ubc9 via the second thioester 
bond formation; thirdly, an isopeptide bond is formed between SUMO family proteins and 
their substrates via the mutual co-operative reaction between Ubc9 and E3 protein ligases 
(known as Siz1p, Siz2p/Nfi1p and Mms21p in yeast; PIAS in higher eukaryotes) (Bossis and 
Melchior, 2006, Hay, 2005, Boggio et al., 2004, Makhnevych et al., 2009, Rouleau et al., 
2008, Vertegaal et al., 2006, Wilkinson and Henley, 2010). The SUMO-conjugating E2 
enzyme Ubc9 is the only E2 enzyme in the SUMO conjugation pathway and as such is an 
important target in studying SUMOylation.  
 
SUMO conjugated proteins are susceptible to specific sumo isopeptidases cleavage 
including the Ulp family in yeast (Ulp1 and Ulp2) and the SENP proteins (SENP1-8), 
resulting in de-sumoylation (Bossis and Melchior, 2006, Drag and Salvesen, 2008, Hang and 
Dasso, 2002). The endogenous constitutively active SENPs can rapidly deconjugate SUMO 
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from its substrates, creating a dynamic balance between SUMO addition and deconjugation; 
prevention of deSUMOylation in Schizosaccharomyces pombe has resulted in slow growth 
and increased sensitivity to replicative stress, suggesting that the deSUMOylation dynamics 
is important to the SUMO cycle (Békés et al., 2011).  
 
Many targeted conjugates contain the SUMO consensus motif ψKxE; ψ is a large 
hydrophobic residue, K is the acceptor lysine and x is any residue (Hay, 2005). SUMO-1 
also contains consensus sequences for Ubc9 direct binding which is critical for SUMO-1 
modifications (Sampson et al., 2001). SUMOylation can also occur at lysine residues outside 
the consensus motifs and not all ψKxE motifs can be SUMOylated (Wilkinson and Henley, 
2010). Non-consensus motifs have been identified, for example, the GTPase Rac1 was 
found within the polybasic region non-consensus sites for SUMO conjugation mainly 
(Castillo-Lluva et al., 2010).  
 
1.3 SUMOylation and Cancer  
The SUMOylation substrates include proteins encoded by oncogenes and tumour 
suppressor genes, which are important in cell growth, differentiation and apoptosis; given by 
these SUMO-substrates, SUMOylation is expected to play regulatory roles in tumorigenesis 
(Alarcon-Vargas and Ronai, 2002). One study showed that Ubc9 could promote breast 
cancer MD-MB-231 cell invasion and metastasis in a SUMOylation-independent manner (S 
Zhu et al., 2009). Ubc9 is also up-regulated in breast, ovarian head and neck and lung 
cancer (Wu et al., 2009). More evidence has shown that Ubc9 can promote cell proliferation 
in epithelial ovarian cancer cells in vitro (Dong et al., 2013); Ubc9 could promote lung and 
breast cancer cell invasion and metastasis in vivo (Dong et al., 2013, Wu et al., 2009, Li et 
al., 2013a). Alterations in Ubc9 expression may be responsible for tumour chemo-sensitivity 
(Mo et al., 2004). Since SUMOylation has been implicated in many types of cancers, where 
Ubc9 plays a central role in the SUMO pathway, it has led to potential studies in rational 
drug design, virtual screening and more approachable interactive partners in SUMOylation 
(Duan et al., 2009).  
 
Mutations in the BRCA1 gene have been previously shown to associate with increased risk 
for inherited breast and ovarian cancers (Qin et al., 2011); Yunlong Qin et al. study showed 
that the wildtype BRCA1a proteins can bind to nuclear chaperone Ubc9 E2 enzyme, which 
can suppress ovarian cancer cell growth; mutant BRCA1a is dysregulated with Ubc9 binding 
and this leads to mislocalization of mutant BRCA1 proteins, loss of ER-α repression and loss 
of growth suppression of BRCA1 proteins causing hereditary and sporadic ovarian cancers 
(Qin et al., 2012).  
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A number of oncogenes and tumour suppressor genes encoded proteins including PML, 
Mdm2, p53, c-Myb, c-Jun and Rb etc, undergo SUMOylation (Baek, 2006). SUMOylation is 
important in cellular responses to DNA damage and key oncogenic pathways driven by c-
Myc and K-Ras mutations may be addicted to SUMOylation; Myc may also regulate 
SUMOylation and marked increase in the expression of genes which encode regulators of 
the SUMOylation pathway were found in human Myc-driven lymphomas resulting in hyper-
SUMOylation in these tumours (Hoellein et al., 2014). Recent findings suggest that SUMO 
modifications of transcriptional responses may be required for tumour invasion and 
SUMOylated proteins may be potentially molecular markers for metastatic tumours, such as 
in melanoma (Ganesan et al., 2007). Many more SUMOylation substrates include p53, p63, 
p73, Mdm2, c-Jun, NFκB, IκBα, viruses including cytomegalovirus (CMV), herpes simplex 
virus and human papillomavirus E1 (Uchimura et al., 2004, Buschmann et al., 2001, Da 
Silva-Ferrada et al., 2012, Alarcon-Vargas and Ronai, 2002). 
 
For other examples, oncogenic activities of MafA gene is negatively regulated by 
SUMOylation; dysregulated transcriptional MafA contributes to multiple myeloma (MM) in 
humans (Kanai et al., 2010). In MM patients plasma cell lysates samples, UBE21 was 
elevated hence SUMOylation was markedly enhanced; p53 was found to be SUMOylated in 
the MM patients and MM cell lines; several other signalling molecules are also Ubc9 target 
substrates including Smad4, c-Jun, NFkB etc (Driscoll et al., 2010, Li et al., 2013a). In Myc-
high human breast cancers i.e. MDA-MB-231, loss of SAE1/2 enzymatic activities by using 
SAE1/2 gene shRNAs (short hairpins RNAs) has the strongest synthetic lethality upon Myc 
hyperactivation; clinically, depletion or low SAE2 express may correlate with less aggressive 
tumours and longer metastasis-free survival in patients, where active SAE2 is required for 
mitotic spindle functions in Myc-dependent tumour growth (Kessler et al., 2012).The tumour 
suppressor HIC1 gene was also shown that 314 lysine residue to be the same target for both 
SUMOylation and acetylation, which is also a direct gene target for p53 (Stankovic-Valentin  
et al., 2007). 
 
The transcription factor p53 is well known to be mutated in various tumour cell types; p53 
was shown to be modified by SUMO-1 at C-terminal with a single motif K386 (Rodriguez et 
al., 1999, Gostissa et al., 1999, Kwek et al., 2001, Müller et al., 2000). FAK has been known 
as a tumorigenic marker, which also has a binding site in the N-terminal proline-rich domain 
of p53 (Golubovskaya et al., 2008). c-Jun is modified by SUMO-1 at a single lysine residue 
K229, which may be negatively regulated by SUMO-1 (Müller et al., 2000). Both p53 and c-
Jun are regulated by the ubiquitin-proteasome pathway; p53 mutant showed unaltered 
ubiquitination but defective SUMO-1 conjugation and slightly impaired apoptotic activity, 
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where modification of p53 by SUMO-1 and Ubc9 may be important for its full biological 
activity (Müller et al., 2000). 
 
1.4 General Aspects of SUMOylation and its Role in Cellular Physiology 
SUMOylation plays a vast role in the cell participating in nearly all parts of cellular 
physiology. Some examples have been listed here. The RanGTPase-activating protein, 
RanGAP1, was first evidence reported and found to be  modified by SUMO-1 but can also 
be conjugated by SUMO 2/3 through compensatory adaptation, which regulates RanGAP1 
localization to the nuclear pore complex also together with Ubc9 and nucleoporin 
Nup358/RanBP2 interactions (Bernier-Villamor et al., 2002). RanGAP1 later has been used 
as positive control in some studies in the discovery of protein SUMOylation.  
 
There are studies which have been done in the neurons of the CNS (central neuron system) 
suggesting that SUMOylation can modulate neuronal differentiation, synapse formation 
control in order to regulate synaptic transmission and neuronal cell survival (Henley et al., 
2014). Accumulating evidence grows and shows that perturbations in neuronal SUMOylation 
can contribute numerous pathological conditions, including Parkinson’s disease, Alzheimer’s 
disease (AD), Huntington’s disease and so on (Martin et al., 2007). α-synuclein can be 
SUMOylated by SUMO-1 and SUMO 2/3 and its pathogenic mechanism is involved in 
protein aggregation in Parkinson’s disease; SUMOylation may react as a prohibition 
mechanism in the huntingtin protein accumulation in Huntington’s disease; SAE2, Ubc9 and 
SENP3 are involved in Alzheimer’s disease, where SNPs (single nucleotide polymorphisms) 
in these genes can co-segregate with AD; the protein tau can be SUMOylated, the 
proportion of SUMOylated tau or ubiquitinylated tau can regulate its accumulation or 
degradation balance in AD (Schorova and Martin, 2016).  
 
The balanced SUMOylation and deSUMOylation pathway is also critical for normal cardiac 
development (Wang and Schwartz, 2010); one of Wang’s studies showed that both 
heterozygous and homozygous SUMO-1 knockout mice displayed congenital heart defects 
(CHDs), atrial septal defects (ASDs) and ventricular septal defects (VSDs) with high 
mortality rates however both were rescued by the cardiac re-expression of the SUMO-1 
transgene, which was critical in the developing embryonic heart (Wang et al., 2011).  
 
In another study, a serum response factor (SRF)-dependent cofactor, myocardin, its activity 
was strongly enhanced by SUMO-1 modification on K445 lysine and co-expressed PIAS1 
association via its E3 ligase activity, which SUMO modification acted to promote myocardin 
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transactivation of the cardiac muscle specific gene expressions in 10T1/2 fibroblasts (Wang 
et al., 2007).   
 
SUMOylation has been extensively known as predominantly a nuclear modification, where it 
was found in the nuclear bodies and chromatin, modifying a large number of chromatin-
remodelling complexes and in the response to DNA damage, of all the proteins, ~66% 
proteins were modified by SUMO were nuclear (Hendriks and Vertegaal, 2016, Hendriks et 
al., 2015c). SUMO modifications play critical roles in many cellular reactions, including cell 
cycle progressions both in invertebrates and mammals, for example, SUMO 2/3 was found 
to localize to centromeres and condensed chromosomes whereas SUMO-1 was localized to 
the mitotic spindle and spindle mid-zone; transcription factor modifications such as human 
topoisomerase I and II in mitosis and histone post-translational modification i.e. HDAC1 and 
4 (histone deacetylase), polycomb group genes, chromatin remodelling, maintaining genome 
stability i.e. SUMO involvement in DNA replication and damage repairing, also in cellular, 
nuclear and vesicle-mediated protein transport i.e. exosomal sorting of microRNA and 
mRNA metabolism (Collavin et al., 2004, Azuma et al., 2003, David et al., 2002, 
Makhnevych et al., 2009, Shiio and Eisenman, 2003, Zhang et al., 2008a, Denison et al., 
2005, Kirsh et al., 2002). 
 
1.5 Crosstalk between SUMOylation and other PTMs and other SUMO Motifs 
Competition between SUMOylation, acetylation, phosphorylation or ubiquitination lysine 
residues for protein-protein interactions, protein conjugation or crosstalk signalling has also 
been known (Wilkinson and Henley, 2010). Global mass spectrometric analysis (MS) has 
been used to uncover the high density and variety of PTMs with the protein substrates being 
modified by different groups covalently (Hunter, 2007). Positive crosstalk is defined as one 
PTM serves as a signal for the addition or removal of a second PTM or serves for a binding 
protein recognition to transmit a second modification; negative crosstalk is defined as direct 
competition for modification of a single residue in a protein or indirect effects, whereas one 
PTM modification can mask the recognition site for a second PTM; there can also be 
combinatorial effects in the binding domains of PTMs crosstalk (Hunter, 2007). SUMOylation 
can be regulated by phosphorylation, ubiquitination and oxidation both positively and 
negatively; acetylation negatively; examples include MEF2A and IκBα, where 
phosphorylation of these substrates close to lysine can inhibit SUMOylation; MEF2A can 
also be acetylated on the same lysine residue, hence antagonizing SUMOylation; this is the 
same for ubiquitination where it can target the same lysine residue such as PCNA, a single 
lysine can be modified by ubiquitination or SUMOylation through negative crosstalk 
regulation (Martin et al., 2007, Grégoire et al., 2006, Hunter, 2007). The SUMOylation 
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pathway is very similar to ubiquitination, where ubiquitination can regulate proteasomal 
degradation of some SUMOylation substrates (Yang et al., 2007, Wilkinson and Henley, 
2010).  
 
Using high-resolution MS, global SUMOylation has been studied in a site-specific manner in 
human cells, indicating that SUMOylated lysines can be ubiquitinated, acetylated or 
methylated therefore in this more specific way, many hundreds of sites have been identified 
to be regulated by SUMOylation, ubiquitination or acetylation (Hendriks et al., 2014). Site-
specific identification has also revealed SUMO-2 targets in cells with not only consensus 
motifs but also with inverted SUMOylation consensus motifs; direct mass spectrometric 
evidence has identified that crosstalk between phosphorylation and SUMOylation with a 
preferred four residues spacer between the SUMOylated lysine and the phosphorylated 
serine (Matic et al., 2010). 
 
The E3 SUMO protein ligase PIAS1 (protein inhibitor of activated STAT) proteins function as 
SUMO-1-tethering proteins and zinc-finger dependent E3 SUMO protein ligases and are 
found to regulate and modulate a number of transcription factors and PIAS-like proteins such 
as AR, p53, c-Jun, septins, and the DJ-1 protein, which are modified by SUMO-1 
conjugation (Kotaja et al., 2002). Non-covalent interactions with SUMO modifications can be 
regulated through SUMO-1, Ubc9 and PIAS1 (Martin et al., 2007). Recently, a SUMO-
binding motif (SBM/SIM) was also identified serving as the receptor for binding SUMO-
modified proteins with the SUMO moiety (Rouleau et al., 2008). PDSM (phosphorylation 
dependent sumoylation motif, ψKxExxSP) is discovered in the majority of transcriptional 
regulators including the erythroid transcription factor GATA-1, MEF2A (myocyte-specific 
enhancer factor 2A) and heat shock factor families (HSFs) (Hietakangas et al., 2006, 
Grégoire et al., 2006). As more new SUMO-conjugating moieties are discovered, this will 
provide valuable information to predict more novel SUMO substrates.  
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1.6 The Fundamental Proteins in Facilitating Cancer Cell Metastasis: the Integrin-
Focal Adhesions Signalling in Cell Migration Machinery 
Integrins are transmembrane heterodimers which are critical for bi-directional signalling as 
‘outside-in’ or ‘inside-out’ signalling (Delon and Brown, 2007). ‘Outside-in’ or ‘inside-out’ 
integrin signalling with FAs is important in EMT migration and metastasis (Grunert et al., 
2003). ‘Outside-in’ integrin signalling is induced by binding of an ECM ligand which causes 
conformational change and integrin clustering, leading to intracellular alterations such as 
phosphorylation; also when the cancer cells were encountering in their microenvironment, 
extracellular signals activation can influence cell survival and proliferation, cytoskeletal 
structure and polarity, focal adhesions, migration and invasion (Anthis and Campbell, 2011).  
‘Outside-in’ signalling can be triggered by clustering of integrin i.e. the heterodimers forming 
hetero-oligomers, which stimulates and recruits multivalent protein complexes to integrin 
cytoplasmic domains; these have been activated previously by the binding of the 
extracellular ligands to the ectodomains of integrins and these intracellular recruitment of 
protein complexes can include focal complexes and focal adhesions (Shattil et al., 2010). 
 
Cell migration on extracellular matrix ECM requires the turnover of integrin formed focal 
adhesions, i.e. in the assembly and disassembly process (Carragher et al., 2003, Chao et al., 
2010); integrins consist α- and β-subunits which bind to collagens, laminins, fibronectin, 
fibrin and vitronectin according to each α, β subunit combination (Geiger, 2011); deletion in 
the highly conserved β1 gene confers defects in adhesions, cell proliferation and survival 
(Legate et al., 2006). Understanding the mechanism of integrin signalling is important in 
cellular physiology, as they have been shown to regulate a diverse range of cellular 
functions including initiation, progression and metastasis in solid tumours.  
 
Different cell lines express different types of integrin isoforms. For example, integrin α5β1, 
αvβ3, αvβ6 can be upregulated in some tumours but their normal expressions are low or 
usually undetectable in most adult epithelia, which make them attractive therapeutic drug 
targets (Desgrosellier and Cheresh, 2010). α5β1 integrin is bound with fibronectin adhesively 
and they are tensioned by actin and myosin II in two forms: the relaxed adhesive bonds or 
tensioned adhesive bonds; inhibitors of actin and myosin II could block the α5β1 
integrin/fibronectin tensioned adhesive bonding, parallel with a dose-dependent reduction of 
FAK phosphorylation on Y397 downstream (Friedland et al., 2009). The bidirectional 
outside-in and inside-out αvβ3 integrin-mediated signalling cascade transcends through the 
extracellular signal-regulated kinase (ERK1/ERK2), mitogen-activated protein kinase (MAPK) 
and phospoinositide 3-kinase (PI-3’K) in MDA-MB-231 breast cancer cells, which could 
regulate breast cancer cell proliferation and survival (Vellon et al., 2006). The αvβ3 integrin 
27 
expression was altered and higher expression of αvβ3 with actin were shown in primary 
breast cancer cells, correlated with their higher motility requirements indicating the malignant 
potential of the breast cancers (Havaki et al., 2007), in particularly, tumour-specific integrin 
αvβ3 contributes to spontaneous breast tumour metastasis to the bone (Sloan et al., 2006). 
 
Integrin signalling is involved the clustering of integrins and the recruitment of kinases as 
well as scaffolding molecules, such as FAK, Src family kinases (SFKs), p130 CRK-
associated substrate (p130Cas), a ternary complex containing an integrin-linked kinase (ILK), 
the adaptor proteins PINCH (particularly interesting Cys-His-rich protein) and parvin required 
for integrin-mediated functions in cell migration, angiogenesis and survival (Desgrosellier 
and Cheresh, 2010, Legate et al., 2006, Kim et al., 2011). Cancer cell invasion and migration 
require regulated integrin-mediated focal adhesions. The regulation molecules include the 
RIAM (Rap1-GTP-interacting adaptor molecule), which mediates the recruitment of talin to 
the integrin-cell membrane in FA dynamics (Goult et al., 2013b). 
 
Collagen, fibronectin, fibrinogen, gelatin have been used in the study of cell migration. 
Collagen was the basis of extracellular matrix ECM used in vitro to study cancer cell 
metastasis and invasion, as the cancer cells required their ECM microenvironment niche to 
disseminate (Ngoc, 2012, Lu, 2012). 2 mg/ml collagen has been used to form the collagen 
matrix, as this concentration has been suggested to form a matrix mesh size (<1µm), which 
was significantly smaller than the cell body and nucleus (Bloom et al., 2008). The use of 
reconstituted and polymerised rat tail type I collagen matrices can affect the formation, 
structure and rigidity of the collagen fibres, additionally, this has enabled the study of tumour 
cell behaviour, morphology and FAs formation in 3D environments (Artym and Matsumoto, 
2010, Wolf, 2009). Type I collagen telopeptides contain critical lysine residues which after 
oxidation support collagen covalent cross-linking formation in vitro to maintain the matrix 
fibril structure (Sabeh et al., 2009, Wolf, 2009, Cukierman et al., 2002, Kim, 2005). The 
collagen matrix thickness, density, tension, orientation, stabilisation, the distance from the 
hard substrates and protein overexpression represent significant factors which can have an 
impact on the number, shape and composition of the adhesions in 3D observation (Zaman et 
al., 2006, Harunaga and Yamada, 2011). 
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Figure 4. Schematic model of focal adhesions molecular architecture in three layers: the integrin 
signalling layer, the force transduction layer and the actin regulatory layer and the main FAs include 
the integrin, FAK, paxillin, talin, vinculin, zyxin, VASP, α-actinin in the integrin signalling and force 
transduction layers together associated with the actin to exert force on the cell edge, taken from 
(Kanchanawong et al., 2010)  
 
Focal adhesions are discrete, elongated ‘plaques’ found at the peripheral or central parts of 
the cell usually associated to the ends of actin filament bundles (Huttenlocher, 2011). In 
Figure 4, many proteins have been identified and studied including talin, FAK (focal 
adhesion kinase), vinculin, paxillin, VASP, α-actinin, zyxin and so on.  
 
The spatial nanoscale of protein organization in FAs has been mapped using 3D super-
resolution fluorescence microscopy, revealing integrins and actin were vertically separated 
by a ~40nm FA core region consisting three main functional layers: an integrin-mediated 
signalling layer in close proximity with the cell membrane and the extracellular domain ECM 
(integrin cytoplasmic tail, FAK and paxillin); an intermediate force transducing layer (talin and 
vinculin); an actin-filament regulatory layer (VASP, zyxin and α-actinin), illustrated as a 
model of the FA molecular architecture based on experimentally determined protein 
positions in Figure 4 (Kanchanawong et al., 2010). This has demonstrated a well-organized 
architecture of FAs, which provides valuable information on the study of protein-protein 
interactions and regulatory functions in FAs.  
 
The initial steps of local invasion consist of dynamic changes in the cell-ECM matrix and cell-
cell adhesion controlled by signalling pathways (Friedl, 2011). FAs are important in cell 
crawling movement, i.e. in mesenchymal cell migration, FAs dynamic activities, rapid 
assembly and disassembly processes are controlled and regulated spatiotemporally at the 
leading edge or the rear end of the migrating cell (Broussard et al., 2008, Chan et al., 2010); 
29 
lamellipodial structure is usually found at the leading edge to facilitate protruding and the 
interactions with the ECM signalling, where the cell protrusions also associate with 3D 
motility enhancement specifically (Meyer et al., 2012, Prass et al., 2006); actin-filament 
polymerisation directs lamellipodium formation and protrusion; also actin-filament converges 
with myosin-II motors which contracts and pulls on strong FAs generating traction forces, 
this causes upward bending, cell body translocation, adhesion release and turnover at the 
cell front, adhesion retraction and weak adhesion disassembly at the cell rear, all of which 
direct the cell movement forward (Lock, 2008, Parsons et al., 2010, Webb, 2002).  
 
This adhesion turnover process has been presented in a simple diagram in Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
 
 
          
 
            
 
Figure 5. Simplified schematic diagram of FAs formation and assembly at the lamellipodial leading 
edge, where the cell-ECM substrate attachment and cell extension is processed at the lamellipodium 
and new FA are formed; for the cell to migrate in a directional manner, the cell needs to develop its 
filopodia/lamellipodia in response to a stimulus at the cell leading edge, the GTPases Rac 1, Rho and 
Cdc42 are required for the control of cell lamellipodia structural formation and regulation of the new 
FAs; The new formation of FAs close to cell leading edge provide traction force for the cell to move 
the cell body forward. This forward movement is also accompanied by the FAs retraction and 
disassembly at the cell rear end and these turned over FAs can be proteolytically cleaved by a family 
of calcium-activated proteases, calpains, therefore promoting FA disassembly and facilitating cell 
migration, modified from (Frame et al., 2002) 
Cell extension at the lamellipodium and 
new adhesions are formed: Rac 1, Rho, 
Cdc42 required 
Contraction force: 
Cell body movement  
De-adhesion and 
retraction: 
Proteolytic cleavage 
calpain 
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Figure 5 has shown a simplified diagram of the lifetime of FA turnover and cell migration. 
The FAs can form an adhesome at the local cell-ECM substrate coupling to the cytoplasmic 
integrin β tail at the transmembrane, together with actin stress fibres and myosin-II, which 
acts as a dynamic motor cell migration machinery.  
 
It is thought that FA assembly is an event of sequential recruitment of individual or groups of 
adhesion components rather than stabilized large cytoskeletal complexes, occasionally 
adhesions may come into the contact simultaneously (Webb et al., 2002); Conversely, FA 
disassembly seems also not to be a simple reversal mechanism of the FA assembly event 
(Webb et al., 2002). The integrin, adhesion proteins and actin linkage becomes more 
organized in migrating cells, which indicates an increase in efficiency in adhesion signalling 
(Brown et al., 2006). The adhesion strength also affects the rate of migration 
spatiotemporally, where little adhesion provides insufficient tracking force and too much 
adhesion immobilizes cell movement (Gupton and Waterman-Storer, 2006). Several factors 
regulate the FA turnover and cell migration. The sequential recruitment order of FAs has 
been simplified in a diagram in Figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic compositions of FAs: the integrin α/β interacts with the ECM at the focal contacts, 
which consist of structural and regulatory proteins that can transmit outside-in signals and also relay 
inside-out signals to obtain activated integrin state at the ECM-substrate surfaces. The kindlin family 
proteins have also been key players in assisting talin activation of integrins. The first binding of paxillin 
and talin recruits FAK and vinculin binding to the FA contacts. α-actinin can be phosphorylated by 
FAK and binds to vinculin and actin-myosin stress fibres; zyxin also binds to α-actinin and the 
actomyosin network but zyxin is only present in mature FA. The protein tyrosine kinase Src and the 
adaptor protein p130Cas are also associated with FAK in the FA contacts, modified from (Mitra et al., 
2005) 
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Inside-out integrin signalling is dependent on talin and kindlin and inactivation is mediated by 
Src family kinases (SFKs) tyrosine phosphorylation of the β-tail and filamin binding (Shattil et 
al., 2010, Anthis and Campbell, 2011). Many signalling molecules can activate integrin 
including the ECM proteins i.e. fibronectin, laminin and collagen; GTPase Rap1A and RIAM 
(Critchley and Gingras, 2008, Kim et al., 2011, Anthis and Campbell, 2011). A simplified 
diagram is presented in Figure 7. 
 
 
Figure 7. Simplified inside-out integrin signalling in the recruitment of talin to the cell membrane: the 
agonists bind to the G-protein coupled receptors and increase the concentration of calcium and DAG 
(diacyl glycerol) cellular level; this then activates a GEF (guanine nucleotide exchange factor) that 
activates the Rap1 (belonging to the GTPase family); Rap1 promotes the exchange of GDP to GTP, 
active Rap1 also interacts with RIAM and this recruits talin to the cell membrane; kindlin is also 
associated with talin to enhance integrin signalling. Inactivated integrin is stabilized by filamin binding 
to its β-tail, modified from (Anthis and Campbell, 2011) 
 
Rap1-GTP recruits RIAM (the small GTPase Rap1-interacting adaptor molecule) to the 
membrane; RIAM binding to talin rod domain recruits talin to the membrane; talin binds and 
activates integrin, and recruits actin cytoskeleton; sequentially, conformational changes in 
the talin-RIAM complex binding causes competitive binding of vinculin head to talin, also 
vinculin tail binding links FAs to actin (Izard and Vonrhein, 2004, Goult et al., 2013b, 
Humphries et al., 2007). Upon FA recruitment, vinculin structure stays in an active 
conformation, which also leads to binding of vinexin, ponsin, VASP and actin-related 
proteins Arp 2/3 to the neck; actin, PIP2 and paxillin to the vinculin tail (Humphries et al., 
2007, Zamir and Geiger, 2001).  
 
Integrin-talin assembling also recruits FAK, which binds to Src in Figure 6; this dual kinase 
FAK-Src can bind and phosphorylate other scaffold proteins such as paxillin and p130Cas, 
which can regulate Src-FAK-Crk interactions with Rac, this is required for FA turnover, 
lamellipodia formation and cell migration (Mitra, 2006, Schaller, 2001, Kraynov et al., 2000, 
Westhoff et al., 2004). FAK also interacts with Arp 2/3 which is regulated by the Wiskott-
Aldrich Syndrome Protein (WASP) (Pollard and Borisy, 2003). Arp2/3 initiates the new actin 
filaments polymerization (Galbraith et al., 2007). Calpain-2/FAK-Src is linked and regulated 
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in FAs network-actin disassembly, i.e. proteolysis of FAK (Westhoff et al., 2004). Also, RIAM 
dependent MEK-1 activation pathway was required for efficient FAs disassembly (Coló et al., 
2012). 
 
FAs also impact actin contraction and polarization through Rho GTPase protein (Huveneers 
and Danen, 2009). Rho GTPase hydrolysis (GTP to GDP) is regulated through the opposing 
activities of guanine nucleotide exchange factor (GEFs) (Huveneers and Danen, 2009). 
Cell membrane protrusions/lamellipodial ruffling and spreading at the leading edge in 
migrating cells requires Rac1 (Rho GTPase family), Cdc42 and actin cytoskeleton at the cell 
front (Figure 5) (Petrie and Yamada, 2012); whereas in the retractive cell body and rear end, 
active RhoA is required to recruit ROCK which phosphorylates cytoskeletal proteins and 
generates actomyosin contractility by actin stress fibres; also proteolytic degradation of ECM 
is assisted with integrin-mediated directional cell migration (Ram, 2005, Wolf, 2003, Sahai, 
2003). RhoA-ROCK-myosin II signalling dictates the mode of 3D cell migration (Petrie and 
Yamada, 2012). 
 
Actin cytoskeleton-myosin linkage to FAs exerts tension and contractile forces which leads 
to cell motility (Hu et al., 2007, Giannone et al., 2007). Actin fibres have been shown to be 
polymerising along the leading edge of moving protrusions and pushing synchronously with 
primed β1 integrin-mediated FAs sideways (Galbraith et al., 2007). In lamellipodia of the 
leading edge, actin polymerisation is regulated by WASP/WAVE family Arp2/3 complex, 
profilin, cortactin, cofilin, LIM kinase, Rho family GTPases, PtdIns (3,4,5)P3, Rac and Cdc42 
(Yamaguchi and Condeelis, 2007, Huveneers and Danen, 2009). Other signalling molecules 
such as the WASP-Arp 2/3 pathway, cofilin, Cdc42 are necessary for invadopodia protrusion 
formation and invasion of the cancer cells (Yamaguchi et al., 2005, Yamaguchi and 
Condeelis, 2007, Chan et al., 2009, Ridley, 2011). 
 
1.6. 1 Post Translational Modifications of Focal Adhesions 
Focal adhesions are known to be regulated by PTMs and the regulation of FAs may not be 
subjected to only one PTM, competitions or co-operative reactions can occur, which 
increases the complexity of the post-translational regulatory mechanism of FAs. For example, 
the focal adhesion kinase, FAK, a tyrosine kinase, was discovered to be a substrate of the 
viral Src oncogene initially and later identified to be a highly tyrosine-phosphorylated protein 
localized in the integrin-cell adhesion sites, which can enhance Src SH2 (Src-homology 2) 
domain binding to FAK through phosphorylation at Tyr-397 and further phosphorylation of 
FAK at Tyr-576/577 leading to full activation (Mitra, 2006, Chan et al., 2009, Hsia et al., 
2003).  
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FAK has been associated with metastatic potential in vivo and reported in many tumours 
including breast, ovarian, colon, prostate, melanoma, thyroid, pancreatic, head and neck and 
so on (Chan et al., 2009, Golubovskaya et al., 2007, Cance et al., 2013, Cance et al., 2000).  
FAK has also several tyrosine phosphorylation sites including Tyr-397, 407, 576, 577, 861 
and 925 (Mitra et al., 2005). Adhesion turnover involves many tyrosine kinases and 
phosphatases, which many of them are engaged in FAK signalling (Broussard et al., 2008). 
These are Src, p190RhoGAP, Rho kinase (ROCK), Cdc42 and myosin light chain kinase 
(MLCK) etc (Schober et al., 2007, Chan et al., 2009). FAK has been an important signalling 
factor which is involved in cancer cell adhesion and migration, tumour angiogenesis and 
progression (Mitra, 2006, Parsons, 2003). The N-terminal FERM (protein 4.1, ezrin, radixin 
and moesin homology) domain of FAK has been an active area for research, the FERM 
domain enables integrin-FAK activation, associates a signalling linkage from EGF (epidermal 
growth factor) receptors, PDGF (platelet-derived growth factor) receptors and G-protein 
coupled receptors and recently, the FERM domain of FAK was found to be covalently 
modified by SUMO at ε-amino position of lysine 152 (Mitra et al., 2005). 
 
FAK is a protein substrate for SUMOylation. FAK has been shown to be SUMOylated (Yao 
et al., 2011, Kadaré et al., 2003). In the yeast two-hybrid screen, the N-terminal domain of 
FAK was found to interact with PIAS1, which promoted SUMO-1 conjugation to FAK at K152 
and this enhanced its autophosphorylation (Yao et al., 2011, Kadaré et al., 2003). 
Autophosphorylation was an important function for FAK, which induced high affinity binding 
site for SH2 domain of Src (Kadaré et al., 2003). Moreover, Kadaré et al. study showed that 
SUMOylation of FAK occurred in the nucleus mostly and possibly independent of cell 
adhesion, as PIAS1 is a nuclear protein predominantly, suggesting that cytoplasmic FAK 
may undergo nucleocytoplasmic cycling, which allowed its nuclear SUMOylation at K152 in 
the presence of PIAS1 (Kadaré et al., 2003). In Yao et al. study, inhibiting protein 
SUMOylation after 6 hours ginkgolic acid treatment in HEK293T cells (human embryonic 
kidney 293) showed a significant decrease in SUMO1 and SUMO 2/3 conjugation and a 
reduction in Tyr-397 phosphorylation in the SUMOylated form of FAK. These may suggest 
SUMOylation of FAs, such as FAK, could alter protein localization; SUMOylation of FAK may 
additionally regulate signalling at the adhesion as well as in the nucleus. SUMOylation is 
critical in regulating FAK kinase activity and signalling and a global crosstalk for 
SUMOylation-modulated phosphorylation. 
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1.7 Talin and Vinculin  
Talin is an important cytosolic protein associated with β1 integrin to the cytoskeleton, found 
in the membrane-enriched fraction containing Golgi and endoplasmic reticulum (Martel et al., 
2000). Talin in mammalian cells exists as 2 isoforms, talin 1 and talin 2, the role of talin in FA 
formation and maintenance is unique, where talin not only is required for linking integrin to 
actin filaments, but talin together with kindlin 1 and 2 are all required for integrin activation 
(Geiger et al., 2009, Montanez et al., 2008, Anthis and Campbell, 2011). Talin is a 270kDa 
molecule consisting of the N-terminal head domain (F0, F1, F2 and F3 subdomains/FERM 
domain) of 50kDa and the C-terminal rod domain (tail domain) of 220kDa, which the rod 
domain has binding sites for vinculin and actin and this leads to inside-out integrin activation 
(Anthis et al., 2009, Critchley and Gingras, 2008, Garcı́a-Alvarez et al., 2003).  
 
One study has described that intramolecular interactions of talin as an autoinhibition phase, 
disruption of talin autoinhibition could result in morphogenetic defects during fly development 
and a process involved in wound healing called dorsal closure was much delayed, moreover, 
this was resulted from reduced talin turnover (Ellis et al., 2013). Therefore, talin 
autoinhibition could provide a link and modulate adhesion turnover and adhesion stability 
critical for normal morphogenesis (Ellis et al., 2013).  
 
Talin has been known to co-stimulate with integrin activation, regulate FA turnover and 
pathways have been elucidated: RIAM has been implicated in talin activation to activate β3 
integrin activation (Critchley and Gingras, 2008); the proteolysis of talin by the intracellular 
calcium-dependent protease, calpain has been shown to be critical for FA disassembly, 
specifically, the adhesion turnover was a rate-limiting step mediated by talin proteolysis and 
the disassembly of vinculin, paxillin and zyxin were dependent on the ability of calpain 
cleavage of talin (Franco et al., 2004); integrin signalling via FAK and Src promotes the 
binding of PIP kinase PIPK1γ90 to the F3 domain of talin and the translocation of talin to the 
plasma membrane, therefore, talin may activate integrin and provide the bridges to actin 
cytoskeleton (Critchley, 2004). The talin distribution in the cell not just found in the cell-ECM 
junctions, such as in the FA, but also found in the basal surface of the epithelial / endothelial 
cells in contact with basement membrane, in the myotendinous junctions of skeletal muscle 
cells, in the endothelial cell-cell junctions, neuromuscular junctions, in the platelets and so on 
(Critchley, 2004). 
 
The molecular structure of talin and its binding partners have been elucidated and a 
simplified diagram of talin is presented in Figure 8. 
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Figure 8. The structural model and binding domains of full-length talin 1: the atypical FERM N-
terminal head domain of talin is linked to the flexible C-terminal talin rod by an unstructured linker of 
~80 residues. At the linker/neck region, it contains a calpain-2 cleavage site (between Q433 and 
Q434). The talin rod contains 62 α-helices, which are grouped into 4- or 5-helix bundles (R1-R13) and 
a single helical dimerization domain (DD). The talin rod also contains multiple vinculin binding sites 
(R1 helix number 4, R2 helices 6, 9, R3 helices 11, 12, R6 27, R7 36, R8 33, R10 46, R11 50 and 
R13 58). Many domain binding partners have been mapped onto the structure of talin 1, such as 
F2F3 contains actin and FAK binding sites, F3 domain contains β-integrin (IBS1), PtdIns(4,5)P2 and 
PtdInsP kinase Iγ binding sites; talin rod also contains a second binding site for actin (R4-R8) and β-
integrin (IBS2); the C-terminal contains the THATCH domain, where actin also binds and the 
dimerization domain (DD), modified from (Calderwood et al., 2013) 
 
Figure 8 represents the structural model of talin 1. The F3 domain of talin contains a 
canonical phosphotyrosine binding (PTB) fold which can directly bind to the membrane 
proximal NPxY/F motif of the cytoplasmic β integrin tail; the F2/F3 domains have binding 
surface for the membrane and modify its orientation relative to the bilayer (Kalli et al., 2010, 
Domadia et al., 2010). The talin rod domain has also been revealed with a second integrin 
binding site, the integrin binding site 2 (IBS2), which is essential for linking integrin β 
subunits to the cytoskeleton (Rodius et al., 2008, Moes et al., 2007). 
 
Talin contains ~11 vinculin binding sites (VBSs) in the rod domain and the rest of the rod 
denoted as the grey box numbers in Fig. 8 represents ~62 amphipathic helices (Patel et al., 
2006). Talin can be cleaved by calpain-2 between the head and the rod domain, which has 
previously shown to be important in FA turnover (Garcı́a-Alvarez et al., 2003, Bate et al., 
2012). Vinculin could also be cleaved by calpain into fragments (Serrano and Devine, 2004).  
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From the SUMOplot analysis, which has speculated talin or vinculin could be both 
SUMOylated. Since the list of SUMOylated substrates is growing rapidly, whether FAs could 
be SUMOylated in vitro or in vivo will be crucial to understand cell migration. The talin-
vinculin interactions is crucial in FA, since talin molecule has many VBSs binding sites and 
the structural vinculin binding domain with talin has been elucidated (Roberts and Critchley, 
2009). 
 
1.8 The Inhibitors Used in this Study 
 
Small Molecule Inhibitors of Protein SUMOylation: Ginkgolic Acid 
Until recently, very few small molecule probes were available to study the critical role of 
SUMOylation in cancer. Two small molecule inhibitors have been reported, which appear to 
both target the E1 SUMO-conjugating enzyme (SAE1/2), these are ginkgolic acid (Fukuda et 
al., 2009a) and Kerriamycin B (Fukuda et al., 2009b). Both inhibitors completely inhibit the 
SUMOylation of RanGAP1-C2 in vitro with GA at a concentration of 10µM and Kerriamycin B 
at a concentration of 20µM; moreover, both inhibitors directly bind to E1 and completely 
block the formation of the E1-SUMO-1 thioester intermediate both in vitro and in vivo with 
GA at a concentration of 10µM and Kerriamycin B at a concentration of 20µM, but without 
affecting ubiquitination (Fukuda et al., 2009a, Fukuda et al., 2009b). 
 
The Ginkgo biloba L. is the oldest tree species and has survived over millions of years on 
earth (Bilia, 2002). The Ginkgo biloba leaf extracts and some of their constituents appear to 
have antitumor activities (DeFeudis et al., 2003). The Ginkgo biloba leaf extracts have also 
been shown to have antioxidant effects, cardiovascular protective effects, stress alleviating 
effects, antiangiogenic effects and prevention of neurodegenerative diseases (Ahlemeyer 
and Krieglstein, 2003, DeFeudis and Drieu, 2004, Zhou et al., 2004). Ginkgolic acid (GA) is 
an extract from the Ginkgo biloba tree leaves, which appears to have allergenic properties 
and it is quantified in the Ginkgo extraction as less than 5 ppm, with two other main active 
compounds as flavonoids and terpenoids (Mahadevan and Park, 2008, Smith and Luo, 
2004). 
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Figure 9. Showing the carboxylic COOH group and the long aliphatic chain in ginkgolic acid (15:1) 
(Fukuda et al., 2009a) 
 
 
In Fukuda’s study, they have shown that both the carboxylic group and the long aliphatic 
chain are important for binding to E1 and hence for inhibition of SUMOylation (the carboxylic 
group and the aliphatic chain of GA are shown in Figure 9); they have also shown that 
100µM GA can inhibit the SUMOylation of p53; since p53 can be modified by SUMO-1 on 
lysine residue 386 in vitro and in vivo (Gostissa et al., 1999, Rodriguez et al., 1999). 
 
2-D08 (2’,3’,4’-trihydroxyflavone) 
 
 
 
 
 
Figure 10. 2-D08, a synthetic oxygenated flavonoid (Kim et al., 
2014) 
 
 
A newly developed SUMOylation assay which used a microfluidic electrophoretic mobility 
shift system as a type of medium throughput kinetic screening between the protein substrate 
and the products of enzymatic reactions to directly monitor the product formation has found 
that out of 500 screened small molecules and compounds, 10 compounds showed more 
than 90% inhibition of SUMOylation reaction after 100 minutes performance; 2-D08 had the 
most potent inhibitory activities (Kim et al., 2013). 2-D08 was found to inhibit the conjugation 
of SUMO-1, SUMO-2 and SUMO-3 to IkBα (Kim et al., 2013); additionally, 2-D08 was 
capable of inhibiting SUMOylated topoisomerase-I fragment with a concentration of 30µM in 
vitro and in two breast cancer cell lines ZR-75-1 and BT-474, pre-treatments with 2-D08 
could inhibit the camptothecin-induced rapid accumulation of SUMOylated topoisomerase-I 
(Kim et al., 2013). 2-D08 was concluded a novel, cell permeable and mechanistically unique 
inhibitor of protein SUMOylation (Kim et al., 2014), however, its specific role in the inhibitory 
effects of protein SUMOylation is still unclear. 
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3-B08 or Gossypetin (3,5,7,8,3′,4′-hexahydroxyflavone) 
 
 
Figure 11. 3-B08, also known as gossypetin, the chemical 
structure of the commercially available flavone derivative 
(Jeong et al., 2009, Kim et al., 2013) 
 
 
Gossypetin, also known as 3-B08, has been shown to have the second most potent 
inhibitory effects of protein SUMOylation alongside GA30 (30 µM) being the positive control 
for the protein SUMOylation activity (Kim et al., 2013).  
 
Gossypetin has originally been shown to have antimutagenic, antioxidant, antimicrobial and 
antiatherosclerotic effects (Chen et al., 2013, Jeong et al., 2009, Francis et al., 1989). 
Gossypetin was found to inhibit protein oxidation and lipid peroxidation (Chen et al., 2013); 
gossypetin had an atheroprotective role against the oxidized low-density lipoprotein (ox-LDL) 
induced injury in human umbilical vein endothelial cells (HUVECs) (Lin, 2015).  
 
Spectomycin B1 
 
 
 
 
Figure 12. The structure of 
spectomycin B1 identified using an in 
situ cell-based screening system 
(Hirohama et al., 2013) 
 
 
 
The first identified Ubc9 inhibitor known as spectomycin B1, which was shown to bind to the 
E2 enzyme, the Ubc9 enzyme directly and also exhibited to inhibit estrogen-dependent 
proliferation of MCF7 human breast cancer cells, leading to its potential to develop as a 
therapeutic agent against hormone dependent breast cancers (Hirohama et al., 2013). 10µM 
of spectomycin B1 can inhibit the SUMOylated RanGAP1 in vitro (IC50 value is 4.4 µM) and 
100µM spectomycin B1 treatment for 24 hours can inhibit in vivo p53 SUMOylation; 
furthermore, 10µM of spectomycin B1 can inhibit the E2 Ubc9-SUMO-1 thioester bond 
intermediate formation but not the E1-SUMO-1, indicating that spectomycin B1 is a direct 
and selective target for binding to E2 Ubc9 enzyme (Hirohama et al., 2013). 
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1.9 Cell Lines Used for this Study 
Breast cancer has been difficult to treat, as multiple mechanisms are involved and the 
tumour microenvironments are vital for its metastasis (Boudreau and Myers, 2003). In breast 
cancers, tumour induced angiogenesis has been considered the first evidence as the pre-
invasive stage of high grade solid ductal carcinoma in situ (Boudreau and Myers, 2003). The 
most famous known HER-2 /neu oncogene (also known as the epidermal growth factor 
receptor 2 ERBB2) has been amplified in human breast cancer cell lines and is a significant 
indicator/predictor with the overall time to relapse or survival in breast cancer patients 
(Slamon et al., 1987). The histological different types of invasive breast carcinoma and 
possible models of breast cancer metastasis have been summarized (Weigelt et al., 2005). 
MDA-MB-231 cell line is a type of invasive and metastatic breast cancer cell line and has 
been used for this study. 
 
Osteosarcoma (OS) is a type of highly malignant tumour, approximately one thirds of the 
patients are not responding to chemotherapy and the effective and alternative treatments are 
still missing due to its early onset mostly lacking a predisposing lesion, only < 2% shown 
with prevalence of inheritance with the majority of tumours being sporadic, high genetic 
heterogeneity and infrequency with enough patients cohorts to compensate for the high 
genetic variability, these are a few factors that make osteosarcoma a difficult tumour type to 
study and treat (Mohseny et al., 2011, Mohseny, 2012). The human osteosarcoma U2OS 
cell line was derived from a moderately differentiated sarcoma of the tibia of a 15 year old 
girl in 1964 (Niforou et al., 2008). Spectral karyotyping analysis and cytogenetic analysis 
have revealed chromosomal instability, structural rearrangements and alterations and high 
incidence of aneuploidy in the OS tumours and cell lines (Bayani et al., 2003). The U2OS 
cell line has been used in this study as a different type of tumour cell line to MDA-MB-231 
cells. 
 
1.10 The Hypothesis: SUMOylation Plays an Important Role in the Regulation of Focal 
Adhesions, which are essential in Cell Migration 
From the literature, emerging evidence has shown that SUMOylation is critical in 
tumorigenesis. In this current study, SUMOylation has been hypothesized to play a critical 
role in regulating the dynamic activities of FAs in cancer cell migration.  
 
To start with, several steps have taken place: SUMOylation inhibitors including ginkgolic acid 
(GA), 2-D08, gossypetin have been used in both MDA-MB-231 cells and U2OS cells to 
investigate their effects on FA number, size and turnover dynamics. The GA and the Ubc9 
siRNA has been used in the MDA-MB-231 cell migration studies. The initial studies have led 
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to the study of the identification of which FA proteins could be SUMOylated in MDA-MB-231 
cells and U2OS cells. Three different IP methods have been developed. Later, two additional 
cell lines were used, the CMK11-5 cells and the platelets. A mass spectrometry study was 
conducted to validate and confirm the FA protein SUMOylation. Finally, the mechanism of 
FA protein SUMOylation in different cell types has been compared. These study approaches 
have been used to investigate how the changes in the dynamic activities of FAs could affect 
cancer cell migration and metastasis, where SUMOylation has been hypothesized to 
regulate this diverse process.  
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Chapter 2 – Materials and Methods 
 
2.1-2.4 Cell Culture  
Three cell lines were used for studying SUMOylation in the regulation of focal adhesions. 
MDA-MB-231 human breast cancer cell line (ATCC), the U2OS human bone osteosarcoma 
cell line (ECACC, European Collection of Authenticated Cell Cultures) and the human 
megakaryocyte-like cell line, CMK11-5 cell line (purchased from the Health Sciences 
Research Resources Bank in Japan). 
 
2.1 Media Preparation  
MDA-MB-231 cells were maintained in DMEM (Dulbecco’s Modified Eagle’s Medium 1X) 
containing 1 g/L D-glucose, L-glutamine and pyruvate, 500 ml media (Gibco), which was 
supplemented with 10% (v/v) fetal bovine serum (FBS, 50 ml, Gibco) and 5.5 ml of 1% v/v 
Penicillin/Streptomycin (10,000 units/ml penicillin, 10,000 µg/ml streptomycin, Gibco). The 
cells were grown in T75 flasks at 37°C/5% CO2 humidified environment. Serum free DMEM 
media was also made in a 50ml Falcon tube without FBS but added with 
Penicillin/Streptomycin for experiments.  
 
CMK11-5 cells were maintained in RPMI media at 37°C/5% CO2 environment. The RPMI 
media (containing L-glutamine, Gibco) was supplemented with 10% (v/v) fetal bovine serum 
(FBS, 50 ml, Gibco) only.  
 
U2OS cells were routinely maintained in McCoy's 5A (Modified) Media 1X containing L-
glutamine (500 ml, Gibco), which was supplemented with 10% (v/v) fetal bovine serum (FBS, 
50 ml, Gibco) and 5.5 ml of 1% v/v Penicillin/Streptomycin (10,000 units/ml penicillin, 10,000 
µg/ml streptomycin, respectively, Gibco). The cells were grown in T75 flasks at 37°C/5% 
CO2 humidified environment.  The serum free McCoy’s 5A modified media was also made 
together in a 50ml Falcon tube. 
 
PBS pH 7.4 (1x, phosphate buffered saline, Gibco) (with no CaCl2 and MgCl2) was used to 
wash the monolayer of MDA-MB-231 cells and U2OS cells grown in the T75 flask. OPTI-
MEM I (1x, Gibco) reduced serum medium (containing HEPES, 2.4 g/L sodium bicarbonate 
and L-glutamine) was used for the siRNA transfection experiments.  
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2.2 Routine Cell Passage 
For routine cell passage, the MDA-MB-231 cells were grown in T75 flasks and washed with 
10 ml PBS once; the cells were trypsinized with 2 ml of 0.05% Trypsin-EDTA (1X, Gibco) at 
37°C/5% CO2 humidified environment for 5-10 minutes. The cells were detached from the 
bottom of the flask and were resuspended with 3 ml of fresh DMEM media to inactivate the 
trypsin. The cell suspension was mixed well to ensure single cell separation. The cells were 
seeded at 1:6 or 1:8 splitting ratio; 0.6-0.8 ml of the cell resuspension was added with 20 ml 
fresh DMEM media into a new T75 flask. The cells were incubated at 37°C/5% CO2 
humidified environment for 3-4 days until 80% confluence (2-4 x 106 cells, 95% viability) and 
ready to be split again.  
 
The growth media for U2OS cells was removed and the cells were washed with 10 ml PBS 
once. The cells were trypsinized with 2 ml of 0.05% Trypsin-EDTA (1X, Gibco) at 37°C/5% 
v/v CO2 humidified environment for 5-10 minutes. The cells were resuspended with 3 ml 
fresh McCoy’s 5A modified media and it was mixed well. The cells were seeded at 1:6 ratio. 
They were maintained in new T25 flasks at 37°C/ 5% v/v CO2 humidified environment for 3-4 
days until 80% confluence and ready to be split again. 
 
The CMK11-5 cells were grown in cell suspension in RPMI media at 37°C/5% v/v CO2 
humidified environment. Some CMK11-5 cells could differentiate to spread and attach to the 
bottom of the flask. At 80% confluence, all the cells grown in suspension in the culture media 
was taken into a sterile 50 ml tube and the tube was spun down at 1500 rpm for 5 minutes. 
The differentiated cells stuck to the flask were thrown away. The media was removed from 
the 50 ml tube and the cell pellet was resuspended with 2 ml fresh RPMI media. The cells 
were split at 1:5 or 1:6 ratios depending on the confluency. 0.3-0.6 ml of the cell 
resuspension was added with 20 ml fresh RPMI media into a new T75 flask. The cells were 
incubated at 37°C/5% CO2humidified environment for 2-3 days until they were ready to split 
again. 
 
2.3 Haemocytometry 
The haemocytometer was moistened and affixed with a clean glass cover-slip, where the 
coverslip would adhere by suction to the centre. 25µl of a well-mixed cell suspension was 
pipetted at one edge of the coverslip and run through the empty space. The cells were 
counted in 4 large corner squares and the number was recorded.  
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A formula was used: 
Average count of cells in 4 squares x 104 (conversion factor) = cell concentration / ml 
1 x 105 cells was usually the starting number for experiments, the formula was as: 
 
The number of cells wanted /cell concentration (C1)                 x    Volume (ml) 
The cell concentration obtained in the cell suspension (C2) 
 
2.4 Freezing and Thawing the Cells 
Freezing buffer was prepared in FBS with 10% DMSO (i.e. 5 ml DMSO+45 ml FBS). The 
cells from 1 T75 flask (MDA-MB-231 vs. U2OS cells) were trypsinized with 2 ml trypsin, left 
for incubation for 10 minutes in the incubator and resuspended in 3 ml fresh media. They 
were transferred into 15 ml Falcon tubes and centrifuged down at 3000 rpm for 10 minutes. 
The supernatant was removed from each tube and the cell pellet was resuspended in 8 ml 
freezing buffer. 1.5 ml or 2 ml cell suspension in the freezing buffer was aliquoted into the 
cryo vials. The vials were labelled with the cell line name, the date and the initials. The vials 
were put into the 100% isopropyl alcohol-containing container Mr Frosty freezing container. 
This was to achieve -1°C/minute rate of cooling for cell preservation in the -80°C for 24 
hours. Then the vials were wrapped in the metal wire and plastic rack and frozen in liquid 
nitrogen for long term storage.  
 
The vials were taken up from liquid nitrogen and immediately put into the 37°C water bath 
for thawing. The 1.5 ml or 2 ml of the defrosted cell suspension was transferred into a 15 ml 
Falcon tube. 10 ml fresh media was added to the tube and mixed well with the cells. The 
tube was centrifuged down at 3000 rpm for 10 minutes. The supernatant was removed. 5 ml 
fresh media was added to the cell pellet and resuspended well. The 5 ml cell suspension 
was added into a new T75 flask with 20 ml fresh media in it. The flask was left in the 
incubator and the media was changed every 2 days. 1 week was needed for the cells to 
grow. 
 
2.5 DNA Plasmid Extraction and Purification: HA SUMO-2, GFP-Vinculin, 
mEmerald-Vinculin and GFP-Talin  
pcDNA3 HA-Sumo2 WT was a gift from Guy Salvesen (Addgene plasmid # 48967); 
pGFP(C3)-Vinculin was a gift from Klaus Hahn (Addgene plasmid # 30312); mEmerald-
Vinculin-N-21 was a gift from Michael Davidson (Addgene plasmid # 54304);  GFP-Talin 1 
was a gift from Anna Huttenlocher (Addgene plasmid # 26724). HA SUMO-2, 
mEmerald/GFP-vinculin or GFP-talin 1 plasmids were bought from Addgene and obtained in 
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E.coli bacteria-containing stabs in small glass bottles. The bacterial stab contained the 
inserted DNA plasmid construct, which could be stored at 4°C for up to 2 weeks. 
 
2.5. 1 LB Media and Bacto Agar Preparation 
Luria-Bertani (LB) media was prepared by adding tryptone (10 g), yeast extract (5 g), NaCl 
(10 g) and 1 litre deionized H2O in a clean bottle. The solution was shaken thoroughly until 
all the solutes were dissolved. The pH was adjusted to 7.0 using pH monitor with 5 M NaOH. 
The bacto agar for plates was made by adding 15 g agar with the LB medium solutes in 
another bottle to make up 1 litre deionized H2O (agar was added 7.5 g for 500 ml LB 
solution). Both LB medium and bacto agar were autoclaved before the addition of antibiotics 
(ampicillin: the stock concentration 100 mg/ml, the working concentration 100 µg/ml; 
kanamycin: the stock concentration 50 mg/ml, the working concentration 50 µg/ml, 
recommended by Addgene).  
The LB medium and the bacto agar were allowed to cool on the bench at room temperature 
to about ~50-55 °C. Both of the LB medium and the bacto agar were split into 500 ml bottles; 
the LB medium or the bacto agar bottles were added with ampicillin and kanamycin 
respectively after they were cooled. The bacto agar was poured into the culture medium 
plates labelled with corresponding antibiotics (ampicillin or kanamycin) near to a hot flame 
for sterility. The plates were allowed to cool at room temperature. Once cooled, the plates 
were sealed with parafilm and stored at 4 °C before use and kept up to 3 weeks.  
 
2.5. 2 The Selection of the Antibiotics-resistant DNA Plasmids and the Growth of the 
Bacterial Broth 
DNA/RNA free eppendorf tubes were labelled with each plasmid name and negative control 
(Table 1). The competent E.coli I cells (Mach 10, Promega) were taken from -80°C and 
thawed on ice for 20 minutes. For each plasmid tube and the negative control tube, 400 µl 
LB medium with 50 µl of competent cells were added using the sterile pipette tips near to the 
hot flame, respectively. The negative control tube only contained the competent cells in LB 
medium. 1 sterile pipette tip of the bacteria was streaked from the corresponding bacterial 
stab glass bottles and mixed into the labelled plasmid eppendorf tubes. All the tubes were 
shaken at 80 rpm at 37°C in the water bath for 1 hour initially. 
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Tube 1 - Negative control + 400 µl LB 
medium only 
+ 50 µl E.coli 
competent cells 
Tube 2 Kanamycin 
resistance 
mEmerald-Vinculin 
plasmid 
+ 400 µl LB 
medium only 
+ 50 µl E.coli 
competent cells 
Tube 3 Kanamycin 
resistance 
GFP-Vinculin 
plasmid 
+ 400 µl LB 
medium only 
+ 50 µl E.coli 
competent cells 
Tube 4 Kanamycin 
resistance 
GFP-Talin 1 
plasmid 
+ 400 µl LB 
medium only 
+ 50 µl E.coli 
competent cells 
Tube 5 Ampicillin 
resistance 
HA SUMO-2 
plasmid 
+ 400 µl LB 
medium only 
+ 50 µl E.coli 
competent cells 
 
Table 1. Transfection: 1 tip of the bacteria from streaking contained the plasmid of interest, which was 
added with the competent cells and the LB medium for incubation 
 
The agar plates were taken out from 4°C and warmed up at room temperature. 250 µl liquid 
from each plasmid eppendorf tube was dropped onto the centre of the antibiotics-resistant 
agar plate (with ampicillin or kanamycin) and spread evenly across the whole surface area of 
the plate using a sterile VWR® polypropylene cell spreader. All these steps were done near 
to the hot flame. mEmerald-vinculin, GFP-Vinculin or GFP-Talin 1 plasmid/competent cells 
liquid mixture was spread and grown on the kanamycin-resistant agar plate; the HA SUMO-2 
liquid mixture was spread on the ampicillin-resistant agar plate. For the negative control, 200 
µl of the mixture was spread onto the ‘+ Amp negative control’ plate for HA SUMO-2; 200 µl 
of the mixture was spread onto the ‘+ Kana negative control’ plate for mEmerald-Vinculin, 
GFP-Vinculin and GFP-Talin 1.  
 
All the plates were incubated overnight (12-16 hours) at 37°C. This was enough time for the 
bacteria to grow and form colonies, only if the competent cells had taken up the antibiotic-
resistant plasmids. After overnight incubation, in all the plasmid agar plates, they had formed 
colonies of bacteria; in the negative control plates, there were no colonies formed. For each 
plasmid extraction, a single bacterial colony was picked using the sterile tip near to the hot 
flame, which would minimize the chances of obtaining a mixture of plasmids during the 
preparation. The single colony was mixed completely in 10 ml LB medium containing the 
antibiotics in a 15 ml Falcon tube. There were 4 tubes prepared and they were put in the 
shaking incubator at 200 rpm for up to 8 hours at 37 °C. A cloudy mixture was observed for 
each tube, which was then poured into conical flasks (4 flasks were autoclaved with the 
sponges on top previously) containing 200-250 ml LB medium with antibiotics. All the 4 
conical flasks were incubated overnight up to 16 hours optimally with vigorous shaking to 
obtain a high yield of bacteria containing the plasmid of interest.  
 
The next day, for each flask, the broth was split into 50 ml Falcon tubes. The bacteria pellet 
was obtained using the cooling centrifuge (MULTIFUGE X3R, Thermo Scientific) at 4814 g 
for 15 minutes at 4ºC. For efficient pellet lysis, lysate filtration, DNA binding, washing and 
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eluting, the QIAGEN HiSpeed Plasmid Maxiprep Kit was used to extract, purify and collect 
the ultrapure DNA plasmid.  
 
2.5. 3 Maxiprep Kit
After centrifugation, the supernatant was removed from each 50 ml Falcon tube and the tube 
was drained. (The cell pellet could be stored at -20°C). The bacterial pellet was resuspended 
in 10 ml P1 (50mM Tris-Cl, 10mM EDTA, pH 8.0) resuspension buffer containing RNase A 
(final concentration 100 µg/ml, 1:1000). Each tube was vortexed until no pellet clump was 
seen. 10 ml lysis buffer P2 (200mM NaOH, 1% SDS) was added and mixed thoroughly and 
incubated for 5 min. No vortexing was needed. 
 
The QIAfilter cartridges were prepared. The caps were screwed onto the outlet nozzle of 
each cartridge and left to stand. 10 ml chilled neutralization buffer P3 (3M potassium 
acetate, pH 5.5) was added into each tube. A fluffy white precipitate containing genomic 
DNA, proteins and cell debris etc became visible. The mixture was mixed completely with 
the buffer.  
 
The cell lysate from each 50 ml tube was poured directly into each cartridge and incubated 
at room temperature for 10 min. The cartridges were left still on the stand. A precipitate 
containing proteins, genomic DNA and detergent was floated and formed a layer on top of 
the solution.  
 
The HiSpeed Maxi Tips were prepared. 10 ml equilibration buffer, QBT was poured into each 
Tip and allowed to empty by gravity flow. The cap was removed from each cartridge and the 
plunger was gently inserted into each cartridge. The cell lysate was filtered into each 
equilibrated Tip until all the lysate was passed through the cartridge. The cleared lysate was 
allowed to enter the resin by gravity flow in the Tip. The Tip was washed with 60 ml wash 
buffer, QC. The buffer was allowed to move through the Tip by gravity flow. The DNA was 
eluted from the column with 15 ml elution buffer, QF. The eluate was collected in each tube. 
 
The DNA was precipitated by adding 10.5 ml room temperature isopropanol (2-propanol) to 
the eluted DNA. It was mixed and incubated at room temperature for 5 min. The 30 ml 
syringes were prepared. The QIA precipitator Maxi Modules were attached onto the outlet 
nozzle of the syringes. The plungers were pulled out first then the modules were inserted.  
 
The eluate/isopropanol mixture was transferred into each 30 ml syringe and the plunger was 
pushed. The eluate mixture was filtered through each precipitator module using constant 
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pressure. The flow-through was discarded. The precipitator was removed first then the 
plunger was pulled out. The precipitator was re-attached and 2 ml 70% ethanol was added 
to the 30 ml syringe. The DNA was washed by inserting the plunger and pressing the 
ethanol through the precipitate using constant pressure. 
 
The precipitator was removed first and the plunger was pulled out. The precipitator was 
added back and the plunger was inserted and pushed quickly and forcefully. This was to dry 
the membrane by pressing the air and to prevent ethanol carryover.  
 
The precipitator was attached to a new 5 ml syringe and a 1.5 ml collection tube was held 
over (autoclaved). 1-2 ml TE buffer was added to the 5 ml syringe. The plunger was pushed 
and the DNA was eluted into the collection tube using constant pressure X2. No excess 
pressure was used. The ultrapure DNA for each plasmid could be stored at -20°C. 
 
mEmerald Vinculin  861.6 µg/ml 
GFP-Vinculin (1) 297 µg/ml 
GFP-Vinculin (2) 331.8 µg/ml 
GFP-Talin 1 414.5 µg/ml 
HA SUMO 2 (1) 294.9 µg/ml 
HA SUMO 2 (2) 337.5 µg/ml 
 
Table 2. The concentration of each plasmid in µg/ml 
 
A NanoDrop spectrophotometer 2000 (Thermo Scientific, Labtech International) was used to 
measure the DNA plasmid yield; once calibrated with the ‘blank’, the samples were 
measured as dsDNA µg/ml. The concentration of each plasmid was summarised in Table 2. 
 
2.6 Drug Treatment: Ginkgolic Acid, Gossypetin and 2-D08  
Ginkgolic acid C15:1 was dissolved in DMSO [0.1 %] (molecular mass of GA: 346.5 g/mol, 
Sigma-Aldrich). 100 mM GA stock was prepared by adding 144.3 µl filtered sterile DMSO to 
the 5 mg GA. 5 µl GA was aliquoted into sterile eppendorf tubes and stored at - 20°C. For 
the experiments, 100 µM final concentration of GA was used. A two-step series of dilution 
was done. To each 5 ul, 45 µl fresh normal media was added (1:10). In the T25 culture flask, 
30 µl of this 50 µl GA was mixed in 2.97 ml normal media (1:100), this was added to each 
treated flask (2-5 x 105 cells plated originally = 60~70% confluence). GA treatment was done 
for 15 mins, 30 mins, 1 hour, 6 hours, 18 hours or 24 hours depending on the previous 
experiments. In a 6-well plate, 20 µl GA (of the 50 µl GA [1:10]) in 1.98 ml fresh normal 
media (1: 100) was added to each treated well for 15, 30 or 60 minutes incubation (1 x 105 
cells plated originally) in the IHC experiments.  
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For the gossypetin (3-B08) and 2-D08, these were also prepared as 100 mM stock 
concentration. Gossypetin (250 mg, G-500) was bought from INDOFINE Chemical 
Company, Inc. (ICC) and 2-D08 could be found at Merck Millipore. They were also dissolved 
in DMSO and aliquots stored at -20°C.  
 
DMSO control was used as the same as the inhibitors, i.e. 5 µl DMSO was added with 45 µl 
medium. 10 µl diluted DMSO was added in 990 µl medium to make 1 ml total media. The 
cells were treated with each inhibitor at the desired concentration and time; in the 6-well 
plate, the total media amount was added as 2 ml and the T25 flask was filled with 4 ml 
media.  
 
2.7 Focal Adhesion Turnover Assay 
 
2.7. 1 DNA Plasmid Transfection 
1 x 105 MDA-MB-231 cells were firstly plated in each well of a 6-well plate 1 day prior to 
transfection. 1 µg DNA plasmid was added with the 100 µl serum free DMEM media in a 
sterile eppendorf tube for each FA plasmid separately. 1 µg GFP-FAK (695 µg/ml), 1 µg 
GFP-talin 1 (414.5 µg/ml, Addgene, #26724) or 1 µg GFP-vinculin (297 µg/ml, Addgene, 
#30312) was mixed in the 100 µl serum free DMEM media and the eppendorf tube end was 
tapped gently. 3 µl FuGENE HD transfection reagent (Promega) was added to each 
eppendorf tube and the tube end was tapped gently again. The FA plasmid mixture was 
incubated at room temperature for 15 minutes. Then the talin plasmid mixture was added 
drop by drop to the 2 wells labelled as control talin vs. GA talin; the FAK plasmid mixture 
was added to control FAK vs. GA FAK; the vinculin plasmid mixture was added to control 
vinculin vs. GA vinculin. Each plate was swirled gently. The cells were incubated for 8 hours 
initially in the incubator before they were trypsinized and transferred on collagen. 
 
2.7. 2 Non-Compressed Collagen Coating 
The collagen matrices were prepared by mixing 4.41 mg/ml chilled rat tail type I non-
pepsinized collagen in acetic acid (final concentration 2 mg/ml, BD Biosciences) with DMEM 
1X (100 µl/ml, 10X), 15-20 µl of the 1 M NaOH per diluted 1 ml collagen solution (pH 
normalized to 7.0, until the mixture colour was just changed from yellow to pink purple) and 
the chilled culture media to make up to 2 ml collagen mixtures. All the ingredients were 
mixed thoroughly on ice and care was taken to avoid bubble formation in the mixture 
solution. 200-400 µl of the collagen mixture was added to the centre of ibidi glass bottom 
dishes forming a ‘ring patch’. The collagen gel was allowed to polymerize and solidify in 5% 
CO2/95% v/v humidified air environment at 37°C for 20-30 minutes.  
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2.7. 3 2.5D Cell Culture 
After 8 hours transfection, the MDA-MB-231 cells in each well were trypsinized (200 µl 
trypsin/well) and 200 µl fresh DMEM media was added per well for re-suspension (400 µl 
total cell suspension/well). 200 µl of the cell suspension from each non-transfected control 
and the GA treated well was pipetted into the matching collagen-coated ibidi glass bottom 
dishes (control and GA treated dishes). The cells were seeded around the edge of the 
‘collagen patch’ and left in the incubator to attach and settle for another 20-30 minutes. 
Finally, 1.5 ml fresh DMEM media was added to cover the set collagen matrix. The cells 
were maintained in this environment overnight prior to GA treatment.  
 
The next day, single MDA-MB-231 cells were aligned ‘front-to-rear’ along the edge of the 
collagen ring at the ‘interphase / border’ moving along the collagen patch edge; some other 
cells were moving adjacent towards the border and gradually they could form ‘clumps’ of 
cells; some cells were already migrated through into the 3D collagen matrix. 100 µM GA was 
added to the treated ibidi dishes; the cells were incubated in 2 ml GA-containing fresh media 
for 1.5-2 hours (‘talin’, ‘FAK’ or ‘vinculin’ GFP plasmid transfected cells) prior to confocal 
microscopy.  
 
To determine the FA turnover, live-cell timelapse imaging was taken as 1s, 2s or 8s per 
scanning for each control or GA treated ibidi dish for 5-10 minutes. These movies were 
analysed later to look at the FA number, size and turnover. 
 
2.8 Immunocytochemistry 
 
2.8. 1 Cell Growth on Coverslips  
Glass coverslips were put in the wells of a 6-well plate and were immersed in 100% 
methanol for 15 minutes in the culture hood for washing. The methanol was then aspirated 
and the coverslips were left to dry. The coverslips were then coated with a thin layer of 0.2% 
w/v gelatin and left to dry up to 1 hour. MDA-MB-231 cells were resuspended in culture 
media from T75 flasks and plated on each coverslip in the 6-well plate as 60-70% 
confluence. The plate was left in the incubator overnight at 5% CO2/95% humidified air 
environment at 37°C. 
 
The next day, MDA-MB-231 cells were treated with GA, Gossypetin and 2-D08 to look at 
their effects on talin or vinculin containing FAs number and size. 100µM GA treatment was 
done as 15, 30 and 60 minutes. For the other inhibitors 2-D08 and gossypetin, the 
experimental treatment time was 1 hour and the concentration was also 100 µM.  
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U2OS cells were prepared for the IHC experiments to study the effects of GA and the other 
inhibitors 2-D08 and gossypetin on talin or vinculin containing FAs number and size. For the 
U2OS cells, the inhibitor treatment time was chosen as 15 minutes or 1 hour and the 
concentration for each inhibitor used was 100µM.  
 
2.8. 2 Immunocytochemistry Staining 
The culture media was aspirated in each well in the 6-well plate and the cells were washed 
in pre-warmed PBS once at room temperature. The cells were fixed in 4% v/v PFA for 20 
minutes at room temperature. The cells were washed with PBS for 10 minutes x3 then 
incubated with 0.5% v/v Triton-X100 for 10 minutes at room temperature. The cells were 
then washed in PBS for 10 minutes x3. The cells were blocked with 10% v/v goat serum for 
10 minutes. Then the cells were incubated with primary antibodies (1:100 dilution) for 1 hour 
(1 µl primary antibody, 4 µl GS mixed in 94 µl PBS). This 100 µl solution was spread onto 
the whole area of the coverslip evenly. After washing with PBS 5 minutes x 3, the cells were 
incubated with secondary antibodies (1:100 dilution) for 1 hour in the dark (1 µl secondary 
antibody, 4 µl GS mixed in 94 µl PBS). The cells were washed in PBS for 5 minutes x 3 in 
the dark. 1 drop of DAPI solution (VECTASHIELD®, Vector Laboratories, Inc.) was added on 
the glass slides in the dark. A needle tip was used to take out the coverslip from each well 
carefully. The coverslip side with the cells ‘on’ was covered onto the glass slide immersed 
with DAPI in the dark. Nail polish was used to brush the borders of the coverslips to fix them 
onto the slides. All the glass slide samples could be then stored in slide boxes at 4°C and 
ready for confocal microscope scanning. 
 
2.8. 3 Experimental Controls  
In the preliminary experiments the specificity of labelling was tested using controls in which 
the staining was performed without the primary antibodies or in the absence of the cells. This 
gave no significant fluorescent labelling. 
 
2.8. 4 Primary and Secondary Antibodies for IHC Experiments 
1 Mouse anti-talin 1 monoclonal antibody reacting with an N-terminal epitope in 
human talin between amino acids 139-433, Clone TA205, 1 mg/ml, MAB1676, 
Merck Millipore (1:100) 
 
2 Mouse anti-vinculin monoclonal antibody, 1 mg/ml, MAB3574, Merck Millipore 
(1:100) 
 
3 Alexa-Fluor 488 conjugated goat anti-mouse antibody, Fisher (1:100) 
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2.9 Confocal Microscopy and Live-Cell Imaging 
100x OIL lens (1.5 or 150 µm working distance) was used for the observation of FAs 
turnover. GALVANO mode was chosen, where ‘interlock’ was removed to ensure safe 
transmitted light from the lasers and E100 was changed to L100 confocal with the 
fluorescent lamp shutter box closed. The image was taken in the 1024*1024 format in the 
xyz plane. To do 3-dimensional planes of an image or look closer at a focal adhesion, fast z-
stack slices of an image was scanned indicating a ‘top’ and a ‘bottom’ of the image; line 
averaging 4x-16x was taken according to the level of the noise background; the Z/Y position 
indicated where the section was taken away from the bottom of the culture dish. Fluorescent 
filters include DAPI (405), GFP (488), Cherry (630) and Cy5 (640-750). The laser fast mode 
was on and used as ½ (2 scanning/second). The pinhole size was 1.2 which ensures optimal 
light capture. Pixel saturation indicator was always turned on to allow maximum 1% 
saturation.  
 
Timelapse movies for FA turnover were generated to record at 2s, 8s or 10s intervals 
scanning of the ‘control’ and ‘GA treated’ samples for 5 minutes and 10 minutes period. The 
CO2 chamber was connected to each culture dish to keep the pH at balance for live-cell 
imaging. GFP laser channel was used and set with the laser intensity and exposure time to 
ensure the noise background and the brightness of the image were kept in balance. The 
images were saved as ND2/Tiff files ready for data analysis. 
 
2.10 Phase-Contrast Live-Cell Timelapse 
 
2.10. 1 Cell Growth in 3D Collagen Matrix  
The collagen matrix was made (diluted 2 mg/ml collagen + 1x DMEM + 1 M NaOH: see 2.7. 
2) and mixed up with the MDA-MB-231 cells, which was prepared up to 10 ml diluted 
collagen mixture. 125-200 µl cell suspensions were mixed in 1 ml collagen mixture x 10. 12-
well plate was used for the cell migration experiments. For each well in the 12-well plate, 
600-800 µl of the mixed collagen containing the cells was pipetted and spread fully across 
the well area. The 12-well plate was left in the incubator for 30 minutes for the collagen 
matrix to set. 2 ml DMEM media was added into each well. The cells were grown overnight 
in the 3D collagen matrix.  
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2.10. 2 Drug Treatments 
The MDA-MB-231 cells were treated with 25 µM, 50 µM or 100 µM of GA. In the 12-well 
plate, 3 triplicate wells were set up as 1 group treatment. 3 groups of treatment were set up 
as 25 µM, 50 µM or 100 µM GA treatments. The controls were prepared to each group 
treatment. MDA-MB-231 cells were also treated with 25 nM scrambled siRNA / Ubc9 siRNA 
(described in 2.17). The MDA-MB-231 cells were grown in 2 mg/ml 3D collagen matrix in the 
6-well plate overnight. 3 wells were set up for the Ubc9 siRNA timelapse experiment. A 
single concentration 25 nM siRNA / 25 nM scrambled siRNA mixture (in 0.2x Lipofectamine 
dilution) was used; 1 well was set up as the negative control. 200-400 µl cell suspension in 
DMEM media were mixed in the 1 ml collagen mixture and a total volume of 1000-1500 µl 
final collagen mixture was added to each well surface. The timelapse experiment was run for 
a period 24-48 hours. The timelapse movies were taken for 2 separate rounds, i.e. the first 
24 hours and the second 24 hours. 
 
2.10. 3 Live-Cell Timelapse Microscopy 
After adding GA or Ubc9 siRNA, the plate was sealed with Parafilm and a ‘hole’ was made in 
the side of the plate wall; this was to connect with the CO2 supply needle. The plate was put 
onto the pre-warmed NikonTie timelapse microscope stage immediately. The plate was 
checked to make sure that it was fitted onto the stage with care. Live-cell imaging timelapse 
was initialized, where the microscope, the camera, the lamp, the temperature control unit 
and the CO2 chamber were previously switched on. The temperature unit was set up as 
37°C. The CO2 pressure was fixed and controlled as between 70-80 mmHg. The light was 
adjusted at 1/3 light. NIS Elements software was selected. The exposure on the camera 
settings was set as 45ms and the background was selected as auto white.  
 
10x Microscope lens was selected on the microscope with perfect focus or the auto-focus 
(PFS) on. When in focus, the eyepiece E100 was changed to L100, the focus was then only 
used with the fine focus button. ND timelapse programme was set up, where 24hrs 
timelapse movie was selected as the total time treatment; x/y point positions were selected 
in each non-treated and treated wells with 5 or 6 points at different eye fields. The interval 
time frame was set as 20 minutes. The camera was adjusted as live-fast with normal high 
quality capture. At the end of the experiment, multi-points were split to extract multiple files 
and then the movies were saved. The movies were analysed using Image J to study the cell 
migration compared between the non-treated and the treated conditions. 
 
 
53 
2.11 Western Blotting 
 
2.11. 1 Bradford Protein Assay 
A1-H1 in one 96-well plate were plated with 195µl Bradford reagent (Br) (blank). A2-3 – H2-3 
were plated with 195 µl Br and 5 µl of bovine serum albumin (BSA) standard at 25, 125, 250, 
500, 750, 1000, 1500 or 2000 µg/ml. The plate was stirred at 1000 / min for 30s. A standard 
protein absorption curve was generated and R2 value = 0.95-0.99. Then, 5 µl of samples 
was plated in triplicate wells mixed with 195 µl Br and the plate was stirred. In the unknown 
protein concentration table, the mean concentration value was used to calculate an equal 
amount of protein loading (the protein loading concentration was 20-50 µg used) before 
electrophoresis and the loading volume per well was 40-45 µl. The equation as: 
 
Volume to load / well = Sample n protein mean Cn x 40µl 
                                     Sample n+1 protein mean Cn+1 
 
2.11. 2 Western Blotting Buffers (Manually Prepared) 
5x Tris-glycine electrophoresis running buffer: 15.1 g Tris base (Fisher Scientific), 94 g 
glycine (Fisher Scientific) were dissolved in 900 ml distilled H2O, then added with 50 ml 10% 
v/v SDS. This was made up to 1 L solution. 1x Tris-glycine electrophoresis running buffer: 
400 ml 5x Tris-glycine was mixed with 1600 ml ddH2O to make up 2 L solution. These were 
stored at room temperature. 
 
10% v/v SDS (sodium dodecyl sulphate): 50 g SDS was dissolved in 450 ml ddH2O which 
was made up to 500 ml stock solution. It was stored at room temperature. 
 
Transfer buffer: 2.9 g glycine, 2.8 g Tris base and 200 ml methanol were dissolved in 1 L 
ddH2O. It was stored at room temperature.  
 
10x TBS (Tris buffer saline): 80 g NaCl (Fisher Scientific), 2 g KCl (Fisher Scientific) and 30 
g Tris base were dissolved in 800 ml ddH2O initially; the pH was adjusted to 7.4 using 
concentrated HCl and this was made up to 1 L final solution. 1x TBS: 100 ml 10x TBS was 
mixed with 900 ml ddH2O. These were stored at room temperature. 
 
TBST (TBS-Tween-20): 0.1% v/v Tween-20 (Sigma) as 1ml Tween-20 was dissolved in 1 L 
1x TBS. It was stored at room temperature.  
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5x SDS boiling gel-loading buffer stock solution: 312.5 mM Tris base (1.514 g), 10% v/v SDS 
(4 g), 50% v/v glycerol (20 g) final amount taken as 15.9 ml, 25% v/v mercaptoethanol (10 g) 
final amount taken as 9 ml and 0.0125% v/v bromophenol blue (5 mg) were dissolved in the 
final volume 40 ml ddH2O and stored in -20°C. This was the 5x stock solution.  
 
2.11. 3 Electrophoresis 
4-20% Mini-PROTEAN® TGX™ precast 50 µl / 10-well Gels (Bio-Rad) were prepared in the 
tank. The samples were loaded according to the calculations from Bradford assay; 7 µl 
protein marker was loaded in lane 1. 1x Tris-glycine running buffer was poured to the mark 
4-gel or 2-gel. Electrophoresis was set at 180V, 0.05A (1 gel=0.05A, 2 gels=0.05A x 2 = 0.1 
A and so on) initially for protein running separation according to protein size, gel pore size 
and electrode charge. After the stacking gels, the current was changed to 0.03A for the 
resolving gel separation (1 gel=0.03A, 2 gels=0.06A and so on). 
 
2.11. 4 Membrane Transfer 
The PVDF membranes were cut as 8 cm x 8.5 cm. The semi-dry transfer paper was 
prepared according to the area of the membrane. The gel area was 6 x 8.5 cm2. The current 
was set as the membrane area x 0.8 x 0.001 mA/cm2 and the transfer voltage was at 250V. 
The PVDF membrane was soaked in methanol for 5 minutes. 6 transfer papers were soaked 
in transfer buffer for 10 minutes and placed on the transfer blotter. A roller was used to roll 
the paper gently to get rid of the excess transfer buffer and make it even surface. 3 soaked 
papers were placed underneath; the membrane was placed on top of the 3 soaked papers; 
the gel was put on top of the membrane carefully; the other 3 soaker papers were placed on 
top of the gel. This was the ‘sandwich’ and the transfer was set running for 1.5 hrs. 
 
2.11. 5 Blocking 
5% v/v milk-TBST was prepared for blocking non-specific binding of the proteins for 40 
minutes. After blocking, the membrane was washed in 1x TBST, 10 minutes x 3 on a rotator 
machine.  
 
2.11. 6 Primary and Secondary Antibodies 
Primary antibodies were prepared in 2% v/v BSA-TBST (see the antibody dilutions 2.12 
Antibodies). The membrane was incubated with the 1° antibody overnight on a rotator 
machine in the cold room at 4°C. The next day, the membrane was washed in 1x TBST, 10 
minutes x 3. The secondary antibodies were prepared in 1% v/v milk-TBST. For HRP-
conjugated 2° antibodies, anti-mouse or anti-rabbit were used as 1:3000; anti-goat HRP was 
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1:5000. The membrane was incubated with the 2° antibodies for 1 hour on a rotator 
machine. The membrane was then washed in 1x TBST, 10 minutes x 3.  
 
2.11. 7 Band Detection 
ECL-prime reagent (GE Healthcare) was used. 0.5 ml solution A mixed with 0.5 ml solution 
B was spread onto the membrane evenly and left for 1 minute in the dark. The luminescent 
image analyser ImageQuant LAS 4000 mini (GE Healthcare) was used and detection of the 
bands was carried out in the dark. Auto-exposure time was selected with super-resolution. 
ImageQuant software was used to map the digital information to the appropriate pixel 
location on the monitor, which gave an accurate image of the original membrane. 
 
2.11. 8 Primary and Secondary Antibodies for WB Experiments 
1 Mouse anti-UBC9 monoclonal antibody (C-12) raised against amino acids 1-81 of 
UBC9 of human origin, 200 µg/ml, sc-271057, Santa Cruz Biotechnology, INC. 
(WB: 1:250-500)  
 
2 Rabbit anti-GAPDH antibody, 1 mg/ml, G9545, Sigma (WB: 1:1000) 
 
3 Donkey anti-goat IgG-HRP: 200 µg/0.5ml, sc-2020, Santa Cruz Biotechnology, 
INC. (1:5000) 
 
4 Anti-mouse IgG-HRP, Sigma (1:3000) 
 
5 Anti-rabbit IgG-HRP, Sigma (1:3000) 
 
 
2.12 Ubc9 siRNA Knockdown and Western Blotting 
 
2.12. 1 GAPDH siRNA Knockdown 
Previous experiments were done with the Silencer® siRNA Starter Kit (Invitrogen) to knock 
down GAPDH as the control for the Ubc9 siRNA knockdown experiment. Lipofectamine® 
RNAiMAX Reagent (Invitrogen) was used for Ubc9 siRNA knockdown experiments. 
 
16 µl of GAPDH siRNA or scrambled siRNA was mixed with 384 µl nuclease-free water to 
give 2µM stock concentration. 30nM final concentration of GAPDH siRNA or scrambled 
control was used: 45 µl of the GAPDH siRNA or scrambled control was mixed with 300 µl 
OPTI-MEM®I reduced serum medium (modified Eagle’s MEM medium, Gibco) to use per 
well in the 6-well plate. 7-well volume was made for the siRNA and the OPTI-MEM medium, 
mixed together. 
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MDA-MB-231 breast cancer cells were grown in 6-well plate overnight. The cells were 
washed with PBS once. Then, the cells were trypsinized with 0.2 ml trypsin, left for 5 
minutes, then 0.2 ml normal medium was resuspended the cells in medium. Half (0.2 ml) cell 
suspension was plated into new well/per plate, 1.8 ml normal medium was added to each 
well. 
 
NeoFX diluted transfection reagent was prepared. 5 µl of the NeoFX with 300 µl OPTI-MEM 
medium was for each well/per plate, 7-well volume was also made for NeoFX and OPTI-
MEM medium, mixed together. Once NeoFX and OPTI-MEM medium was mixed, it was left 
to stand for 10 minutes. The diluted GAPDH / scrambled siRNA was mixed with the diluted 
NeoFX respectively and left to stand for 10 minutes. 600 µl each GAPDH / scrambled 
siRNA/non-transfected control was added to each well containing 2 ml media. The cells were 
left in the incubator for 2 days. After 24 hours, the media was changed; after 48 hours, whole 
cell lysates were made.  
 
2.12. 2 Ubc9 siRNA Knockdown 
5 nmole Ubc9 siRNA / scrambled siRNA powder (Invitrogen/Life technologies, 4390824) was 
prepared to make 20 µM siRNA stock. 250 µl nuclease-free H2O was added to 5 nmol siRNA 
power gave 20 µM stock (=20 pmol/µl). The siRNA / scrambled was diluted in OPTI-MEM 
medium. The experiment was done in T25 flasks, where 2.5 was the conversion factor for 
the siRNA amount added in T25 flasks. From 20 µM stock: 7.5 µl siRNA was added with 
OPTI-MEM medium to make 750 µl total diluted siRNA, mixed well. Lipofectamine 
transfection reagent was diluted as 1x, 0.5x or 0.2x, each was mixed with OPTI-MEM 
medium. For the Opti-MEM medium, 150 x 2.5 x 2 = 750µl was taken for each siRNA / 
scrambled siRNA. Each calculation was prepared as doubled amount (x2, Table 3).  
 
20 µM siRNA 
stock 
Diluted Ubc9 
siRNA/scrambled 
siRNA [0.2 µM] 
Diluted 
Lipofectamine 
reagent 1x 
Diluted 
Lipofectamine 
reagent 0.5x 
Diluted 
Lipofectamine 
reagent 0.2x 
Volume 3.75 x 2 = 7.5 9 x 2.5 x 2 = 45 11.25 x 2 = 22.5 4.5 x 2 = 9 
OPTI-MEM 
medium 
750-7.5 = 742.5 750-45 = 705 750-22.5 = 727.5 750-9 = 741 
 
Table 3. The amount of the Ubc9 siRNA, scrambled siRNA or the Lipofectamine reagent added in 
each preparation in T25 flask; the total diluted volume was1500 µl. 7.5 µl siRNA in 750 µl=1:100 
dilution [0.2 µM]; 7.5 µl siRNA in 1500 µl=1:200 dilution [0.1 µM/100nM] 
 
In Table 3, 7.5 µl Ubc9 siRNA or scrambled siRNA was prepared. 9 µl x 2.5 = 22.5 µl of 
Lipofectamine reagent was used as 1x concentration according to the RNAiMAX transfection 
protocol online (converted from 6-well plate to T25 flask volume). For 0.5x diluted 
Lipofectamine concentration, 9 ÷ 2 x 2.5 = 11.25 µl was calculated but 22.5 µl was prepared 
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practically. Similarly, for 0.2x diluted Lipofectamine concentration, 9 ÷ 5 x 2.5 x 2 = 9 µl was 
prepared. The OPTI-MEM medium volume was calculated for each treatment accordingly. 
1x105 cells were plated in each T25 flask. Ideally, the cells would be 60-70% confluent on 
the day of transfection. The cells were maintained in 4 ml normal DMEM media in the 
incubator 5% CO2/95% v/v humid air at 37°C overnight.  
 
In practice, initially, the diluted siRNA (750 µl) was mixed with diluted 1x Lipofectamine 
reagent (750 µl) as a total volume of 1500 µl; this was left to stand for 5 minutes. After 
mixing, the siRNA concentration was 100 nM. For the final siRNA 25 nM concentration (1:4), 
1.125 ml of the mixed total siRNA [100 nM] was mixed with 3.375 ml of the normal media as 
a total volume of 4.5 ml, which was 25 nM. Therefore, the cells were washed with PBS once 
and replaced with 3.375 ml fresh media (3 ml using the sterile pipette, 0.375 ml using the 
sterile tips); then 1.125 ml of the diluted siRNA or scrambled siRNA was added in each T25 
flask accordingly. This was set up as 24hr vs. 48hr transfection experiment. Practically, 
adjusted methods were also used with lower concentrations of the Lipofectamine reagent as 
0.5x or 0.2x, where the Ubc9 siRNA / scrambled siRNA / 0.5x vs. 0.2x Lipofectamine was 
combined as 4x volume in 15 ml falcon tube. See the calculations in Table 4: 
 
20µM siRNA stock F Tube 1- Diluted 
siRNA [0.2 µM] 
(µl) 
F Tube 2- Diluted 
scrambled siRNA 
[0.2 µM] (µl) 
F Tube 3- Diluted 
Lipofectamine 
reagent 0.5x 
(µl) 
F Tube 4- Diluted 
Lipofectamine 
reagent 0.2x 
(µl) 
Volume 7.5 x 4 = 30 7.5 x 4 = 30 22.5 x 4 = 90 9 x 4 = 36 
OPTI-MEM medium 742.5 x 4 = 2970 742.5 x 4 = 2970 727.5 x 4 = 2910 741 x 4 = 2964 
Total 
siRNA/Lipofectamine 
+ OPTI-MEM 
medium volume 
3000 
Add 750 to mix 
(divided 4) 
3000 
Add 750 to mix 
(divided 4) 
3000 
Add 750 to mix 
(divided 4) 
3000 
Add 750 to mix 
(divided 4) 
 
Table 4. The calculation for each volume used in the treatment 
 
The diluted Ubc9 siRNA, diluted scrambled siRNA, 0.5xand 0.2x Lipofectamine reagent 
were prepared and left in the culture hood. Meanwhile, the cells were checked at 60-70% 
confluent. The media in all the flasks was aspirated off. Initially, 3.375 ml fresh media was 
added to each flask. The diluted Ubc9 siRNA or the scrambled siRNA was mixed with the 
diluted Lipofectamine quickly. Each Ubc9 siRNA / scrambled siRNA mixture was set as 24hr 
or 48hr, i.e. 0.5x Lipofectamine 24hr vs. 48hr or 0.2x Lipofectamine 24hr vs. 48hr. 750 µl 
siRNA or Lipofectamine was added in each eppendorf tube and all the mixed tubes were 
incubated for 5 minutes in the hood. 1.125 ml of the prepared mixed diluted 
siRNA/scrambled siRNA + the diluted Lipofectamine (0.5x or 0.2x) was added to each 
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labelled T25 flask. In the negative control flasks, 1.125 ml of the OPTI-MEM media was 
added to each flask. One of the flasks was set as Lipofectamine (LIPO) alone negative 
control. After this, whole cell lysates were made, which were ready for western blotting. 
 
For the siRNA treatment in 6-well plate, the calculations were stated in Table 5: 
20 µM siRNA stock Diluted siRNA/scrambled 
[0.2 µM] 
Diluted Lipofectamine 
reagent 0.5x 
Diluted Lipofectamine 
reagent 0.2x 
Volume 1.5 x 2 = 3 4.5 x 2 = 9 1.8 x 2 = 3.6 
OPTI-MEM medium 297 291 296.4 
 
Table 5. The amount of siRNA or the Lipofectamine added in each preparation in 6-well plate. Total 
diluted volume=600 µl. 3 µl siRNA in 600µl: 1:200 dilution = [0.1 µM]; from 0.1 µM: 100nM  25 nM: 
1:4 dilution 
 
In Table 5, 3 µl (10 µM) siRNA was used according to the company’s online protocol for 6-
well plates. 20 µM stock siRNA was prepared previously. 1.5 µl was used. Practically, 
doubled amount was taken (x2, Table 5); similarly for the OPTI-MEM medium as doubled 
amount of 150 µl was taken. 9 µl of Lipofectamine was taken in the 6-well plate as 1x 
concentration. For doubled amount, 9 µl for 0.5x Lipofectamine or 3.6 µl for 0.2x 
Lipofectamine was used.  
 
The MDA-MB-231 cells were grown on coated coverslips in a 6-well plate overnight. The 
cells were checked for confluence between 60-70% confluent prior to treatment. Once 
prepared, the diluted siRNA and Lipofectamine mixtures were incubated for 5 minutes. 2 ml 
total volume was added to each well. For the final 25 nM diluted siRNA concentration, 0.5 ml 
mixed total siRNA [100 nM] was added with 1.5 ml fresh medium [25 nM]. After 48hr 
treatment, the cells were immuno-fixed with the talin-1 antibody. 
 
For the IHC, cell migration and the western blotting experiments in the MDA-MB-231 cells, 
the siRNA mixture concentrations were adjusted as 1x, 0.5x or 0.2x, finally, 0.2x LIPO was 
used to prevent off-targeted effects of the siRNA. 
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2.13 Quantitative Data Analysis: Image J 
Image J (1.48v) was used to count the time period of focal adhesion turnover (second). In 
the 2s, 8s or the 10s timelapse movies, each frame selected with Image J represented one 
2s, 8s or 10s interval. In each frame, several focal adhesions were followed through the time 
period of the movie. The time was noted for one focal adhesion to appear and disappear, i.e. 
the visualization of the timelapse movie with the ‘appearing second’ frame and ‘disappearing 
second’ frame was based on the FA turnover lifetime. This was done for all the movies to 
calculate the mean turnover time of a focal adhesion, i.e. GFP-talin, GFP-FAK or GFP-
vinculin. 
 
Image J was used to calculate the mean area and size of a focal adhesion in these 
timelapse movies. Each image threshold was adjusted first from the ‘image’ button. The 
upper and lower bar values for the threshold measure were noted and adapted for each 
image. This was to ensure only focal adhesion ‘dots’ were selected with a red colour 
background (within the threshold tail). The image would be black and white once the settings 
were made. All the FAs ‘dots’ would be made as areas of ‘white colour’. The image was 
made ‘binary’ in the ‘process’ button. This would reverse the FAs colour to ‘black’ and the 
background to ‘white’. The image was selected from the ‘process’ with ‘binary’ to make it 
‘watershed’, where the ‘black’ colour of FAs area would be drawn boundaries according to 
the ‘original’ timelapse image. Then the image was ready to analyse ‘particles’ from the 
‘analyze’ button. The size of the particle was set at 20µm – Infinity (pixel units ticked) for the 
image. Each ‘particle’ was counted as ‘ellipses’ shape. The FAs would be processed as 
‘ellipse shaped’ only in the image. The mean number (count) and average size (µm2) were 
displayed as ‘Summary’ results.  
 
Image J was used to measure the mean number or size in the IHC z-stack images. The z-
stack image was moved to the level until all the FAs appeared. The image was made 8-bit. 
The image was adjusted with the ‘image’ threshold button until only the FAs were seen with 
the background colour set as ‘red’. Then the changes made were ‘applied’. The background 
colour changed to black. The image was made ‘binary’ from the ‘process’ button and the 
background changed to ‘white’ leaving the ‘FAs’ set as ‘black. In this step, all the FAs could 
be measured as a mean total number or mean size. However, in the later IHC experiments, 
most of the experiments were measured as each 1 single cell manually selected around the 
cell boundary and the mean FAs number or size were calculated according to ‘per cell’. The 
measurement was chosen from the ‘analyse’ ‘particles’. The pixel unit was ticked and the 
circularity was set as 0.00-1.00. The FAs shape was set as ‘ellipses’.  
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Image J was used to analyse the speed and the directionality of cell migration using the 
plugins with the MTrackJ selected. Up to 300 cells were tracked in the non-treated and the 
treated wells. For 1 new cell movement, the tracking orbit of the cell would be noted as a 
‘new colour’ and once the tracking was finished, each tracking ‘colour’ would be saved. The 
results were included as the total length of the cell (µm), the distance for a cell to move from 
the previous point (D2P) and the D2S (distance to start) which were recorded. The equation 
was used as: 
 
Speed = Total cumulative length a cell migrated (to pixel) / µm 
                Total time (hr) 
 
Directionality = D2S 
                        Total cumulative cell migration length  
 
Image J was also used to measure the gel band area from western blotting experiments. 
The gel image was selected using ‘analyse’ ‘gels’. The image was made 32-bit type and a 
rectangle box was used to draw around the bands of interests. This would give a number ‘1’ 
in the rectangle box. Then the gels were ‘plotted lanes’ from the rectangle box drawn. ‘A 
straight line’ button was selected to draw the vertical line on each band ‘peak’ generated 
down at where the peak tail ended, separating between each band ‘peak’. A ‘wand tracking 
tool’ was used to select on the separated band ‘peak’; each peak area underneath selected 
would give the band area in the summary table. These data were stored in Excel and each 
FAs band area i.e. talin was calculated against GAPDH band area as a ratio.  
 
2.14 Statistics 
Excel has been used to store the ‘summary’ data sheets from Image J. Graphpad prism has 
been used to obtain the graphs and the data was presented as mean ± SEM. One-way 
ANOVA with a post Tukey test or two-tailed unpaired student’s t-test have been performed 
for any data significant differences (p< 0.05).  
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Chapter 3 - SUMOylation Plays an Important Role in the Dynamics 
and Turnover Rate of Focal Adhesions and Cell Migration 
 
3. 1 Introduction and Hypothesis 
SUMOylation has been extensively studied in nuclear functions including nuclear body 
organization, transcriptional regulation, pre-mRNA splicing, chromatin remodelling, cell cycle 
control, genome maintenance stability etc, but much less is known about its roles outside of 
the nucleus (Hendriks and Vertegaal, 2016).  
 
Four distinct ways of membrane extensions at the leading edge have been elucidated in cell 
migration namely as lamellipodia and filopodia, these are involved with the actin 
polymerization directly pushing the plasma membrane forward; invadopodia, the actin 
polymerization couples with the ECM-degrading metalloproteases to facilitate cell migration 
through a clear path; and membrane blebs, these are involved with the actomyosin 
contractility of the membrane and the reversible detachment of the membrane from the 
cortical actin cytoskeleton (Ridley, 2011). The highly dynamic lamellipodia has been 
integrated with a second co-localized structure behind, known as the lamella, where it is 
coupled with actomyosin contraction and substrate adhesion contributing to protrusion and 
cell migration (Ponti et al., 2004). The lamellipodia and lamella are very distinct: the 
lamellipodia has high concentration of Arp 2/3 and ADF / cofilin whereas the lamella has a 
high levels of myosin II and tropomyosin (Ponti et al., 2004). Collective cell movement 
requires adhesive cell-cell contacts, front-rear asymmetry with ruffling / lamellipodial 
structure at the cell leading edge and the trailing edge of the cell (Hegerfeldt et al., 2002). 
Molecular mechanisms controlling collective cell migration and mesenchymal migration 
involve the cell-substrate interactions, cell-cell interactions, matrix-degrading enzymes 
(matrix metalloproteinases and serine proteases), β1 integrin-mediated adhesion dynamics, 
the structure of the actin cytoskeleton producing tracking forces, cell-cell adhesion molecules 
such as cadherin etc and signalling towards the cytoskeleton (Rho GTPases) (Friedl et al., 
2004, Friedl, 2004). As previously mentioned, the EMT type of cell migration represents an 
important development of cell movement in tumour invasiveness and metastasis (Kalluri and 
Weinberg, 2009). In most types of mesenchymal and collective cell migration, integrin β1/β3-
mediated adhesions are involved in focal contacts, e.g. MDA-MB-231 breast cancer cells are 
spindle-shaped cells which use integrins and proteases for adhesion and matrix remodelling, 
respectively (Friedl, 2004). In most studies, 2D glass coverslip, 2D fibronectin or gelatin 
coated surfaces or 3D collagen matrix lattice have been widely used to study cell migration 
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and these techniques are used for the determination of focal adhesions (FAs) number and 
size in cell migration.  
 
 
 
 
 
 
 
 
 
Figure 13. Showing the 2D glass coverslip in a 6-well plate and 2.5D collagen ECM environment set 
up in a glass bottom ibidi dish. The cells were either placed on top of the glass coverslip or placed at 
the edge of the collagen or on top (red colour) for them to grow, which has been used in this study to 
determine the FA dynamics 
 
Figure 13 shows the 2D glass coverslip as the standard method used to detect FA dynamics 
in cells which have been previously grown on coverslips. The FA expression in these cells 
plated on coated glass coverslips is different to the cells grown on 2.5D collagen surface. 
The red ring of collagen has been plated in the centre of a glass bottom dish. The cells were 
plated and grown either on the glass surface, lined up on the interface of the collagen or on 
the top surface of the collagen. SUMOylation inhibitors have been used to treat the cells 
grown in these two environments in order to investigate the effects of the regulatory role of 
SUMOylation on the FA dynamics and cancer cell migration.  
 
In the two cell lines used, the MDA-MB-231 cell line expresses high level of integrin subunits 
α2, α3, αv, β1, α5β1 and αvβ3 (Mierke et al., 2011, Morini et al., 2000, Taherian et al., 2011) 
and the osteosarcoma U2OS cell line expresses β1 and αvβ3, which are directly correlated 
with the metastatic potential of osteosarcoma (Nguyen et al., 2016, Levinson et al., 2002). 
Integrins are α/β heterodimeric transmembrane glycoprotein receptors that respond to FA 
assembly and ECM components signalling i.e. laminin, vitronectin, fibrinogen, fibronectin 
(α5β1) and collagen I (Pankov et al., 2000, Petit and Thiery, 2000). There are three major 
groups of proteins which associate with the β integrin cytoplasmic domains: the proteins 
involved in FA assembly are talin, vinculin, α-actinin, filamin etc, which interact with the 
intracellular domains of integrin β1 and β3 and participate in FA assembly (Martel et al., 
2000, Petit and Thiery, 2000, Brakebusch and Fässler, 2003). The scaffolding adaptors e.g. 
kindlin, paxillin and catalytic adaptors e.g. Src, ERK, FAK are also regulatory proteins which 
associate with the integrin β cytoplasmic tails (Legate and Fässler, 2009). Of these, proteins 
involved in integrin-FA assembly such as the catalytic adaptor, FAK can be SUMOylated and 
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the role of SUMOylation in the dynamics and turnover rate of talin, vinculin and FAK is 
investigated, which are important in cancer cell migration and metastasis.  
 
Hypothesis 
Focal adhesion proteins including FAK, talin and vinculin have been the main focus in this 
study. FAK has been shown to be SUMOylated; this has led to the study of SUMOylation of 
other FA proteins. Therefore, talin, vinculin and FAK containing FAs have been studied. The 
hypothesis of this study was that SUMOylation plays a critical role in cancer cell migration. 
Focal adhesions are known to facilitate cancer cell migration.  
 
In this study, an invasive and metastatic basal-like ER negative breast cancer cell line 
(carcinoma) MDA-MB-231 was used. The typical MDA-MB-231 cell consists of a lamellipodia 
structure at its leading edge and is known to form focal adhesions. In this study, this cell line 
was used initially to study their FA dynamics and the effects of SUMOylation on the FAs in 
cell migration.  
 
U2OS is a human osteosarcoma cell line, which was used to determine and confirm the 
effects of the inhibition of SUMOylated FAs in the MDA-MB-231 cells, since the quantitative 
proteome of this U2OS cell line was studied and the data on the SUMOylation-related 
proteins were previously shown (Beck et al., 2011b).  
 
Various inhibitors including GA, gossypetin, 2-D08 and the Ubc9 siRNA have been used in 
MDA-MB-231 cells and U2OS cells to study the effects of inhibition of SUMOylation on the 
dynamic activities of FAs (i.e. FA number, size and turnover) as altered FA dynamics 
resulting from the inhibition of SUMOylation could have a big impact on cell migration. 
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3. 2 Blocking SUMOylation with Ginkgolic Acid Leads to Increased Number of Talin 
Containing FAs 
MDA-MB-231 cells were grown on 0.2% gelatin-coated glass coverslips overnight and the 
cells were treated with 100µM ginkgolic acid at different time intervals. Talin-1 antibody was 
used in the immunostaining experiments for visualizing the talin containing FAs. The mean 
talin containing FAs number or size were quantified using Image J. One-way ANOVA with 
post-hoc Tukey test was performed to analyse the differences between the untreated control 
and GA treatment at 15, 30 or 60 minutes. 
 
In Figure 14, the cells expressed talin-containing FAs in the representative untreated control 
panel vs. GA 100µM at 15, 30 or 60 minutes panel. The effects of 100µM GA on the mean 
talin containing FAs number or size were summarised in Figure 15. 
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Figure 14.  
Immunostaining of talin 
containing FAs in MDA-
MB-231 cells for 
untreated cells in the 
control vs. 100µM GA 
treatment at 15, 30 or 
60 minutes (n=3, 
representative images 
of the talin containing 
FAs in the control vs. 
GA treated samples. In 
each control vs. GA 
treated sample, the red 
arrow pointing a single 
cell was zoomed in and 
presented on the right 
image showing the 
expression of talin 
containing FAs in the 
cell. Left images scale 
bar: 20 µm (right 
images: zoomed in, 
Plan Apo λ 100x Oil 
Lens with 0.2µm/pixel) 
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Talin n=3 
Mean ±  SE 
Number 
Mean ± SE 
Size µm
2
 
Number of cells 
counted 
Control 
218.9 ± 21.1 1.28 ± 0.065 277 
GA 15 mins 
442.6 ± 46.0 1.16 ± 0.110 178 
GA 30 mins 
333.2 ± 39.4 1.46 ± 0.171 201 
GA 60 mins 
514.0 ± 66.7 1.09 ± 0.113 251 
 
Figure 15. The mean talin containing FAs number or size measurements in MDA-MB-231 cells 
analysed from the immunostaining images as a total number of 3 combined experiments for the 
untreated cells in the control vs. 100µM GA treatment at 15, 30 or 60 minutes (data was presented as 
mean ± SEM, p<0.0001***, n=3, individual replicates) 
 
In Figure 15, the number of the talin containing FAs was counted. The mean total talin 
containing FAs number was significantly increased from 219 ± 21 for the untreated cells to 
443 ± 46 for the 100µM GA 15 minutes treated cells (**).  Compared with the control, GA 
100µM at 60 minutes treatment significantly increased the mean total talin containing FAs 
number from 219 ± 21 to 514 ± 67 (p<0.0001 ***).  
 
GA 100µM treatment at 15, 30 or 60 minutes did not cause any effects in the mean talin 
containing FAs size compared with the untreated control in the cells.  
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3. 3 Inhibition of SUMOylation with GA in MDA-MB-231 Cells Grown on the Top of 
2mg/ml Collagen Causes Increased Number, Size and Turnover of Focal Adhesions 
The 2.5D ECM model for studying the turnover of FAs was set up using the 2mg/ml rat-tail 
collagen I, where MDA-MB-231 cells were seeded around the set patch of the collagen rings 
and grown on the top of the collagen or at the collagen interphase overnight. The seeded 
cells were previously transfected with GFP-FA plasmids, including GFP-talin, GFP-vinculin 
or GFP-FAK for 8 hours before seeding. These cells were grown in the 2.5D ECM 
environment and then treated with 100µM GA for 2 hours. High magnification confocal live-
cell imaging timelapse movies were then taken for 5 or 10 minutes period with intervals of 
every 2s, 8s or 10s; some frame images were selected shortly from a 10s-interval/5 minutes 
FAs turning over timelapse movie and shown in Figure 16. This was to illustrate the fast 
dynamic turning over of the talin containing FAs. This model was used to study the effects of 
100µM GA treatment after 2hrs on the FA number, size or turnover time.  
 
Various time interval timelapse movies were conducted as 2s, 8s or 10s-interval movies; the 
turnover time of each FA was analyzed manually. The mean turnover time of each GFP-FA 
type was analysed by combining a total number of 5 experiments in the GFP-talin turnover 
experiments, 6 for the GFP-FAK turnover experiments or 4 for the GFP-vinculin turnover 
experiments. The turnover time unit was represented in second.  
 
The mean FA number or size was measured using the Image J particles function and an 
unpaired student’s t-test was conducted to analyse the differences before and after GA 
treatment in the mean number, size and turnover time of the talin, FAK or vinculin containing 
FAs.  
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Figure 16. These images were taken from a 5-minute timelapse movie selectively and made black 
and white by Image J. GFP-talin plasmid transfection in the MDA-MB-231 cells in the untreated 
control cell showing the dynamic turnover of the talin containing FAs in a ‘appearing’ and 
disappearing’ fashion during a live-cell imaging timelapse experiment. The three red arrows in the first 
image showing: the cells were seeded on the top of the collagen mesh; the talin containing FAs in this 
one particular cell were turning over in seconds: the blue arrow in 10-20s images: the duration 
turnover time of this one talin containing FA was turning over in 10s, where it was appearing at 0s, 
continuing to be present for 10s and disappearing at 20s, indicating that the turnover time for this 
particular talin containing FA was 10s; the green arrow in the 1 min:50s image: this one talin 
containing FA just appeared at 110s, indicating that it only appeared at this particular time and new 
talin containing FA formation was continuously taking place; the purple arrow from 50s to 1 min:30s: 
these talin containing FAs seemed to split and fuse joining closer to each other throughout this time 
period (scale bar = 10µm). 
 
 
 
0:0 0:10 0:20 
0:50 0:60 1:10 
1:20 1:30 1:50 
0:0 
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In Figure 16, in the first panel, one talin containing FA appeared at 10s and disappeared at 
20s (blue arrow) indicating the duration turning over time of this one particular talin 
containing FA was 10s. Some other talin containing FAs appeared at different time frames 
e.g. in the last image at 1 min: 50s, this particular talin containing FA appeared at the cell 
front edge pointing upwards. Talin containing FAs may also split or fuse closer together at 
different time frames during the timelapse experiment. In this way, this model was capable of 
visualizing dynamic FAs expressed by the GFP FA plasmids during the collagen set-up. The 
MDA-MB-231 cells were then treated with 100µM GA for 2 hours in this 2.5D ECM 
environment. 
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3. 3. 1. GA Treatment Increases the Mean Talin Containing FAs Number, Size and 
Turnover Time  
The mean number, size and turnover time of talin containing FAs was measured using 
Image J.  Two tailed unpaired t-tests showed significant differences before and after GA 
100µM 2h treatment; where the mean number of talin containing FAs was increased 
significantly, the mean size of talin containing FAs was increased significantly and the mean 
turnover time of talin containing FAs was increased significantly. 
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Figure 17. Showing the mean number, size and turnover time of talin containing FAs measurements 
between the control untreated MDA-MB-231 cells and the 100µM GA 2hrs treated cells from the GFP-
talin transfection live-cell imaging timelapse movies (n=5, individual replicates, data was presented as 
mean ± SEM, p<0.0001***).  
 
In Figure 17, in the GFP-talin turnover assay, the mean number, size or turnover time of the 
talin containing FAs was increased significantly after 100µM GA 2 hours treatment 
compared with the control. The mean talin containing FAs number was increased 
significantly from 62 ± 1 to 102 ± 2 (p<0.0001 ***); the mean talin containing FAs size was 
increased significantly from 0.835 ± 0.009 µm2 to 0.944 ± 0.027 µm2 (p<0.0001 ***); also, the 
 
Talin (n=5, p<0.0001***) 
Mean ± SE 
FA Number 
Mean ± SE 
Size (µm
2
) 
Mean ± SE 
Turnover 
time (s) 
Adhesion 
number 
counted 
Talin: Control  62.1 ± 1.41 0.835 ± 0.009 34.3 ± 2.29 280 
Talin:  GA 100µM 2h 102 ± 2.11 0.944 ± 0.027 59.5 ± 4.24 182 
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mean talin containing FAs turnover time was increased significantly from 34.3 ± 2.29 s to 
59.5 ± 4.24 s (p<0.0001 ***). 
 
3. 3. 2. GA Treatment Increases the Mean FAK Containing FAs Number, Size and 
Turnover Time  
The mean number, size or turnover time of FAK containing FAs was measured using Image 
J.  Two tailed unpaired t-tests showed significant differences before and after GA 100µM 2h 
treatment; where the mean number of FAK containing FAs was increased significantly, the 
mean size of FAK containing FAs was increased significantly and the mean turnover time of 
FAK containing FAs was increased significantly. 
C
on
tr
ol
 
M
 2
h

G
A
 1
00
0
10
20
30
40
50
60
70
80
90
100
110
120
***
F
A
K
 C
o
n
ta
in
in
g
 F
A
s
: 
M
e
a
n
 N
u
m
b
e
r
C
on
tr
ol
 
M
 2
h

G
A
 1
00
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
***
F
A
K
 C
o
n
ta
in
in
g
 F
A
s
: 
A
v
e
ra
g
e
 S
iz
e
 (

m
2
)
C
on
tr
ol
M
 2
h

G
A
 1
00
0
10
20
30
40
50
60
70
***
F
A
K
 C
o
n
ta
in
in
g
 F
A
s
: 
T
u
rn
o
v
e
r 
T
im
e
 (
S
)
 
 
 
 
 
 
 
 
 
Figure 18. Showing the mean number, size and turnover of FAK containing FAs measurements 
between the control untreated MDA-MB231 cells and the 100µM GA 2hrs treated cells from the GFP-
FAK transfection live-cell imaging timelapse movies (n=6, individual replicates, data was presented as 
mean ± SEM, p<0.0001***).  
 
 
FAK (n=6, p<0.0001***) 
Mean ± SE 
FA Number 
Mean ± SE 
Size (µm
2
) 
Mean ± SE 
Turnover 
time (s) 
Adhesion 
number 
counted 
FAK: Control 52.4 ± 1.29 0.833 ± 0.012 31.5 ± 1.70 342 
FAK: GA 100µM 2h 91.8 ± 2.31 0.920 ± 0.014 50.0 ± 4.03 163 
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In Figure 18, in the GFP-FAK turnover assay, the mean number, size or turnover time of the 
FAK containing FAs was increased significantly after 100µM GA 2 hours treatment 
compared with the control. The mean FAK containing FAs number was increased 
significantly from 52 ± 1 to 92 ± 2 (p<0.0001 ***); the mean FAK containing FAs size was 
increased significantly from 0.833 ± 0.012 µm2 to 0.920 ± 0.014 µm2 (p<0.0001 ***); also, the 
mean FAK containing FAs turnover time was increased significantly from 31.5 ± 1.70 s to 
50.0 ± 4.03 s (p<0.0001 ***).  
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3. 3. 3. GA Treatment Increases the Mean Vinculin Containing FAs Number, Size and 
Turnover Time  
The mean number, size or turnover time of vinculin containing FAs was measured using 
Image J.  Two tailed unpaired t-tests revealed significant differences before and after GA 
100µM 2h treatment; where the mean number of vinculin containing FAs was increased 
significantly, the mean size of vinculin containing FAs was increased significantly and the 
mean turnover time of vinculin containing FAs was increased significantly. 
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Figure 19. Showing the mean number, size and turnover of vinculin containing FAs measurements 
between the control untreated MDA-MB-231 cells and the 100µM GA 2hrs treated cells from the GFP-
vinculin transfection live-cell imaging timelapse movies (n=4, individual replicates, data was presented 
as mean ± SEM, p< 0.0001***, vinculin turnover time p=0.0014**).  
 
 
 
Vinculin (n=4, p<0.0001***, 
turnover time p=0.0014) 
Mean ± SE 
FA Number 
Mean ± SE 
Size µm
2
 
Mean ± SE 
Turnover time (s) 
Adhesion number 
counted 
Vinculin: Control 44.0 ± 1.38 0.808 ± 0.011 27.4 ± 3.00 128 
Vinculin: GA 100µM 2h 84.7 ± 1.62 0.982 ± 0.014 47.2 ± 6.00 83 
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In Figure 19, in the GFP-vinculin turnover assay, the mean number, size or turnover time of 
the vinculin containing FAs was increased significantly after 100µM GA 2 hours treatment 
compared with the control. The mean vinculin containing FAs number was increased 
significantly from 44 ± 1 to 85 ± 2 (p<0.0001 ***); the mean vinculin containing FAs size was 
increased significantly from 0.808 ± 0.011 µm2 to 0.982 ± 0.014 µm2 (p<0.0001 ***); also, the 
mean vinculin containing FAs turnover time was increased significantly from 27.4 ± 3.00 s to 
47.2 ± 6.00 s ( p=0.0014 **).  
 
The mean number, size or turnover time were increased significantly in all the three GFP-
tagged FAs after 100µM GA 2hrs treatment compared to the control, which could predict 
slower cell migration. To determine if inhibiting SUMOylation could lead to changes in cell 
migration speed and total cell movement length, 24 hours timelapse experiment was 
conducted where single cell movement was tracked using MTrack J in Image J. 
 
3. 4 GA at 25, 50 or 100µM Leads to Decreased Speed of Cell Migration and Reduced 
Total Cell Migration Length 
To determine the effects of GA on cell migration, phase-contrast timelapse was performed. 
The MDA-MB-231 cells were seeded in 2mg/ml rat-tail collagen I and grown overnight prior 
to GA treatments. The next day, at time point 0, the cells were treated with GA at 25, 50 or 
100µM in the triplicate wells/12-well plate for each treatment. The cells in the control wells 
were treated with 0.1% DMSO in DMEM media. The cells were then followed for a period of 
18-24hrs on the timelapse microscope with 10x lens used for cell migration.  
 
The tracking of each cell was shown in Figure 20. Each cell was denoted with a coloured 
number and manual tracking starts from time 0 until the last time interval of the movie 
finishes. The speed of cell migration, total length of each cell travelled and the directionality 
could be analysed using MTrackJ.  
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Figure 20. Manual tracking of each cell in a control experiment using MDA-MB-231 cells, 
representative images were shown. Single cell was denoted with a coloured number and the tracking 
was finished till the movie finished. The path of each cell travelled from start to end and the total travel 
distance could be recorded using MTrackJ.  
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Figure 21. Showing the mean speed of cell migration, the mean total cell migration length and the 
mean directionality measurements from the timelapse experiments; GA at 25, 50 or 100µM after 24hr 
period reduced the mean speed of cell migration and the mean total migration distance significantly 
compared with the control in the MDA-MB-231 cells; GA at 100µM only increased the directionality in 
the MDA-MB-231 cells (n=3, individual replicates, data was presented as mean ± SEM, p<0.0001***). 
24h, n=3 
Mean ± SE 
Speed (µm/hr
-1
) 
Mean ± SE 
Total Length 
(µm) 
Mean ± SE 
Directionality 
Cell tracking 
number 
Control 20.1 ± 0.341 421.7 ± 9.14 0.219 ± 0.008 361 
GA 25µM 14.6 ± 0.330 325.5 ± 8.50 0.227 ± 0.010 255 
GA 50µM 13.7 ± 0.337 305.2 ± 9.10 0.210 ± 0.010 248 
GA 100µM 12.4 ± 0.306 263.7 ± 8.06 0.286 ± 0.012 273 
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In the 24 hours timelapse experiment, single cells were tracked shown in Figure 20. Each 
time interval was 20 minutes for a period of 24 hours. The speed of cell migration was 
represented as the total cell migration length divided by the time of experiment, shown in µm 
/ hr-1. The directionality was represented as the ‘distance to start (D2S)’ divided by the total 
cell migration length (D2S / µm). The results were summarised as a total number of 3 
combined experiments in Figure 21.  
 
In Figure 21, after 24hrs cell tracking, compared with the control, the mean speed of cell 
migration was decreased significantly after 25µM GA treatment from 20.1 ± 0.341 µm/hr-1 to 
14.6 ± 0.330 µm/hr-1 (p<0.0001 ***). Similarly, the mean speed of cell migration was 
decreased significantly after 50µM GA treatment from 20.1 ± 0.341 µm/hr-1 to 13.7 ± 0.337 
µm/hr-1 (p<0.0001 ***); the mean speed of cell migration was decreased significantly after 
100µM GA treatment from 20.1 ± 0.341 µm/hr-1 to 12.4 ± 0.306 µm/hr-1 (p<0.0001 ***).  
 
Similarly, compared with the control, the mean total cell migration length was decreased 
significantly after 25µM GA treatment from 421.7 ± 9.14 µm to 325.5 ± 8.50 µm (p<0.0001 
***); the mean total cell migration distance was decreased significantly after 50 µM GA 
treatment from 421.7 ± 9.14 µm to 305.2 ± 9.10 µm (p<0.0001 ***); the mean total cell 
migration length was decreased significantly after 100 µM GA treatment from 421.7 ± 9.14 
µm to 263.7 ± 8.06 µm (p<0.0001 ***).  
 
The mean directionality was only increased significantly after 100µM GA treatment from 
0.219 ± 0.008 to 0.286 ± 0.012 (p<0.0001 ***). GA at 25µM or 50µM was not significant at 
increasing the mean cell movement directionality (ns). However, even in the control, 0.219 
indicated random movement of the cells as the value was much smaller than 1; the more the 
value is close to 1 the cells would move along in a more straight and directed tracking line. 
Although GA at 100µM caused a little bit more directional than random cell migration, 0.286 
was not very close to 1, therefore directionality of the cells was not affected. 
 
3. 5 Ubc9 siRNA Knockdown Reduces the Ubc9 Expression  
MDA-MB-231 cells were transfected with the Ubc9 siRNA or the scrambled siRNA (prepared 
in 0.2x diluted Lipofectamine® RNAiMAX reagent, 25nM) for 48 hours. The results were 
summarised in Figure 21 as a total number of 4 combined experiments. In Figure 22, 
compared with the negative control, after 48 hours, the Ubc9 E2 enzyme expression was 
decreased significantly from 99.2 ± 5.51% (Ubc9/GAPDH ratio *100%) to 49.6 ± 4.19% 
(p<0.0001 ***); also, compared with the scrambled siRNA, the Ubc9 expression was 
decreased significantly from 101.0 ± 4.65% to 49.6 ± 4.19% (p<0.0001 ***); whereas the 
77 
scrambled siRNA control working as a control did not cause the knockdown effect in the 
Ubc9 expression. Therefore, Ubc9 siRNA transfection at this transfection concentration was 
used in the IHC and western blotting experiments to determine the mean number, size and 
the half-life of the FAs. GAPDH was not found to have any amino acid motifs that could be 
SUMOylated, therefore, it was chosen as the control for the Ubc9 siRNA experiment.  
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Figure 22. Ubc9 siRNA and scrambled siRNA treatments for 48hrs (25nM final concentration); Ubc9 
siRNA treatment in the MDA-MB-231 cells caused knockdown of Ubc9 E2 enzyme, the bar chart was 
presented as Ubc9 vs. GAPDH ratio (n=4, data was presented as mean ± SEM, p<0.0001***). 
 
The concentrations of the Lipofectamine® RNAiMAX reagent used to mix with the Ubc9 
siRNA or the scrambled siRNA was ranged from 0.2x, 0.5x to 1x (diluted siRNA transfection 
reagent Lipofectamine® RNAiMAX used, see method: 2.12). The diluted 0.2x concentration 
of Lipofectamine® RNAiMAX was used, indicating that mixing 0.2x Lipofectamine® RNAiMAX 
reagent with the Ubc9 siRNA or the scrambled siRNA for 48 hour transfection represented a 
significant knockdown in the Ubc9 E2 enzyme, leaving the scrambled siRNA control 
unaffected.   
 
 
 
 
 
siRNA  Scrambled ctrl  Negative ctrl 
GAPDH-37kDa 
Ubc9-18kDa 
WB 
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3. 6 Ubc9 siRNA 48hrs Treatment Leads to Increased FA Number and Size Similarly to 
the GA 100µM Treatment; However, Ubc9 siRNA Treatment Also Causes Cell 
Membrane Ruffling 
MDA-MB-231 cells were treated with the 0.2x diluted Lipo mixture with Ubc9 siRNA, 
scrambled siRNA or negative control for 48 hours. The talin containing FAs number or size 
were measured using Image J. The effects of Ubc9 siRNA 48h treatment in the cells caused 
membrane ruffling, which were shown in Figure 23. 
 
MDA-MB-231 cells were immunostained with the talin-1 antibody and the selective images 
are shown for the Ubc9 siRNA treated cells expressing talin containing FAs, shown in Figure 
23. Image A was presented as one of the z-stack frame images showing at the depth where 
talin containing FAs could be observed in the z-stack; by adjusting the focal plane, the cell 
membrane structure was shown in image B. In the Ubc9 siRNA treated cells, it seemed that 
Ubc9 siRNA caused small membrane ruffling with the red arrows indicating the plasma 
membrane area in Fig 23 B.  
 
Figure 23. Showing the observation changes of the cell morphology in the Ubc9 siRNA treated MDA-
MB-231 cells causing Ubc9 knockdown effects. The cells were stained with the anti talin-1 antibody. 
Images A+B represented the same image at different z-stack plane: A showed the expression of talin 
at the bottom of the cells; B showed the confocal plane near to the cell membrane; the red arrows 
indicated the cell membrane ruffling after 48 hours of Ubc9 siRNA treatment (scale bar = 20 µm) 
 
 
After 25nM Ubc9 siRNA or scrambled siRNA treatment for 48 hours, the mean FA number or 
size was measured and the data was shown in Figure 24.  
Ubc9 siRNA: cell structure 
B 
Ubc9 siRNA: Talin 
A 
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Figure 24. Showing that the mean talin containing FAs number or size measurements after 25nM 
Ubc9 siRNA or scrambled siRNA 48hrs treatments in the MDA-MB-231 cells (n=4, individual 
replicates, data was presented as mean ± SEM, p<0.0001***) 
 
Each single cell was selected manually per image and the mean talin containing FAs 
number or size was measured using Image J: counting particles function and was 
represented as mean talin containing FAs number / per cell in Figure 24. 
 
Compared with the untreated control, the mean talin containing FA number increased 
significantly after 25nM Ubc9 siRNA treatment from 47 ± 3 to 75 ± 5 (p<0.0001 ***). 
Similarly, compared with the 25nM scrambled siRNA, the mean talin containing FAs number 
was increased significantly after 25nM Ubc9 siRNA 48hrs treatment from 55 ± 4 to 75 ± 5 
(**). Compared with the untreated control, the mean size of talin containing FAs was also 
increased significantly after 25nM Ubc9 siRNA 48hrs treatment from 0.596 ± 0.021 µm2 to 
0.697 ± 0.014 µm2 (p<0.0001 ***).  
 
Talin n=4 Mean ± SE 
Number 
Mean ± SE 
Size µm
2
 
number of cells 
counted 
Negative control 47.1 ± 3.27 0.596 ± 0.021 255 
Scrambled siRNA 55.2 ± 3.99 0.640 ± 0.016 173 
Ubc9 siRNA 74.8 ± 4.59 0.697 ± 0.014 240 
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3. 7 Combining 100µM GA and 25nM Ubc9 siRNA Treatment does not further Increase 
the FAs Number or Size 
The use of GA together with Ubc9 siRNA could increase the mean number or size of the 
talin containing FAs, compared to untreated cells. However, the combinations of GA and 
Ubc9 siRNA did not produce additional increase in the mean number or size of the FAs 
compared to each treatment on its own. MDA-MB-231 cells were treated with 100µM GA 
first for 1 hour (GA was not removed) then treated with 25nM Ubc9 siRNA or 25nM 
scrambled siRNA for 48 hours. The cells were then immunostained with the anti talin-1 
antibody and the mean number or size of the FAs were measured using Image J both in the 
Ubc9 siRNA only samples and in the combination samples.  
 
The results were summarised in Figure 25 as a total number of 4 combined experiments. 
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Figure 25. Ubc9 siRNA alone (25nM) or the combination of GA (100µM) with the Ubc9 siRNA (25nM) 
give significant increases in the mean talin containing FA number or size, though the combination 
gives similar effects compared to the Ubc9 siRNA alone, there is no further increase in the mean talin 
number or size (n=4, individual replicates, data presented as mean ± SEM, p<0.0001***) 
 
In Figure 25, compared with the negative control, the mean talin containing FAs number was 
increased significantly after the combinations of 100µM GA 1h with 25nM Ubc9 siRNA 48hr 
treatment from 47 ± 3 to 76 ± 5 (p<0.0001***); the mean talin containing FAs number was 
increased significantly after 25nM Ubc9 siRNA 48hrs treatment alone from 47 ± 3 to 75 ± 5 
(p<0.0001***). However, the combinations of 100µM GA 1hr with 25nM Ubc9 siRNA 48hrs 
did not cause further increase in the mean talin containing FAs number compared with 25nM 
Ubc9 siRNA 48hrs treatment alone (ns, p=0.83).  
Talin n=4 Mean ± SE 
Number 
Mean ± SE 
Size µm
2
 
Negative control 47.1 ± 3.27 0.596 ± 0.021 
Scrambled siRNA 55.2 ± 3.99 0.659 ± 0.018 
GA 1h + scrambled siRNA 57.5 ± 4.02 0.649 ± 0.019 
Ubc9 siRNA 74.8 ± 4.59 0.697 ± 0.014 
GA 1h + Ubc9 siRNA 76.2 ± 5.05 0.706 ± 0.016 
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The mean talin containing FAs size was increased significantly after the combinations of 
100µM GA 1h with 25nM Ubc9 siRNA 48hr treatment from 0.596 ± 0.021 µm2 to 0.706 ± 
0.016 µm2 (p<0.0001***). The mean talin containing FAs size was increased significantly 
after 25nM Ubc9 siRNA 48hrs treatment alone from 0.596 ± 0.021 µm2 to 0.697 ± 0.014 µm2 
(p<0.0001***). However, the combinations of 100µM GA 1hr and 25nM Ubc9 siRNA 48hrs 
treatment did not cause further increase in the mean talin containing FAs size (ns, p=0.66).  
 
3. 8 Ubc9 siRNA Knockdown Leads to Reduced Speed of Cell Migration for Both 25h 
and 48h Timelapse  
MDA-MB-231 cells were treated with 25nM Ubc9 siRNA or scrambled siRNA for 25 hours 
first and for another 23 hours. The mean speed of cell migration, the mean total cell 
migration length and the mean directionality were measured as a total number of 3 
experiments shown in Figure 26. 
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Figure 26. Showing that the mean speed of cell migration, mean total migration length and mean 
directionality measurements after 25nM Ubc9 siRNA or scrambled siRNA treatments for 25hrs period 
in the MDA-MB-231 cells (n=3, individual replicates, data was presented as mean ± SEM, 
p<0.0001***) 
 
MDA-MB-231 cells were grown in 2mg/ml collagen overnight then treated with 25nM Ubc9 
siRNA and the timelapse experiment was recorded for a period of 25 hours.  
 
In Figure 26, compared with the negative control, the mean speed of cell migration was 
decreased significantly after  25nM Ubc9 siRNA 25hrs treatment from 25.5 ± 0.465 µm/hr-1  
to 18.6 ± 0.297 µm/hr-1 (p<0.0001***). Similarly, compared with the scrambled siRNA, the 
mean speed of cell migration was decreased significantly after 25nM Ubc9 siRNA 25hrs 
treatment from 24.2 ± 0.404 µm/hr-1 to18.6 ± 0.297 µm/hr-1 (p<0.0001***).  
 
25h, n=3 
Mean ± SE 
Speed (µm/hr
-1
) 
Mean ± SE 
Total Length 
(µm) 
Mean ± SE 
Directionality 
Cell tracking 
number 
Negative 
control 
25.5 ±0.465 610.0 ± 13.6 0.158 ± 0.007 289 
Scrambled 
siRNA 
24.2 ± 0.404 591.1 ± 10.2 0.183 ± 0.008 335 
Ubc9 
siRNA 
18.6 ± 0.297 473.7 ± 7.78 0.180 ± 0.007 375 
84 
Compared with the negative control, the mean total cell migration distance was also 
significantly decreased after 25nM Ubc9 siRNA 25hrs treatment from 610.0 ± 13.6 µm to 
473.7 ± 7.78 µm (p<0.0001***); compared with the scrambled siRNA, the mean total cell 
migration distance was significantly decreased after 25nM Ubc9 siRNA 25hrs treatment from 
591.1 ± 10.2 µm to 473.7 ± 7.78 µm (p<0.0001***).  
 
The mean directionality of the cell migration was not significantly affected compared 
between the negative control and the Ubc9 siRNA or the scrambled siRNA and the Ubc9 
siRNA. 
 
The MDA-MB-231 cells were also grown in 2mg/ml collagen then treated with 25nM Ubc9 
siRNA for 24 hours first in the incubator, then at the post-24h time point, the migration of the 
cells were recorded in the timelapse experiment for a 48 hours treatment. The results were 
summarised as a total number of 4 combined experiments in Figure 27.  
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Figure 27. Showing that the mean speed of cell migration, mean total migration length and mean 
directionality measurements after 25nM Ubc9 siRNA or scrambled siRNA treatments for 48hrs period 
in the MDA-MB-231 cells (n=4, individual replicates, data was presented as mean ± SEM, 
p<0.0001***) 
 
In Figure 27, compared with the negative control, the mean speed of cell migration was 
decreased significantly after 25nM Ubc9 siRNA 48hrs treatment from 18.3 ± 0.236 µm/hr-1 to 
14.1 ± 0.189 µm/hr-1(p<0.0001***). Similarly, compared with the scrambled siRNA, the mean 
speed of cell migration was decreased significantly after 25nM Ubc9 siRNA 48hrs treatment 
from 17.2 ± 0.308 µm/hr-1 to 14.1 ± 0.189 µm/hr-1 (p<0.0001***).  
 
48h, n=4 
Mean ± SE 
Speed (µm/hr
-1
) 
Mean ± SE 
Total Length 
(µm) 
Mean ± SE 
Directionality 
Cell tracking 
number 
Negative 
control 
18.3 ± 0.236 390.9 ± 5.46 0.251 ± 0.010 292 
Scrambled 
siRNA 
17.2 ± 0.308 367.3 ± 6.94 0.262 ± 0.010 290 
Ubc9 
siRNA 
14.1 ± 0.189 299.3 ±3.88 0.269 ± 0.008 350 
86 
Compared with the negative control, the mean total cell migration distance of the cells was 
decreased significantly after 25nM Ubc9 siRNA 48hrs treatment from 390.9 ± 5.46 µm to 
299.3 ± 3.88 µm (p<0.0001***). Compared with the scrambled siRNA, the mean total cell 
migration distance of the cells was decreased significantly after 25nM Ubc9 siRNA 48hrs 
treatment from 367.3 ± 6.94 µm to 299.3 ± 3.88 µm (p<0.0001***).  
 
The mean directionality of the cells after 48hrs was not significantly changed between the 
negative control and the Ubc9 siRNA treatment or the scrambled siRNA and the Ubc9 
siRNA treatment. 
 
3. 9 Other SUMOylation Inhibitors Also Cause an Increase in the Mean FAs Number or 
Size 
 
3. 9. 1. GA, Gossypetin or 2-D08 1hour Treatments Cause an Increase in the Mean 
Number or Size of Vinculin Containing FAs 
MDA-MB-231 cells were grown on 0.2% v/v gelatin coated coverslips overnight and then 
treated with GA, Gossypetin or 2-D08 at 100µM for 1 hour. The cells were then 
immunostained with a vinculin antibody and the mean number or the size of vinculin 
containing FAs were measured after each inhibitor treatment. 
 
In Figure 28, the results were summarised as a total number of 4 combined experiments. 
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Figure 28. The mean vinculin containing FAs number or size measurements per cell after 100µM GA, 
Gossypetin or 2-D08 1hr treatment in the MDA-MB-231 cells (n=4, individual replicates, data was 
presented as mean ± SEM, p<0.0001***) 
 
In Figure 28, compared with the control, the mean vinculin containing FAs number was 
increased significantly after 100µM GA 1hr treatment from 34 ± 2 to 61 ± 4 (p<0.0001***) . 
Compared with the control, the mean vinculin containing FAs number was increased 
significantly after 100µM 2-D08 1hr treatment from 34 ± 2 to 43 ± 2 (*). Gossypetin had no 
significant effects in the mean number of the vinculin containing FAs (p=0.21).  
 
100µM GA 1 hour treatment was more effective in increasing the mean vinculin FAs number 
than 100µM 2-D08 1 hour treatment (p<0.0001***). 
 
Vinculin n=4 Mean ± SE 
Number 
Mean ± SE 
Size µm
2
 
Number of cells 
counted 
Control 1hr 33.5 ± 1.78 0.643 ± 0.021 159 
GA 1hr 61.0 ± 4.18 0.866 ± 0.031 118 
Gossypetin 1hr 36.5 ± 1.49 0.766 ± 0.014 230 
2-D08 1hr 43.0 ± 1.96 0.763 ± 0.017 231 
88 
All of the three inhibitors GA, Gossypetin or 2-D08 at 100µM for 1hr treatment increased the 
mean size of the vinculin containing FAs significantly compared with the control. 
 
The mean vinculin containing FAs size was increased significantly after 100µM GA 1hr 
treatment from 0.643 ± 0.021 µm2 to 0.866 ± 0.031 µm2 (p<0.0001***). The mean vinculin 
containing FAs size was increased significantly after 100µM Gossypetin 1hr treatment from 
0.643 ± 0.021 µm2 to 0.766 ± 0.014 µm2 (p<0.0001***).  The mean vinculin containing FAs 
size was increased significantly after 100µM 2-D08 1hr treatment from 0.643 ± 0.021 µm2 to 
0.763 ± 0.017 µm2 (p<0.0001***). 
 
100µM GA 1hr treatment was more effective in increasing the mean vinculin containing FAs 
size than 100µM Gossypetin or 2-D08 at 1hr treatment (**).  
 
3. 9. 2. GA, Gossypetin or 2-D08 1 hour Treatments Cause an Increase in the Mean 
Number or Size of Talin Containing FAs 
MDA-MB-231 cells were grown on 0.2% v/v gelatin coated coverslips overnight and then 
treated with GA, Gossypetin or 2-D08 at 100µM for 1 hour. The cells were then 
immunostained with the anti talin-1 antibody and the mean number or size of the talin 
containing FAs were measured after each inhibitor treatment. The results were summarised 
as a total number of 4 combined experiments in Figure 29. 
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Figure 29. Mean talin containing FAs number or size measurements per cell after 100µM GA, 
Gossypetin or 2-D08 at 1hr treatment in the MDA-MB-231 cells (n=4, individual replicates, data 
presented as mean ± SEM, p<0.0001***) 
 
In Figure 29, compared with the control, the mean talin containing FAs number increased 
significantly after 100µM GA 1hr treatment from 45 ± 3 to 56 ± 3 (*). Gossypetin or 2-D08 at 
1hr treatment did not have any significant effects in the mean talin containing FAs number 
compared with the control.  
 
All of the three inhibitors GA, Gossypetin or 2-D08 at 1hr treatment significantly increased 
the mean talin containing FAs size compared with the control. The mean talin containing FAs 
size was increased significantly after 100µM GA 1hr treatment from 0.439 ± 0.017 µm2 to 
0.636 ±0.015 µm2 (p<0.0001 ***); the mean talin containing FAs size was increased 
significantly after 100µM Gossypetin 1hr treatment from 0.439 ± 0.017 µm2 to 0.531 ± 0.016 
Talin n=4 Mean ± SE 
Number 
Mean ± SE 
Size µm
2
 
Number of cells 
counted 
Control 1hr 45.4 ± 2.60 0.439 ± 0.017 138 
GA 1hr 55.8 ± 2.87 0.636 ± 0.015 226 
Gossypetin 1hr 54.4 ± 2.96 0.531 ± 0.016 169 
2-D08 1hr 52.7 ± 1.87 0.519 ± 0.010 226 
90 
µm2 (p<0.0001 ***); The mean talin containing FAs size was increased significantly after 
100µM 2-D08 1hr treatment from 0.439 ± 0.017 µm2 to 0.519 ± 0.010 µm2 (**).  
 
100µM GA 1hr treatment was more effective in increasing the mean talin containing FAs 
size than the 100µM Gossypetin or 2-D08 1hr treatment (p<0.0001***).  
 
U2OS Cells 
 
3. 9. 3. GA or 2-D08 Treatments Caused an Increase in the Mean Number of Vinculin 
Containing FAs  
U2OS cells were used to determine the mean vinculin containing FA number or size. U2OS 
cells were grown on 0.2% v/v gelatin coated coverslips overnight and then treated with 
100µM GA, Gossypetin or 2-D08 for 15 minutes. The cells were then immunostained with an 
anti-vinculin antibody and the mean number or size of the vinculin containing FAs were 
measured after each inhibitor treatment. The results were summarised as a total number of 
3 combined experiments in Figure 30.  
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Figure 30. Mean vinculin containing FAs number or size measurements per cell after 15 minutes of 
100µM GA, Gossypetin or 2-D08 treatments in U2OS cells (n=3, individual replicates, data presented 
as mean ± SEM, p=0.0008 **) 
 
In Figure 30, compared with the control, the mean vinculin containing FA number was 
increased significantly after 100µM GA 15 minutes treatment from 46 ± 3 to 67 ± 5 
(p=0.0008 **). Compared to the control, 100µM 2-D08 after 15 minutes treatment also 
significantly increased the mean vinculin containing FAs number from 46 ± 3 to 65 ± 4 
(p=0.0008 **). The mean vinculin containing FAs size was not affected.  
 
 
 
 
Vinculin n=3 Mean ± SE 
Number 
Mean ± SE 
Size µm
2
 
Number of cells 
counted 
Control 15 mins 46.1 ± 2.96 0.901 ± 0.038 90 
GA 15 mins 67.4 ± 4.65 0.876 ± 0.027 107 
Gossypetin 15 mins 59.7 ± 3.07 0.927 ± 0.027 109 
2-D08 15 mins 65.4 ± 4.29 1.01 ± 0.028 103 
92 
3. 9. 4. GA or Gossypetin Treatments Caused an Increase in the Mean Number of 
Vinculin Containing FAs; 2-D08 Caused an Increase in the Mean Size of Vinculin 
Containing FAs  
The U2OS cells were grown on 0.2% v/v gelatin coated coverslips overnight and then 
treated with 100µM GA, Gossypetin or 2-D08 for 1 hour. The cells were then immunostained 
with the anti-vinculin antibody and the mean number or size of the vinculin containing FAs 
were measured after each inhibitor treatment. The results were summarised as a total 
number of 3 combined experiments in Figure 31.  
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Figure 31. Mean vinculin containing FAs number or size measurements per cell after 1 hour of 
100µM GA, Gossypetin or 2-D08 treatments in the U2OS cells (n=3, individual replicates, data 
presented as mean ± SEM, p=0.0021 **) 
 
In Figure 31, compared with the control, the mean vinculin containing FA number was 
increased significantly after 100µM GA 1 hour treatment from 67 ± 4 to 88 ± 5 (*).  
Vinculin n=3 Mean ± SE 
Number 
Mean ± SE 
Size µm
2
 
Number of cells 
counted 
Control 1hr 66.7 ± 4.22 0.868 ± 0.027 95 
GA 1hr 87.5 ± 4.68 0.888 ± 0.034 94 
Gossypetin 1hr 91.9 ± 5.08 0.982 ± 0.039 97 
2-D08 1hr 85.4 ± 5.37 1.06 ± 0.052 77 
93 
Compared with the control, 100µM Gossypetin after 1 hour treatment significantly increased 
the mean number of the vinculin containing FAs from 67 ± 4 to 92 ± 5 (p=0.0021 **).  
 
Compared to the untreated cells, 100µM 2-D08 after 1 hour treatment significantly increased 
the mean size of the vinculin containing FAs from 0.868 ± 0.027 µm2 to 1.06 ± 0.052 µm2 
(p=0.0020 **). 
 
3. 9. 5. GA or 2-D08 Treatments Caused an Increase in the Mean Number of Talin 
Containing FAs 
U2OS cells were grown on 0.2% v/v gelatin coated coverslips overnight and then treated 
with 100µM GA, Gossypetin or 2-D08 for 15 minutes. The cells were then immunostained 
with the anti-talin-1 antibody and the mean number or size of the talin containing FAs were 
measured after each inhibitor treatment. The results were summarised as a total number of 
3 combined experiments in Figure 32.  
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Figure 32. Mean talin containing FAs number or size measurements per cell after 15 minutes of 
100µM GA, Gossypetin or 2-D08 treatments in the U2OS cells (n=3, individual replicates, data 
presented as mean ± SEM, p<0.0001***) 
 
In Figure 32, compared with the control, the mean talin containing FA number was increased 
significantly after 100µM GA 15 minutes treatment from 49 ± 3 to 85 ± 6 (p<0.0001***). 
Compared with the control, 100µM 2-D08 after 15 minutes treatment significantly increased 
the mean talin containing FAs number from 49 ± 3 to 70 ± 6 (*). 
 
 
 
 
Talin n=3 Mean ± SE 
Number 
Mean ± SE 
Size µm
2
 
Number of cells 
counted 
Control 15 mins 48.7 ± 3.11 0.648 ± 0.017 92 
GA 15 mins 85.2 ± 6.27 0.674 ± 0.014 71 
Gossypetin 15 mins 61.6 ± 6.14 0.621 ± 0.013 52 
2-D08 15 mins 70.4 ± 5.77 0.596 ± 0.012 61 
95 
3. 9. 6. GA or 2-D08 Treatments Caused an Increase in the Mean Number of Talin 
Containing FAs; 2-D08 Caused an Increase in the Mean Size of Talin Containing FAs  
U2OS cells were grown on 0.2% v/v gelatin coated coverslips overnight and then treated 
with 100µM GA, Gossypetin or 2-D08 for 1 hour. The cells were then immunostained with 
the anti-talin-1 antibody and the mean number or size of the talin containing FAs were 
measured after each inhibitor treatment. The results were summarised as a total number of 
3 combined experiments in Figure 33.  
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Figure 33. Mean talin containing FA number or size measurements per cell after 1 hour of 100µM 
GA, Gossypetin or 2-D08 treatments in the U2OS cells (n=3, individual replicates, data presented as 
mean ± SEM, p=0.0003 ***) 
 
 
 
 
Talin n=3 Mean ± SE 
Number 
Mean ± SE 
Size µm
2
 
Number of cells 
counted 
Control 1hr 51.6 ± 4.75 0.599 ± 0.021 68 
GA 1hr 74.6 ± 4.82 0.602 ± 0.008 91 
Gossypetin 1hr 62.8 ± 3.88 0.587 ± 0.008 65 
2-D08 1hr 82.6 ± 5.21 0.663 ± 0.015 68 
96 
In Figure 33, compared with the control, the mean talin containing FAs number was 
increased significantly after 100µM GA 1 hour treatment from 52 ± 5 to 75 ± 5 (**). 
Compared to the control, 100µM 2-D08 after 1 hour treatment significantly increased the 
mean talin containing FAs number from 52 ± 5 to 83 ± 5 (p=0.0003 ***). 
 
Compared to the control, 100µM 2-D08 after 1 hour treatment significantly increased the 
mean talin containing FAs size from 0.599 ± 0.021 µm2 to 0.663 ± 0.015 µm2 (**). 
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Summary of This Study: Inhibition of SUMOylated Focal Adhesions 
Inhibitors Immunostaining: 
fixed cell 
 
Mean number of focal 
adhesions increased 
significantly 
(numbers/per cell) 
Immunostaining: 
fixed cell 
 
Mean size of focal 
adhesions increased 
significantly 
(µm
2
/per cell) 
GFP-tag FAs turnover 
assay: live cell 
 
Mean number 
(numbers/per cell), size 
(µm
2
/per cell) and turnover 
time (s) of focal adhesions 
increased significantly 
 
 
 
 
 
 
GA (E1) 
(Fukuda et al., 
2009a) 
MDA-MB-231+ 
1 hour: 
Talin: 45 vs. 56 
Vinculin: 34 vs. 61 
 
U2OS+ 
15 minutes: 
Talin: 49. vs. 85 
Vinculin: 46 vs. 67 
 
1 hour: 
Talin: 52 vs. 75 
Vinculin: 67 vs. 88 
MDA-MB-231+ 
 
1 hour: 
Talin: 0.44 vs. 0.64 
Vinculin: 0.64 vs. 0.87 
 
 
 
MDA-MB-231+   2 hours: 
Talin: 
Number: 62 vs. 102; 
Size: 0.84 vs. 0.94 
Turnover: 34.3 vs. 59.5 
Vinculin: 
Number: 44 vs. 85 
Size: 0.81 vs. 0.98 
Turnover: 27.4 vs. 47.2 
FAK: 
Number: 52 vs. 92 
Size: 0.83 vs. 0.92 
Turnover: 31.5 vs. 50.0 
 
 
 
 
2-D08 
(Kim et al., 2013) 
 
MDA-MB-231+ 
1 hour: 
Vinculin:34 vs. 43 
 
U2OS+ 
15 minutes: 
Talin: 49 vs. 70 
Vinculin:46 vs. 65 
1 hour: 
Talin: 52 vs. 83 
MDA-MB-231+ 
1 hour: 
Talin: 0.44 vs. 0.52 
Vinculin: 0.64 vs. 0.76 
 
U2OS+ 
1 hour: 
Talin: 0.60 vs. 0.66 
Vinculin: 0.87 vs. 1.1 
n/a 
Gossypetin 
(Chen et al., 2013, 
Lin, 2015) 
U2OS+ 
1 hour: 
Vinculin: 67 vs. 92 
MDA-MB-231+  1 hour: 
Talin: 0.44 vs. 0.53 
Vinculin: 0.64 vs. 0.77 
n/a 
Ubc9 siRNA (E2) 
48hrs treatment 
MDA-MB-231+ 
Talin: 47 vs. 75 
MDA-MB-231+ 
Talin: 0.60 vs. 0.70 
n/a 
GA+Ubc9 siRNA 
49hrs treatment 
MDA-MB-231+ 
Talin: 47 vs. 76 
MDA-MB-231+ 
Talin: 0.60 vs. 0.71 
n/a 
The speed of cell migration decreased significantly (µm/hr
-1
) after the Inhibition of SUMOylated focal 
adhesions: 3D collagen matrix 
GA (E1) 
MDA-MB-231 24 hours: 
20.1 < 14.6 < 13.7 < 12.4 
Ubc9 siRNA (E2) 
MDA-MB-231 25 hours: 25.5 <18.6 
48 hours: 18.3 < 14.1 
 
Table 6. Summarising the changes in the mean number, size and turnover of FAs in two different cell 
lines used: the MDA-MB-231 cells and the U2OS cells and in two different microenvironments: the 
immunostaining fixed-cell cell culture environments and the 2.5D 2 mg/ml collagen type I 
microenvironments; the summary of the effects after the inhibition of SUMOylation on cell migration 
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Discussion 
GA increased the mean number and size of FAs in MDA-MB-231 cells and U2OS cells. In 
live-cell experiments, GA increased the mean number, size and turnover time of talin, 
vinculin or FAK containing FAs in MDA-MB-231 cells. 2-D08 and gossypetin increased the 
mean number and size of FAs in MDA-MB-231 cells and U2OS cells. Ubc9 siRNA increased 
the mean number and size of the talin containing FAs in MDA-MB-231 cells. GA and siRNA 
treatments decreased the speed of cell migration in MDA-MB-231 cells.   
 
The dose used in this study (100µM GA) was also used in the inhibition of SUMOylated 
RanGAP1-C2 and p53; other concentrations were used as 1µM and 10µM for RanGAP1-C2 
and 10µM and 100µM of GA completely inhibited the SUMOylation of RanGAP1-C2 in vitro; 
10, 25 and 50µM of GA were used for p53 and 100µM GA inhibited the SUMOylation of p53 
in vivo; GA at 10, 25, 50 and 100µM did not affect ubiquitination in vivo for 4 hours treatment 
(Fukuda et al., 2009a). 25, 50 and 100µM of GA were used in the cell migration study, which 
reduced the speed of cell migration. 100µM GA treatment in HEK293 cells for 6 hours 
resulted in significant decrease in SUMO-1 and SUMO 2/3 conjugation and in global protein 
tyrosine phosphorylation; a specific example of tyrosine kinases, FAK, was shown that 
100µM GA treatment for 6 hours showed a decrease in tyrosine phosphorylation of Tyr-397 
in the SUMOylated form of FAK (Yao et al., 2011).  
 
The effects of 2-D08 are discussed in some examples. 2-D08 at 10µM and 30µM inhibited 
SUMOylated IkBα with SUMO-1 modification; 2-D08 at 30µM inhibited SUMOylated IkBα 
with SUMO-2 and SUMO-3 modification; 30µM 2-D08 inhibited SUMOylated topoisomerase 
I in ZR-75-1 and BT-474 breast cancer cells (Kim et al., 2013). GA, but not 2-D08, inhibits 
E1 (SAE)-SUMO-1 thioester formation; GA, but not 2-D08 inhibits Ubc9-SUMO-1 thioester 
formation; whereas 2-D08 inhibits the transfer of SUMO-1 from the E2 thioester to the 
SUMO substrate with no disruption in other biochemical steps (Kim et al., 2013). 3-B08 or 
gossypetin has also been selectively screened as an inhibitor for SUMOylation reaction (Kim 
et al., 2013). These studies have shown that GA is an E1 (SAE) inhibitor and can inhibit E1 
activation (Fukuda et al., 2009a); 2-D08 is a pathway-selective inhibitor, 100µM 2-D08 does 
not affect global ubiquitination (Kim et al., 2013); GA and 2-D08 are specific inhibitors for 
SUMOylation and not ubiquitination inhibitors, however, it does not rule out their activities in 
cellular pathways other than SUMOylation and ubiquitination.  
 
Inhibition of SUMOylation is not the only activity of these inhibitors. It was reported that more 
than 100µM GA was necessary for activating protein phosphatase type 2Cα (PP2Cα) in 
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vitro: incubation with GA at 600µM for 24 hours could increase the activity of cytosolic 
PP2Cα by 14-fold, which was responsible for the neurotoxic effects in chicken embryo 
neurons (Ahlemeyer et al., 2001). 2-D08 is a synthetic flavone which has radical scavenging 
property (Seyoum et al., 2006). Gossypetin could inhibit PMA induced activation of nuclear 
factor-kB (NF-kB) signalling in MDA-MB-231 cells and it caused a slight increase in the 
MMP-9 matrix metalloproteinase-9 and COX-2 cyclooxygenase-2 mRNA transcript levels 
(Amrutha et al., 2014). Gossypetin was shown to possess potent neuraminidases inhibitory 
effects and in vitro anti-influenza viral activities (Jeong et al., 2009). GA, 2-D08 and 
gossypetin have antioxidant and antimutagenic effects (Zhou et al., 2004, DeFeudis et al., 
2003, Francis et al., 1989, Mahadevan and Park, 2008).  
 
Protein substrate modification with SUMO relies on a single E2 enzyme, Ubc9 in the 
SUMOylation pathway, where Ubc9 is unique among E2 enzymes in its capability to 
specifically recognize and conjugate SUMO1 or SUMO 2/3 to their substrates (Gareau and 
Lima, 2010, Tatham et al., 2001, Sampson et al., 2001). In the absence of specific inhibitors, 
Ubc9 siRNA was used to knock down the expression of Ubc9. Some studies on Ubc9 siRNA 
knockdown have been shown. Ubc9 siRNA knockdown could inhibit in vivo p53 
SUMOylation and β-estradiol-induced cell proliferation in MCF7 cells (Hirohama et al., 
2013). Ubc9 siRNA transfection caused impaired melanoma cell proliferation and melanoma 
cell apoptosis; moreover, incubation of Ubc9 siRNA (100nM) in the presence of the cytotoxic 
drug cisplatin (20µM) increased its sensitivity from 35% to 70% in metastatic growth phase 
(MGP) melanomas; Ubc9 siRNA treatment (100nM) with paclitaxel (20µM) also achieved 
70% cell apoptosis in MGP melanomas (Moschos et al., 2007). Ub9 siRNA (25nM) was used 
and it reduced cell migration significantly in this study. 
 
There are advantages and disadvantages to using siRNA. Generally, the small interfering 
RNA can be easily introduced into the target cells with high efficiency, but the resources are 
non-renewable and the transfection effect is only transient (Campeau and Gobeil, 2011, 
Mocellin and Provenzano, 2004). The siRNA is designed to ensure that it targets specifically 
to the protein mRNA of interest without off-targeted effects, this is its specificity; meanwhile, 
the siRNA is expected to have a desirable effect in the knockdown efficiency, which is its 
potency (Shan, 2010). The disadvantage of siRNA is its unwanted off-targeted effects. To 
obtain highest knockdown efficiency and minimal off-targeted effects, nanomolar or even 
lower concentrations have to be determined specifically for each cell type used.  
 
The combinatorial use of GA and Ubc9 siRNA in MDA-MB-231 cells had similar results and 
from the two treatments together compared to individual treatments did not produce a further 
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increase in the mean FAs number and size. This suggests that GA and Ubc9 siRNA are 
pathway selective inhibitors, shown in Figure 34.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Summarising in the regulatory role of SUMOylation in the focal adhesions; the inhibition of 
SUMOylation prolongs the time of FA disassembly leading to increased time of FA turnover, which 
may have also affected cell signalling downstream of the integrin mediated FA to actin; the cells could 
be initiated with other compensatory mechanisms from slower turnover and impaired dynamics of FA, 
which the cells were produced with more FAs and larger FAs. SUMOylation may be upregulated in 
persistent FA turnover and FA disassembly. 
 
Figure 34 summarises the proposed regulatory role of SUMOylation in focal adhesions. After 
blocking protein SUMOylation, the number, size and turnover of FAs increased, suggesting 
SUMOylation may be important in regulating FAs. This leads to the idea that SUMOylation 
could be playing a critical role in the dynamic activities and turnover of FAs. The inhibition of 
protein SUMOylation leads to the stability of FAs; the mature FAs cannot break down or 
disassemble and therefore accumulate and increase in size. The larger FA accumulation 
leads to increased FA turnover time and results in reduced cell migration. Any newly 
synthesized FA proteins will be prevented from SUMO conjugation. Therefore, SUMOylation 
may have a critical regulatory role in FA disassembly. Integrin mediated FAs are important in 
cell migration (Huttenlocher, 2011, Zaidel-Bar and Geiger, 2010). Proper dynamics of FAs 
are essential as the trailing adhesions or the adhesions at the cell rear are periodically 
released to allow rapid movement (Broussard et al., 2008). SUMOylation may regulate FAs 
specifically during their rapid disassembly.  
 
However, the inhibitory effects cannot be ruled out of changes in other cell signalling 
pathways. Inhibition of FA disassembly decreases cell migration. The effects of slowed down 
cell migration may also indicate the interruption of SUMOylated FAs in the inside-out integrin 
signalling. Further studies will be needed to determine the inhibitory effects on cell migration 
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are reversible or not. FA disassembly is precisely controlled by signalling pathways and the 
regulation of actin-myosin tensile forces; the specific regulatory or adaptor proteins 
associated need to be investigated in future experimental work. 
 
Ubc9 siRNA treatment caused some effects in cells during the cell migration study. Ubc9 
siRNA knockdown showed membrane ruffling on the frontal surface of the cells in some 
MDA-MB-231 cells, whilst the FAs were still able to be observed around the cell membrane. 
This observation of membrane ruffling represents a question if the Ubc9 siRNA treatment 
was able to affect cell plasticity. The inhibition of SUMOylation may have interrupted the 
lamellipodia formation resulting in misshapen membrane polarisation. One study has shown 
that the membrane ruffles in cell migration could be resulted from inefficient lamellipodia 
adhesion and actin filament compartment reorganization; suboptimal cell-substrate adhesion 
e.g. inefficient integrin-ligand interaction led to significant reduced lamellipodia persistence 
and inefficient cell migration resulted in a dramatic increase in ruffle frequency (Borm et al., 
2005). Membrane protrusion and cell adhesion process are highly and physically coupled; 
failed lamellipodia to establish stable adhesions are detached from the substrate and 
retracted centripetally toward the cell body (DeMali and Burridge, 2003).  
 
Another aspect from this effect is that tumour cells have been shown to be capable of 
remarkable plasticity and can move in a proteolysis-independent manner using membrane 
blebs (Ram, 2005, Wolf, 2003). The membrane blebs are formed either from the transient 
detachment of the cell membrane from the actin cortex or the localized rupture of the actin 
cortex, where the amoeboid blebbing cells migrate due to actomyosin contraction (Charras, 
2008b, Lorentzen, 2011, Frackler, 2008). Tumour cells can use blebs as an alternative to the 
lamellipodia-driven migration in 3D environments switching between bleb mode and 
filopodia-lamellipodia mode (Charras, 2008a, Yoshida and Soldati, 2006). The transitions 
between mesenchymal and amoeboid migration modes are associated with actin protrusivity 
and actomyosin contractility independent of the cell morphology, polarity and adhesions, 
which the contractile actin cortex is crucial in driving bleb retraction (Bergert et al., 2012, 
Charras et al., 2006). The morphology of mesenchymal migrating cells and amoeboid cells 
are different, the mesenchymal migrating cells have adherent, long and extended tail from 
the cytoplasmic cell body, which leaves a trailing path behind when they move; whereas in 
amoeboid cells the tail is almost disappeared and rounded, which de-adhesion and tail 
retraction is much more efficient and migration is faster (Mitchison and Cramer, 1996, 
Charras, 2008a, Lammermann, 2009). Currently, the effect of inhibition of SUMOylation on 
cell plasticity is unknown but it may be important in cancer metastasis.  
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Ubc9 has other effects in the cells. Ubc9 was shown to promote breast cancer cell invasion 
and metastasis in a SUMOylation-independent manner, which was distinct from its role in 
conjugating SUMO to protein substrates (Zhu et al., 2010). A case-control study in 181 
breast cancer cases and 277 controls has shown that the variability of the polymorphism of 
the Ubc9 gene is associated with an increased risk of ductal breast cancer occurrence 
(Wozniak et al., 2014). Ubc9 expression levels were much higher in ovarian tumours (Mo et 
al., 2005) and up-regulated in breast, head and neck and lung cancer (Wu et al., 2009).  
 
Directionality is an important indicator in cell motility; directional persistent cell movement is 
accomplished by the formation and stabilization of actin-rich membrane protrusions, 
lamellipodia maintenance determining the orientation of the cell leading edge, actin-myosin 
contraction convergence on the regulation of Rho family GTPases, topography of the ECM, 
cell polarity and cell adhesion (Petrie et al., 2009). In the presence of GA, some of the cells 
become less retractile, i.e. the leading edge of the cells were less extensive with spiky 
protrusion activities and some cells were almost stuck in one point; compared to the control, 
MDA-MB-231 cells were spindle-shaped and their lamellipodial structures were constantly 
protruded and retracted, this occurred less frequently in the GA treated cells.  
 
During cell migration, there are other factors involved in SUMOylated such as Rac 1 and the 
cytoskeleton. Rac 1 (Rho GTPase family) has been discovered to conjugate with SUMO-1 
and Rac 1 interacts with a SUMO E3 ligase, PIAS3; this controls Rac 1-GTP levels and is 
required to increase Rac 1 activation, stimulate optimal cell migration and invasion in relation 
to hepatocyte growth factor (HGF) signalling (Castillo-Lluva et al., 2010).  Rac 1 or Cdc42 
activation is required for Arp 2/3-dependent actin polymerisation (Bergert et al., 2012). Cell 
membrane protrusions/lamellipodial ruffling and spreading at the leading edge in migrating 
cells requires Rac1, Cdc42 and actin cytoskeleton mediated by integrin αvβ3 (Petrie and 
Yamada, 2012, Parsons et al., 2010, Huveneers and Danen, 2009). The inhibition of 
SUMOylation caused impaired FA disassembly resulting in decreased speed of cell 
migration; however, the effects accounted for the decrease in cell migration cannot be 
excluded for Rac1 SUMOylation.  
 
LC-MALDI/MS/MS analysis of TAP-purified proteins have identified actin as a putative 
SUMO-1 and SUMO-3 substrate (Rosas-Acosta et al., 2005). Several other studies have 
also applied proteome-wide approaches to identify SUMOylated substrate proteins and 
shown actin is a substrate (Panse et al., 2004, Vertegaal et al., 2004, Wohlschlegel et al., 
2004). Emerging evidence has shown several SUMOylated targets in the cytoskeleton 
including the microtubules, i.e. α/β tubulin; microfilaments, i.e. actin and Rac 1 and 
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intermediate filaments i.e. vimentin (Alonso et al., 2015). Vimentin (vimentin354) was shown 
to be modified by SUMO-1 in the nucleus in invasive glioblastoma multiforme cells; the 
SUMOylated vimentin354 was stimulated by PIAS3, which played an important role in the 
inhibition of glioma cell migration (Wang et al., 2010). Actin cytoskeleton-myosin linkage to 
FAs exert tension and contractile forces which leads to cell motility (Hu et al., 2007, 
Giannone et al., 2007). Nuclear actin has been firstly shown to be modified by SUMO 2 and 
SUMO 3 in vitro and in vivo; computational modelling and site-directed mutagenesis have 
identified K68 and K284 are critical SUMO binding sites for the SUMOylation of actin 
(Hofmann et al., 2009).  
 
Similarly, inhibiting protein SUMOylation in cells could affect the cytoskeleton e.g. actin, as 
FA associates with actin, however, these potential SUMOylation substrates need to be 
determined individually to see whether they can be SUMOylated firstly. Antibodies against 
cytoskeleton e.g. microtubule and actin can be used in the IHC studies to visualize the 
effects of these SUMOylation inhibitors on cytoskeleton, count for the number or size of 
microtubules or actin to determine whether any changes on cytoskeleton could be resulted 
from the inhibition of SUMOylation. 
 
The microenvironments are important for the cells. Non-compressed rat tail collagen type I 
matrix has been used in the FA turnover (live cell) experiments to enable the observation of 
FAs in 2.5D experimental conditions, as the tumour microenvironment is important, the 
differences in matrix type and the composition of the matrix could affect the formation of 
FAs. The ECM softness can significantly influence cell-matrix adhesions (Zaman et al., 
2006). An increase in matrix stiffness can increase the number and size of focal adhesions 
(Gu et al., 2014). 3D migration assays have been used for the analysis of cell migration 
process, as breast cancinoma cells move within a 3D collagen matrix network (Entschladen 
et al., 2005). 
 
In this study, a 2.5D collagen matrix system was used, where MDA-MB-231 cells were 
grown on the collagen border forming a tracking path aligned with the collagen interphase or 
the cells were seeded on top of the collagen. MDA-MB-231 cells were previously transfected 
with GFP-talin-1, GFP-vinculin or GFP-FAK plasmids. The cells seeded in this 2.5D collagen 
matrix model expressed GFP-tagged FA proteins dynamically over a short period of time 
(optimal transfection window was within 24 hours from the transfection point), which was 
useful to apply and study the effects of the inhibitor GA caused in the changes of the 
dynamic FAs activities. These GFP-tagged FA transfected cells could also be imaged using 
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Reflection imaging on the confocal microscope, which reflects away the light making the 
collagen matrix visible and the FA proteins expressed by the cells could be seen.  
 
In this experiment, FAs were difficult to detect in the 3D collagen matrix when the cells were 
fully embedded, which could make the analysis difficult and inaccurate. From the literature, 
FAs were not easily detectable in cells embedded deeply in 3D matrix, several explanations 
have been proposed for the lower expressions of FAs in 3D: their turnover time was too fast, 
their occupied size was uncertain or the down-regulation of FAs was mediated through post-
transcriptional mechanism (Kubow and Horwitz, 2011, Fraley et al., 2011, Wang, 2003). In 
Kubow and Horwitz’s study using rat tail collagen with the mesenchymal cell line U2OS 
osteosarcoma and HT1080 fibrosarcoma cells transfected with the EGFP-paxillin construct 
under the ‘crippled’ CMV (cytomegalovirus) promoter control showed reduced fluorescence 
background, which revealed adhesions in 3D collagen matrix; as over-expression of 
fluorescently-labelled proteins such as GFP-tag FA proteins could accumulate and cause 
molecular diffusion in the cytoplasm, which resulted in diffused fluorescence background and 
masked the actual observation of the adhesion ‘dots’ in 3D cellular compartments (Kubow 
and Horwitz, 2011, Fraley et al., 2010). The truncated CMV promoter could reduce protein 
expression from the EGFP paxillin plasmid resulting in lowered plasmid copy number than 
EGFP-paxillin and enhanced visualisation of paxillin in U2OS and HT-1080 cells (Kubow and 
Horwitz, 2011).   
 
Another study showed that using GFP-talin encoding baculovirus, discrete adhesions and 
their dynamics were visualized and analysed during cell migration in a 3D environment 
(Deakin and Turner, 2011). Using intravital imaging from cancer cells injected into the deep 
dermis of mice, the existence of adhesion aggregates (GFP-paxillin and GFP-vinculin) were 
able to be shown for the first time in vivo and these adhesion aggregates seemed to share 
similarities with the ones found in 3D collagen matrices (Geraldo et al., 2012). 
 
Fraley et al. suggested that when the distance of the cells expressing FAs from the matrix 
substrate was 200 µm or more suggesting the cells were fully embedded in the matrix, the 
FAs were hardly seen; in their experiment, the number and size of FAs (paxillin or zyxin) in 
HT1080 cells were automatically measured using a thresholding technique in NIS-Elements 
software, which also showed that the number of FAs was decreased from 20/per cell in 2D 
environment to 14/per cell in 2.5D environment to 4/per cell in 3D (<200µm) and it was no 
longer detected in 3D (>200µm); similarly, the size of FAs was decreased from 1µm2/per cell 
in 2D environment to 0.4µm2/per cell in 2.5D environment and further down to 0.25µm2/per 
cell in 3D (<200µm) until no longer seen in 3D (>200µm) (Fraley et al., 2011). 
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The formations of the FAs are different in 2.5D collagen matrix and 2D fixed gelatin coated 
coverslips (Table 6). In the 2D cell culture microenvironments, the cells were grown on hard 
surfaces and the cells responded to the changes in the stiffness of the substrate they were 
surrounded in (Discher et al., 2005). The dimensionality of the cells in connective tissues or 
organs are embedded deeply whereas the cells are adhered and flattened on 2D standard 
tissue culture ECM-coated coverslips or surfaces (Geiger, 2011). The mechano-sensing FA 
formation is different in different surfaces, which this could affect adhesion, spreading and 
the tension forces generated at the cell protrusions (Goldmann and Ingber, 2002). In tissues 
cells are in contact with multiple layers of ECM components and consequently, several types 
of integrin may be activated creating multiple signalling cascades in vivo (Wozniak et al., 
2004). The microenvironments in vivo are very heterogeneous and complex, however, it has 
been suggested that 2D FAs are an exaggerated version of FAs in 3D (Wozniak et al., 
2004). Given the complexities of the environment in vivo which makes imaging FAs 
extremely challenging, the role of SUMOylation in FA turnover in vivo will require significant 
further study. 
 
The FA number, size and turnover time in MDA-MB-231 cells have been compared with the 
other types of cells in the literature. The dynamics of vinculin to its recruitment to FA is 
tension-dependent; higher tension/force applied across vinculin is associated with adhesion 
assembly and increase in size (Grashoff et al., 2010). The rate of assembly of adhesion is 
increased upon force increases (Hákonardóttir et al., 2015). Fibronectin-mediated FAK 
activation was tension-dependent to integrin α5β1 in HT1080 cells (Seong et al., 2013). 
Vinculin itself is important in FA turnover; vinculin-/- mouse embryo fibroblasts MEFs showed 
smaller, much less abundant but a higher turnover rate FAs compared to wild type MEFs 
(Saunders et al., 2006). The mean vinculin containing FA number was 100 and the mean 
vinculin containing FA size was 0.8 µm2 in NIH3T3 mouse fibroblast cells (Humphries et al., 
2007), compared to 34 and 0.64 µm2 in 2D experimental conditions in MDA-MB-231 cells, 
the mean vinculin containing FAs number was nearly halved and the mean vinculin 
containing FAs size was smaller in MDA-MB-231 cells compared to NIH3T3 cells 
(Humphries et al., 2007). The lifetime of FAs in embryonic fibroblast cells on FN coated 
coverslips was less than 2 minutes (Ren et al., 2000), compared to MDA-MB-231 cells in this 
study, the mean turnover time of FAs was 34.3s (talin), 31.5s (FAK) or 27.4s (vinculin), 
which was much faster, indicating the different substrate surfaces the cells were grown on 
(collagen I was used in the FA turnover study) and the different cell phenotype. In wild type 
keratinocytes on coated FN coverslips, the mean vinculin containing FAs size was 1.6 µm2 
and the turnover time was 30 minutes (Schober et al., 2007), which was doubled the mean 
size of vinculin containing FAs in MDA-MB-231 cells and the turnover time was much longer 
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in the keratinocytes. The vinculin FA number was 102 in MCF10a human breast epithelial 
cells (Bays et al., 2014). The vinculin FA size was about 0.4 µm2 in MDA-MB-231 cells, 
perhaps they were under different experimental conditions as these cells were transfected 
with a control siRNA, subcloned or coinfected with retroviruses (Yang et al., 2009). Fast cell 
migration is correlated with intermediate FAs lifetime and rapid renewal of the FA proteins; 
moreover, the FA lifetime is inversely correlated with FAs strength, where the epithelial cells 
on FN coated coverslips showed that at high FN (30 µg/ml) with high adhesion strength, the 
FAs did not disassemble within 45 minutes, at intermediate FN (10 µg/ml) or low FN (5 
µg/ml), FAs average lifetime was 17 and 9 minutes (Gupton and Waterman-Storer, 2006). 
Therefore, the FAs number, size and turnover time was dependent on the cell line studied 
and the ECM matrix used. MDA-MB-231 cells were known to be motile and invasive, which 
accounts for the fast turnover time of their FAs.  
 
The inhibition of SUMOylation using various inhibitors have increased the mean FA number 
and size significantly in MDA-MB-231 cells and U2OS cells. This implies that SUMOylation 
plays an important role in the dynamic activities of FA in cell migration. This leads to the next 
step to identify whether talin and vinculin are protein substrates for SUMOylation and can be 
SUMOylated.  
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Chapter 4 – SUMOylation of Talin and Vinculin  
 
4. 1 Introduction and Hypothesis 
 
Talin Turnover in FAs and Cell Migration 
Talin has two isoforms, talin 1 and talin 2, talin 1 is essential for integrin-mediated cell 
adhesion (Debrand et al., 2009). Talin contains the globular N-terminal FERM (band 4.1, 
ezrin, radixin and moesin) domain (F0-F3 domains), which binds to the proximal Asn-Pro-x-
Tyr (NPxY) motif in β-integrin cytoplasmic regions; the C-terminal tail domain of talin 
contains actin binding sites (ABS) (Ziegler et al., 2006). The FERM domains F3 binds to 
integrin β tails whilst F1 and F2 are required for membrane association and integrin 
activation, cell spreading and FA assembly (Elliott et al., 2010). The rod domain of talin 
contains multiple vinculin binding sites (VBSs) (Gingras et al., 2005). Talin is autoinhibited by 
an intramolecular interaction between the FERM and the rod domains, which are highly 
conserved sequences in human and flies and talin autoinhibition is required for 
morphogenesis (Ellis et al., 2013). Talin autoinhibition is essential and a key process in the 
mechanism of controlling integrin activation and cell adhesion, where the C-terminal rod 
domain of talin specifically masks a region involved in the interaction of the phosphotyrosine 
binding domain (PTB)  of the N-terminal talin head, allosterically locking up talin in a closed 
conformation whilst this PTB domain of talin is competitive for integrin β membrane proximal 
cytoplasmic tail binding (Goksoy et al., 2008).  
 
The talin head consists of amino acids 1-400 and the talin head is linked via the linker 
residues between 401-481 and at the linker regions it contains calpain-2 mediated cleavage 
sites between Q433 and Q434, followed by the C-terminus long flexible talin rod domain 
consisting of the amino acids from 482-2541 (13 helical bundles, R1-R13) (Bate et al., 
2012). It has been shown that the talin, FAK, Src, p130CAS, paxillin, myosin light-chain 
kinase (MLCK) and the ECM signalling regulated-kinases engaged with the integrin are 
critical in FA turnover (Lebart and Benyamin, 2006). 
 
The small GTPase Rap1 and its effector RIAM bind directly to talin leading to talin-
dependent integrin activation and recruitment of talin to the plasma membrane (Goult et al., 
2013a). Talin and RIAM focal complexes can activate integrin at the cell leading edge, where 
FA maturation is required of talin and vinculin FA complexes (Goult et al., 2013b). The 
binding of vinculin and RIAM to talin R2R3 domain is mutually exclusive: the binding of 
vinculin to talin requires both protein partners domain unfolding (Gingras et al., 2006) and 
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talin and vinculin binding is found in mature FA; whereas RIAM can bind to talin R2R3 folded 
domain directly and is found in nascent FA (Goult et al., 2013b). 
 
The binding of talin to β integrin and the interactions between talin, vinculin and actin are 
also strengthened and regulated by Phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) 
indicating this lipid mediator is involved in focal adhesion assembly (Ling et al., 2002). The 
recruitment of talin to the plasma membrane and its localization to the integrin-mediated FAs 
in spreading cells is facilitated by the phosphorylation of type I phosphatidylinositol 
phosphate kinase isoform-γ 661 (PIPKIγ661, an enzyme that makes PtdIns(4,5)P2), 
PIPKIγ661 is phosphorylated by c-Src and phosphorylation is regulated by FAK; PIPKIγ661 
tyrosine phosphorylation increases its binding affinity of PIP2 to talin head and talin binding 
between PIPKIγ661 and β1 integrin may regulate dynamic FA turnover (Ling et al., 2003, 
Ling et al., 2002).  
 
Talin is one of the first FA proteins proteins that recruits to integrin binding and triggers FA 
assembly to activate downstream signalling, which the cells can respond to (Shattil et al., 
2010). Talin-1 can regulate cell migration and metastasis in 3D, and it has been reported 
that overexpression of talin-1 enhanced prostate cancer cell adhesion, migration and 
invasion by activating survival signals through phosphorylation of FAK and Src and 
mediating anoikis resistance in vitro (Sakamoto et al., 2010); shRNA talin-1 knockdown 
resulted in significant suppression of prostate cancer cell migration and invasion in vitro and 
significant inhibition of metastasis in vivo (Sakamoto et al., 2010). Talin-1 was reported as a 
valuable marker for diagnosis and prognosis of hepatocellular carcinomas (Zhang, 2011). 
p130Cas, Src and talin regulate oral carcinoma invasion and cisplatin-resistance (Sansing et 
al., 2011). Cell adhesions and remodelling of the ECM requires bidirectional integrin 
signalling and linkages between ECM, integrin and cytoskeleton; cells lacking both talin 1 
and 2 could abolish ECM-integrin-cytoskeleton linkage, particularly, downstream FAK 
signalling was severely affected and the cells form unstable lamellipodial spreading on 
substrates, where the traction force generation was also diminished (Zhang et al., 2008b). 
 
The calcium-dependent protease, calpain, is able to regulate the focal adhesion complex 
disassembly (Bhatt et al., 2002). A list of calpain substrates including the focal adhesions, 
focal complexes, podosomes or integrin-containing clusters that can be cleaved by calpain 
include: α-actinin, filamins, talin, vinculin, paxillin, FAK, integrin β1, β3, zyxin, cortactin, 
spectrin, P130CAS, PKC, RhoA and tubulin etc (Lebart and Benyamin, 2006, Glading et al., 
2002). Calpain mediated proteolysis of talin is critical for FA disassembly and the cleavage 
of the other FAs such as vinculin etc are also dependent on the ability of calpain to cleave 
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talin, therefore this is important in the regulation of FA turnover (Liu and Schnellmann, 2003, 
Franco et al., 2004). The talin head and rod liberated by the calpain-2 cleavage has been 
shown to be important in FA turnover (Bate et al., 2012). The cleavage of talin separates the 
N-terminal 47kDa talin head domain from the C-terminal rod domains and this cleaved talin 
head was found to have a 6-fold higher binding affinity for the integrin β3 tail than the intact 
talin (Yan et al., 2001). This mechanism of action of talin cleavage may contribute to the 
clustering and activation of these integrin receptors (Yan et al., 2001).  
 
Vinculin Turnover in FAs and Cell Migration 
Vinculin contains the 90-kDa globular head N-terminus domain and the 30-kDa tail C-
terminus domain connected by a proline-rich hinge region (Miller et al., 2001). The C-
terminal tail region of vinculin contains conserved region for direct paxillin binding associated 
with the focal contacts (Bendori et al., 1989, Wood et al., 1994). Vinculin is also autoinhibited 
by a head-tail Vh-Vt intramolecular interaction, which mask the binding sites for talin in the 
Vh D1 domain and actin, paxillin and phosphatidylinositol (4, 5)-biphosphate (PIP2) binding 
sites to the Vt domain (Cohen et al., 2005, Janssen et al., 2006). The vinculin head Vh 
contains D1-D4 domains and the vinculin tail Vt consists D5 (Bakolitsa et al., 2004). Vinculin 
is activated through talin and α-actinin high-affinity vinculin binding sites (VBSs) buried in 
talin rod domain and these VBSs are sufficient to disrupt the Vh-Vt intramolecular 
interactions of vinculin, which induces conformational change allowing talin and α-actinin 
binding to Vh and for the vinculin to bind to F-actin in its Vt domain (Bois et al., 2006, Borgon 
et al., 2004). 
 
The formation of tumour metastases are associated with the phenotypic changes in reduced 
cell adhesion and increased cell motility, which are related with the loss of vinculin (Carisey 
and Ballestrem, 2011). The cells lacking vinculin or with much reduced vinculin level were 
usually less spreading, less adhesive i.e. containing smaller and fewer adhesion plaques 
and became much more motile (Xu et al., 1998, Rodríguez Fernández et al., 1993, Coll et 
al., 1995). Upregulated expression of vinculin could alter locomotion properties of the cells, 
which were severely supressed (Fernández et al., 1992). So far, 19 binding partners of 
vinculin have been identified including talin-1, α-actinin, catenin α/β, vinexin α/β, VASP, 
Arp2/3, paxillin, F-actin, calpain, PIP2 and so on (Carisey and Ballestrem, 2011).  
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Hypothesis 
The previous chapter has shown that the inhibition of protein SUMOylation using GA, 2-D08, 
gossypetin and Ubc9 siRNA produces more numerous FAs, larger FAs and prolonged FA 
turnover time. Moreover, inhibiting protein SUMOylation decreases the speed of cell 
migration in MDA-MB-231 cells. This suggests that SUMOylation plays a critical regulatory 
role in the dynamic activities of the FAs, particularly in the disassembly of FA turnover. Talin 
and vinculin are focal adhesion proteins, which are important in their recruitment to integrin 
and in focal adhesions disassembly. Therefore, in this study, talin and vinculin have been 
studied to determine whether talin or vinculin can be SUMOylated. 
 
Three different immunoprecipitation methods have been used in two cell lines: MDA-MB-231 
cells and U2OS cells. The first IP experiments were conducted using whole cell lysates to 
investigate whether endogenous talin or vinculin could be SUMOylated. Then, a HA-tagged 
SUMO-2 plasmid was used. This would introduce the HA-tagged SUMO plasmids into the 
cells for them to overexpress SUMO-2 level transiently. This IP method would generate 
consistently precipitated SUMOylated proteins. A third IP method was to use a SUMO 
VIVATM Binding Assay system to investigate whether talin or vinculin could be SUMOylated 
within isolated concentrated focal adhesions.  
 
A possible consequence of SUMOylation is its potential role in FA protein-protein 
interactions. Co-immunoprecipitations in the presence of inhibitors GA, 2-D08, gossypetin 
and Ubc9 siRNA would be used to investigate the role of SUMOylation in protein-protein 
interactions in both cell lines. 
 
4.2 Method Development 
In order to immunoprecipitate the individual talin or vinculin proteins in the MDA-MB-231 
cells or the U2OS cells, specified IP methods were developed and modified. The cells were 
initially immunoprecipitated only with the endogenous talin, vinculin or SUMO 2/3 to 
determine in the western blotting whether they could be SUMOylated. Later, the cells were 
transfected with the HA-tagged SUMO-2 plasmids to overexpress SUMO-2. A third method 
was to use a SUMO binding column kit and a SUMO binding assay was developed.  
 
The methods were developed as: IP and WB detection of the SUMOylated talin or vinculin in 
the whole cell lysates only or reverse IP and WB; IP SUMO-2 and WB detection: transfection 
of the cells with the HA-tagged SUMO-2 plasmid; SUMO VIVATM binding assay – detection 
of the SUMOylated talin or vinculin and its use in the isolation of the FAs; more concentrated 
FA collection – investigation on the cleavage of talin. 
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4.2. 1 Antibodies for IP and WB Experiments 
The antibodies used in the IP experiments were the N-terminus and the C-terminus 
antibodies which could detect the N or C terminal ends of the molecules. For example, the 
antibodies from Santa Cruz (c-9 or H-300) could detect N-terminal of talin at 230kDa; the 
antibody from Merck Millipore could detect N-terminal of talin at 250kDa. 
 
Primary antibodies 
1 Purified mouse anti-HA.11 epitope tag monoclonal antibody, 1 mg/ml, 16B12, Biolegend 
(IP: 1:100-150) 
 
2 Anti-GFP mouse monoclonal antibody [9F9.F9] ab1218, abcam (IP: 1:150-200) 
 
3 Mouse anti-talin 1 monoclonal antibody reacting with an N-terminal epitope in human 
talin between amino acids 139-433, Clone TA205, 1 mg/ml, MAB1676, Merck Millipore 
(IP: 1:100, WB: 1:1000) 
 
4 Mouse anti-talin monoclonal antibody (C-9) raised against amino acids 1-300 mapping at 
the N-terminus of talin of human origin, 200 µg/ml, sc-365875, Santa Cruz 
Biotechnology, INC. (WB: 1:200) 
 
5 Rabbit anti-talin polyclonal antibody (H-300) raised against amino acids 1-300 mapping 
at the N-terminus of talin of human origin, 200 µg/ml, sc-15336, Santa Cruz 
Biotechnology, INC. (WB: 1:200)  
 
6 Rabbit anti-vinculin polyclonal antibody (H-300) raised against amino acids 1-300 
mapping at the N-terminus of vinculin of human origin, 200 µg/ml, sc-5573, Santa Cruz 
Biotechnology, INC. (WB: 1:200)  
 
7 Rabbit anti-filamin 1 polyclonal antibody (H-300) raised against amino acids 2348-2647 
mapping at the C-terminus of filamin 1 of human origin, 200 µg/ml, sc-28284, Santa Cruz 
Biotechnology, INC. (WB: 1:200)  
 
8 Goat anti-filamin 1 polyclonal antibody (N-19) mapping near the N-terminus of filamin 1 
of human origin, 200 µg/ml, sc-7565, Santa Cruz Biotechnology, INC. (WB: 1:200)  
 
9 Goat anti-SUMO 2/3 polyclonal antibody (N-18) mapping at the N-terminus of SUMO-2 
of human origin,200 µg/ml, sc-26969, Santa Cruz Biotechnology, INC. (WB: 1:250-500)  
 
10 Rabbit anti-SUMO 2/3 polyclonal antibody detecting at the N-terminus, 0.5 mg/ml, 
P61956, Millipore (WB: 1:1000)  
 
11 Rabbit anti-SUMO-2 (Sentrin-2) polyclonal antibody, 519100, Invitrogen (WB: 1:1000) 
 
12 Mouse anti-UBC9 monoclonal antibody (C-12) raised against amino acids 1-81 of UBC9 
of human origin, 200 µg/ml, sc-271057, Santa Cruz Biotechnology, INC. (WB: 1:250-
500)  
 
13 Rabbit anti-GAPDH antibody, 1 mg/ml, G9545, Sigma (WB: 1:1000) 
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Secondary Antibodies 
1 Alexa-Fluor 546 conjugated donkey anti-rabbit antibody, Fisher (Cy3, 1:1000) 
 
2 Alexa-Fluor 647 conjugated donkey anti-goat antibody, Fisher (Cy5, 1:1000) 
 
 
4.2. 2 Immunoprecipitation and Western Blotting (IP and WB) 
 
IP Preparation with Whole Cell Lysates: 6-well Plates for GA 15, 30 or 60 Minutes 
MDA-MB-231 cells were grown on 0.2% gelatin coated coverslips. After GA 15, 30, 60 
minutes, the media was aspirated and the cells were washed in cold PBS once. In each time 
point, 1 ml cold RIPA buffer (25 mM Tris HCl pH 7.6, 150 mM NaCl, 1% v/v NP-40, 1% v/v 
sodium deoxycholate, 0.1% v/v SDS, Thermo Fisher Scientific) with 1x protease inhibitor 
cocktail (10 µl, 1:100, PIC, Calbiochem®) was added to the cells for each well at the time 
point. The 1 ml whole cell lysates sample was split as 500 µl x 2 for each well. For the 
immunoprecipitation sample preparations (IPs), 500 µl lysed cell solution for each well was 
collected in an eppendorf tube and kept on ice; for the whole cell lysates samples, 500 µl 
lysed cell solution was transferred in another eppendorf tube and 80 µl 6x RSTB buffer was 
added to the whole cell lysates, vortexed and kept on ice or stored at -20°C.  
 
IP Preparation with Whole Cell Lysates: T25 Flasks  
MDA-MB-231 cells were grown on T25 flasks overnight. After drug treatment i.e. GA 6 
hours, the media was aspirated in the T25 flasks (control and treated) and the cells were 
washed in cold PBS once. 3 ml cold PBS was added to each T25 flask. A sterile disposable 
cell scraper (Fisher scientific) was used to get the cells detached. The cells were re-
suspended in 3 ml cold PBS and transferred into cold 15 ml Falcon tubes on ice. The cells 
were then centrifuged at 1500 rpm for 10 minutes at 4°C. The cell pellet was formed in the 
tube and the PBS was drained. 297 µl cold RIPA buffer mixed with 3 µl PIC was added to 
the cell pellet in the tube. A needle was used to re-suspend and shear the pellet with forces. 
Each Falcon tube was stood on ice for 30 minutes. The cell suspension from each Falcon 
tube was then transferred into a cold eppendorf tube and centrifuged at 13, 000 rpm for 15 
minutes at 4°C. The supernatant was transferred into a new cold eppendorf tube and kept 
on ice; the pellet was discarded. 15 µl of the prepared cell supernatant in each eppendorf 
tube (‘control’ and ‘treated’) was used for Bradford assay. The rest of the supernatant 
samples were added with 5x RSTB buffer, vortexed and stored at -20°C. 
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IP and Reverse IP with the Whole Cell Lysates  
2-5 x 105 cells were plated in each T25 flask initially. The IP talin or vinculin samples 
(Western blotting: IB with SUMO 2/3 ab) and the reverse IP SUMO 2/3 samples (IB: with 
talin or vinculin ab) were prepared as shown in Table 7. After whole cell lysates 
preparations, each endogenous IP sample was added with the FA antibody (talin or vinculin, 
single antibody used). Western blotting was done with the SUMO 2/3 (N-18) goat polyclonal 
antibody (Santa Cruz). The reverse endogenous IP sample was added with the SUMO 2/3 
antibody and the reverse WB would be done with the FA antibodies (talin or vinculin ab). For 
the whole cell lysates prepared in the 6-well plates, the samples (500 µl control or treated) 
were centrifuged at 10.000 rcf for 10 minutes at 4°C. The supernatant was transferred into a 
new eppendorf tube for each sample.  
 
Endogenous IP: Talin Control GA 15 minutes GA 30 minutes GA 60 minutes 
6-well plate 500µl wcl + talin ab 500µl wcl + talin ab 500µl wcl + talin ab 500µl wcl + talin ab 
T25 flask 300µl wcl + talin ab 300µl wcl + talin ab 300µl wcl + talin ab 300µl wcl + talin ab 
Western Blotting IB: SUMO 2/3 IB: SUMO 2/3 IB: SUMO 2/3 IB: SUMO 2/3 
Endogenous IP: 
SUMO 2/3 (reverse) 
Control GA 15 minutes GA 30 minutes GA 60 minutes 
6-well plate 500µl wcl + 
SUMO2/3 ab 
500µl wcl + 
SUMO2/3 ab 
500µl wcl + 
SUMO2/3 ab 
500µl wcl + 
SUMO2/3 ab 
T25 flask 300µl wcl + 
SUMO2/3 ab 
300µl wcl + 
SUMO2/3 ab 
300µl wcl + 
SUMO2/3 ab 
300µl wcl + 
SUMO2/3 ab 
Western Blotting IB: Talin IB: Talin IB: Talin IB: Talin 
 
Table 7. The endogenous IP experiments were only done with the whole cell lysates prepared from 
either 6-well plate or T25 flask. For each IP sample i.e. control vs. GA treated, only 1 antibody was 
added into each sample. This experiment was repeated for the vinculin antibody used, i.e. all the 
samples were prepared and each of the endogenous IP samples were added with vinculin ab only 
and the reverse SUMO 2/3 IP remained the same 
 
Normally, for a T25 flask whole cell lysate, the concentration of the cell lysate i.e. the total 
protein concentration calculated from Bradford assay was around 1~1.5 
mg/ml=1000~1500µg/1000µl. For example, for 1500µg/1000µl, in around 300 µl there was 
500 µg total protein concentration. For the talin/vinculin antibody (1mg/ml=1000µg/1000µl, 
Millipore), 2 µg of the antibody was needed per 100-500 µg of the total protein. Therefore, 2 
µl of the talin/vinculin antibody was added to the sample. In practice, 1.2-1.5 µl was added 
per 300 µl sample. For the talin-1 (H-300, c-9) or the filamin-1 (H-300) antibodies 
(200µg/1ml, Santa Cruz) used, in practice, 10-15 µl was used for doing the IP (2-3 µg 
antibody used) and 25 µl was used for doing western blotting. 10 µl SUMO 2/3 goat 
polyclonal antibody (200 µg/ml, 2 µg final concentration) was added per 500 µl or 6 µl per 
300 µl sample and rotated in the cold room at 4°C overnight. 
 
200 µl of the protein A/G plus-agarose beads was taken into an eppendorf tube and span at 
2000 rcf for 1min at 4°C; then the beads were washed in 0.3 ml cold RIPA buffer x 3 and 
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spun at 2000 rcf for 1minute at 4°C after each wash. The beads were re-suspended in 1.3 
ml of cold RIPA buffer (13 samples aliquots); then 100 µl of the re-suspended beads in RIPA 
buffer was added to each sample tube. The samples were then incubated with the beads in 
RIPA buffer at 4°C for 2 hours on the rotating machine. After rotating, the samples in the 
eppendorf tubes were span at 2000 rcf for 1 minute at 4°C. The first supernatant was 
removed and obtained into a new eppendorf tube for each sample tube. They were labelled 
as 1st supernatant and added with the 1x loading buffer directly. All the sample tubes were 
then washed in 0.3 ml cold RIPA buffer x3. A pellet was obtained in each sample tube after 
each washing pulling down the beads bound with the antibody attaching to the protein of 
interest. The pellet was kept and the RIPA washing buffer was discarded. After washing, 100 
µl 1x loading buffer was added to each beads-containing sample tube and vortexed. All the 
1st supernatant and the eluted IP samples were then boiled at 95°C for 5 minutes. 
 
The samples tubes were span for 1 minute at 2000 rcf at 4°C, leaving the beads in the pellet 
at the bottom of the tube (the pulled down talin/vinculin or the SUMO protein were separated 
in the supernatant). The supernatant in 1x loading buffer for each sample tube was 
transferred into a new eppendorf tube ready for western blot or stored at -20°C. The pellet 
beads were discarded. 
 
4.2. 3 pcDNA3 HA SUMO-2 WT Plasmid Transfection, Immunoprecipitation and 
Western Blotting 
 
HA SUMO-2 Plasmid Transfection / 6-well Plates and IHC 
1 x 105 MDA-MB-231 cells were firstly plated and grown on 0.2% v/v gelatin coated 
coverslips in a 6-well plate 1 day prior to transfection.  
 
 
 
 
 
 
Table 8. The HA SUMO-2 plasmid transfection time for MDA-MB-231 cells for 6-well plates 
 
In Table 8, MDA-MB-231 cells were grown in the 6-well plate and transfected with the HA 
SUMO-2 plasmid first (in 100 µl serum free DMEM media: 3.4 µl HA SUMO-2 plasmid was 
added first and a range of 6.8-10.2 µl PEI Polyethylenimine was added the last). The cells 
were left for incubation for 24 hours. Then, for both control and GA 1hr wells, the cells were 
HA-SUMO 2 transfection 6-well plate Control GA 1hr 
Per well/volume 2 ml 2ml 
Mixing for 15 minutes 100µl serum-free media: 
HA+PEI 1:3 
3.4µl+6.8-10.2µl (range) 
100µl serum-free media: 
HA+PEI 1:3 
3.4µl+6.8-10.2µl (range) 
24hr transfection incubation + mixture + mixture 
GA treatment at 100µM Media change only Media change + GA 
STOP time IHC IHC 
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washed with PBS once and fixed in 4% v/v PFA immediately for 20 minutes. Immunostaining 
was processed and the cells were stained with the mouse HA antibody and Alexa 488 anti-
mouse secondary antibody. 
 
HA SUMO-2 Plasmid Transfection / T25 Flasks 
The MDAMB231 cells were plated out and grown in T25 flasks as 70-80% confluence 
overnight. 216-234 µl serum free DMEM media (total volume 250 µl) was added with 8.5 µl 
HA SUMO-2 plasmid to a sterile eppendorf tube shown in Table 9, the tube end was tapped 
gently several times. 7.5-25.5 µl PEI (Polyethylenimine, 1 mg/ml) transfection reagent was 
added to the mixture the last and the tube end was tapped gently to mix the content well. 
HA-SUMO 2 
transfection 
T25 flask 
(2.5x factor) 
Control 
1 flask 
GA 15 mins 
1 flask 
Control 
1 flask 
GA 30 mins 
1 flask 
Control 
1 flask 
GA 60 mins 
1 flask 
Per 
flask/volume 
5 ml 5 ml 5 ml 5 ml 5 ml 5 ml 
 
Mixing for 
15 minutes 
250µl serum-
free media: 
HA+PEI    1:3 
8.5µl+ 
7.5-25.5µl 
250µl serum-
free media: 
HA+PEI    1:3 
8.5µl+ 
7.5-25.5µl 
250µl serum-
free media: 
HA+PEI    1:3 
8.5µl+ 
7.5-25.5µl 
250µl serum-
free media: 
HA+PEI    1:3 
8.5µl+ 
7.5-25.5µl 
250µl serum-
free media: 
HA+PEI    1:3 
8.5µl+ 
7.5-25.5µl 
250µl serum-
free media: 
HA+PEI    1:3 
8.5µl+ 
7.5-25.5µl 
24hr 
incubation 
+ mixture + mixture + mixture + mixture + mixture + mixture 
3
rd
 day: 
GA treatment 
at 100µM 
Media 
change only 
Media 
change + GA 
Media 
change only 
Media 
change + GA 
Media 
change only 
Media 
change + GA 
STOP time Wash in PBS Wash in PBS Wash in PBS Wash in PBS Wash in PBS Wash in PBS 
 
Table 9. The HA SUMO-2 plasmid transfection in the MDA-MB-231 cells for T25 flasks; this was used 
in the IP experiments. 
 
Table 9 shows the outlines of the T25 flasks prepared and the time for this experiment. The 
amount of HA SUMO-2 plasmid mixtures were prepared in the eppendorf tubes according to 
the number of the T25 flasks needed i.e. control flasks vs. GA flasks. The optimal plasmid 
DNA and the PEI was prepared as 1:3 ratio, however, PEI was also used as much as up to 
25.5 µl and the range was used between 7.5-25.5 µl. The amount for the serum free media, 
HA SUMO-2 plasmid or the PEI prepared was also accounted for the 2.5x bigger surface 
area than 1 well/6-well plate. The Eppendorf tubes were stood in the culture hood for 
incubation at room temperature for 15 minutes.  
 
After 15 minutes, the HA SUMO-2 plasmid mixture was added into each T25 flask containing 
5 ml fresh DMEM media and the transfection time was left for 24 hours. After 24 hours, 100 
µM GA was added into the treatment flasks accordingly and the incubation time was 15, 30 
or 60 minutes. In the control flasks, the media was changed only. Antibodies for GAPDH and 
total Akt were also used for these samples in the western blot experiments to determine 
116 
whether GAPDH or Akt could be SUMOylated, therefore they could be used as experimental 
controls for these HA-tagged SUMO-2 IP experiments.  
 
Immunoprecipitation Using the HA SUMO-2 Plasmid 
All the T25 flasks were washed with PBS once. All the buffers and steps were prepared on 
ice. The lysis buffer was prepared as 300 µl Pierce RIPA lysis and extraction buffer (Thermo 
Fisher scientific), 3 µl protease inhibitor cocktail (PIC 1x, 1:100, Calbiochem) and 50 µM N-
Ethylmaleimide (NEM, stock concentration 100mM: 50mg NEM dissolved in 4ml double 
distilled H2O, reagent for the covalent modification of cysteine residues in proteins, Sigma) 
were added into an eppendorf tube and mixed well. The lysis buffer was prepared enough 
according to the number of T25 flasks needed. The PBS was removed completely from the 
T25 flask and the 300µl lysis buffer was added into each T25 flask directly. A sterile 
disposable cell scraper (Fisher scientific) was used to scrape all the cells in the lysis buffer 
attached on the bottom of the T25 flask. The whole cell lysate from the T25 flask was 
collected into a new eppendorf tube immediately and all the whole cell lysate tubes collected 
from each T25 flask were left on ice. No centrifugation steps were used. 
In practice, 1.5-3 µl of the mouse IgG1 anti-HA.11 epitope tag antibody (1 mg/ml, Biolegend, 
for IP used as 1:100-200) was added into each labelled 300µl cell lysate tube as control or 
treated. All the sample tubes were rotated with continuous mixing overnight at 4°C. The 
PierceTM protein A/G magnetic beads solution (10mg/ml in H2O containing 0.05% NaN3, 1ml, 
Thermo scientific) was gently mixed until all of the beads were uniformly resuspended. 16 µl 
of the A/G magnetic beads was added into each corresponding eppendorf tube and placed 
into the magnetic stand (Millipore) to capture the beads. The beads were washed with 500 µl 
TBST (1x) once in each tube. The beads were captured using the magnetic stand in each 
tube, the TBST solution was discarded. Each 300 µl wcl sample tube was added with the 16 
µl washed magnetic beads correspondingly and mixed well. All the tubes were rotated for 1h 
at 4°C with continuous mixing.  
The sample tubes were re-engaged with the magnet to capture the beads. The first 
supernatant was removed into a new corresponding eppendorf tube and stored for each 
sample tube labelled as supernatant control or supernatant treated. The sample tubes were 
dis-engaged from the magnet and the beads were washed with 500 µl TBST x 3; with each 
washing, the beads were re-engaged with the magnet and the TBST solution was discarded. 
110 µl of the 1x RSTB buffer was added to each IP sample tube (prepared from 1 T25 flask). 
In practice, 110 µl was appropriate for doing 2 4-20% Mini-PROTEAN® TGX™ precast 
polyacrylamide gels (10-well, 50 µl, Bio-Rad). For the supernatant samples, each tube was 
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added with 1x RSTB. The IP beads sample tubes and the supernatant samples containing 
1x RSTB buffer were boiled at 95°C for 5 minutes. Then, the IP tubes were put on the 
magnetic stands to isolate the RSTB solution liberating the precipitated antigens of proteins 
from the insoluble protein A/G magnetic beads. These were labelled as IP control or IP 
treated samples.  
Western Blotting with Fluorescence 
For western blots, 3.5 µl precision plus protein™ dual colour standards was added at the 
stacking well lane 1 of the 4-20% gel. 50 µl from each prepared IP sample was loaded into 
the corresponding stacking well. 1x running buffer was prepared from 10x Tris/Glycine/SDS 
electrophoresis buffer (Bio-Rad) and filled to the mark indicated on the gel tank. The proteins 
were run through the resolving gel at constant voltage 150V for 45 minutes by SDS-PAGE.  
The electrophoresis was stopped until the protein tracking dye migrated just over the black 
mark gel end. The trans-blot® semi-dry transfer cell (Bio-Rad) was used for protein transfer. 
1 gel size was 8.6 x 6.7 cm; all the papers cut were taken for the size of 1 gel. 6 blotting 
chromatography papers (GE Healthcare, WhatmanTM) were soaked in the anode buffer (final 
volume 500 ml: 18.165g 300mM Tris, 100ml 20% methanol prepared in 400ml Nano pure 
H2O, dissolved and pH=10.4) for 3-5 minutes and put on the transfer cell. 1 hydrophobic 
Immobilon®-FL PVDF transfer membrane at pore size 0.45 µm (Millipore, best use for 
fluorescence scanning) was soaked in 100% methanol for 5 minutes; then the membrane 
was put on top of the 6 anode buffer soaked papers. The gel was then covered on top of the 
membrane evenly with no bubbles. 6 blotting papers were soaked in the cathode buffer (final 
volume 500 ml: 1.514g Tris, 2.624g amino caproic acid, 100ml methanol prepared in 400ml 
Nano pure H2O, dissolved and pH=9.2) for 3-5 minutes and put on top of the gel. The excess 
buffer was removed from the edge of the transfer ‘sandwich’. The transfer was set at 15V for 
1.5 hrs.  
The membrane was blocked in 5% v/v BSA in TBST solution (BSA, Bovine Serum Albumin, 
First Link, Ltd) for 20 minutes. Then the membrane was blotted with the primary antibody. 
For example, talin H-300 detecting at the N-terminus of human talin (rabbit polyclonal, Santa 
Cruz biotechnology) or vinculin H-300 detecting at the N-terminus of human vinculin (rabbit 
polyclonal, Santa Cruz biotechnology), in practice, these 2 primary antibodies were prepared 
as 25µl added with 5ml of 2% BSA-TBST solution (1:200). Depending on the size of the 
membrane used, the primary antibody used was between 20-25µl. The membrane was 
incubated with the primary antibody overnight at 4°C with continuous rotation.  
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The membrane was washed with 1x TBST 3 times, each time was 10-15 minutes washing. 
Then the membrane was added with the secondary antibody. The secondary antibodies 
used were Alexa Fluor® 546 donkey anti-rabbit IgG (H+L) (red colour, life technologies) or 
Alexa Fluor® 647 donkey anti-goat IgG (H+L) (blue colour, life technologies). Alexa 546 is 
equivalent to Cy3, which would be scanned by the green laser on the Typhoon at 532nm; 
Alexa 647 is Cy5, which would be scanned by the red laser at 635nm. The antibody was 
prepared in 5ml 2% BSA-TBST solution. The membrane was incubated with the secondary 
antibody solution for 1hr at 4°C with continuous rotation. After secondary antibody 
incubation, the membrane was washed with 1x TBST for 3 times, each time 10-15 minutes. 
 
Fluorescent Scanning 
The membranes were ready for fluorescent scanning and imaging using the Typhoon FLA 
9500 (GE Healthcare). The Typhoon machine has multiple imaging modes which can 
produce digital images from chemiluminescent, fluorescent or radioactive samples. It 
scanned the membrane with 2 lasers: green as Cy3, Channel 1 or red as Cy5, Channel 2, 
which led to the ﬂuorescent dye (secondary antibodies) on the samples emitting light. The 
secondary antibodies were the Alexa 546 donkey anti-rabbit (pink) Cy3 (which could detect 
GAPDH, SUMO etc) or the Alexa 647 donkey anti-mouse (blue) Cy5 (talin, Ubc9 etc), which 
could detect the proteins of interest for separate channels. The membrane was placed onto 
the glass platen of the Typhoon instrument. The scanner control software was selected with 
550-600 scanning parameters; the dye colours were appropriately selected, which the green 
laser (532 nm) or the red laser (633 nm) could illuminate and produce fluorochrome, which 
would emit light with a characteristic spectrum. The optical system directs the light through 
the emission filters, which passes the emitted light to the PMT (photomultiplier tube) only 
within the filter’s bandwidth. The signal can then be converted into digital images. The level 
of signal is proportional to the amount of fluorescence in the membrane. ImageQuant was 
used to quantify the variations in the signal and the bands area. 
 
4.2. 4 VIVA BindTM-SUMO Kit and Western Blotting 
 
Whole Cell Lysates Preparations for Non-Flushed Cells with Fibronectin Coating 
The T25 flasks were coated with the human fibronectin (hFN) previously before cell plating. 
0.4ml of thawed 2mg/ml hFN solution was mixed with 4.6ml cold PBS to make up 150µg/ml 
working stock solution. For coating each T25 flask, 15µg/ml final concentration was used. 
2.5ml of the diluted hFN was added to each T25 flask to coat the base. The hFN solution 
119 
was left for 1 hour incubation at room temperature in the culture hood. Then the hFN solution 
was aspirated off and the flasks were washed with PBS gently.  
 
For the non-flushed MDA-MB-231 cells preparation, the cells were plated into the required 
number of hFN coated T25 flasks and grown on coated hFN for 2 days in the incubator. The 
next day, the cells were treated with 100µM GA for 1 hour and also the control flasks were 
prepared. For the T25 flasks, 250-300µl lysis buffer supplemented with 50mM NEM (the 
lysis buffer was included in the SUMO Kit containing 50mM Tris-Cl, pH 7.5, 150mM NaCl, 
1% NP40, 0.5% deoxycholate, 200mM iodoacetamide, 0.1% v/v protease inhibitor cocktail 
III, Roche) was added to each flask immediately and the cells were scraped off. 1 T25 flask 
wcl collected as 250-300µl was enough to add 1 SUMO matrix volume as 40µl or up to 75µl. 
All the samples collected in eppendorf tubes were kept on ice.  Sonication for the samples 
was done on ice for about 10s.  
 
VIVA BindTM-SUMO Matrix Preparation 
All the preparations were done on ice. The VIVAbindTM SUMO matrix (viva bioscience) was 
resuspended by inverting the tube gently several times. 40µl VIVAbindTM SUMO matrix 
suspension was aliquoted into required number of capped VIVA biospinTM columns. 250µl 
equilibration buffer (made with 50mM Tris-Cl at pH 7.5, 150mM NaCl and 1% NP40) was 
added into each capped column and mixed with the SUMO matrix for 1 minute. The base 
cap was then removed and the columns placed in clean eppendorf tubes and centrifuged at 
5000g for 1 minute to collect the matrix. The flow through was discarded. The matrix wash 
and collection was repeated at least 2 times.  
 
VIVA BindTM-SUMO Assay 
200-300µl cell lysate was added to each capped VIVAbindTM SUMO matrix column and 
mixed by inversion. The cell lysate with the matrix for each capped column was incubated at 
4°C overnight with continuous rotation. Input samples were also prepared as the whole cell 
lysates only for the control vs. GA 1 hour. The next day, the column base was uncapped and 
the column was placed in a VIVA biospinTM collection tube. The collection tubes were 
centrifuged at 5000g for 1 minute to collect the matrix. The first flow through was removed 
and retained as 1st supernatant unbound fraction. These unbound samples were later added 
with 1x RSTB buffer and noted as control unbound vs. GA unbound. The input and the 
unbound samples were calculated for the protein loading control using the Bradford assay. 
The columns were replaced in the corresponding collection tubes and the materials were 
washed with 250µl wash buffer (made with 50mM Tris at pH 7.5, 250mM NaCl and 1% 
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NP40). The collection tubes were centrifuged at 5000g for 1 minute to collect the matrix and 
the flow through was discarded. The materials were washed 3 times.  
 
Elution of Captured SUMOylated Proteins 
The columns were capped again and 100µl 1x RSTB SDS-PAGE sample loading buffer was 
added to each capped column and mixed by inversion. The columns were placed in heat-
protected clean microfuge tubes. The tubes were heated to 95°C for 5 minutes. The base 
caps were removed and the columns were centrifuged at 5000g for 1 minute to collect the 
eluted materials. These were ready to run on the gels. The input, unbound and eluted 
samples were run on 4-20% gradient gels. The eluted samples were run twice on the gels. 
The IP eluted samples were blotted with talin or vinculin antibody and GAPDH antibody for 
each membrane.  
 
4.2. 5 Isolation of Focal Adhesions with the VIVA BindTM-SUMO Kit and Western 
Blotting 
 
Figure 35. The isolation of FA outlined method shown in three steps 
 
 
Culture media removed and wash in PBS 
3-5 minutes hypotonic shock 
Cell bodies, membrane, nucleus removed with hydrodynamic force 
Collect isolated FA in denaturing lysis buffer 
Sonication 
STEP 2 
Cultured MDA-MB-231 intact cells on 15 µg/ml human fibronectin  STEP 1 
Unbound whole cell lysate fraction Elution of captured SUMOylated proteins 
SUMO binding assay STEP 3 
Protein identification by western blot and proteomic analysis 
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The focal adhesion isolation protocol was modified from Waterman C.M. 2011 (Integrin and 
cell adhesion molecules, methods and protocols, chapter 19) in Figure 35. MDA-MB-231 
cells were grown on fibronectin (15µg/ml) coated T25 flasks or petri dishes and left in the 
incubator at 37°C/5% CO2 for 1-2 days. The dishes were prepared as control petri dishes x3 
and GA 1h dishes x3. A higher concentrated isolated FA whole cell lysates were also 
prepared as control petri dishes x6 and GA 1h dishes x6. The culture media was removed 
and the cells were washed in 1x PBS once. The osmotic shock and the trituration steps were 
optimized for the MDA-MB-231 cells. The cells were incubated in 2.5mM low ionic strength 
TEA buffer (Triethanolamine, Sigma, 7.5mg TEA was dissolved in 20ml ddH2O, pH 7.0) for 
3-5 minutes at room temperature. This would give the cells a hypotonic shock, which gave 
osmotic pressure inside the cells, as the cells were observed a little bit swelling in the cell 
body and around the cell plasma membrane indicating the membrane integrity was 
weakened. At this time, the cells were given strong trituration quickly to remove the nuclei, 
soluble proteins and materials of the cytoplasm. An Ultra Waterpik® Waterflosser® Jet water 
flush was used, which the tank was filled with 1x flushing buffer containing 20ml of 1x PBS 
mixed with 200µl 1x PIC and 50mM NEM. The trituration pressure was set between ‘0’ and 
‘1’ and the nozzle of the waterflosser was held at about 150° angle with a slight tilt towards 
the neck of the T25 flask or the edge of the petri dish. It was sprayed evenly and carefully 
across the entire dish/flask area with the nozzle back and forth. The spraying lasted for 
about 8~10s. This gives hydrodynamic force on the cells to flush out cell bodies, nuclei, cell 
plasma membranes leaving only focal adhesions adhered on the bottom of the T25 flasks or 
the petri dishes. The excess buffer was removed and the cells were washed with fresh PBS 
once. The flushing buffer was collected after each spraying and recycled for use in trituration 
of the next dish. The isolated FAs were collected in denaturing lysis buffer. 100µl RIPA 
containing 1µl PIC and 20µl 20mM NEM was added to each dish and a cell scraper was 
used to remove and collect the rest remaining cell contents. Sonication was supplied to the 
collected FA samples for about 10s on ice.  
 
The flushed FA samples were then run through the SUMO binding kit column containing 
40µl SUMO matrix to obtain ‘unbound’ and ‘eluted’ samples. ‘Input’ samples were also run 
through for the samples which were probed for GAPDH. Some eluted samples were stored 
at -20°C for proteomic analysis later. The protein amount of the isolated FAs was compared 
between the non-flushed and the first flushed unbound samples. Antibodies used were talin, 
vinculin, FAK, paxillin, α-actinin, α-tubulin, phosphor-Rac1/Cdc42 and actin which are known 
FA or FA associated proteins. Antibodies including total Akt, phospho-Akt, phospho-p44/42 
MAPK (Erk1/2), E-cadherin, cleaved caspase 3 and RhoA were also used to detect these 
proteins in the flushed wcl samples. In the higher concentration of FA isolation experiment, 
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the eluted samples were split in eppendorf tubes x3 and loaded onto separate gels x3. For 
western blot, the samples were run with 50µl loaded on the 4-20% precast gel. Talin and 
vinculin primary antibodies were used.  
 
Stripping and Re-blotting with the Isolated FA Samples 
The membranes were washed in TBST x3. 1x stripping buffer (Millipore) made from 
0.5ml+4.5ml ddH2O was added to each membrane sealed in the plastic bag and rotated for 
20 minutes at room temperature. The stripping buffer was removed and the membrane was 
washed in TBST x3. The membranes were re-blocked in 5% v/v BSA-TBST for 20 minutes. 
Then the membranes were blotted with the vinculin primary antibody and incubated 
overnight.  
 
4.2. 6 Co-Immunoprecipitation 
MDA-MB-231 cells or U2OS cells were grown in T25 flasks overnight. 1 set of 4 T25 flasks 
of cells were transfected with the GFP-Talin 1 plasmid (414.5µg/ml) as IP talin and 2 sets of 
4 T25 flasks of cells were transfected with the mEmerald-vinculin plasmid (861.6µg/ml) as IP 
vinculin (Table 10). In total 12 T25 flasks were prepared. The transfection ratio was 1:3. 
Then IP whole cell lysates were made by using the mouse GFP antibody for these IP talin or 
IP vinculin samples, pulling down all the talin or vinculin proteins for each cell line used. 
Western blotting was done; in the IP talin and WB experiments, these samples were blotted 
with filamin-1 or actin antibodies; in the IP vinculin WB experiments, these samples were 
blotted with talin-1 antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10. Showing the transfection time and different drug treatments for each T25 flask 
 
In Table 10, 6µl GFP-talin 1 or 3µl mE-vinculin plasmid (1 µg plasmid DNA used and applied 
for 2.5x surface area in T25 flask) was mixed with 7.5µl PEI; the mixture was added into the 
corresponding T25 flask for 24 hours incubation. Then the cells were treated with GA, Goss 
HA-SUMO 2 
transfection 
T25 flask 
Control 1hour 
1 flask 
GA 1hour 
1 flask 
Goss 1hour 
1 flask 
2D08 1hour 
1 flask 
Per flask/volume 5 ml 5 ml 5 ml 5 ml 
Mixing for 
15 minutes 
 
 
IP talin 
 
IP vinculin 
250µl serum-free 
media: 1:3 
250µl serum-
free media: 1:3 
 
250µl serum-
free media: 1:3 
 
250µl serum-
free media: 1:3 
 
GFP-talin 1+PEI 
6µl+7.5µl 
GFP-talin 1+PEI 
6µl+7.5µl 
GFP-talin 1+PEI 
6µl+7.5µl 
GFP-talin 1+PEI 
6µl+7.5µl 
mE-vinculin+PEI 
3 µl+7.5µl 
mE-vinculin+PEI 
3 µl+7.5µl 
mE-vinculin+PEI 
3 µl+7.5µl 
mE-vinculin+PEI 
3 µl+7.5µl 
24hr 
incubation 
+ mixture + mixture + mixture + mixture 
3
rd
 day: 
drug treatment 
at 100µM 
Media change 
only 
Media change + 
GA 
Media change + 
Gossypetin 
Media change + 
2D08 
STOP time Wash in PBS Wash in PBS Wash in PBS Wash in PBS 
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or 2-D08 for 1 hour at 100µM final concentration. Whole cell lysates were made. 1.5µl of the 
anti-GFP antibody was added into each IP whole cell lysates samples. All the samples were 
incubated at 4°C for continuous rotatory mixing overnight; 16µl of the washed protein A/G 
magnetic beads were added into each IP samples for immunoprecipitation and the steps 
were described in the IP methods previously; these samples were ready for WB experiments.  
 
4.2. 7 Co-Transfection with siRNA and HA SUMO-2 Plasmid 
MDA-MB-231 cells were grown on T25 flasks overnight. The cells were transfected with 
25nM Ubc9 siRNA the next day for 24 hrs. Then at the 24 hrs point, the cells were 
transfected with the HA-SUMO-2 plasmid for 24 hrs. This would be within the time as the 
Ubc9 siRNA transfection time was for 48 hrs. Then the cells were made whole cell lysates 
and IP samples were prepared. Western blotting was done and talin primary antibody was 
used. 
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Results 
 
4. 3. 1 IP and WB Reveals Talin is SUMOylated 
IP samples were prepared from MDA-MB-231 whole cell lysates. In Figure 36, for the IP 
SUMO 2/3 samples, any proteins that were bound with SUMO were precipitated, western 
blotting was done to probe with the talin antibody (two antibodies were used in various 
repeated experiments: talin-1 Millipore, c-9 Santa Cruz); the talin antibody used was able to 
detect the N-terminus of the talin molecule. On the membrane, talin at 250kDa was seen in 
both of the untreated control samples and the GA treated 15, 30 or 60 minutes samples. For 
the IP talin samples, all the talin proteins in the whole cell ysates were precipitated and WB 
was done to probe with the SUMO 2/3 antibody, which detected the SUMOylated talin band 
at 250kDa in both of the untreated control samples and the GA treated 15, 30 or 60 minutes 
samples on the WB membrane. All the antibodies used were made in different species.  
 
Figure 36. IP SUMO 2/3 and WB probing for talin detected the SUMOylated talin at 250kDa in the 
untreated control 15, 30 or 60 minutes and in the 100µM GA 15, 30 or 60 minutes treated cells; for the 
IP talin and WB probing for SUMO 2/3 also detected the SUMOylated talin at 250kDa in the untreated 
control 15, 30 or 60 minutes and in the GA 15, 30 or 60 minutes treated cells. Both IPs were shown 
from the whole cell lysates preparations only in the MDA-MB-231 cells, n>3 repeated more than 3 
replicate experiments (representative immunoblots are shown) 
 
In the IP SUMO 2/3 experiment, after 60 minutes of 100µM GA treatment, much less 
SUMOylated talin was detected compared to GA at 15 and 30 minutes treatment. Similarly, 
in the IP talin experiment, less SUMOylated talin was obtained in the GA 60 minutes 
treatment. In these experiments, the IPs and immunoblots have shown the intact full-length 
of talin band at 250kDa from the whole cell lysates preparations only.  
 
IP: SUMO 2/3, IB: Talin 
         MDA-MB-231 cells                              
Ctrl     GA      Ctrl       GA       GA    Ctrl       
 15      15       30        30         60      60 (mins)              
IP: Talin, IB: SUMO 2/3  
      MDA-MB-231 cells                       
Ctrl     GA     Ctrl       GA     GA      Ctrl  
 15      15       30        30      60       60  (mins)         
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4. 3. 2 IP and WB Reveals Vinculin is SUMOylated  
The IP SUMO 2/3 experiments (samples prepared from whole cell lysates only) have shown 
SUMOylated vinculin in MDA-MB-231 cells in Figure 37. Similarly, after 100µM GA 1 hour 
treatment, it has shown a lower amount of SUMOylated vinculin in the cells compared to the 
untreated controls or GA 2h treatment.  
 
 
 
 
 
Figure 37. IP SUMO 2/3 and WB probing for vinculin showing the SUMOylated vinculin at 130kDa in 
both of the untreated control and 100µM GA treatment at 1hr or 2hrs samples in the MDA-MB-231 
cells, n>3 repeated more than 3 replicate experiments (representative immunoblots are shown) 
 
 
4. 3. 3 HA-tag SUMO-2 Plasmid Transfection Shows the Expression of SUMO-2 in the 
Cytoplasm and in the Nucleus of the MDA-MB-231 Cells 
MDA-MB-231 cells were transfected with the HA-tagged SUMO-2 plasmid and left for 24 
hours incubation. The anti-HA tag primary antibody was used in the IHC experiment to stain 
SUMO-2 in the cells. The cells were also stained with DAPI (blue staining for the nucleus).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. The HA-tagged SUMO-2 plasmid transfection in MDA-MB-231 cells showing SUMO-2 
expression in grey; DAPI was shown as blue on the right picture. The transfection efficiency was 
optimized to express SUMO-2 in the cells. SUMO-2 was expressed in the nucleus and in the 
cytoplasm (scale bar =20µm) 
 
In Figure 38, SUMO-2 was expressed in the nucleus and in the cytoplasm of the MDA-MB-
231 cells. In this experiment, the transfection with the HA-tag SUMO-2 plasmid in the cells 
would increase the expression of SUMO-2 level in the cells, which were used in the IP 
experiments. This method would also increase the chance of capturing SUMOylated proteins 
in the cells for the IP experiments. 
    GA       Ctrl          GA         Ctrl  
    2h         2h           1h          1h 
              
IP: SUMO 2/3, IB: Vinculin 
130kDa 
+ HA-tagged SUMO-2: Grey + Nucleus DAPI staining: Blue 
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4. 3. 4 GAPDH or Akt are not SUMOylated 
In the HA-tagged IP experiments, 100µM GA was used to treat the cells at 30 and 60 
minutes. GAPDH and Akt antibodies were used to determine whether GAPDH or Akt could 
be SUMOylated in MDA-MB-231 cells, as there is no evidence that they can be 
SUMOylated. They were used as a negative control. 
 
        HA IP: SUMO-2, IB: GAPDH                                    HA IP: SUMO-2, IB: Total Akt 
 
 
Figure 39. HA-tagged SUMO-2 IP and WB showing that GAPDH and Akt were only in the WB whole 
cell lysates but not in the HA IP pull-down SUMO-2 samples in the MDA-MB-231 cells 
 
In Figure 39, the HA-tagged SUMO-2 IP samples were on the left half of the IB membrane, 
the first supernatant whole cell lysates samples were on the right half of the IB membrane as 
a control for the experiments. GAPDH at 37kDa was found in the cells only in the whole cell 
lysates prepared samples; total Akt was found in the cells only in the whole cell lysates. In 
the HA IP SUMO-2 pulldown samples, GAPDH was not seen at 37kDa in any of the 
samples; similarly, total Akt was not seen at 60kDa in any of the samples. This suggests that 
the GAPDH or the total Akt were present in the cells, but they may not be SUMOylated.  
 
4. 3. 5 HA-tag SUMO-2 IP Detects both Full-length SUMOylated Talin and Fragments of 
Talin 
MDA-MB-231 cells were prepared for the HA-tagged IP SUMO-2 samples. The cells were 
treated with 100µM GA for 15, 30 or 60 minutes. Anti-HA tag mouse primary antibody was 
added to all samples and incubated at 4°C overnight; the HA IP samples were then added 
with the protein A/G magnetic beads to immunoprecipitate the SUMO binding proteins. 
Western blotting was done to probe for talin using the talin primary antibody (H300, Santa 
Cruz). The membranes were also probed for SUMO 2/3 using the SUMO 2/3 primary 
         HA IP & IB                          Whole cell lysates  
     Ctrl   GA    Ctrl     GA            Ctrl     GA    Ctrl     GA 
     30     30     60      60               30      30      60     60 (mins) 
                                                     
          HA IP & IB                Whole cell lysates 
Ctrl    Ctrl     Ctrl    GA        Ctrl     GA    Ctrl     GA  
30      30      60      60         30       30      60      60 (mins) 
                                                            
37kDa 
60kDa 
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antibody. All the antibodies used were made in different species to avoid cross-reaction of 
the antibodies.  
 
           HA IP: SUMO-2, IB: Talin                                      HA IP: SUMO-2, IB: SUMO-2 
 
 
 
 
 
 
 
 
 
 
 
 
Combined Cy3 and Cy5 Channels: 
The overlay: Alexa 546 anti-rabbit ab 
detecting talin=Cy3 (talin, green) and 
the Alexa 647 anti-goat ab detecting 
SUMO-2/3=Cy5 (SUMO-2/3, red)  
 
Figure 40. HA-tag SUMO-2 IP and 
WB showing that in all the samples in 
the untreated control and the 100µM 
GA treated 15, 30 or 60 minutes 
samples, talin at 230kDa was 
detected in the HA-tag SUMO-2 IP 
pulldown samples in the MDA-MB-
231 cells; talin fragments were also 
detected: the arrows indicating bands 
between 75-100kDa, 37-50kDa; the 
bands at 230kDa and 37-50kDa were overlaid on the overlay immunoblot. Bands at 50kDa and 
25kDa were also shown. The total talin was present in the whole cell lysates in both of the control and 
GA at 30 minutes as a control of the IP experiments. n=5 (representative experiment immunoblots are 
shown) 
  
In Figure 40, 5 experiments were done to demonstrate the SUMOylation of talin. In these 
HA-SUMO 2 IP pulldown experiments, all the SUMO modified proteins were precipitated. On 
the immunoblots, SUMOylated talin were shown as full-length protein at 230kDa in all the 
samples (depending on the antibody used). After GA 60 minutes treatment, a lesser amount 
of SUMOylated talin was detected compared to the control 60 minutes.  
 
In both of the control and the GA treated samples, other fragments of the talin bands were 
seen (shown pointed with the black arrows). There were four other fragmented bands of talin 
230 
kDa 
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detected. The fragmented bands were ranged as: one fragment band was between 75-
100kDa in all of the samples including the untreated control samples and the GA treated 
samples; one band was at 50kDa in all of the samples; one fragment was between 37-
50kDa and this band was most likely at 47kDa detected as the head of talin, which was in 
the control samples and in the GA 30 minutes sample, however, this band was less detected 
in the GA 15 minutes and GA 60 minutes treatment samples; one band was shown at 25kDa 
in all of the samples.  
 
On the SUMO-2 membrane, there were two very faint bands ranged above 230-250kDa in 
all of the samples; there were also four prominent bands showing ranged as: one band was 
detected at 150kDa in all of the samples; one band was at 50kDa in all of the samples; one 
band was detected between 37-50kDa and was likely to be at 47kDa in all of the samples; 
however, this band was less shown in the GA 15 minutes and GA 60 minutes treatment; one 
band was at 25kDa in all of the samples.  
 
On the overlay membrane, the bands at 50kDa and 25kDa were overlaid together in both of 
the separate membranes; the bands at 230kDa and 47kDa were also overlaid, as the 
overlaid bands at 47kDa were less detected in the GA 15 minutes and the GA 60 minutes 
samples. From these overlaid bands, it suggests that these fragmented bands of talin must 
also be SUMOylated. Looking closely, the fragments between 37-50kDa (and more likely to 
be the 47kDa head of talin) were gone on the Talin membrane after 100µM GA 15 and 60 
minutes treatments, on the SUMO-2 membrane, these bands were also less shown; on the 
overlay membrane after 100µM GA 15 and 60 minutes treatments they were less detected. 
The evidence of the cleaved products of talin molecules after 100µM GA 15 minutes 
treatment were confirmed in platelets (discussed in Chapter 6).  
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4. 3. 6 HA-tag SUMO-2 IP Detects SUMOylated Vinculin  
HA-tagged IP samples were prepared from MDA-MB-231 cells and western blotting was 
done to probe for vinculin and SUMO-2/3 on the membrane.  
 
      HA IP: SUMO-2, IB: Vinculin                      HA IP: SUMO-2, IB: SUMO-2 
 
 
 
 
 
 
 
 
 
 
 
Combined Cy3 and Cy5 Channels 
The overlay: Alexa 546 rabbit ab 
detecting vinculin=Cy3 (vinculin, 
green) and the Alexa 647 anti-goat ab 
detecting SUMO-2=Cy5 (SUMO-2, 
red) 
Figure 41. HA-tag SUMO-2 IP and 
WB showing that vinculin can be 
SUMOylated in the IP SUMO-2 
pulldown samples in both of the 
control and GA treated 15, 30 or 60 
minutes in the MDA-MB-231 cells, n=3 
(representative immunoblots are 
shown) 
 
In Figure 41, cleaved vinculin seemed to be immunoprecipitated in the IP SUMO-2 pulldown 
in all controls and GA treated 15, 30 and 60 minutes samples.  
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4.3. 7 SUMO VIVATM Binding Assay and IP SUMOylated Talin or SUMOylated Vinculin 
in Isolated FAs 
This isolation of FAs method was used and modified from Waterman C.M. 2011 (Integrin 
and cell adhesion molecules, methods and protocols, chapter 19). The purpose of FA 
isolation from cultured cells was to maintain the native FA protein structure and composition 
leaving them bound to culture flask/dish substratum, whilst removing substantial cytoplasmic 
membrane-bound organelles, nuclei and most cell plasma membrane with careful 
hydrodynamic force. As this method unavoidably preserved a significant amount of the 
cytoskeletons including the F-actin, tubulin etc, it was modified in practice to maintain FA 
structure and composition as the FA and actin cytoskeleton are interdependent structures.  
 
In Figure 42, MDA-MB-231 cells were prepared as whole cell lysates without flushing to 
detect their FA proteins. Talin, vinculin, FAK and actin were present in the cells. This serves 
as a control for the ‘flushing method’. In Figure 43, the cells were also prepared as flushed 
unbound whole cell lysates samples and the first run-through whole cell lysates from the 
SUMO binding columns were kept to detect their main FA proteins. Talin, vinculin, FAK, α-
actinin, α-tubulin and actin were present in the flushed unbound whole cell lysates. 
Surprisingly, phospho-Rac1/cdc42 (Ser71) was also found in the flushed unbound whole cell 
lysate samples. The cytoplasmic proteins and the others that are not directly associated with 
the FAs including total Akt, phospho-Akt, Phospho-p44/42 MAPK (Erk1/2), E-cadherin, 
cleaved caspase 3 and RhoA were absent in the collected flushed whole cell lysate samples 
indicating the cell bodies were removed.  
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Figure 42. MDA-MB-231 cells were grown on fibronectin-coated T25 flasks and whole cell lysates 
were prepared without ‘flushing’ to detect their focal adhesions in the cells. The samples were run 
through the SUMO binding columns and kept as the first run-through unbound supernatant. Talin, 
vinculin, FAK and actin were present in the cells using the antibodies correspondingly.  
 
In the non-flushed unbound whole cell lysates samples in Figure 42, talin, vinculin, FAK and 
actin were present, which were used as a control to compare with the flushed unbound 
whole cell lysates samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43. MDA-MB-231 cells were grown on fibronectin-coated T25 flasks and the cells were given 
‘flushing’ using the water flosser. The flushed cells were collected from the flasks, whole cell lysates 
were made and the samples were run through the SUMO binding columns and kept as the first run-
through unbound supernatant. Talin, vinculin, FAK, α-actinin, actin, α-tubulin and phospho-
Rac1/cdc42 were present in the flushed unbound whole cell lysates, indicating that the ‘flushing’ 
method could still keep the FA proteins in the preparations. The cytoplasmic proteins were absent in 
the flushed unbound whole cell lysates including the total Akt, phospho-Akt, phospho-p44/42 MAPK 
(Erk1/2), E-cadherin, cleaved caspase 3 and RhoA.  
‘Non-flushed’ Unbound Whole Cell Lysates 
Actin 
42kDa 
Talin 
250kDa 
Vinculin 
130kDa 
FAK 
125kDa 
E-cadherin 125kDa 
RhoA 21kDa  
Cleaved Caspase 3 17, 
19kDa 
Phospho-Akt 
(Ser473) 60kDa 
Total Akt 60kDa 
Phospho-p44/42 MAPK 
(Erk1/2) 44kDa 
‘Flushed’ Unbound Whole Cell Lysates 
α-actinin 
105kDa 
Phospho-
Rac1/cdc42 (Ser71) 
25kDa Vinculin 
130kDa 
Talin 
250kDa 
FAK 
125kDa Actin 42kDa 
α-tubulin 
50kDa 
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In Figure 43, the cells were flushed using the water flosser. The main FA proteins including 
talin, vinculin, FAK, α-actinin, actin, α-tubulin and phospho-Rac1/cdc42 were present in the 
flushed unbound whole cell lysates, indicating that the ‘flushing’ method was able to keep 
the FA proteins in the preparations. The cytoplasmic proteins were absent in the flushed 
unbound whole cell lysates including the total Akt, phospho-Akt, phospho-p44/42 MAPK 
(Erk1/2), E-cadherin, cleaved caspase 3 and RhoA, indicating that the flushing method could 
remove the cell body. 
 
The flushed isolation of FA protein samples were prepared for MDA-MB-231 cells (3x petri 
dishes for the control and 3x petri dishes for the GA 1hr treated). In the flushed isolated FA 
‘eluted’ samples, GAPDH was probed on the WB membranes in Figure 44. GAPDH was 
found in the ‘input’ and ‘unbound’ samples but not found in the ‘eluted’ samples. In Figures 
45 and 46, talin and vinculin were found to be bound with SUMO and eluted down through 
the columns, indicating that talin or vinculin could be SUMOylated.  
                                             
 
 
 
 
 
 
 
 
 
 
 
Figure 44. SUMO binding assay using the SUMO matrix and binding columns in the IP SUMO and 
WB experiments has shown that GAPDH was present in the ‘unbound whole cell lysates’ control or 
GA1hr treatment samples or in the ‘input whole cell lysates’ control or GA 1hr treatment samples, but 
GAPDH was not found in the eluted IP control or GA 1hr treated samples, suggesting that GAPDH 
was not SUMOylated in the MDA-MB-231 cells. This was shown as a negative control for the SUMO 
binding assay experiments. n=3 (representative immunoblots were shown) 
 
In Figure 44, GAPDH was not SUMOylated in MDA-MB-231 cells as GAPDH was not found 
to be SUMO-bound and not shown after the elution during the SUMO columns binding 
process. 
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Figure 45. SUMO binding assay using the SUMO matrix and binding columns in the IP SUMO and 
WB experiments has shown that talin or vinculin could be SUMOylated in the isolated focal adhesions 
in the MDA-MB-231 cancer cells; this was done as ‘control’ experiments with no GA treatments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. SUMO binding assay using the SUMO matrix and binding columns in the IP SUMO and 
WB experiments probing for talin or vinculin has shown that talin was found in the flushed isolated 
eluted FAs indicating talin could be SUMOylated in the FAs; after 100µM GA 1hr treatment, less talin 
that were SUMOylated were detected compared with the non-treated control; vinculin was also 
SUMOylated in the FAs. These experiments have shown that only the full-length of talin or vinculin 
were SUMO-bound, n=3 (representative immunoblots were shown) 
 
In Figure 45 and 46, talin or vinculin could be SUMOylated in the FAs. These also have 
shown that only intact full-length of talin or vinculin that were SUMOylated were bound with 
SUMO in the columns and pulled down. In Figure 46, in the GA 1 hour treated sample for 
talin, there was less SUMOylated full-length talin detected than in the control 1 hour 
samples. 
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SUMO VIVATM Binding Assay with the More Concentrated Isolated FAs Detects 
SUMOylated Talin and SUMOylated Vinculin, but with Fragmented Products 
MDA-MB-231 cells were grown on the fibronectin-coated petri dishes and grown for 2 days. 
The cells were then treated with 100µM GA for 1 hour. The cells were flushed and the FAs 
were collected. The FAs were collected from six dishes for the control and 6 dishes for the 
GA 1 hour treated. These samples were transferred into the SUMO binding columns and 
incubated at 4°C overnight. The eluted samples were prepared and used in the WB 
experiments to determine whether talin or vinculin could be SUMOylated. 
 
SUMO-Bound Assay IP: SUMO, IB: Talin    SUMO-Bound Assay IP: SUMO, IB: Vinculin 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. SUMO binding assay using the SUMO matrix and binding columns in the IP SUMO and 
WB experiments probing for talin showing that talin was present in the IP SUMO pulldown in both of 
the control and the GA 1hr treatment suggesting that talin could be SUMOylated in the focal 
adhesions in MDA-MB-231 cells; similarly, vinculin was also found in the SUMO binding eluted IP 
control and GA 1hr treatment samples suggesting that vinculin could be SUMOylated. These 
experiments were done to collect more concentrated flushed cells as the focal adhesions were 
collected from 6 petri dishes for the controls and 6 petri dishes were collected for the GA treatment at 
1hr, n=3 (representative WB immunoblots were shown) 
 
In Figure 47, the full-length intact talin at 250kDa was present in the eluted IP SUMO binding 
samples including the control and GA 1 hour treatment samples; similarly, intact vinculin at 
130kDa was found to be in the eluted IP SUMO binding samples in both of the control and 
GA 1 hour treatment. These experiments suggest that intact talin or intact vinculin can be 
SUMOylated. However, more bands of talin were seen in the IP SUMO pulldown on the WB 
membrane shown with the black arrow, where these bands were ranged as: a band at 
250kDa were found in both of the control and 100µM GA 1 hour treatment; a band was at 
220kDa in both of the control and GA 1 hour treatment and this was likely to be the rod 
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domain of talin; a band was at 100kDa in both of the control and GA 1 hour treatment 
representing further cleavage in the rod domain of talin; a band was found at 50kDa in both 
of the control and GA 1 hour treatment; a band was found at 47kDa in both of the control 
and GA 1 hour treatment; there was also a band at about 15kDa in both of the control and 
GA 1 hour treatment. The most prominent talin bands in the eluted IP SUMO binding 
samples were the bands at 250kDa, 220kDa, 100kDa and 47kDa. All of these bands 
suggest that these must be products of talin that were binding with SUMO during the SUMO 
binding assay, suggesting that these fragmented products of talin must also be SUMOylated.  
 
GA 1hr treatment reduced the amount of the eluted intact talin at 250kDa; similarly, vinculin 
at 130kDa was less shown after GA 1 hr treatment.  
 
These results suggest that as more of the MDA-MB-231 cells were used in the isolation of 
FAs experiments, the cleaved products of FAs were able to be detected, however, they were 
not able to be detected or obtained during the endogenous IP experiments where SUMO-2 
was not overexpressed and the IP experiments were done only using the whole cell lysates. 
 
One of the effects of GA was also shown in the unbound whole cell lysates, where these 
samples were prepared as the first run-through supernatant and run on the WB membrane 
and kept as a ‘control’ for the IP eluted samples. It seemed that more products of the FAs 
i.e. talin in the unbound whole cell lysates were shown after GA 1 hour treatment and these 
effects was quite frequently seen in the experiments, also in the HA-tag SUMO-2 IP 
experiments.  
 
4.3. 8 Ubc9 siRNA Transfection with HA-tag SUMO-2 plasmid Transfection  
MDA-MB-231 cells were grown in the T25 flasks overnight and then transfected with the 
Ubc9 siRNA for 24 hours first then the cells were added with the HA-tag SUMO-2 plasmid 
for another 24 hours transfection. IP samples were prepared and the samples were run on 
the PAGE gels.  
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       HA IP: SUMO-2, IB: Talin        HA IP: SUMO-2, IB: SUMO 2/3                    Overlay  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. Ubc9 siRNA transfection in the MDA-MB-231 cells for 48 hours treatment with the HA IP 
SUMO-2 and WB showing that talin at 230kDa was SUMOylated in the Ubc9 siRNA, scrambled 
siRNA and negative control samples (the talin antibody used was the H300, Santa Cruz). The 
Overlay: Alexa 546 rabbit ab detecting talin=Cy3 (talin, green) and the Alexa 647 anti-goat ab 
detecting SUMO-2=Cy5 (SUMO-2, red), n=3 
 
In Figure 48, the cells were treated with the Ubc9 siRNA and also transfected with the HA-
tag SUMO-2 plasmid. Talin was shown in the IP SUMO-2 samples at 230kDa suggesting 
that talin was SUMOylated in the Ubc9 siRNA, scrambled siRNA and negative control 
samples. However, even after 48 hours Ubc9 siRNA treatment, SUMOylated talin was still 
able to be detected at the time where Ubc9 siRNA treatment was finished at 48 hours, 
suggesting that even after knocking down the Ubc9 siRNA for 48 hours, there were still 
enough Ubc9 enzyme to accompany talin to interact with the SUMO-2 proteins, since the 
inhibition may have reduced the newly formed expression of Ubc9 enzyme but the Ubc9 
enzyme that were already produced and present in the cells before the inhibition may still be 
available for attaching SUMO-2 to the talin containing FAs. In the overlay, the bands 
between 37-50kDa most likely to be 47kDa as the head of talin and 15kDa were overlaid, 
suggesting that these must be SUMOylated products, since any bands detected must be 
SUMOylated proteins that could be immunoprecipitated.  
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4.3. 9 Effect of Gossypetin and 2-D08 Treatments on Talin SUMOylation 
MDA-MB-231 cells were grown in the T25 flasks overnight and then treated with 100µM 
gossypetin and 2-D08 for 1 hour. HA-tag SUMO-2 IP samples were prepared and the 
samples were run on PAGE gels.  
 
                HA IP: SUMO-2, IB: Talin                       HA IP: SUMO-2, IB: SUMO-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Combined Cy3 and Cy5 Channels: 
The Overlay: Alexa 546 anti-rabbit ab detecting 
talin=Cy3 (talin, green) and the Alexa 647 anti-
goat ab detecting SUMO-2/3=Cy5 (SUMO-2/3, 
red) 
Figure 49. HA-tag SUMO-2 IP & WB showing 
that talin can be SUMOylated with 100µM 
gossypetin or 2-D08 1hr treatment in the MDA-
MB-231 cells, the intact talin was present in the 
DMSO control 1hr whole cell lysates as a control 
for the IP experiments, n=5 
 
 
 
In Figure 49, talin was SUMOylated at 230kDa in both of the DMSO control and the 
gossypetin or 2-D08 treatment on the HA IP: SUMO-2, IB: Talin membrane. Talin was seen 
with many products and these products of talin must also be SUMOylated to be 
immunoprecipitated with SUMO-2.  
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4.3. 10 Focal Adhesion Expression was not Affected after GA or Ubc9 siRNA 
Treatment 
MDA-MB-231 cells were grown in T25 flasks overnight and then treated with 100µM GA for 
6 hours. Whole cell lysates were made after 6 hours treatment. FA antibodies were used in 
WB experiments to detect talin, FAK or vinculin level in the whole cell lysates.  
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Figure 50. 100µM GA after 6 hours treatment in the MDA-MB-231 cells does not change the FAs 
talin, FAK or vinculin expression compared with the control (n=3). 
 
In Figure 50, the expression of the total amount of talin containing FAs in the MDA-MB-231 
cells was not significantly affected after 100µM GA 6 hours treatment compared with the 
control; similarly, the expression of FAK or vinculin containing FAs in the MDA-MB-231 cells 
was not significantly affected after treatment. This suggests that after the inhibition of 
SUMOylation, the FA proteins level in the cells was not changed.  
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MDA-MB-231 cells were treated with Ubc9 siRNA for 48 hours. Whole cell lysates were 
made after 48 hours treatment. FA antibodies were used in WB experiments to detect talin, 
FAK or vinculin protein level in the whole cell lysates. Ubc9 siRNA treatment after 48 hours 
treatment did not affect the degradation of FA proteins. 
Talin
N
eg
at
iv
e 
co
nt
ro
l 4
8h
Sc
ra
m
bl
ed
 s
iR
N
A
 4
8h
U
bc
9 
si
R
N
A
 4
8h
0
10
20
30
40
50
60
70
80
90
100
T
a
li
n
/G
A
P
D
H
 R
a
ti
o
FAK
N
eg
at
iv
e 
co
nt
ro
l 4
8h
S
cr
am
bl
ed
 s
iR
N
A
 4
8h
U
bc
9 
si
R
N
A
 4
8h
0
10
20
30
40
50
60
70
80
90
100
F
A
K
/G
A
P
D
H
 R
a
ti
o
         Vinculin
N
eg
at
iv
e 
co
nt
ro
l 4
8h
Sc
ar
m
bl
ed
 s
iR
N
A
 4
8h
U
bc
9 
si
R
N
A
 4
8h
0
10
20
30
40
50
60
70
80
90
100
V
in
c
u
li
n
/G
A
P
D
H
 R
a
ti
o
 
 
 
 
 
 
Figure 51. 25nM Ubc9 siRNA after 48 hours treatment in the MDA-MB-231 cells does not change the 
FAs talin, FAK or vinculin expression compared with the control (n=3). 
 
In Figure 51, Ubc9 siRNA treatment did not affect the total amount of the FA proteins 
including talin, FAK or vinculin compared with the control. 
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4.3. 11 Talin is SUMOylated in U2OS Cells 
U2OS cells were grown in T25 flasks overnight and then treated with 100µM GA. The IP 
samples were prepared with the whole cell lysates only and the primary talin-1 antibody was 
added to these samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52. IP talin-1 and WB showing that in all the IP talin samples in the untreated control and the 
100µM GA 15 or 60 minutes treated samples, talin at 250kDa was detected when SUMO 2/3 was 
probed for in the U2OS cells; the total talin was present in the whole cell lysates in the control 60 
minutes as a control of the IP experiments. n=4 (representative experiment immunoblots are shown) 
 
In Figure 52, SUMOylated talin at 250kDa was able to be detected in the untreated control 
and 100µM GA treated samples in U2OS cells, confirming the SUMOylation of talin in these 
cells. The intact talin was SUMOylated at 250kDa; however, there are also other products 
present suggesting that these may also be SUMOylated talin products. The bands were 
ranged as: two bands were present near at 250kDa in all of the samples; one prominent 
band was between 100-150kDa in all of the samples; one band was between 37-50kDa and 
this was probably the enriched head of talin at 47kDa; SUMO bands at 15kDa were present. 
These band patterns in the U2OS cells were quite similar compared to the MDA-MB-231 
cells.  
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4.3. 12 HA-tag SUMO-2 IP Detects SUMOylated Full-Length Talin and Fragments of 
Talin 
U2OS cells were transfected with the HA-tag SUMO-2 plasmid overnight. The cells were 
treated with 100µM GA for 15 or 60 minutes. The IP samples were prepared with magnetic 
beads and the IP samples were run on the WB gels probed with talin (N-terminus antibody).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53. HA-tag SUMO-2 IP and WB showing that in all the IP SUMO-2 samples in the untreated 
control and the 100µM GA, Gossypetin or 2-D08 1hr treated samples, full-length talin at 230kDa was 
detected when talin was probed for in the U2OS cells, however, the fragments of the SUMOylated 
talin were clearly seen n=3 (the representative experiment immunoblots were shown here) 
 
In Figure 53, the full-length intact talin at 230kDa was SUMOylated in the control and treated 
samples, but it was much reduced in the gossypetin 1 hour treated sample. The fragments of 
the SUMOylated talin were: the bands between 75-100kDa was present in the control 1 hour 
or GA 1 hour and 2-D08 1 hour treated samples, but it was absent in the gossypetin 1 hour 
treated sample. The bands between 37-50kDa (talin head at 47kDa) was present in the 
control 1 hour or GA 1 hour and 2-D08 1 hour treated samples, but it was absent in the 
gossypetin 1 hour treated sample.  
 
4.3. 13 SUMOylation may Cause an Interruption of the FA Proteins Complex  
MDA-MB-231 cells were grown in T25 flasks overnight and then the cells were transfected 
with the GFP-Talin plasmid overnight. The cells were treated with 100µM GA, gossypetin or 
2-D08 for 1 hour. The GFP Talin IP samples were prepared by adding the primary GFP 
antibody overnight and then adding the magnetic beads for 2 hours to pull down all the talin 
proteins in the cells. The samples were then run on the WB gels to probe for filamin-1 (N-
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terminus H300, Santa Cruz). All the antibodies used were made in different species to avoid 
antibody cross reactions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54. GFP IP and WB showing that in all the IP GFP samples in the untreated control and the 
100µM GA, gossypetin or 2-D08 1hr treated samples, full-length talin was bound with filamin-1 
detected in the MDA-MB-231 cells when probing for filamin-1 on the WB membrane, however, there 
was less filamin-1 detected in the control 1hr than in the 100µM GA, gossyptein or 2-D08 1hr treated 
samples n=3 (the representative experiment immunoblots were shown here) 
 
In Figure 54, the full-length talin was present in a complex with filamin-1 in the MDA-MB-231 
cells, as filamin-1 was detected following IP of talin. Filamin-1 was present in all samples. It 
seems that SUMOylated FAs may cause the interruption of the talin-filamin-1 complex in the 
cells, as the GA, gossypetin or 2-D08 treated samples, compared with the control, seemed 
to have immunoprecipitated more filamin-1 after inhibitor treatments, suggesting that 
SUMOylation of FAs may affect the FA protein-protein interactions.   
 
MDA-MB-231 cells were grown in T25 flasks overnight and then the cells were transfected 
with the mEmerald-Vinculin plasmid overnight. The cells were treated with 100µM GA, 
gossypetin or 2-D08 for 1 hour. The GFP Vinculin IP samples were prepared by adding the 
primary GFP antibody overnight and then adding the magnetic beads for 2 hours to pull 
down all the vinculin proteins in the cells. The GFP IP vinculin samples were run on the WB 
gels to probe for talin (N-terminus, H300 ab, Santa Cruz). All the antibodies used were made 
in different species to avoid antibody cross reactions.  
 
 
 
Ctrl        GA       Goss      2-D08 
1h         1h          1h          1h 
Filmain-1at 
280kDa 
GFP IP: Talin, IB: Filamin-1  
250- 
 
150- 
 
100- 
  75- 
 
   
 50- 
 
  37- 
  25- 
  20- 
 
  15- 
  
  10- 
50kDa 
143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55. GFP IP and WB showing that in all the IP GFP samples in the untreated control and the 
100µM GA, gossypetin or 2-D08 1hr treated samples, full-length talin was bound with vinculin 
detected in the MDA-MB-231 cells when probing for vinculin on the WB membrane, however, there 
was less talin detected in the gossypetin 1hr than in the control 1hr or the 100µM GA and 2-D08 1hr 
treated samples n=3 (the representative experiment immunoblots were shown here) 
 
In Figure 55, the full-length talin was present in the complex with vinculin in the MDA-MB-
231 cells, as the talin was detected following IP of vinculin. Full length talin was detected at 
230kDa in the control or GA and 2-D08 treated samples, but it was much less detected in 
gossypetin treated sample. The bands at 100kDa were present in the control or GA and 2-
D08 treated samples, but it was absent in the gossypetin treated sample. Similarly, the 
bands between 37-50kDa (47kDa more likely to be talin head) was present in the control or 
GA and 2-D08 treated samples, but it was gone in the gossypetin treated sample. It seems 
that the inhibition of SUMOylated FAs has caused the interruption of the talin-vinculin 
complex in the cells, suggesting that the inhibition of SUMOylation may affect the FA protein-
protein interactions.   
 
MDA-MB-231 cells were transfected with the GFP-Talin plasmid overnight. The cells were 
treated with 100µM GA, gossypetin or 2-D08 for 1 hour. The GFP Talin IP samples were 
prepared by adding the primary GFP antibody overnight and then adding the magnetic 
beads for 2 hours to pull down all the talin proteins in the cells. The GFP IP talin samples 
were run on the WB gels to probe for actin. All the antibodies used were made in different 
species to avoid antibody cross reactions.  
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Figure 56. GFP IP and WB showing that in all the IP GFP samples in the untreated control and the 
100µM GA, gossypetin or 2-D08 1hr treated samples, actin was bound with talin detected at the 
42kDa in the MDA-MB-231 cells when probing for actin on the WB membrane, however, there was 
less actin detected in GA 1hr than in the control, gossypetin or 2-D08 1hr treated samples n=3 (the 
representative experiment immunoblots were shown here) 
 
In Figure 56, the actin was present in the complex with talin in the MDA-MB-231 cells, as the 
actin was detected following IP of talin. Actin was present in the control or GA, gossypetin 
and 2-D08 treated samples. Actin was found to be SUMOylated in the mass spectrometry 
results (Chapter 5) and it was found to be bound with talin together in the cells.  
 
4.3. 14 Determination of Inhibition of SUMOylated FAs on FA Protein-Protein 
Interaction in U2OS Cells 
U2OS cells were grown in T25 flasks overnight and then the cells were transfected with the 
GFP-Talin plasmid overnight. The cells were treated with 100µM GA, gossypetin or 2-D08 
for 1 hour. The GFP Talin IP samples were prepared by adding the primary GFP antibody 
overnight and then adding the magnetic beads for 2 hours to pull down all the talin proteins 
in the cells. The GFP IP talin samples were run on the WB gels to probe for filamin-1. All the 
antibodies used were made in different species to avoid antibody cross reactions.  
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Figure 57. GFP IP and WB showing that in all the IP GFP samples in the untreated control and the 
100µM GA, gossypetin or 2-D08 1hr treated samples, full-length talin was bound with filamin-1 
detected in the U2OS cells following IP of talin, however, there was less filamin-1 detected in the GA 
1hr than in the control 1hr, gossypetin or 2-D08 1hr treated samples n=3 (the representative 
experiment immunoblots were shown here) 
 
In Figure 57, full-length talin was present in the complex with filamin-1 in the U2OS cells. 
Filamin-1 at 280kDa was less shown in the GA treated sample than in the control or the 
gossypetin and 2-D08 treated samples. The band at ~100kDa was only shown in gossypetin 
treated sample.  
 
U2OS cells were transfected with the mEmerald-Vinculin plasmid overnight. The cells were 
treated with 100µM GA, gossypetin or 2-D08 for 1 hour. The GFP Vinculin IP samples were 
prepared by adding the primary GFP antibody overnight and then adding the magnetic 
beads for 2 hours to pull down all the vinculin proteins in the cells. The GFP IP vinculin 
samples were run on the WB gels to probe for talin (N-terminus, H300 ab, Santa Cruz). All 
the antibodies used were made in different species to avoid antibody cross reactions.  
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Figure 58. GFP IP and WB showing that in all the IP GFP samples in the untreated control and the 
100µM GA, gossypetin or 2-D08 1hr treated samples, full-length talin was bound with vinculin 
detected in the U2OS cells following IP of vinculin, however, less talin was detected in the GA 1hr 
than in the control 1hr or the 100µM gossypetin and 2-D08 1hr treated samples n=3 (representative 
experiment immunoblots were shown) 
 
 
In Figure 58, full-length of talin was present in the complex with vinculin in the U2OS cells. 
Full length talin was detected at 230kDa in the control or 100µM GA, gossypetin and 2-D08 
treated samples; however, talin at 230kDa was less detected in the GA treated sample. The 
bands at 100kDa were present in the control or gossypetin and 2-D08 treated samples, but it 
was absent in the GA treated sample. Similarly, the bands between 37-50kDa (47kDa more 
likely to be talin head) was present in the control or gossypetin and 2-D08 treated samples, 
but it was gone in the GA treated sample. It seems that the inhibition of SUMOylated FAs 
caused the interruption of the talin-vinculin complex suggesting the inhibition of SUMOylation 
of FAs may affect FA protein-protein interactions.   
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Discussion 
In this study, three different IP methods, the endogenous IP, the HA-tag SUMO-2 IP and the 
SUMO binding assay have shown that the intact talin was SUMOylated consistently in MDA-
MB-231 cells and U2OS cells. This has also been shown with vinculin. The endogenous IP 
and the SUMO binding assay have shown that the intact vinculin was SUMOylated 
consistently. Inhibiting SUMOylation probably leads to more cleavage of talin. SUMOylation 
may also have a potential role in FA protein-protein interactions. 
 
SUMO 1, SUMO 2/3 proteins work closely with the SUMO proteases in the cycle as a 
steady-state regulatory system (Makhnevych et al., 2009), inhibiting the E1 enzyme inhibits 
the SUMO conjugating process, which means that SUMO 2/3 could not be conjugated to 
protein substrates by SAE1/SAE2 and Ubc9 (Tatham et al., 2001). 100 µM GA targets the 
E1 enzyme in the SUMOylation pathway; 2-D08 and gossypetin  have also been shown to 
be potent inhibitors for protein SUMOylation; 25nM Ubc9 siRNA targets the E2 Ubc9 
enzyme in the SUMOylation pathway; these inhibitors have been discussed previously. 
These inhibitors were used to prevent FA proteins from modified through SUMO 2/3 covalent 
binding, therefore blocking SUMO 2/3 attachment to these FA substrate proteins consensus 
motifs and resulting in inhibition of protein SUMOylation. SUMO 2/3 is mostly expressed in 
the cytoplasm and in the nucleus, the inhibitors may also have inhibitory effects in the SUMO 
2/3 free pool (Hay, 2005). The HA-tag SUMO-2 plasmid transfection showed that SUMO-2 
was expressed prominently in the nucleus and in the cytoplasm of cells. SUMO 1 has not 
been determined in these experiments as SUMO-1 is mostly expressed in the nucleus but 
these inhibitors could also affect SUMOylated proteins through SUMO-1 conjugations.  
 
For talin SUMOylation, one effect of the inhibitors was that compared to the untreated cells, 
it seemed to decrease the SUMOylated intact talin, which obtained much less consistently in 
the endogenous IP, HA-tag SUMO-2 IP and the SUMO binding assay after 1 hour of 100µM 
GA treatment. This effect with the inhibitor may be transient within the first 1 hour of 
treatment, however, the treatment time can be critical since SUMOylation is a dynamic 
process, given at any time in vivo, only less than 1% of the proteome can be SUMOylated 
(Johnson, 2004), which makes it crucial to grasp the slight changes caused during the 
treatment time and the effects on the SUMOylated proteins in FA turnover. 
 
The full-length of talin consists of an N-terminal FERM domain linked to a flexible rod 
comprised of R1-R13 amphipathic helical bundles, which ends with the dimerization domain 
(DD), which forms the anti-parallel coil-coil dimer (Goult et al., 2013a). The F3 head domain 
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of talin has higher affinity for binding to the β3 integrin tail leading to integrin activation 
(Calderwood et al., 2002). Normally, the interactions between integrin, talin and vinculin 
binding are crucial in FA assembling; SUMO modification to these adhesion proteins may be 
a new mechanism to regulate FA disassembly, the binding of vinculin to talin in the focal 
adhesion, hence its regulatory role in adhesion turnover. 
 
To better understand how SUMOylation regulates talin and vinculin in the focal adhesion, the 
method used to isolate and collect focal adhesions was modified from Waterman, 2011’s 
protocols (Kuo et al., 2012). In this study, they developed and validated the isolation of focal 
adhesions method. They isolated human foreskin fibroblasts (HFF1) focal adhesions, 
followed by protein identification analysis of peptides using multidimensional protein 
identification technology mass spectrometry (MudPIT MS) and protein identification with 
SEQUEST (Kuo et al., 2011). The focal adhesions including talin, vinculin, paxillin, actin, 
pFAK397 etc were present in the isolated FA fractions before actin and fibrin 
immunodepletion (Kuo et al., 2011). This method was adopted for this study. In this study, 
the intact talin or the intact vinculin was shown to be SUMOylated within the isolated FA, 
making the role of SUMOylation in the FA more dynamic and diverse, which serves as a 
useful tool to study the individual protein SUMOylation in the FA adhesion. 
 
Full-length talin was SUMOylated. There were also fragments of talin which were shown to 
be SUMOylated. Numerous motility related adhesion proteins have been found to be calpain 
proteolytic substrates, where the MAP kinase kinase (MEKK1) associated with FAK acting 
upstream of ERK works in the regulation of phosphorylating and activating calpain-2, thereby 
it mediates talin cleavage, resulting in adhesion disassembly, transformation and cell 
migration (Franco and Huttenlocher, 2005). These FAs have been consistently produced 
with cleaved products, which were SUMOylated. In MDA-MB-231 cells, the results with the 
more concentrated isolated FA lysates used has shown more clearly the cleaved fragments 
of talin: they consisted of the rod domain at 220kDa, cleaved product at 100kDa and the 
cleaved head domain of talin at 47kDa and these were observed in both control and GA 1 
hour treated samples. In contrast, in the whole cell lysates unbound samples: no rod domain 
of talin being cleaved at 220kDa was seen in both control and GA 1 hour treated samples, 
confirming the eluted samples were pulled down with the SUMO matrix and these cleaved 
products must be SUMOylated fragments of talin. Furthermore, looking more closely in the 
HA-tag IP SUMO-2 experiments, the effects of the inhibitor 100µM GA treatment at 15 
minutes and 60 minutes have abolished the 47kDa cleaved head of talin, compared to the 
controls and GA 30 minutes; full-length of talin was less obtained in the SUMO binding 
assay after GA 1 hour treatment.   
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Talin has been described in two conformational states in the literature as the inactive and 
active states. Probably, talin was in its activated state in the cancer cells, where SUMO-2 
modification has been persistently required for talin, under the conditions when SUMO-2 was 
stably overexpressed, as the endogenous SUMOylated talin has not always been stably 
expressed and obtained. These results suggest that the talin containing FAs in the cancer 
cells were consistently cleaved, probably by calpain-2 and the intact talin was consistently 
conjugated with SUMO-2; the SUMOylated intact talin and the consistent talin proteolysis 
resulting in cleaved SUMOylated head and rod domain of talin are required for talin turnover.  
 
The increased turnover time of the FAs may result from the loss of the cleaved SUMOylated 
head domain or the SUMOylated rod domain of talin after the first 1 hour of inhibitor 
treatments, which indicates that inhibiting SUMOylation could disrupt the talin turnover and 
FA disassembly. In all the three IP methods used, the IP was pulling down talin that was in 
FAs, but perhaps it was a cytoplasmic pool of talin that was pulled down, where these 
cytoplasmic SUMOylated talin were sufficient to contribute to fast and dynamic FA turnover. 
This was interesting (as it was also observed in the Co-IPs): the effects of the inhibitors have 
caused the loss of the cleaved products of talin, i.e. the loss of SUMOylated head domain 
and rod domain of talin could lead to the loss of the F3 head domain of talin binding to 
integrin β3 tail, therefore affecting talin turnover. Similarly, the talin rod domain contains a 
second lower-affinity integrin binding site (Ziegler et al., 2008), inhibiting SUMOylation could 
result in the loss of the rod domain of talin binding to integrin. SUMO modification site can 
also be in the extended loops: the talin head F1 domain has an unstructured loop at the 
same positions of its respective F1 domains between amino acid 132-170 and the loop 
residues does not interact with the other regions of the FERM domain (Goult et al., 2010, 
Elliott et al., 2010, Bouaouina et al., 2012). 
 
The stability of the helical bundles which make up the talin rod is critical in determining the 
activity of individual vinculin binding sites (VBSs), where these VBSs are defined by the 
hydrophobic residues in the amphipathic helices that are buried within the helical bundles of 
the talin rod (Patel et al., 2006). The C-terminal of talin rod (220kDa) consists of the R1-R13 
13 helical bundles, where the N-terminal region of talin rod R2 and R3, each contains two 
VBSs atypically (Yao et al., 2014). Talin (residues 482-889) binds to vinculin head domain 
Vd1 with high affinity, indicating that one or more of the four VBSs are active which likely 
represents the vinculin binding domain in intact talin (Patel et al., 2006). Vinculin has been 
found to have a stabilizing role in the focal adhesion; vinculin can exist in an open 
conformational state in focal adhesions in the actin-binding conformation in spreading cells 
(Chen et al., 2005). The first evidence of the cleaved vinculin into 95kDa head domain and 
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30kDa tail fragment was produced by the sepharose-immobilized protease V8 in a specific, 
dose-dependent manner and this intramolecular interactions of vinculin was important to the 
modulation of talin binding in the focal adhesion i.e. talin rod domain could compete for 
binding to the vinculin head domain and this 95kDa cleaved head of vinculin had higher 
affinity in binding to talin than the intact vinculin molecule (Johnson and Craig, 1994). Talin, 
rather than α-actinin, is the major protein involved in the activation of vinculin, since talin 
colocalizes with vinculin in the focal complexes and with the majority of FA proteins including 
β3-integrin, talin, vinculin, FAK, paxillin, α-actinin, VASP and zyxin, except tensin have 
shown 80-90% very high degrees of colocalization with phosphotyrosine at the large, 
elongated FAs of the regions further from the cell edge in endothelial cells (Zaidel-Bar et al., 
2003). The cleaved vinculin at ~100kDa in the HA-IP overexpression with SUMO-2 in both 
MDA-MB-231 cells and U2OS cells probably showed that this head domain of vinculin had 
higher affinity for binding to talin. 
 
SUMOylation may play a general role in protein-protein interactions, where SUMO 
modification could probably provide a new binding site for interactions with the other proteins 
(Song et al., 2004). In the Co-IPs, talin was immunoprecipitated in the MDA-MB-231 cells 
and looked for its interaction partners, filamin-1 and actin. Talin was able to be co-
immunoprecipitated with filamin-1 or actin in MDA-MB-231 cells suggesting that talin was 
associated with filamin-1 or actin in the same adhesion complex. Similarly, talin was 
associated with filamin-1 in U2OS cells. Vinculin was also co-immunoprecipitated with talin 
in both MDA-MB-231 cells and U2OS cells, suggesting that since talin has multiple vinculin 
binding sites (VBSs), they were coupled together in the same adhesion complex. Talin and 
filamin-1 can crosscompete for integrin binding; the structurally defined talin binding and 
filamin binding regions of β integrin tails overlap (Kiema et al., 2006). In the Co-IPs, 
SUMOylation may have its role in talin and filamin interactions in the regulation of FA 
turnover.  
 
 
The association between vinculin and talin is force-dependent and therefore, their 
interactions are critical in FA turnover. The N-terminal region of RIAM contains two talin 
binding sites, which bind synergistically to R2-R3 rod domain of talin; at the same time, the 
vinculin head domain Vd1 can bind to the R2-R3 region of talin therefore displacing RIAM 
from association with talin, this suggests that RIAM and vinculin binding to talin is mutually 
exclusive (Calderwood et al., 2013). This has further made the interaction of talin and 
vinculin more dynamic and also the FA turnover is spatially and temporally controlled. The 
vinculin tail Vt competes with the talin rod domain for the binding to the vinculin head Vh D1 
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domain (amino acid residues 1-258) hence inducing the activation of vinculin from its auto-
inhibited conformation, which also requires the Vh D4 domain (residues 710-836) interface 
(Cohen et al., 2005). Therefore, SUMOylation may be required for the interaction of vinculin 
with talin, inhibiting protein SUMOylation caused a reduction in their interactions. Treatment 
with 100µM gossypetin for the first 1 hour in MDA-MB-231 cells or 100µM GA 1 hour in 
U2OS cells in Co-IP experiments showed the reduction in the intact SUMOylated talin at 
230kDa, 100kDa talin rod fragmented product and the 47kDa talin head. All the fragmented 
products must be SUMOylated since they were immunoprecipitated. Talin association with 
vinculin is required for fast FA turnover. Talin rod domain has up to 11 vinculin binding sites 
(VBSs). Inhibition of SUMOylation caused the depletion in the rod domain of talin which 
inhibited vinculin binding. The talin head was also lost which could abolish its binding to the 
integrin. These suggest that SUMOylation is important in talin and vinculin protein 
interactions. 
 
Talin has been shown to have the C-terminal actin binding domain, where this core actin-
binding domain as a region of highly conserved residues is a five-helix bundle linked to the 
C-terminal helix and is responsible for talin dimerization; specifically, this dimerization helix 
itself (residues shown 2494-2541) is essential for F-actin binding (Gingras et al., 2008). The 
single mutation of K2445 results in significant reduction in the F-actin binding to the talin C-
terminal domain (Gingras et al., 2008). Interestingly, this K2445 residue has been predicted 
with high probability for SUMO modification in both of the SUMOplot and GPS SUMO 
programmes. The co-IP of talin and actin in MDA-MB-231 cells showed that after 1 hour of 
100µM GA treatment, actin band at 42kDa was less obtained, suggesting that the inhibition 
of SUMOylation may have diminished talin and actin binding interactions, indicating 
SUMOylation may be important in talin and actin association.  
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The Proposed Simplified Model for the Role of SUMOylation in the Regulation of FA 
Turnover and the Protein Interactions of Integrin, Talin, Vinculin and Actin: SUMO 
may be required for the FA Disassembly  
 
 
Figure 59. A simplified illustration of the interactions between β3 integrin, talin, vinculin and actin 
binding in the adhesion complex: talin or vinculin are in their steady-state equilibrium in the cells; talin 
is activated through integrin inside-out signalling: this makes the talin rod domain competing with the 
vinculin Vh D1 domain and activates the vinculin from its auto-inhibited conformation. The recruitment 
of vinculin Vh binding to talin rod through the VBSs continues to incorporate F-actin binding to FERM 
domain or C-terminal THATCH domain of talin and onto the Vt domain. SUMO-2 conjugation is 
required consistently for talin or vinculin modifications and this process happens very dynamically 
within the FA adhesion complex; K2445 is a predicted lysine with a high probability for SUMO binding 
as well as actin binding in the talin C-terminal rod; once SUMOylation was inhibited, the newly 
synthesized SUMO-2 proteins were inhibited from modifying newly produced talin or vinculin 
probably. The talin containing FAs that were SUMOylated previously and the cleaved SUMOylated 
fragments of talin associated with the vinculin interactions in the cells were also inhibited and lost, this 
effect was accounted for inhibition of FA disassembly. 
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Recently, proteomics has been used to analyse the total protein extracts in U2OS cell line: 
the total protein extracts were separated by 2D gel electrophoresis and analysed by matrix-
assisted laser desorption ionisation-mass spectrometry (MALDI-MS) and MALDI-MS-MS 
following protein identification and 237 different gene products were identified (Niforou et al., 
2008). They have found that the tumour suppressive genes p53 and pRb were functional in 
the U2OS cells. Later, a global analysis of both mRNA and protein levels using sequence-
based transcriptome analysis (RNA-seq) and SILAC-based mass spectrometry analysis was 
conducted in three different human cell lines, the U2OS, the A-431 an epidermoid squamous 
cell carcinoma and the U-251 brain glioblastoma; where 5399 proteins were identified in 
U2OS by MS and 5333 proteins were common in all three cell lines (Lundberg et al., 2010). 
Another study has shown a new method with filter-aided sample preparation (FASP) and 
identified 2750 proteins in Hela cells (Wisniewski et al., 2009). The large-scale absolute 
cellular protein abundance that constitutes a cell is very important in understanding their 
function and evolution (Beck et al., 2011a). In Beck et al.’s study, they quantified the copy 
number of focal adhesion proteins and SUMO, Ubc9 etc per cell in the human tissue culture 
U2OS cell line in Table S1, where the U2OS cells expressed ~10,000 proteins at least (Beck 
et al., 2011a), this was one of the first studies with the most comprehensive proteome map 
in a U2OS cell line by far, which is very useful to compare the data obtained with this study 
and to predict the quantity of the SUMOylated focal adhesions related functions in the 
cancer cells used, as Beck et al. also have found and predicted that the regulatory functions 
of proteins i.e. cell adhesion were often correlated with large variable protein families 
however in very low abundance principally in a cell. This leads to the idea that the FA 
proteins involved in post-translational modifications i.e. SUMOylation will be mostly 
conducted with very low abundance proteins.  
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Bone osteoscarcoma U2OS cell line: Quantitative proteome of focal adhesions and 
SUMOylation related protein copy number / per cell 
Talin-1 456000 Integrin β5 30000 SUMO-conjugating 
enzyme Ubc9 
392000 
Vinculin 276000 Integrin β1 113000 SUMO activating enzyme 
subunit 1 SAE1 
198000 
FAK 3290 Integrin α5 2970 SUMO activating enzyme 
subunit 2 UBA2/SAE2 
152000 
Filamin A 824000 Integrin 
α3 
44500 Small ubiquitin-related 
modifier 1 SUMO-1 
22800 
Calpain-2 344000 Integrin αV 27200 E3 SUMO-protein ligase 
RanBP2 
17400 
SUMO-2 889000 Integrin 
α2 
13400 E3 SUMO-protein ligase 
PIAS1 
1530 
 
Table 11. The complete quantitative proteome of U2OS cell line: the copy number of the cell 
adhesion related proteins and the SUMOylation proteins per cell are included here from Beck et al.’s 
study. 
 
From Beck’s study (Beck et al., 2011a) in Table 11, the copy number of SUMO-2 was nearly 
doubled the copy number of talin-1, whereas the copy number of Ubc9 was relatively at a 
comparable level to the copy number of talin-1 and vinculin. Filamin A was similar to the 
number of SUMO-2. This has suggested that in a U2OS cell, the copy number of the 
SUMOylated talin, vinculin, FAK or filamin A all depends on the ratio of the E1 enzyme 
SAE1/UBA2, SUMO-conjugating E2 enzyme Ubc9 and SUMO-2 conjugation through the 
ligation E3 enzyme in each step of the SUMOylation cycle and this process is highly 
regulated and dynamic in equilibrium balance with the cytoplasmic SUMO pool. Relatively, 
only a small fraction of the protein substrate, often less than 1% that is SUMOylated at any 
given time (Johnson, 2004). For talin, 1% of talin can get SUMOylated which is 1% of 
456000 to be 4560 copy number of SUMOylated talin molecule. For vinculin that gets 
SUMO-2 modification would be 2760 copy number of SUMOylated vinculin. This could 
suggest that with the IP experiments shown, the endogenous individual FA protein would be 
expressed stably with a HA tag of SUMO-2 to obtain the SUMOylated FA before and after 
the inhibitors treatments. Also with the Ubc9 siRNA knockdown, there would be time 
required before the SUMOylated individual FA and the free SUMO pool to be diminished.  
 
The expression of FA WB experiments have shown that the total FA protein levels were not 
affected long-term after 6 hours of 100µM GA treatments or 48 hours of 25nM Ubc9 siRNA 
treatments; the expression of FA total protein level was not significantly changed even after 
the inhibition of protein SUMOylation globally. The inhibition of SUMOylated FAs did not 
necessarily decrease the pool of the FAs. This may suggest that inhibiting protein 
SUMOylation does not induce protein ubiquitination at the same time necessarily. The 
balance of SUMOylation pathway for the FAs is highly regulated and controlled; the 
reactions for the SUMOylation of FAs can be competitive for the other post-translational 
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modifications PTMs, such as phosphorylation, acetylation, ubiquitination, this increases the 
complexity of the SUMO role in the assembly and disassembly of FAs.  
 
In the SUMO binding assays, where concentrated isolated FA lysates were used, there was 
also a nice comparison between the SUMOylated intact talin and the total talin level in the 
cells after 100µM GA 1 hour treatment: the eluted SUMOylated intact talin obtained less 
compared to its control, whereas for the total talin level, the unbound talin fraction in the 
whole cell lysate seemed to increase more in the GA treated sample than the control. When 
after the inhibitor treatment, it increased the total FA levels in the whole cell lysates, which 
was observed quite consistently in the cells, similarly, this effect was seen in the IP filamin-1 
experiments, too. This has suggested that after the GA 1 hour treatment, there was a 
transient disruption and imbalance in the SUMOylation cycle, which could affect the fractions 
of the talin protein being SUMOylated.  
 
The talin head domain binding can be competitive between ubiquitination and 
phosphorylation: the talin head can bind to Smurf 1, which is an E3 ubiquitin ligase involved 
in cell migration; the calpain-2 mediated cleavage of the talin head can be degraded via the 
binding of talin head to Smurf 1 mediated ubiquitination; the talin neck can also be 
phosphorylated by Cdk5 at Ser425 within the talin amino acid sequence 393-433, where Cdk5 
is a regulator of cell migration and cancer metastasis and this results in the inhibition of the 
talin head binding to Smurf 1 therefore it prevents talin head from ubiquitination and 
degradation (Huang et al., 2009). In order to investigate the effects between talin 
ubiquitination and SUMOylation, the cells would be treated with the inhibitors and 
immuoprecipitated and blotted with ubiquitin antibodies to determine if the inhibition of 
SUMOylation could affect ubiquitylation of FAs. It has shown that inhibition of SUMOylation 
did not induce ubiquitylation of FAs, i.e. talin, which was done in the platelets (data not 
shown, references to Dr. Diana Barker).   
 
In the double transfection IP experiments, where MDA-MB-231 cells were transfected with 
the Ubc9 siRNA first then with the HA-tag SUMO-2 plasmid for a total time of 48 hours, 
SUMOylated intact talin was still detectable. This has indicated that after 48 hours of Ubc9 
siRNA treatment, there was still time to achieve the depletion in the pool of SUMOylated FAs, 
but the first transient effects of the inhibitors were important and critical to determine the 
effects in the FA turnover after the inhibition of protein SUMOylation. 
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The reversible post-translational modifications of proteins including acetylation, 
phosphorylation or ubiquitylation is governed by the recognition of specific interaction 
domains, which regulates the plasticity of protein-protein interactions (Ullmann et al., 2012). 
The lysine-directed modifications can be positively or negatively regulated between 
ubiquitylation and SUMOylation; for example, IkBα can be mono-SUMOylated or poly-
ubiquitinylated on K21; phosphorylation could also inhibit or enhance protein SUMOylation 
(Bossis and Melchior, 2006). The attachment of SUMO paralogues to target substrate 
proteins is not only through the covalent binding but can also be through a noncovalent 
binding to the SUMO-interaction motifs (SIMs), which either SIM N terminal or C terminal 
binding to SUMO is mediated by hydrophobic and electrostatic interactions and the binding 
could be weakened with increasing ionic strength (Escobar-Cabrera et al., 2011). These 
SIMs bind to the SUMO moiety that is conjugated to Ubc9, thereby these SUMO substrate 
can promote their own conjugation (Wang and Dasso, 2009). The site-specific acetylation of 
SUMO-1 at K37 or SUMO-2 at K33 have revealed a central regulatory mechanism in the 
selective modulation of SUMO-SIM interactions, where K37/K33 acetylation abolished the 
binding of SUMO to SIMs in PML protein, Daxx and PIAS family members, thereby affecting 
the dynamics of PML nuclear bodies and attenuating SUMO and PIAS-mediated gene 
silencing; this acetyl-dependent switch expands the regulatory functions of SUMO signalling 
(Ullmann et al., 2012). Daxx, a transcriptional co-regulator, also contained a bona fide SIM 
that could bind to SUMO-1 in a parallel orientation: this Daxx-SIM can be phosphorylated by 
CK2 kinase at residues S737 and S739, where this Daxx-SIM phosphorylation causes Daxx 
binding preference towards SUMO-1 conjugation and enhances Daxx to sensitize stress-
induced cell apoptosis via anti-apoptotic gene repression (Chang et al., 2011).These indicate 
that not only consensus motif in protein are modified by SUMO, other interaction domains 
can also be important in protein SUMO modification and these are determined in the next 
step in the Mass Spectrometry and bioinformatics studies.  
 
The total Akt has been used in the HA-tagged SUMO-2 IP experiments as a negative 
control. The proto-oncogene Akt can be SUMOylated, which has been identified as a novel 
mechanism for activating Akt function, mediating cell proliferation, cell migration and 
tumorigenesis; however, Akt could be modified by SUMO-1 and enhanced by SUMO E3 
ligase PIAS1 and reversed by the SUMO protease SENP1 and K276 was identified to be a 
major SUMO-1 acceptor lysine site (Li et al., 2013b). Compared to this study, total Akt was 
used as a substrate to probe for SUMO-2/3 modification and there were hardly any bands 
seen in the IP-HA-SUMO-2 samples in the negative control experiments, as Akt SUMO-1 
modification shifted up with bands at higher molecular weights. It can be seen that some of 
the proteins could be modified by SUMO-1 and Akt is an example.  
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Three IP methods have shown that talin and vinculin were identified to be SUMOylated for 
the first time. SUMOylation also plays a role in the protein-protein interactions of the FAs. 
Once protein SUMOylation was inhibited globally, the SUMOylated FA proteins were less 
obtained. There have been other FA proteins that were predicted to be SUMOylated using 
the SUMOplot and GPS SUMO bioinformatics software i.e. FAK, actin and filamin-1. This 
leads to the next step to confirm that the FAs that were previously SUMOylated in the cells 
could be identified in the mass spectrometry analysis hence increasing the chance of 
identifying SUMOylated proteins in the FAs and other FA related proteins/adaptors and IP & 
western blotting will be conducted to confirm the SUMO modified substrates from the mass 
spectrometry data, i.e. filamin-1.  
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Chapter 5 – The Identification of Focal Adhesion Proteins Which 
Can be SUMOylated 
 
5.1 Introduction and Hypothesis 
Mass spectrometry analysis have revealed more than 1000 SUMOylated lysines in 539 
proteins (Tammsalu et al., 2014). Several approaches have been developed to discover the 
putative SUMO substrates, using the yeast Saccharomyces cerevisiae system, human 
HEK293 cells, the non-covalent SUMO interacting motifs (SIMs), SUMO fusion technology, 
LC-MALDI-MS/MS etc to selectively enrich and identify SUMOylated proteins, as for any 
given protein, the amount of post-translational modified protein is only a small fraction of the 
total cellular pool (Rosas-Acosta et al., 2005, Galisson et al., 2011, Da Silva-Ferrada et al., 
2013, Butt et al., 2005). The most successful studies providing novel SUMO substrates for 
identifying the SUMOylation proteome has been in the yeast S. cerevisiae, as SUMO was 
independently discovered during yeast two-hybrid screens; this system has supplied with 
unlimited amounts of starting material, can be easily scaled-up and manipulation 
accompanied with high accuracy and stringency of the LC-MS/MS analysis instrument 
(Wykoff and O’Shea, 2005, Wohlschlegel et al., 2004, Rosas-Acosta et al., 2005, Denison et 
al., 2005). The new strategies for investigating SUMO conjugation, recognition or de-
conjugation have become more important to recognize SUMO modification motifs that are 
not only common to the SUMO-GG signature peptides but to the uncommon motifs (Da 
Silva-Ferrada et al., 2012).  
 
Computational programmes have been developed to identify potential SUMOylation sites in 
proteins to match the motif B-K-x-D/E, i.e. using the SUMOplot programme. However, there 
could be other SUMOylation sites which cannot be identified due to their low abundance in 
peptide trypsinolysis used for mass spectrometry. There are other motifs that were identified 
recently:  a SUMO-binding motif (SBM) denoted as V/I-X-V/I-V/I (defined as an amino acid 
sequence motif) was identified by NMR spectroscopic characterization of interactions among 
SUMO-1 and SUMOylated protein peptides that were known to bind to SUMO and this motif 
was able to bind to all SUMO paralogues SUMO 1-3 and this newly identified SBM was 
responsible for the interactions within RanBP2/Nup358 and SUMOylated RanGAP1 (Song et 
al., 2004). The SUMO interaction motifs (SIMs) motifs interact non-covalently with SUMO 
and their recognition still seems limited (Kerscher, 2007). SIM domains have been found in 
the E3 ubiquitin ligase RNF4 (RING finger protein 4), where these repeated four tandem 
SIMs were for selective interactions with the poly SUMO-modified proteins  leading to their 
degradation (Kung et al., 2014). The previously identified B-K-x-D/E i.e. Ψ–K–X–E binds to 
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E2 enzyme for covalent modification by SUMO but it cannot bind to SUMO noncovalently 
(Song et al., 2004).  
 
Tandem mass spectrometry amino acid sequencing is a direct, unbiased and sensitive 
approach to determine post-translational modification sites, where the tandem mass 
spectrometry analysis involves the proteolysis of protein conjugates by trypsin to the 
identification of these modification sites; the successful identification of SUMOylation sites 
depends heavily on the sensitivity of the mass spectrometer and the retrieval of the low 
abundance SUMOylated peptides for fragmentation (Knuesel et al., 2005). Other 
approaches to identify SUMO substrates include overexpressing the SUMO isoforms which 
each contains an N-terminal histidine tag and a tryptic cleavage site at the C terminus, they 
can be stably expressed in human cells such as HEK293 cells to selectively enrich and 
identify SUMOylated peptides from human cells by affinity enrichment and mass 
spectrometry  (Osula et al., 2012, Galisson et al., 2011). 
 
Several programmes have been used for the bioinformatic identification and prediction of 
protein SUMOylation. Two of them have been used in this study. The SUMOplot™ analysis 
program predicts the probability of the SUMO consensus sequence associated in the 
protein-SUMO attachment; the SUMOplot™ score system has two criteria: direct amino acid 
match to the SUMO consensus sequence and the substituted amino acid residues exhibiting 
similar hydrophobicity to the consensus amino acid residues (SUMOplotTM analysis 
programme, Abgent).  
 
A new generation group-based prediction system (GPS) algorithm GPS SUMO was firstly 
used as a prediction tool for both protein SUMOylation sites and SUMO interaction motifs 
SIMs (Zhao et al., 2014). In their study, they stated that approximately 40% of SUMOylation 
sites do not conform to the canonical consensus motif of B-K-x-D/E i.e. Ψ–K–X–E and 
recently nearly ten types of SIMs were experimentally identified but only representing a small 
proportion of the SIMs, therefore GPS SUMO was developed as a reliable tool to construct 
the SIMs data sets (Zhao et al., 2014). Many other programmes have been developed such 
as SUMOsp, seeSUMO web server, SUMOpre etc with many performance measure 
evaluations such as accuracy, sensitivity, specificity, strength and MCC (Matthews 
correlation coefficient) (Teng et al., 2012, Xu et al., 2008). 
 
The two prediction tools for SUMOylation in this study can be found at 
http://sumosp.biocuckoo.org/ and http://www.abgent.com/sumoplot  
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In this study, human cell lines have been used to identify and confirm potential SUMO 
targets. The validity of the LS/MS proteomics approach have been confirmed by performing 
subsequent western blotting experiments for filamin-1 and determining the predicted 
SUMOylation sites on the protein amino acid sequences. The simplified filamin-1 structure is 
shown in Figure 60. 
 
 
 
 
 
 
 
 
Figure 60. Simplified diagram of the structure of filamin-A (filamin-1): filamin-1 has C-terminal 
dimerization domain and N-terminal ABD domain (actin binding domain), it also has Rod 1 and Rod 2 
domain which are the major protein partner interaction domains, Modified from (Popowicz et al., 2006) 
 
Filamin-A (filamin-1) is a large actin-binding protein and filamins link the actin network to 
cellular membrane to integrate with cellular signalling for cell locomotion; filamins are located 
both at the cell leading edge and the rear of motile cells where they can directly regulate 
actin cytoskeleton remodelling important for cell protrusions and retractions (Zhou et al., 
2009). Filamin-1 can bind to the cytoplasmic tail of β integrin to prevent integrin activation in 
cells, where they could undergo intramolecular auto-inhibition of integrin binding; this is 
important for controlling cell adhesion and migration (Pentikäinen and Ylänne, 2009).  
 
Hypothesis 
Chapter 3 and 4 have shown that the focal adhesion proteins, talin and vinculin can be 
SUMOylated and that SUMOylation plays a critical regulatory role in the dynamic activities of 
the FAs in cancer cells, where inhibiting protein SUMOylation caused increased numbers of 
FAs and enlarged FAs. SUMOylation may have a diverse role in the regulation of cell 
migration. The FA proteins assemble and form FA adhesion complex at the membrane 
fractions. Therefore, in this Chapter, it was hypothesized that not just one FA protein could 
be SUMOylated, but SUMOylation may be implicated in the regulation of FA adhesion 
complex and FA protein-protein interactions.  In this study, MDA-MB-231 cells, platelets, and 
a human megakaryocyte-like cell line, CMK11-5 cells, have been used to investigate, identify 
and confirm whether talin, vinculin and other FA proteins in the adhesion complex and any 
proteins associated in the inside-out integrin-FA signalling can be SUMOylated.  
 
Rod 1 
ABD 
Hinge 1 
Hinge 2 
Rod 2 
Dimerization 
domain 
C 
N 
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Methods 
 
5.2 Mass Spectrometry 
A two-step process has been done to obtain the mass spectrometry samples. The MDA-MB-
231 cells, platelets and the CMK11-5 cells were prepared for the SUMO VIVATM Binding 
Assay system. Next, these samples were followed through for the mass spectrometry 
preparations. Firstly, MDA-MB-231 cells and the CMK11-5 cells were treated and prepared 
as control 1 hour vs. GA 1 hour; the platelets samples were prepared as control 30 minutes 
vs. GA 30 minutes. Whole cell lysates were made using the lysis buffer from the VIVAbindTM 
SUMO Kit (see previous method 4.2). The lysis buffer was added with 50mM NEM 
additionally and prepared for the number of sample tubes needed. For CMK11-5 cells, the 
cell suspensions were centrifuged at 1500 rpm for 5 minutes. The media was removed and 
the cell pellets were kept. For each cell pellet, 300µl lysis buffer was added and mixed well 
in the tube. The cell lysates were transferred into the eppendorf tubes and kept on ice. For 
the platelets, blood was taken from the donors directly and the platelets were extracted from 
the blood by centrifugation, isolation and purification. Fresh platelets were prepared and 
used immediately. 1x109 platelets / 6ml were used, which the protein concentration was 
around 0.6mg / 2ml. The platelets were also centrifuged to get the pellets. For each control 
and GA treated samples was added with 200µl lysis buffer and mixed well. 
 
0.1% v/v formic acid was prepared and filtered (pH=4.0). All the sample reactions were done 
on ice. Each sample tube was added with the 40µl VIVAbindTM SUMO matrix suspension. 
Once the sample capped columns were washed with the wash buffer x3 and the unbound 
factions were transferred into separate eppendorf tubes for each sample, the capped column 
was added with 200µl 0.1% v/v filtered formic acid. All the sample columns were mixed and 
rotated on the rotary machine for 5-10 minutes at room temperature. Then the column base 
was uncapped and placed into a new eppendorf tube for each sample. All the sample tubes 
were centrifuged at 5000g for 1 minute to collect eluted materials. The elution fractions could 
then be stored at -20°C and ready to be sent out for mass spectrometry analysis of 
Birmingham University, the functional genomics and proteomics laboratories, School of 
Biosciences, the University of Birmingham. LC-MS/MS analysis has been applied in these 
samples’ analysis.   
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LC-MS/MS (University of Birmingham) 
Trypsin digestion: this step was performed using 10µl of samples (~1-100µg of protein) and 
added 40µl of 100mM ammonium bicarbonate (pH=8). Then the sample was added 50µl of 
10 mM dithiothreitol (DTT) and the samples were incubated at 56 °C for 30 minutes. The 
samples were then cooled to room temperature and cysteines alkylated by the addition of 
50µl of 50mM iodoacetamide, mixed and incubated at room temperature in the dark for 30 
minutes. 25 µl of trypsin gold (Promega, Southampton, Hampshire, UK, 6ng/µl) was 
subsequently added to the samples, which were then incubated at 37 °C overnight.  
 
LC-MS/MS experiment: UltiMate® 3000 HPLC series (Dionex, Sunnyvale, CA USA) was 
used for peptide concentration and separation. The samples were trapped on uPrecolumn 
Cartridge, Acclaim PepMap 100 C18, 5 um, 100A 300um i.d. x 5mm (Dionex, Sunnyvale, CA 
USA) and separated in Nano Series™ Standard Columns 75 µm i.d. x 15 cm, packed with 
C18 PepMap100, 3 µm, 100Å (Dionex, Sunnyvale, CA USA). The gradient used was from 
3.2% to 44% solvent B (0.1% formic acid in acetonitrile) for 30 minutes. Peptides were 
eluted directly (~ 300 nL min-1) via a Triversa Nanomate nanospray source (Advion 
Biosciences, NY) into a LTQ Orbitrap Elite mass spectrometer (ThermoFisher Scientific, 
Germany). The data-dependent scanning acquisition was controlled by Xcalibur 2.1 
software. The mass spectrometer alternated between a full FT-MS scan (m/z 380 – 1800) 
and subsequent collision-induced dissociation (CID) MS/MS scans of the 7 most abundant 
ions. Survey scans were acquired in the Orbitrap with a resolution of 120 000 at m/z 400 and 
automatic gain control (AGC) 1x106. Precursor ions were isolated and subjected to CID in 
the linear ion trap with AGC 1x105. Collision activation for the experiment was performed in 
the linear trap using helium gas at normalized collision energy to precursor m/z of 35% and 
activation Q 0.25. The width of the precursor isolation window was 2 m/z and only multiply-
charged precursor ions were selected for MS/MS. 
 
The MS was run to obtain the spectra of digested peptides from the samples and the MS 
and MS/MS scans were searched against Uniprot database (or supplied by customer) using 
SEQUEST algorithm (Thermo Fisher PD 1.4), where the database could provide theoretical 
spectra / computational calculated masses of peptides from the theoretical trypsin digested 
protein peptides. The protein peptide sequence would be identified by the searching 
software: the data-dependent scanning acquisition was controlled by Xcalibur 2.1 software 
and the survey scans were acquired in the Orbitrap. Variable modifications were 
deamidation (N and Q), oxidation (M) and phosphorylation (S, T and Y). Carbamidomethyl 
(C) modification was for fixed modification. The precursor mass tolerance was 10 ppm and 
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the MS/MS mass tolerance was 0.8Da. Two missed cleavage was allowed and were 
accepted as a real hit protein with at least two high confidence peptides. 
 
If the experimental mass matched the computational calculated mass, the peptide sequence 
would be identified by the searching software and the software has validated the peptide 
sequences identified statistically and these peptide sequences were used to confer which 
proteins were in the samples. The software could only find the peptides which the peptide 
sequences were present in the database. For the Orbitrap the Birmingham proteomics unit 
has used which could identify the length of amino acids between 6 and 14.  
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Results 
 
5.3 The Predictions of SUMOylated Talin Using SUMO-plot and GPS SUMO 
Programmes 
 
The amino acid sequence in the head, linker and rod domain of human talin-1 
  
   1 MVALSLKISI GNVVKTMQFE PSTMVYDACR IIRERIPEAP AGPPSDFGLF  
  51 LSDDDPKKGI WLEAGKALDY YMLRNGDTME YRKKQRPLKI RMLDGTVKTI  
 101 MVDDSKTVTD MLMTICARIG ITNHDEYSLV RELMEEKKEE ITGTLRKDKT  
 151 LLRDEKKMEK LKQKLHTDDE LNWLDHGRTL REQGVEEHET LLLRRKFFYS  
 201 DQNVDSRDPV QLNLLYVQAR DDILNGSHPV SFDKACEFAG FQCQIQFGPH  
 251 NEQKHKAGFL DLKDFLPKEY VKQKGERKIF QAHKNCGQMS EIEAKVRYVK  
 301 LARSLKTYGV SFFLVKEKMK GKNKLVPRLL GITKECVMRV DEKTKEVIQE  
 351 WNLTNIKRWA ASPKSFTLDF GDYQDGYYSV QTTEGEQIAQ LIAGYIDIIL  
 401 KKKKSKDHFG LEGDEESTML EDSVSPKKST VLQQQYNRVG KVEHGSVALP  
 451 AIMRSGASGP ENFQVGSMPP AQQQITSGQM HRGHMPPLTS AQQALTGTIN  
 501 SSMQAVQAAQ ATLDDFDTLP PLGQDAASKA WRKNKMDESK HEIHSQVDAI  
 551 TAGTASVVNL TAGDPAETDY TAVGCAVTTI SSNLTEMSRG VKLLAALLED  
 601 EGGSGRPLLQ AAKGLAGAVS ELLRSAQPAS AEPRQNLLQA AGNVGQASGE  
 651 LLQQIGESDT DPHFQDALMQ LAKAVASAAA ALVLKAKSVA QRTEDSGLQT  
 701 QVIAAATQCA LSTSQLVACT KVVAPTISSP VCQEQLVEAG RLVAKAVEGC  
 751 VSASQAATED GQLLRGVGAA ATAVTQALNE LLQHVKAHAT GAGPAGRYDQ  
 801 ATDTILTVTE NIFSSMGDAG EMVRQARILA QATSDLVNAI KADAEGESDL  
 851 ENSRKLLSAA KILADATAKM VEAAKGAAAH PDSEEQQQRL REAAEGLRMA  
 901 TNAAAQNAIK KKLVQRLEHA AKQAAASATQ TIAAAQHAAS TPKASAGPQP   
 951 LLVQSCKAVA EQIPLLVQGV RGSQAQPDSP SAQLALIAAS QSFLQPGGKM  
1001 VAAAKASVPT IQDQASAMQL SQCAKNLGTA LAELRTAAQK AQEACGPLEM  
1051 DSALSVVQNL EKDLQEVKAA ARDGKLKPLP GETMEKCTQD LGNSTKAVSS  
1101 AIAQLLGEVA QGNENYAGIA ARDVAGGLRS LAQAARGVAA LTSDPAVQAI  
1151 VLDTASDVLD KASSLIEEAK KAAGHPGDPE SQQRLAQVAK AVTQALNRCV  
1201 SCLPGQRDVD NALRAVGDAS KRLLSDSLPP STGTFQEAQS RLNEAAAGLN  
1251 QAATELVQAS RGTPQDLARA SGRFGQDFST FLEAGVEMAG QAPSQEDRAQ  
1301 VVSNLKGISM SSSKLLLAAK ALSTDPAAPN LKSQLAAAAR AVTDSINQLI  
1351 TMCTQQAPGQ KECDNALREL ETVRELLENP VQPINDMSYF GCLDSVMENS  
1401 KVLGEAMTGI SQNAKNGNLP EFGDAISTAS KALCGFTEAA AQAAYLVGVS  
1451 DPNSQAGQQG LVEPTQFARA NQAIQMACQS LGEPGCTQAQ VLSAATIVAK  
1501 HTSALCNSCR LASARTTNPT AKRQFVQSAK EVANSTANLV KTIKALDGAF  
1551 TEENRAQCRA ATAPLLEAVD NLSAFASNPE FSSIPAQISP EGRAAMEPIV  
1601 ISAKTMLESA GGLIQTARAL AVNPRDPPSW SVLAGHSRTV SDSIKKLITS  
1651 MRDKAPGQLE CETAIAALNS CLRDLDQASL AAVSQQLAPR EGISQEALHT  
1701 QMLTAVQEIS HLIEPLANAA RAEASQLGHK VSQMAQYFEP LTLAAVGAAS  
1751 KTLSHPQQMA LLDQTKTLAE SALQLLYTAK EAGGNPKQAA HTQEALEEAV  
1801 QMMTEAVEDL TTTLNEAASA AGVVGGMVDS ITQAINQLDE GPMGEPEGSF  
1851 VDYQTTMVRT AKAIAVTVQE MVTKSNTSPE ELGPLANQLT SDYGRLASEA  
1901 KPAAVAAENE EIGSHIKHRV QELGHGCAAL VTKAGALQCS PSDAYTKKEL  
1951 IECARRVSEK VSHVLAALQA GNRGTQACIT AASAVSGIIA DLDTTIMFAT  
2001 AGTLNREGTE TFADHREGIL KTAKVLVEDT KVLVQNAAGS QEKLAQAAQS  
2051 SVATITRLAD VVKLGAASLG AEDPETQVVL INAVKDVAKA LGDLISATKA  
2101 AAGKVGDDPA VWQLKNSAKV MVTNVTSLLK TVKAVEDEAT KGTRALEATT  
2151 EHIRQELAVF CSPEPPAKTS TPEDFIRMTK GITMATAKAV AAGNSCRQED  
2201 VIATANLSRR AIADMLRACK EAAYHPEVAP DVRLRALHYG RECANGYLEL  
2251 LDHVLLTLQK PSPELKQQLT GHSKRVAGSV TELIQAAEAM KGTEWVDPED  
2301 PTVIAENELL GAAAAIEAAA KKLEQLKPRA KPKEADESLN FEEQILEAAK  
2351 SIAAATSALV KAASAAQREL VAQGKVGAIP ANALDDGQWS QGLISAARMV  
2401 AAATNNLCEA ANAAVQGHAS QEKLISSAKQ VAASTAQLLV ACKVKADQDS  
2451 EAMKRLQAAG NAVKRASDNL VKAAQKAAAF EEQENETVVV KEKMVGGIAQ  
2501 IIAAQEEMLR KERELEEARK KLAQIRQQQY KFLPSELRDE H 
 
Figure 61. The amino acid sequence of human talin-1, its head, linker domain and the dimerization 
domain have been highlighted in the structure of the molecule, where the rod domain of talin consists 
the major part of the amino acid sequence; any lysine residues that were predicted previously to be 
SUMO modified have been highlighted in either red or blue colour: the red lysine residues were the 
motifs with probability score above 0.5 using the SUMOplot; the blue lysine residues were the motifs 
with probability score just under 0.5 
 
In Figure 61, talin-1 molecule has been highlighted in three regions: the head domain (1-400 
amino acids), the linker domain where a calpain-2 cleavage site is located and the rod 
Talin head (1-400 amino acids): 
predicted SUMOylation sites: 
K137, K157, K263, K274 
Talin linker domain (401-481 amino acids): 
Calpain-2 mediated cleavage site:  Q433-
444 
Predicted SUMOylation site: K441 
Talin rod domain (481-2541 amino 
acids): predicted SUMOylation sites: 
K841, K1415, K2063, K2445, K2104, 
K2322, K2375  
Talin dimerization domain (2494-2541 
amino acids): second Calpain-2 cleavage 
site: Q2527-Q2529 
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domain which consists of the talin dimerization domain and it also contains a calpain-2 
cleavage site. In all the three regions of talin: the head, linker and the rod domains, there 
have been predictions of SUMO conjugation sites in the talin-1 molecule and these residues 
were highlighted in red and blue according to the SUMOplot programme predictions.  
 
SUMOplotTM Analysis Programme (Abgent) Predictions on the SUMOylation Sites in 
Talin (Protein ID: Q9Y490): Motif B-K-x-D/E  
Motifs with probability score > 0.5  
Motifs with probability score < 0.5 
 
No. Lysine 
Position 
Peptide Sequence Probability  
Score 
1 K841 DLVNA IKAD AEGES 0.94 
2 K2445 LVACK VKAD QDSEA 0.93 
3 K2063 RLADV VKLG AASLG 0.76 
4 K441 QYNRV GKVE HGSVA 0.67 
5 K1415 GISQN AKNG NLPEF 0.62 
6 K263 AGFLD LKDF LPKEY 0.56 
7 K274 KEYVK QKGE RKIFQ 0.50 
8 K2375 ELVAQ GKVG AIPAN 0.50 
9 K2104 TKAAA GKVG DDPAV 0.50 
10 K137 RELME EKKE EITGT 0.50 
11 K157 LLRDE KKME KLKQK 0.48 
12 K138 ELMEE KKEE ITGTL 0.48 
13 K2322 IEAAA KKLE QLKPR 0.48 
 
GPS SUMO Programme Predictions on the Talin-1 Protein Peptide Sequence 
Position Peptides Score Cut-off Type 
2445 LLVACKVKADQDSEA 44.828 36.625 Sumoylation 
841 SDLVNAIKADAEGES 38.22 36.625 Sumoylation 
300 EAKVRYVKLARSLKT 36.667 36.625 Sumoylation 
1599 -1603 GRAAMEP IVISA KTMLESA 62.07 59.29 SUMO Interaction 
2078 - 2082 AEDPETQ VVLIN AVKDVAK 61.629 59.29 SUMO Interaction 
965 -969 AVAEQIP LLVQG VRGSQAQ 60.904 59.29 SUMO Interaction 
396 - 400 AQLIAGY IDIIL KKKKSKD 60.757 59.29 SUMO Interaction 
388 - 392 QTTEGEQ IAQLI AGYIDII 59.806 59.29 SUMO Interaction 
 
Table 12. SUMOplot predictions on the talin SUMOylation sites, lysine positions with score above 0.5 
were highlighted in red and the position scores below 0.5 were highlighted in blue. Another software 
GPS SUMO programme shows the SUMOylation predictions as well as the SUMO interactions SIMs 
of talin-1 SUMOylation, where the FASTA sequence of talin-1 was inputted and the medium threshold 
was used: the modified positions, modified peptides, score for the modification, cut-off and the type of 
SUMO modifications were presented 
 
In Table 12, talin was predicted to be a protein substrate for SUMOylation using both 
SUMOplot and GPS SUMO programmes. The SUMOplot analysis programme predicts the 
probability of the direct match of the SUMO consensus motif B-K-x-D/E associated in the 
166 
talin-SUMO conjugation and the adjacent lysine residues that could substitute the amino 
acid residues exhibiting similar hydrophobicity to the consensus amino acid residues. The 
probability score of the prediction of the SUMO consensus motif: the lysine residues were 
coloured red with a high probability score above 0.5; the lysine residues were coloured blue 
with a probability score below 0.5. The lysine positions predicted as the SUMO conjugation 
sites were highlighted in red as K841 and K2445 from the SUMOplot programme, which 
were also predicted as the same lysine residues using the GPS SUMO programme, 
indicating these two lysine residues are highly likely to be SUMOylated in talin.  
 
5.4 The Predictions of SUMOylated Vinculin Using SUMO-plot and GPS SUMO 
Programmes 
 
The amino acid sequence in the head, neck region and tail domain of human vinculin 
1 MPVFHTRTIE SILEPVAQQI SHLVIMHEEG EVDGKAIPDL TAPVAAVQAA VSNLVRVGKE 
 61 TVQTTEDQIL KRDMPPAFIK VENACTKLVQ AAQMLQSDPY SVPARDYLID GSRGILSGTS 
121 DLLLTFDEAE VRKIIRVCKG ILEYLTVAEV VETMEDLVTY TKNLGPGMTK MAKMIDERQQ 
181 ELTHQEHRVM LVNSMNTVKE LLPVLISAMK IFVTTKNSKN QGIEEALKNR NFTVEKMSAE 
241 INEIIRVLQL TSWDEDAWAS KDTEAMKRAL ASIDSKLNQA KGWLRDPSAS PGDAGEQAIR 
301 QILDEAGKVG ELCAGKERRE ILGTCKMLGQ MTDQVADLRA RGQGSSPVAM QKAQQVSQGL 
361 DVLTAKVENA ARKLEAMTNS KQSIAKKIDA AQNWLADPNG GPEGEEQIRG ALAEARKIAE 
421 LCDDPKERDD ILRSLGEISA LTSKLADLRR QGKGDSPEAR ALAKQVATAL QNLQTKTNRA 
481 VANSRPAKAA VHLEGKIEQA QRWIDNPTVD DRGVGQAAIR GLVAEGHRLA NVMMGPYRQD 
541 LLAKCDRVDQ LTAQLADLAA RGEGESPQAR ALASQLQDSL KDLKARMQEA MTQEVSDVFS 
601 DTTTPIKLLA VAATAPPDAP NREEVFDERA ANFENHSGKL GATAEKAAAV GTANKSTVEG 
661 IQASVKTARE LTPQVVSAAR ILLRNPGNQA AYEHFETMKN QWIDNVEKMT GLVDEAIDTK 
721 SLLDASEEAI KKDLDKCKVA MANIQPQMLV AGATSIARRA NRILLVAKRE VENSEDPKFR 
781 EAVKAASDEL SKTISPMVMD AKAVAGNISD PGLQKSFLDS GYRILGAVAK VREAFQPQEP  
841 DFPPPPPDLE QLRLTDELAP PKPPLPEGEV PPPRPPPPEE KDEEFPEQKA GEVINQPMMM   H1 
901 AARQLHDEAR KWSSKGNDII AAAKRMALLM AEMSRLVRGG SGTKRALIQC AKDIAKASDE   H2 
961 VTRLAKEVAK QCTDKRIRTN LLQVCERIPT ISTQLKILST VKATMLGRTN ISDEESEQAT H3 H4 
1021 EMLVHNAQNL MQSVKETVRE AEAASIKIRT DAGFTLRWVR KTPWYQ                 H5 
 
Figure 62. The amino acid sequence of the human vinculin: the vinculin molecule has been 
highlighted in three regions: the vinulin head Vh, the intramolecular binding site for the vinculin tail 
and the vinculin tail Vt; there have been many predictions in the SUMO conjugation sites of the 
vinculin molecule; SUMO modified residues were highlighted in red with probability above 0.5 using 
SUMOplot 
 
 
In Figure 62, the vinculin molecule has been highlighted in four regions: the vinculin head 
domain (1-835 amino acids), an intramolecular binding site for the vinculin tail (181-226), the 
proline-rich neck region (836-877) and the vinculin tail domain (877-1066). In the three 
regions of vinculin: the head, the neck region and the tail domains, there have been 
predictions of SUMO conjugation sites in the vinculin molecule and these residues were 
highlighted in red according to the SUMOplot programme predictions.  
 
 
 
Vh (D1, D2, D3, D4, amino 
acids 1-835) 
 
An intramolecular binding site 
for the vinculin tail (181-226) 
 
V proline-rich neck region (836-
877): binding of VASP, ponsin, 
vinexin 
 
Vt (877-1066): binding of PIP2, 
paxillin, actin 
167 
SUMOplotTM Analysis Programme (Abgent) Predictions on the SUMOylation Sites in 
Vinculin (Protein ID: P18206-2, Isoform 1): Motif B-K-x-D/E  
Motifs with probability score > 0.5 
No. Lysine 
Position 
Peptide Sequence Probability 
Score 
1 K731 ASEEA IKKD LDKCK 0.94 
2 K80 MPPAF IKVE NACTK 0.94 
3 K71 TEDQI LKRD MPPAF 0.91 
4 K768 RILLV AKRE VENSE 0.79 
5 K544 RQDLL AKCD RVDQL 0.79 
6 K366 LDVLT AKVE NAARK 0.79 
7 K496 AVHLE GKIE QAQRW 0.67 
8 K453 DLRRQ GKGD SPEAR 0.67 
9 K881 PPPPE EKDE EFPEQ 0.5 
10 K862 DELAP PKPP LPEGE 0.5 
11 K639 FENHS GKLG ATAEK 0.5 
12 K308 ILDEA GKVG ELCAG 0.5 
 
 
 
GPS SUMO Programme Predictions on the Vinculin Protein Peptide Sequence 
Position Peptides Score Cut-off Type 
80 DMPPAFIKVENACTK 50.727 16 Sumoylation 
71 TTEDQILKRDMPPAF 41.438 36.625 Sumoylation 
731 DASEEAIKKDLDKCK 39.463 36.625 Sumoylation 
366 GLDVLTAKVENAARK 19.444 16 Sumoylation 
768 NRILLVAKREVENSE 18.608 16 Sumoylation 
245 -249 SAEINEI IRVLQ LTSWDED 65.014 59.29 SUMO Interaction 
20 - 24 LEPVAQQ ISHLV IMHEEGE 61.265 59.29 SUMO Interaction 
 
Table 13. SUMOplot predictions on the vinculin SUMOylation sites, lysine positions with score above 
0.5 were highlighted in red indicating high probabilities. GPS SUMO programme shows the 
SUMOylation predictions as well as the SUMO interactions SIMs of vinculin SUMOylation, where the 
FASTA sequence of vinculin was inputted and the medium threshold was used: the modified 
positions, modified peptides, score for the modification, cut-off and the type of SUMO modifications 
were presented 
 
In Table 13, vinculin was also predicted to be a protein substrate for SUMOylation using both 
SUMOplot and GPS SUMO programmes. The highlighted lysine residues in black K731, K80 
and K71 have been predicted as the SUMOylation sites using both programmes, indicating 
that these lysine residues could be SUMOylated with a high probability. K768 and K366 are 
also predicted to be the SUMOylation sites in vinculin with lower probability compared to 
these top three lysine residues.  
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5.5 Mass Spectrometry Analysis Identifies Focal Adhesions can be SUMOylated  
 
Protein Score 
The protein score is the sum of the scores of the individual peptides. SEQUEST search 
algorithm was used (Thermo Fisher PD 1.4), for which the software was used to search the 
peptides that were matched with the protein peptides directly; the percolator statistical 
software with FDR (false discovery rate) setting at 0.01 was applied to validate how good the 
matches were for the found peptides: the score is the sum of all the peptide XCorr values 
above the specified score threshold and this XCorr score for each matched peptide was 
validated. With FDR 0.01, a set of threshold values were generated for the ions at different 
charge states and only the peptides found above the specified threshold was considered 
high confidence peptides and they were only sent by the Birmingham Proteomics Unit. The 
analysis from the Birmingham Proteomics Unit has listed the high confidence peptide 
according to the threshold: +1: 0.05, +2: 2.215, +3: 2.46, +4: 3.705, +5: 3.715, +6: 3.72, ≥+7: 
3.725. Only the highest peptide score in each searching above the set threshold was kept, 
all the other peptides under that threshold were filtered out. Only the highest scored peptide 
was used with the Proteome Discoverer application. Whilst a search was performed using 
dynamic modifications, one spectrum might have multiple matches because of permutations 
of the modification site. The higher the score the better it is. 
 
Coverage 
The percent coverage was calculated by dividing the number of amino acids in all found 
peptides by the total number of amino acids in the entire protein sequence. The higher the 
coverage value the better it is for a peptide.  
 
The Mass Spectrometry Identification of SUMOylated Proteins: 
As for the three different cell lines, each cell line was prepared as control and GA treated 
whole cell lysate samples before they were put through the SUMO binding kit columns. All 
the samples sent were set as control and GA treated samples that were obtained with 
SUMOylated proteins as prepared previously. Most of the focal adhesions were completely 
gone after the 1 hour of 100µM GA treatment. 
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MDA-MB-231 cells control 1 hour 
Accession Protein Description Score Coverage 
Q9Y490 Talin-1  73.77 13.58 
B4DW52 cDNA FLJ55253, highly similar to Actin, 
cytoplasmic 1 
48.18 55.62 
A6NDY9 Filamin A  24.81 6.18 
B3KTS5 Voltage-dependent anion-selective channel protein 1  18.20 33.57 
P68366-2 Isoform 2 of Tubulin alpha-4A chain  17.55 18.71 
Q8WU19 Tubulin alpha-1B chain  17.15 24.18 
P07355 Annexin A2  15.43 25.66 
Q86XU5 MYH9 protein  14.23 3.71 
Q96B49 Mitochondrial import receptor subunit TOM6 homolog 13.62 22.97 
P63104 14-3-3 protein zeta/delta  13.42 26.12 
E9PLJ3 Cofilin-1  11.21 35.44 
P61224-2 Isoform 2 of Ras-related protein Rap-1b  10.67 21.17 
D6REL8 Fibrinogen beta chain  9.98 15.81 
M0R1I1 Tubulin beta-4A chain  9.00 35.14 
P01834 Ig kappa chain C region  8.72 51.89 
B4DKM5 Voltage-dependent anion-selective channel protein 2 8.10 13.73 
B0QYP8 Beta-parvin  7.19 7.22 
K7EJ44 Profilin 1 7.08 26.92 
P18206-2 Isoform 1 of Vinculin  5.06 3.38 
 
Table 14. Summarising the identification of SUMOylated proteins in MDA-MB-231 cells for the control 
sample in the MS data analysis (Birmingham Proteomics Unit); these cells were previously prepared 
as whole cell lysates, mixed and incubated with the SUMO matrix-containing columns to obtain eluted 
SUMOylated proteins and reserved in 0.1% formic acid previously 
 
MDA-MB-231 cells GA 100µM treatment 1 hour 
Accession Protein Description Score Coverage 
P21796 Voltage-dependent anion-selective channel protein 1  30.98 45.58 
P07355 Annexin A2  29.05 39.23 
P01834 Ig kappa chain C region  12.13 66.98 
B4DKM5 Voltage-dependent anion-selective channel protein 2  9.62 21.96 
B4DNG6 Annexin  8.75 13.68 
Q96B49 Mitochondrial import receptor subunit TOM6 homolog  8.22 22.97 
H0YFX9 Histone H2A  6.17 20.65 
S6BGE0 IgG H chain  5.89 11.00 
 
Table 15. Summarising the identification of SUMOylated proteins in MDA-MB-231 cells for the100µM 
GA 1 hour treated sample in the MS data analysis (Birmingham Proteomics Unit). These cells were 
previously prepared as whole cell lysates, mixed and incubated with the SUMO matrix-containing 
columns to obtain eluted SUMOylated proteins and reserved in 0.1% formic acid previously 
 
In Table 14, the FA proteins including talin-1 (with high protein score and relatively high 
coverage), actin-1 (with high protein score and high coverage), filamin A (with high protein 
score), tubulin α4A chain, tubulin α1B chain, myosin 9, vinculin, cofilin-1, profilin-1 etc have 
been identified in the MDA-MB-231 cells in the control sample in the MS data analysis. In 
table 15, after 100µM of GA 1 hour treatment, all of them were gone in the sample. 
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CMK11-5 cells control 1 hour 
 
Accession Protein Description Score Coverage 
Q9Y490 Talin-1  269.47 39.87 
Q60FE6 Filamin A  158.23 34.04 
P35579 Myosin-9  94.96 18.52 
B4DW52 cDNA FLJ55253, highly similar to Actin, 
cytoplasmic 1 
72.31 49.57 
P08514-3 Isoform 3 of Integrin alpha-IIb  52.82 25.92 
P12814-2 Isoform 2 of Alpha-actinin-1  40.49 16.12 
P61224-3 Isoform 3 of Ras-related protein Rap-1b  34.11 49.70 
B7Z4U6 Gelsolin  32.10 24.24 
P18206-2 Isoform 1 of Vinculin  31.78 9.10 
X6RJP6 Transgelin-2  28.49 52.41 
B4DQN9 Tubulin beta-7 chain  28.30 22.85 
P08567 Pleckstrin  28.22 32.86 
Q53GA7 Tubulin alpha 6 variant  28.01 26.06 
B4DVY2 cDNA FLJ54184, highly similar to Tropomyosin alpha-
4 chain 
24.00 36.68 
A0A024R9Q1 Thrombospondin 1 23.88 12.05 
D3JV41 Thrombocidin-2 antimicrobial variant  22.41 41.27 
G3V1A4 Cofilin 1 (Non-muscle) 21.53 44.97 
Q9H4B7 Tubulin beta-1 chain  20.93 23.50 
P02675 Fibrinogen beta chain  20.06 22.61 
P68366-2 Isoform 2 of Tubulin alpha-4A chain  18.44 22.40 
P02679-2 Isoform Gamma-A of Fibrinogen gamma chain  17.43 23.34 
B4E2L8 Coagulation factor XIII A chain (EC 2.3.2.13)  16.95 6.55 
P07737 Profilin 1  15.39 50.00 
P68871 Hemoglobin subunit beta  14.63 53.74 
E9M4D4 Hemoglobin alpha-1 globin chain  13.10 69.00 
F5H1C6 Fermitin family homolog 3  13.09 23.78 
P02671-2 Isoform 2 of Fibrinogen alpha chain  12.62 9.47 
L7UUZ7 Integrin beta  12.21 6.22 
Q9H299 SH3 domain-binding glutamic acid-rich-like protein 3  10.12 55.91 
B0QYP8 Beta-parvin  8.25 14.43 
P19105 Myosin regulatory light chain 12A  7.36 17.54 
B4DQX7 Zyxin  7.04 12.53 
H3BQ34 Pyruvate kinase  6.73 17.44 
S6BGE0 IgG H chain  6.68 11.00 
B4DNG6 Annexin  6.51 23.93 
P04075 Fructose-bisphosphate aldolase A  6.00 11.54 
E9PI65 Heat shock cognate 71 kDa protein  5.75 13.69 
E5RGE1 14-3-3 protein zeta/delta  5.39 43.14 
 
Table 16. Summarising the identification of SUMOylated proteins in CMK11-5 cells for the control 
sample in the MS data analysis (Birmingham Proteomics Unit); these cells were previously prepared 
as whole cell lysates, mixed and incubated with the SUMO matrix-containing columns to obtain eluted 
SUMOylated proteins and reserved in 0.1% formic acid previously 
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CMK11-5 cells GA 100µM treatment 1 hour 
 
Accession Protein Description Score Coverage 
B4DKM5 Voltage-dependent anion-selective channel protein 2  25.31 46.67 
P21796 Voltage-dependent anion-selective channel protein 1  24.62 38.16 
B4DVQ0 Actin, cytoplasmic 2  24.04 30.33 
Q8IUK7 ALB protein  13.61 9.09 
Q8WU19 TUBA1B protein  12.88 18.81 
B4DNH8 Annexin  12.24 26.29 
Q9Y277 Voltage-dependent anion-selective channel protein 3  10.94 11.31 
P01834 Ig kappa chain C region  7.10 49.06 
P07737 Profilin 1  6.27 21.43 
E9PI65 Heat shock cognate 71 kDa protein (Fragment) 4.42 14.88 
Q5TCU6 Talin-1  4.23 0.58 
O96008 Mitochondrial import receptor subunit TOM40 homolog 3.84 4.16 
M0QZN2 40S ribosomal protein S5  3.73 11.19 
F8VV32 Lysozyme C  3.46 11.54 
H0YFX9 Histone H2A (Fragment)  3.40 20.65 
A6NDY9 Filamin A 3.22 0.65 
Q6B823 Histone H4 (Fragment)  2.83 23.26 
P02776 Platelet factor 4  2.81 14.85 
G3V1A4 Cofilin 1 (Non-muscle)  2.80 9.40 
Q0MVN7 Integrin subunit aIIb (Fragment)  2.38 6.36 
 
Table 17. Summarising the identification of SUMOylated proteins in CMK11-5 cells after 100µM GA 1 
hour treatment in the MS data analysis (Birmingham Proteomics Unit); these cells were previously 
prepared as whole cell lysates, mixed and incubated with the SUMO matrix-containing columns to 
obtain eluted SUMOylated proteins and reserved in 0.1% formic acid previously 
 
In Table 16, the FA proteins including talin-1 (with high protein score and high coverage), 
filamin A (with high protein score and high coverage), myosin-9 (with high protein score and 
high coverage), actin-1 (with high protein score and high coverage), integrin αIIbβ3 (with 
high protein score and high coverage), α-actinin-1, isoform 2 (with high protein score and 
high coverage), vinculin (with high protein score and relatively high coverage), tubulin β7 
chain, tubulin α6, tubulin β1, tubulin α4A chain, cofilin-1, profilin-1 etc have been identified in 
the CMK11-5 cells in the control sample in the MS data analysis. In table 17, after 100µM of 
GA 1 hour treatment, most of the FA proteins were gone in the GA treated sample, i.e. talin-
1 protein score was 4.23 with only 0.58 protein coverage score; filamin-A protein score was 
3.22 with only 0.65 protein coverage score. 
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Platelets Control 30 minutes 
 
Accession Protein Description Score Coverage 
B4DW52 cDNA FLJ55253, highly similar to Actin, 
cytoplasmic 1 
43.39 42.94 
X6RJP6 Transgelin-2  22.34 46.52 
P61224-2 Isoform 2 of Ras-related protein Rap-1b  14.35 21.17 
G3V1A4 Cofilin 1 (Non-muscle) 13.27 28.19 
P01834 Ig kappa chain C region  12.25 66.98 
P08514-3 Isoform 3 of Integrin alpha-IIb  12.23 6.40 
M0QZN2 40S ribosomal protein S5  8.18 11.19 
D3DX71 LIM and senescent cell antigen-like domains 1 8.17 25.86 
F8VVB9 Tubulin alpha-1B chain  6.66 11.79 
K7EPB9 Tropomyosin alpha-4 chain (Fragment) 6.64 18.18 
B7Z4U6 Gelsolin  6.63 5.81 
S6BGE0 IgG H chain  6.21 11.00 
D3DP16 Fibrinogen gamma chain 5.84 5.99 
P11142-2 Isoform 2 of Heat shock cognate 71 kDa protein  5.78 10.55 
Q5TCU6 Talin 1  5.58 1.03 
 
Table 18. Summarising the identification of SUMOylated proteins in platelets for the control sample in 
the MS data analysis (Birmingham Proteomics Unit); these cells were previously prepared as whole 
cell lysates, mixed and incubated with the SUMO matrix-containing columns to obtain eluted 
SUMOylated proteins and reserved in 0.1% formic acid previously 
 
Platelets GA 100µM treatment 30 minutes 
 
Accession Protein Description Score Coverage 
P01834 Ig kappa chain C region  6.93 33.96 
C9JKR2 Albumin 6.79 6.71 
C9JDS9 Tubulin alpha-4A chain (Fragment) 3.94 8.97 
 
Table 19. Summarising the identification of SUMOylated proteins in platelets after 100µM GA 30 
minutes treatment in the MS data analysis (Birmingham Proteomics Unit). These cells were previously 
prepared as whole cell lysates, mixed and incubated with the SUMO matrix-containing columns to 
obtain eluted SUMOylated proteins and reserved in 0.1% formic acid previously 
 
In Table 18, some of the FA proteins that have been identified in the MDA-MB-231 cells and 
the CMK11-5 cells have also been identified in the platelets in the control sample including: 
actin-1 (with high protein score and high coverage), talin-1, integrin αIIbβ3, tubulin α1B 
chain, cofilin-1 etc have been identified in the MS data analysis. In table 19, after 100µM of 
GA 30 minutes treatment, all of the FA proteins were gone in the GA treated sample.  
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The proteins identified at least in 2 cell lines or in all 3 cell lines were summarised in 
the table below: 
 
All 3 cell lines Talin 1  
All 3 cell lines Actin, cytoplasmic 1 
All 3 cell lines Cofilin 1  
MDA-MB-231 & CMK11-5 Filamin A (Filamin 1) 
MDA-MB-231 & CMK11-5 Vinculin isoform 1 
MDA-MB-231 & CMK11-5 Myosin-9 
MDA-MB-231 & CMK11-5 Tubulin alpha-4A chain, isoform 2 
MDA-MB-231 & Platelets Tubulin alpha-1B chain 
MDA-MB-231 & CMK11-5 Profilin 1 
MDA-MB-231 & CMK11-5 Fibrinogen beta chain 
CMK11-5 & Platelets Fibrinogen gamma chain  
 
Table 20. Summarising some of the FAs appeared in at least 2 cell lines or in all the 3 cell lines after 
the samples were analysed in the MS. These were the whole cell lysates & SUMO binding samples of 
each cell line that obtained the previously SUMOylated proteins and identified in the MS. 
 
In Table 20, the FA proteins have been identified in all three cell lines or in at least two cells 
lines, are: talin-1, actin cytoplasmic 1, filamin A, vinculin, myosin 9, tubulin α4A chain, tubulin 
α-1B chain, cofilin 1 (Non-muscle), profilin-1, fibrinogen beta chain, fibrinogen gamma chain. 
Among these proteins, talin-1, filamin A and vinculin have been done in the IP & WB 
experiments in both of the MDA-MB-231 cells and the U2OS cells. Talin 1 was also looked 
at in platelets.  
 
5.6 STRING Data Analysis Shows the Protein-Protein Interactions in Focal Adhesions  
STRING protein network analysis has been used to obtain talin, vinculin and filamin-A 
protein network analysis. The network nodes represent proteins and post-translational 
modifications and each node in the protein network represents all the proteins produced by a 
single encoding gene locus. The edges in the network represent protein-protein 
associations, which are specific, i.e. the proteins co-interact and contribute to a shared 
function jointly but this co-interaction does not represent their physical binding to each other 
necessarily. The red coloured node represents the query protein and first shell of interactors: 
talin-1, vinculin or filamin-A. 
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Human Talin-1 and Its Interaction Partners: Integrin, Vinculin, Actin, Paxillin, Calpain-2 
etc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
Figure 63. Schematic representation of the various contacts of the protein-protein interactions in the 
talin network established by the string analysis in the focal adhesion contacts: the blue edge was 
represented as the database for the known interactions (e.g. nearly all protein nodes were connected 
with blue edge); the known interactions from experimentally determined were linked by purple edge 
(e.g. talin-1 – paxillin, talin-1 – integrin β1, talin-1 – calpain 2); the black edge represented the co-
expression (e.g. integrin β2 – paxillin, integrin α2b – paxillin; actin-1 – paxillin); the yellow edge 
represented as the text data mining (in nearly all the protein-protein interactions); the light purple (e.g. 
integrin β3-integrin β2-integrin β1) were protein homology 
 
Protein node Predicted functional partners: Score 
PXN Paxillin 0.998 
ITGB3 
 
Integrin, beta 3 (platelet glycoprotein IIIa, 
antigen CD61) 
 
0.998 
VCL Vinculin 0.996 
ITGB1 Integrin, β1 0.993 
PTK2 Protein tyrosine kinase 2 0.993 
 
PIP5K1C 
 
Phosphatidylinositol-4-phosphate 5-kinase, type 
I, gamma 
0.985 
ACTA1 Actin, alpha 1 0.981 
ITGB2 Integrin, β2 0.981 
CAPN2 Calpain 2 0.971 
ITGA2B Integrin, alpha 2b (platelet glycoprotein IIb of 
IIb/IIIa complex, antigen CD41) 
0.970 
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In Figure 63, talin-1 has been in the network associated with vinculin, paxillin, actin α1, 
integrin β1, β3, α2b, calpain-2, protein tyrosine kinase 2 and PIP5K1C Phosphatidylinositol-
4-phosphate 5-kinase, type I, gamma.  
 
Human Vinculin and Its Interaction Partners: Talin, Actin 1, Paxillin and etc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64. Schematic representation of the various contacts of the protein-protein interactions in the 
vinculin network established by the string analysis in the focal adhesion contacts: the blue edge was 
represented as the database for the known interactions (e.g. nearly all protein nodes were connected 
with blue edge); the known interactions from experimentally determined were linked by purple edge 
(e.g. vinculin – talin-1, vinculin – src, vinculin – actinin α1, vinculin – paxillin); the black edge 
represented the co-expression (e.g. vinculin – actinin α1, vinculin – tensin 1, catenin α1- tensin 1, 
paxillin- actinin α1); the yellow edge represented as the text data mining (in nearly all the protein-
protein interactions); the light purple (e.g. vinculin – catenin α1, PTK2 – Src) were protein homology 
Protein node Predicted functional partners: Score 
PXN Paxillin 0.999 
SORBS1 Sorbin and SH3 domain containing 1 0.999 
SRC Src 0.998 
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 0.998 
CTNNA1 Catenin (cadherin-associated protein), 
alpha 1 
0.998 
 
RAVER1 
 
Ribonucleoprotein, PTB-binding 1 0.997 
 
TNS1 
 
Tensin 1 0.997 
TLN1 Talin 1 0.996 
 
ACTN1 
 
Actinin, alpha 1 0.995 
PTK2 Protein tyrosine kinase 2 0.995 
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The protein-protein interaction map of the vinculin network in Figure 64 has shown that 
vinculin is associated with paxillin, sorbin and SH3 domain containing 1, src, cadherin 1, type 
1, E-cadherin (epithelial), catenin (cadherin-associated protein), alpha 1, ribonucleoprotein, 
PTB-binding 1, tensin 1, talin 1, actinin, alpha 1 and protein tyrosine kinase 2. 
 
From the talin or the vinculin protein-protein network and the mass spectrometry 
identification of the previously SUMOylated proteins in the MDA-MB-231 cells, CMK11-5 
cells and the platelets, alterations in one protein in the network such as talin SUMOylation 
could affect a number of signalling proteins in the protein-protein interactions. 
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5.7 Validation of Filamin-A (Filamin-1) as a SUMOylation Substrate  
Filamin A is also known as filamin 1 and it was shown as a SUMOylation substrate in the 
mass spectrometry analysis in the MDA-MB-231 cells and in the CMK11-5 cells. Analysis of 
filamin-1 was done using the SUMOplot and GPS SUMO software to investigate whether 
filamin-1 was predicted to be SUMOylated and if so to obtain the positions at which lysines 
they may be SUMOylated. The highlighted lysine residues in red were predicted as the 
SUMOylation or SUMO interaction sites from the SUMOplot and the GPS SUMO 
programme. 
 
SUMOplotTM Analysis Programme (Abgent) Predictions on the SUMOylation Sites in 
Filamin (Protein ID: P21333, Isoform A): Motif B-K-x-D/E  
 
Motifs with probability score > 0.5 
No. Lysine 
Position 
Peptide Sequence Probability 
Score 
1 K2473 DGPSK VKMD CQECP 0.93 
2 K876 HDASK VKAE GPGLS 0.93 
3 K865 TSPIR VKVE PSHDA 0.93 
4 K520 ELKVT VKGP KGEER 0.82 
5 K2165 HCDLS LKIP EISIQ 0.8 
6 K620 EGPSQ AKIE CDDKG 0.79 
7 K2500 SYLIS IKYG GPYHI 0.77 
8 K1800 VIPFT IKKG EITGE 0.77 
9 K1621 RYTIL IKYG GDEIP 0.77 
10 K1234 AYTVT IKYG GQPVP 0.77 
11 K2631 EYTLV VKWG DEHIP 0.76 
12 K569 RSPFE VKVG TECGN 0.76 
13 K1439 VPGSP FKVP VHDVT 0.74 
14 K1964 MRMSH LKVG SAADI 0.73 
15 K270 FPKAK LKPG APLRP 0.73 
16 K367 AGQHI AKSP FEVYV 0.69 
17 K906 KAAGK GKLD VQFSG 0.67 
18 K781 YGPGV AKTG LKAHE 0.62 
19 K700 EFTVD AKHG GKAPL 0.62 
20 K523 VTVKG PKGE ERVKQ 0.61 
21 K1071 TKPSK VKAF GPGLQ 0.58 
22 K704 DAKHG GKAP LRVQV 0.57 
23 K2623 SYLLK DKGE YTLVV 0.5 
24 K982 VSGLG EKVD VGKDQ 0.5 
25 K958 GGDPI PKSP FSVAV 0.5 
26 K626 KIECD DKGD GSCDV 0.5 
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GPS SUMO Programme Predictions on the Filamin-1 Protein Peptide Sequence 
Position Peptides Score Cut-off Type 
865 PTSPIRVKVEPSHDA 47.746 16 Sumoylation 
876 SHDASKVKAEGPGLS 45.301 16 Sumoylation 
1486 GVAPLQVKVQGPKGL 39.881 36.625 Sumoylation 
299 EPTGNMVKKRAEFTV 39.383 36.625 Sumoylation 
2631 GEYTLVVKWGDEHIP 39.261 36.625 Sumoylation 
2473 IDGPSKVKMDCQECP 37.737 36.625 Sumoylation 
676 DFHPDRVKARGPGLE 37.622 36.625 Sumoylation 
523 KVTVKGPKGEERVKQ 19.972 16 Sumoylation 
620 VEGPSQAKIECDDKG 17.91 16 Sumoylation 
923 - 927 KGDAVRD VDIID HHDNTYT 64.791 59.29 SUMO Interaction 
2035 - 2039 QHVASSP IPVVI SQSEIGD 64.04 59.29 SUMO Interaction 
316 - 320 RSAGQGE VLVYV EDPAGHQ 63.818 59.29 SUMO Interaction 
144 - 148 ILGLIWT LILHY SISMPMW 63.24 59.29 SUMO Interaction 
1136 - 1140 TEPGDYN INILF ADTHIPG 62.415 59.29 SUMO Interaction 
1696 - 1700 CTPDGSE VDVDV VENEDGT 61.103 59.29 SUMO Interaction 
416 - 420 AGAGTGE VEVVI QDPMGQK 60.671 59.29 SUMO Interaction 
1497 - 1501 PKGLVEP VDVVD NADGTQT 60.321 59.29 SUMO Interaction 
 
Table 21. SUMOplot predictions on the filamin-A (filamin-1) SUMOylation sites, lysine positions with 
score above 0.5 were highlighted in red indicating high probabilities. GPS SUMO programme shows 
the SUMOylation predictions as well as the SUMO interactions SIMs of filamin-1 SUMOylation, where 
the FASTA sequence of filamin-1 was inputted and the medium threshold was used: the modified 
positions, modified peptides, score for the modification, cut-off and the type of SUMO modifications 
were presented 
 
 
In Table 21, the highlighted black SUMOylated lysine positions from the SUMOplot 
prediction programme were also predicted using the GPS SUMO programme for the 
SUMOylation of filamin-1. K876 and K865 have been predicted as the top lysine positions 
being SUMOylated using both programmes. In Table 21, filamin-1 has been predicted with 
multiple modified lysine positions using both programmes.  
 
Filamin-1 was a SUMOylation protein substrate from the mass spectrometry analysis and 
filamin 1 was predicted with many SUMOylated lysine positions and with high probability. To 
confirm whether filamin-1 can be SUMOylated, IP was conducted in the MDA-MB-231 cells 
using the HA-tag SUMO-2 plasmid and the cells were transfected and incubated for 24 
hours. The cells were then treated with 100µM GA for 15, 30 or 60 minutes. IP and western 
blotting was done. Filamin-1 can be detected in the MDA-MB-231 cells using 2 different 
antibodies against the N-terminus and the C-terminus to detect the protein. Interestingly, 
filamin-1 was able to be cleaved after the inhibition of SUMOylation at 1 hour treatment.  
 
179 
       HA IP: SUMO-2, IB: Filamin-1                                       HA IP: SUMO-2, IB: SUMO-2  
    (N-19 ab, detecting N-terminus of filamin-1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Combined Cy3 and Cy5 Channels: 
The overlay: the Alexa 546 anti-goat ab 
detecting filamin-1=Cy3 (filamin-1, green) 
and the Alexa 647 anti-rabbit ab detecting 
SUMO-2 Cy5 (SUMO-2, red), n=3  
 
Figure 65. IP and WB showing that filamin-1 
at 270kDa can be SUMOylated in the MDA-
MB-231 cells in both control and GA 15, 30, 
60 minutes treated samples using the N-
terminus antibody.  
 
 
In Figure 65, in the control and GA treated 15, 30 and 60 minutes samples of the IP: SUMO-
2, IB: Filamin-1 membrane, filamin-1 was found to be SUMOylated at 280kDa using the N-
terminus antibody. Bands at ~150kDa and 50kDa were also detected.  
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       HA IP: SUMO-2, IB: Filamin-1                                   HA IP: SUMO-2, IB: SUMO-2 
        (H-300 ab, detecting C-terminus of filamin-1)  
 
 
 
Combined Cy3 and Cy5 Channels: 
The overlay: Alexa 546 anti-rabbit ab 
detecting filamin-1=Cy3 (filamin-1, green) 
and Alexa 647 anti-goat ab detecting 
SUMO-2 Cy5 (SUMO-2, red), n=3 
 
Figure 66. IP and WB showing that filamin-1 
at 270kDa can be SUMOylated in the MDA-
MB-231 cells using the C-terminus antibody.  
 
 
In Figure 66, in the control and GA treated 15, 30 and 60 minutes samples of the IP: SUMO-
2, IB: Filamin-1 membrane, filamin-1 was found to be SUMOylated at 280kDa using the C-
terminus antibody.  
 
5.8 The Predicted SUMO Modified Sites in Known SUMOylated Substrates: p53, Rac1, 
FAK and Actin, Cytoplasmic 1 Using SUMOplot and GPS SUMO Programmes  
As validation of software prediction for SUMOylation sites, SUMOplot and GPS SUMO have 
been used to predict the SUMO modification sites or SUMO interactions in already identified 
and known SUMOylated substrates, p53, Rac1 and actin-1 to determine how stringent these 
programmes are in order to compare the results with the predictions of talin and vinculin.  
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                                                                         First supernatant 
250 – 
150 – 
 
100– 
  75– 
 50– 
  
37– 
25– 
20– 
 
15– 
 10– 
 17kDa 
SUMO 
IP:     Ctrl    GA       Ctrl    GA       Ctrl   GA       WB:   Ctrl   GA 
          15     15         30     30        60     60                  30    30 (mins) 
                                                                            First supernatant 
250 – 
150 – 
 
100– 
  75– 
 
  50– 
  37– 
 
  25– 
  20– 
  15– 
  
  10– 
 
280kDa 
181 
SUMOplotTM Analysis Programme (Abgent) Predictions on the SUMOylation Sites in 
FAK (Protein ID: Q05397): Motif B-K-x-D/E  
 
Motifs with probability score > 0.8 
 
 
 
GPS SUMO Programme Predictions on the FAK Protein FASTA Sequence 
 
 
 
 
 
 
 
 
Table 22. SUMOplot predictions on the FAK SUMOylation sites, lysine positions with score above 0.5 
were highlighted in red using SUMOplot. GPS SUMO programme shows the SUMOylation predictions 
as well as the SUMO interactions SIMs of FAK SUMOylation, where the FASTA sequence of FAK 
was inputted and the medium threshold was used: the modified positions, modified peptides, score for 
the modification, cut-off and the type of SUMO modifications were presented 
 
In Table 22, K152 of FAK is a SUMO modification site which has been validated in 
experimental conditions (Kadaré et al., 2003) and this has been discussed in the discussion 
section. K152 appears both in the first top of the predicting list of positions in the SUMOplot 
and in the GPS SUMO. K834 has also been predicted to be SUMOylated lysine sites using 
both programmes.  
 
 
 
 
 
 
 
 
 
 
 
No. Lysine 
Position 
Peptide Sequence Probability  
Score 
1 K152 FFYQQ VKSD YMLEI 0.93 
2 K834 KEERF LKPD VRLSR 0.91 
Position Peptides Score Cut-off Type 
152 NFFYQQVKSDYMLEI 40.097 36.625 Sumoylation 
903 DSYNEGVKLQPQEIS 39.886 36.625 Sumoylation 
561 VSSNDCVKLGDFGLS 37.265 36.625 Sumoylation 
834 EKEERFLKPDVRLSR 36.977 36.625 Sumoylation 
121 AHPPEEWKYELRIRY 19.022 16 Sumoylation 
267 - 271 CALGSSW IISVE LAIGPEE 73.562 59.29 SUMO Interaction 
972 - 976 LATVDET IPLLP ASTHREI 67.784 59.29 SUMO Interaction 
495 - 499 GVITENP VWIIM ELCTLGE 65.627 59.29 SUMO Interaction 
487 - 491 HPHIVKL IGVIT ENPVWII 62.573 59.29 SUMO Interaction 
182 
SUMOplotTM Analysis Programme (Abgent) Predictions on the SUMOylation Sites in 
p53 (Protein ID: P04637): Motif B-K-x-D/E  
 
Motifs with probability score > 0.8 
No. Lysine Position Peptide Sequence Probability Score 
1 K386 HKKLM FKTE GPDSD 0.85 
 
GPS SUMO Programme Predictions on the p53 Protein FASTA Sequence 
 
 
 
 
 
 
Table 23. SUMOplot predictions on the p53 SUMOylation sites, lysine positions with score above 0.5 
were highlighted in red using SUMOplot. GPS SUMO programme shows the SUMOylation predictions 
as well as the SUMO interactions SIMs of p53 SUMOylation, where the FASTA sequence of p53 was 
inputted and the medium threshold was used: the modified positions, modified peptides, score for the 
modification, cut-off and the type of SUMO modifications were presented 
 
In Table 23, K386 has been both predicted to be the single SUMOylated site in p53, the 
oncogene as the guardian gene in cancer. K386 has been validated to be the SUMOylated 
site in p53 experimentally (Kwek et al., 2001) and this is discussed in the discussion.  
 
SUMOplotTM Analysis Programme (Abgent) Predictions on the SUMOylation Sites in 
Rac1 (Protein ID: P63000): Motif B-K-x-D/E  
 
Position Peptides Score Cut-off Type 
7-11 *MQAIKC VVVGD GAVGKTC 59.593 59.29 SUMO Interaction 
 
Table 24. No motifs has been found for Rac1 consensus SUMO modified motifs; GPS SUMO shows 
the SUMO interactions SIMs of Rac1 SUMOylation, where the FASTA sequence of Rac1 was 
inputted and the medium threshold was used: the modified positions, modified peptides, score for the 
modification, cut-off and the type of SUMO modifications were presented 
 
In Table 24, Rac1 has not been shown with any consensus SUMO modified motifs using 
both SUMOplot and GPS SUMO. Castillo-Lluva et al has shown that in Rac1 the non-
consensus sites within the polybasic region (PBR) of Rac1 as the main location for SUMO 
conjugation: almost 95% of the SUMO-1 modified Rac1 was conjugated at lysine 188, 183 
and 184 or 186 present within the C-terminal PBR of Rac1 (Castillo-Lluva et al., 2010).  
 
 
 
Position Peptides Score Cut-off Type 
386 RHKKLMFKTEGPDSD 17.901 16 Sumoylation 
143 - 147 QLAKTCP VQLWV DSTPPPG 63.665 59.29 SUMO Interaction 
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SUMOplotTM Analysis Programme (Abgent) Predictions on the SUMOylation Sites in 
actin, cytoplasmic 1 (Protein ID: P60709): Motif B-K-x-D/E  
 
Motifs with probability score > 0.8 
No. Pos. Group Score 
1 K284 TFNSI MKCD VDIRK 0.8 
2 K68 RGILT LKYP IEHGI 0.8 
 
GPS SUMO Programme Predictions on the Actin Protein FASTA Sequence 
Position Peptides Score Cut-off Type 
284 TTFNSIMKCDVDIRK 42.92 36.625 Sumoylation 
103 - 107 VAPEEHP VLLTE APLNPKA 63.606 59.29 SUMO Interaction 
 
Table 25. SUMOplot prediction on the actin SUMOylation sites, lysine positions with score above 0.5 
were highlighted in red using SUMOplot. GPS SUMO programme shows the SUMOylation prediction 
as well as the SUMO interaction SIM of actin SUMOylation, where the FASTA sequence of actin was 
inputted and the medium threshold was used: the modified positions, modified peptides, score for the 
modification, cut-off and the type of SUMO modifications were presented 
 
In Table 25, K284 and K68 have been predicted to be the SUMOylation sites for actin; 
computational modelling and site-directed mutagenesis have identified K284 and K68 as 
critical sites for SUMOylating actin experimentally (Hofmann et al., 2009). Here, SUMOplot 
and GPS SUMO have both predicted K284 to be the SUMOylation site in actin; SUMOplot 
also predicted K68 in actin as the SUMOylation site.  
 
The reliability and stringency of the two bioinformatics software have been discussed in the 
discussion section for the prediction of talin, vinculin and filamin-1 SUMOylation. 
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Discussion 
The identification and confirmation of SUMOylated focal adhesion proteins have been 
investigated and validated for the first time in these studies. The discussion for this study 
covers several aspects: the up-to-date list of all the novel SUMOylated proteins discovered 
and identified; the proposed SUMO modified sites in the SUMOylated proteins, some 
proteomics methods have been discussed; the SUMOylation of focal adhesion proteins have 
been identified and validated for the first time, however, the most up-to-date proteomics 
studies still underappreciate the novel identification of these SUMOylated focal adhesion 
proteins; in the future work, focal adhesion mutagenesis will be the next approach. 
 
5.9 The Identification and Validation of SUMOylated FA Proteins 
From the most up-to-date list of all the SUMOylated proteins identified by any of 22 
published proteomic studies or low-throughput studies, only talin-1 and filamin-1 have been 
identified although there was no experimental validation. There has been no vinculin 
SUMOylation identification in any published studies. 
 
In Hendriks and Vertegaal’s study (summarised in Table 26), talin-1, filamin-A, cofilin-1 (non-
muscle), profilin-1, myosin-9 / myosin regulatory light chain 12A, tubulin beta-4A chain, 
tubulin alpha-4A chain, tubulin alpha-1B chain, fibrinogen gamma chain and fibrinogen alpha 
chain have all been identified to be SUMO target protein substrates without additional 
validation e.g. through IP & WB experimental determination. These FA related proteins have 
been identified in this current study and furthermore, talin-1, vinculin and filamin-1 
SUMOylation has been experimentally validated for the first time. Additionally, Hendriks and 
Vertegaal’s most updated study has not yet identified vinculin and actin as SUMOylation 
substrates. This suggests that the MS methods used to identify SUMOylated proteins and 
the MS data analysis in this current study have been in the agreement with the most 
comprehensive study (Hendriks and Vertegaal, 2016), although vinculin SUMOylation was 
not identified suggesting very low abundance SUMO modified proteins could still be missed 
in mass spectrometry experiments. 
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Comparison between the current study and the most up-to-date proteomics 
study 
SUMOylation 
substrates 
Current study: identification with 
MS and validation through IP & WB 
Hendriks and Vertegaal, 
2016 MS study and their 
referenced MS studies: 
identification only 
Talin-1 Identification in all three cell lines: 
MDA-MB-231, CMK11-5, platelets 
 
Validation in all three cell lines: MDA-
MB-231, U2OS, platelets 
Identification only  
Hela cells 
Filamin A 
(Filamin-1) 
Identification in MDA-MB-231 & 
CMK11-5 
 
Validation in MDA-MB-231 and U2OS 
Identification only  
Cofilin-1 (non-
muscle) 
Identification in all three cell lines: 
MDA-MB-231, CMK11-5, platelets 
Identification only 
Profilin-1 Identification in MDA-MB-231 & 
CMK11-5 
Identification only 
Myosin-9 Identification in MDA-MB-231 & 
CMK11-5 
Identification only  
Myosin 
regulatory 
light chain 
12A 
Identification in CMK11-5 only Identification only 
Tubulin beta-
4A chain 
Identification in MDA-MB-231 only Identification only 
Tubulin alpha-
4A chain 
Identification in MDA-MB-231 & 
CMK11-5 
Identification only 
Tubulin alpha-
1B chain 
Identification in MDA-MB-231 & 
platelets 
Identification only 
Fibrinogen 
gamma chain  
Identification in CMK11-5 & Platelets Identification only  
Fibrinogen 
alpha chain 
Identification in CMK11-5 only Identification only 
Vinculin Identification in MDA-MB-231 & 
CMK11-5 for the first time 
Validation in MDA-MB-231 & U2OS 
None 
 
Table 26. Summarising the comparisons between the identification of SUMOylated FA/FA-related 
proteins from Hendriks and Vertegaal’s study in the MS analysis supplementary data and the current 
study of the identification and validation of SUMOylated FA proteins in MDA-MB-231, CMK11-5, 
platelets and U2OS cells 
 
Some of the cytoplasmic SUMOylated proteins have been shown in Table 26 and compared 
to this current study for the identification and validation of the FA and FA-related proteins. 
Hendriks and Vertegaal’s 2016 study has also identified the calpain inhibitor, calpastatin as 
well as calpain-2 as SUMOylation protein substrates, surprisingly as there has no published 
papers for the identification. The proteomics studies for identifying SUMOylation of filamin-1 
has been published in 12 studies with no experimental validation (Bruderer et al., 2011, 
Golebiowski et al., 2009, Becker et al., 2013, Schimmel et al., 2014, Matic et al., 2008, 
Tatham et al., 2011, Schimmel et al., 2008, Impens et al., 2014, Hendriks et al., 2014, 
Hendriks et al., 2015c, Hendriks et al., 2015a, Xiao et al., 2015); the proteomics identification 
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of talin-1 SUMOylation has only been published in two studies with no experimental 
validation and no identification have been published for the SUMO modification site in talin-1 
(Tatham et al., 2011, Becker et al., 2013); for Rac 1 SUMOylation, there has been only 1 
paper published with experimental validation (Castillo-Lluva et al., 2010).  
 
5.10 Software Prediction of SUMOylation Modified Sites in the FA Proteins 
Protein SUMOylation is a very dynamic process, which is involved in many cellular activities. 
In order to determine the functional consequences of protein SUMOylation, it is important to 
determine which lysines are modified.  Although mutational analysis and proteomics 
approaches have been used to identify the majority of known SUMOylated sites, it can be 
time consuming and labour intensive to analyse larger and more complex proteins, 
particularly those with dozens of potential consensus and non-consensus SUMOylation sites 
(Xu et al., 2008). Bioinformatics studies have also been used to identify protein SUMOylation 
sites and these approaches are considerably quicker and simpler to perform. In this study, 
SUMOplot and GPS SUMO have been used to predict the specific modified lysine residues 
in talin-1, vinculin and filamin-1. SUMOplot, along with GPS SUMO and MotifX, is one of the 
first methods available for SUMOylation site prediction, which has been performed on a very 
large test set (Xue et al., 2006). Many SUMOylation substrate sites follow a consensus motif 
ψ-K-X-E, but experimental data and mass spectrometry data have shown that some 
SUMOylation sites do not follow this motif, such as Rac1, where non-consensus sites were 
identified within the C-terminal polybasic region (PBR) of Rac1 as Rac1 lacks a consensus 
motif (Castillo-Lluva et al., 2010); therefore, with SUMO predicting software, sensitivity, 
specificity and accuracy will be important factors to determine its predicting power and not to 
generate false positive sites (Xue et al., 2006). However, additional large-scale and high 
throughput proteomic identification approach may still be required to exclude false negatives.  
 
The SUMOplot and GPS SUMO have been used to predict the SUMOylation of p53, actin, 
cytoplasmic 1, Rac1 and FAK, which are known SUMOylated substrates. The predicted 
lysine positions in these substrates using these bioinformatics programmes have been 
identified and validated exactly as what have been predicted. p53 has been predicted with 
lysine K386 SUMO modified site using both programmes and this lysine has been identified 
and validated experimentally as a SUMO-1 conjugationg site in the literature as the only 
SUMOylation site in p53 (Kwek et al., 2001, Melchior and Hengst, 2002, Gostissa et al., 
1999, Rodriguez et al., 1999).  
 
The N-terminal FERM (protein 4.1, ezrin, radixin and moesin homology) domain of FAK has 
been found to interact with the protein inhibitor of activated STAT1 (PIAS1, an E3-type 
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SUMO ligase) and this interaction was found to be direct; PIAS1 could induce the 
conjugation of SUMO-1 to FAK on K152 as a conserved residue in FAK and this lysine was 
highly likely to be the only one SUMOylation consensus motif and SUMOylated FAK was 
predominantly enriched in the nucleus (Kadaré et al., 2003, Mitra et al., 2005); this lysine 
has also been predicted with the highest probability, identified and validated experimentally. 
Interestingly, no predicted consensus motif have been predicted for Rac1, which is in 
agreement with the finding that Rac1 was SUMOylated in the non-consensus sites within the 
polybasic region of Rac1 as the main location for SUMO conjugation (Castillo-Lluva et al., 
2010); actin has been predicted with K284 SUMO conjugation site using both programmes; 
K68 has been predicted using SUMOplot; site-directed mutagenesis has identified K284 and 
K68 as critical SUMO 2/3 modified sites in actin and both sites are required for the binding of 
SUMO enzymes; cooperativity between K68 and K284 is necessary for SUMO-2 and actin 
complex stability, which is required for the nuclear localization of actin (Hofmann et al., 2009). 
 
The multiple sites for SUMO modifications have been collated comprehensively and shown 
7327 SUMOylation sites in 3617 proteins (Hendriks and Vertegaal, 2016). The majority of 
the SUMOylated proteins are located in the nucleus and are linked to SUMO 1 rather than 
SUMO 2/3 modification; of all the proteins for which SUMOylation evidence exists, ~66% 
were nuclear (Hendriks and Vertegaal, 2016). However, in their study, they have 
summarised all the up-to-date references and listed the one identified SUMOylation modified 
site in filamin-1 as K299 (Schimmel et al., 2014, Hendriks et al., 2014, Hendriks et al., 
2015b); filamin-1 has also been shown with K285 modified site (Hendriks et al., 2015c). 
None of the literature has directly identified any modified SUMOylation sites in talin or 
vinculin yet. There have also been no papers published identifying any SUMOylation 
modified sites for calpain and calpastatin. 
 
In this study, talin and vinculin have been identified as SUMOylated substrates in three cell 
lines: the MDA-MB-231 cells, the U2OS cells, the CMK11-5 cells and the platelets. Talin-1, 
vinculin and filamin-1 SUMOylation have been validated in experiments for the first time in 
this study. There are multiple predicted SUMOylation modified sites in filamin-1 using the 
SUMOplot and GPS SUMO programmes and they have shown K865 and K876 are the 
highest probability SUMOylated lysine sites in filamin-1. Although K299 and K285 SUMO 
modified sites in filamin-1 came through the proteomic high throughput, none of the papers 
have validated filamin-1 SUMOylation experimentally. K299 was also predicted to be a 
SUMOylation site using GPS SUMO but not the SUMOplot. Similarly, more than one SUMO 
modifications and SIM sites for protein-protein interactions in filamin-1 have been predicted 
using SUMOplot and GPS SUMO. This suggests that numerous proteomics studies are 
188 
capable of identifying SUMOylated proteins and the majority of the SUMOylated proteins 
have been identified in the nucleus, however, the consensus motifs or non-consensus 
SUMO modified motifs in the identified SUMOylation protein and their role in the protein-
protein interactions are much less identified and validated, particularly for the cytoplasmic 
proteins that have been identified to be SUMOylated.  
 
Since p53, FAK, actin, cytoplasmic 1 and Rac1 have been predicted for their SUMOylation 
modified sites using the bioinformatics programmes and have validated the literature, this 
has suggested that the top predicted SUMOylation modified sites with the highest scores for 
talin (K841, K2445), vinculin (K731, K80 and K71) or filamin-1 (K2473, K876, K865 and 
K299) are reasonable, reliable and believable and they can be used and applied in the 
further experimental works. The next step for the validation of these predictions is site-
directed mutagenesis.  
 
The published proteomic studies have used several methods to identify and validate the 
putative SUMOylated proteins and SUMOylation modification sites. An advanced system-
wide Protease-Reliant Identification of SUMO Modification (PRISM) with high-resolution MS 
has allowed for the detection of SUMOylated proteins as well as the identification of specific 
SUMO associated sites using wild-type SUMO on endogenous proteins in the cancerous 
Hela cells (Hendriks et al., 2015b). In another study, a novel proteomics approach was 
developed to generate monoclonal antibodies, which could specifically recognize, capture 
and enrich the peptides containing SUMO remnant chains after tryptic digestion of 
SUMOylated proteins, followed by large-scale MS analysis of SUMO modified peptides 
(Lamoliatte et al., 2014). One study has also shown the development of stably transfected 
cell lines expressing a double-tagged modifier under the control of a tightly negatively 
regulated promoter; this has allowed the tagged modifier to be expressed and conjugated to 
the cellular proteins covalently and by tandem affinity purification of the protein pool and the 
identification of the modified proteins with LC and MS, 27 substrates were found to be 
modified by both SUMO-1 and SUMO-3, indicating the SUMO paralogues could be 
functionally distinct (Rosas-Acosta et al., 2005). SUMO-2 and SUMO-3 have been required 
for cells to survive heat shock identified in 766 putative substrates through quantitative 
labelling techniques, stringent purification of SUMOylated proteins, advanced MS technology 
and novel techniques of data analysis (Golebiowski et al., 2009). Many studies have been 
focused on the cell cycle, where an efficient tandem affinity purification strategy was 
developed characterizing SUMO 2/3 modified proteins in mitotic cells and in cells undergoing 
mitotic exit, therefore, combining this purification strategy with cell synchronization and 
quantitative MS (Schou et al., 2014). Similarly, quantitative MS approach has been 
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employed to identify SUMO-2 conjugated substrates during DNA damage (Hendriks et al., 
2015c). High-resolution MS in a site-specific manner has been applied to study global 
SUMOylation in human cells, also including different PTMs that can cross talk with SUMO; 
they have also concluded that the SUMOylated lysines were frequently located in areas 
enriched for charged residues and the SUMOylated regions were depleted for 
phenylalanine, tryptophan, tyrosine, leucine and most particularly for cysteine (Hendriks et 
al., 2014). 
 
Site-directed mutagenesis is the next approach to study protein SUMOylation. Currently, no 
studies have been performed on vinculin or talin SUMOylation using site directed 
mutagenesis. Vinculin can directly interact with talin and actin to control FA formation 
(Humphries et al., 2007). SUMOplot predicts 3 putative SUMOylation sites in talin with high 
probability as K841, K2445 and K2063. Talin rod contains ~11 vinculin binding sites, 2 actin 
binding sites and the binding site for β-integrin tails; talin R2R3 domain, each contains 2 
vinculin binding sites and R2R3 binds to RIAM synergistically; also vinculin and RIAM can 
bind to the N-terminal region of talin rod by mutually exclusive mechanistic events (Goult et 
al., 2013b). This means that K841 lies in the talin rod R3 region, RIAM and vinculin binding 
site, K2445 is in the R13 region, where actin and vinculin binding site also lies; K2063 in the 
R11 region is in the RIAM, vinculin and β-integrin tail binding site (Goult et al., 2013b). As 
binding of talin to RIAM and vinculin regulates FAs assembly and turnover, where 
SUMOylation sites were found in these domains, this may be very important to the function 
of FA regulation and to individual FA proteins, i.e. talin and vinculin specifically, whether 
targeting SUMOylation sites could affect dynamic interactions in FA proteins.  
 
The vinculin tail Vt competes with the talin rod domain for the binding to the vinculin head Vh 
D1 domain and in vinculin SUMO modification sites, the predicted SUMOylation sites K71 
and K80 lie in the N-terminal vinculin head Vh D1 domain, where competition between talin 
tail binding domain and vinculin tail Vt binding to the vinculin head occurs. This suggests that 
SUMOylation may also be involved in the conformational changes of the vinculin molecule, 
where the vinculin head domain could be modified through SUMOylation and this can 
regulate the recruitment of talin-vinculin protein interactions. In the site mutagenesis study, it 
could be predicted to have an effect on vinculin recruitment to FA and disassembly events in 
the FA protein complex, if these SUMO modified sites were mutated.  
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5.11 Validation of the MS Data: Filamin-1 is a Substrate for SUMO Modification  
Filamin 1 also known as filamin A, is an actin cross linking protein which acts as a 
scaffolding protein which could couple and mediate the transmembrane integrin signalling 
with the cell cytoskeleton and therefore regulate FA turnover (Xu et al., 2010). Filamin 1 is 
one of three filamin members of the filamin family (Critchley, 2000). Filamin can also bind to 
integrin β subunit at a site which overlaps with the talin binding sites and therefore filamin 
competes and interferes with talin binding (Calderwood et al., 2013). Filamin 1 and talin can 
both compete for integrin binding: when filamin 1 is bound with the integrin β cytoplasmic 
tail, it could form an extended β strand which would interact with β strands C and D of the 
filamin immunoglobulin-like domain (IgFLN) 21 and this interaction interface was found to be 
overlapped with that of the integrin-talin binding site; the integrin binding PTB-like domain of 
talin could cause inhibition of IgFLN 21 binding to β tail (Kiema et al., 2006). Filamin can also 
be cleaved by calpain; Filamin 1 and talin may compete for calpain-mediated cleavage, 
which would impact on FA disassembly (Xu et al., 2010). 
 
Filamin 1 was identified as a SUMOylated protein during the mass spectrometry analysis. 
Filamin 1 with was identified with high protein score and high coverage in both MDA-MB-231 
and CMK11-5 cells. Further investigation validates that filamin 1 is indeed a SUMOylation 
substrate in both MDA-MB-231 and U2OS cells. The Co-IP results also suggested filamin 1 
was present in the same complex with talin. These results implicate that both talin and 
filamin 1 can be SUMOylated in the focal adhesion, talin and filamin 1 may compete each 
other for integrin binding and SUMOylation of either protein is important in controlling FA 
turnover and cell migration and SUMOylation may be important in the regulation of their 
protein-protein interactions.  
 
5.12 The String Network of the FA proteins 
To investigate protein-protein interactions in the focal adhesion, talin and vinculin have been 
mapped into the STRING protein network with high STRING confidence all within 0.95-0.99 
ranges. Talin-1 interacts with vinculin, integrin β1, β2, β3, α2b, actin α1 subunit, calpain-2, 
paxillin, protein tyrosine kinase 2 (PTK2) and PIP5K1C (phosphatidylinositol-4-phosphate 5-
kinase, type I, gamma) through a wide range of investigations including experimental 
determinations such as co-purification, co-crystallization, yeast2hybrid, genetic interactions 
etc from the primary resources; databases, such as through metabolic pathways, protein 
complexes, signal transduction pathways etc; through text mining or text data mining; 
through co-expression and co-occurrence, where the genes for the protein expressions are 
observed to be correlated in expression or the gene families with their occurrence patterns 
show similarities across a large number of experiments. These determined interactive 
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partners proposed by the STRING have been largely known FA proteins connected in the 
talin network. Many of them including vinculin, actin and calpain-2 could be SUMOylated 
either in the IP & WB experiments or in the prediction programmes & proteomic studies. This 
suggests that the overall role of SUMOylation is very important in the FA protein network and 
by changing protein-protein interactions through SUMOylation, it may be possible to affect 
the neighbouring protein in the network. Vinculin interacts with paxillin, talin-1, actin, protein 
tyrosine kinase 2 in the protein-protein network; similarly, if changing vinculin SUMOylation 
modification, it could affect the other neighbouring interactive partners. The talin network has 
been associated with several types of integrin, this could suggest that SUMOylation is 
probably involved in outside-in or inside-out integrin signalling cell migration pathways and 
from these information, it could be proposed that mutating talin SUMOylation or its predicted 
partners, it could probably alter the functions of these signalling molecules and therefore 
affecting cell migration.  
 
5.13 Future Work: Talin and Vinculin Mutagenesis 
Recently, the PIAS3-mediated SUMOylation of the GTPase Rac1 was reported to be 
required for optimal cell migration, invasion and lamellipodium protrusion indicating a role for 
SUMO in the regulation of cell migration and invasion (Steffen et al., 2013, Castillo-Lluva et 
al., 2010). The link between Rac 1 SUMOylation and FAs is unknown. Rac1-/-MEF cells in 
vitro showed unaffected alterations in number, size and intensity in FAs, where Rac1 can 
contribute to but is not essential for FAs assembly (Steffen et al., 2013). Therefore, 
treatment with general SUMOylation inhibitors such as GA could also affect Rac1, 
complicating the interpretation of cell migration data. In addition, there are likely to be other 
FA proteins that are also regulated by SUMOylation, as well as vinculin and FAK, as 
suggested by this study. 
 
To determine whether inhibiting SUMOylated talin in the cells can directly affect cell 
migration, another approach could be taken in the future work. For example, since talin 2445 
lysine residue was shown to be highly likely to be SUMOylated in the GPS-SUMO database 
and the SUMOplot analysis, site-directed mutagenesis will be applied. This residue will be 
mutated, replaced with non-SUMOylation residues, such as arginine, resulting in a mutant 
talin that cannot be SUMOylated completely. This 2445 residue lies in the C-terminal actin 
binding domain of talin, which also contains a vinculin binding site VBS. By replacing this 
lysine, the interacting reactions of talin with vinculin, actin and integrin can also be 
determined. Talin lysine 841, 2063 and 441 were also predicted to be SUMOylated. Talin rod 
contains at least two actin binding sites and multiple vinculin binding sites VBSs, where the 
best studied lie in the C-terminal R13 domain (Gingras et al., 2008, Calderwood et al., 2013). 
192 
This would suggest that if the talin 2445 lysine residue could be SUMOylated, which is also 
in the R13 domain, this can be very important to explain how SUMOylation can affect 
protein-protein interaction. Creating talin mutants that cannot be SUMOylated will be able to 
investigate these issues. In this way, FA studies and cell migration will be conducted to 
confirm whether SUMOylation of talin (or vinculin) at this lysine residue is essential and 
required for cell migration.  
 
Vinculin site-directed mutagenesis was investigated in preliminary studies as this molecule is 
nearly half the protein size compared to talin. Experimental works were started with the 
mEmerald vinculin plasmid. However, there were difficulties with the vinculin mutagenesis 
work. It required several primers with the point mutation inserted in each primer, a cloning 
vector with either ends cut complementary to the PCR products generated using these 
primers. The problem has been in the cloning process. Many attempts have been done but 
the cloning has not obtained the mutated amino acid exchanged for the original amino acid 
successfully. As a result, new methods will have to be developed and different cloning vector 
may also be used and a different mutagenesis kit will also be tried to use for future work. In 
vitro test and analysis could be done to express these newly cloned plasmids in the cells; 
cells would also be expressed with the wild type FA plasmid as a control for the test. 
Competition could happen between the wild type and mutated FA plasmid expressions in the 
cells; percentage of the mutation expression against normal expression, how non-
SUMOylated mutated FA plasmid expression in the cells affects FA number, size, turnover, 
cell migration and protein-protein interactions could be analysed. 
 
There have been studies on the promiscuity of the lysine modification, since lysine can be 
modified by SUMO and ubiquitin at a competitive level. A significant overlap of about 20% 
came through the proteomics study between ubiquitin and acetylation highlighting the 
extensive competitive crosstalk at site modification level; among SUMOylation and 
ubiquitination came through the mixed-chain conjugation interaction (Danielsen et al., 2011). 
Another study showed that the methyltransferase Ezh2-mediated talin 1 methylation on 
K2454 promoted turnover of focal complexes (Gunawan et al., 2015), where the predicted 
SUMO modification site K2445 is very close to K2454.  
 
These suggest that even mutating a lysine resulting in non-SUMOylation function of the 
protein we cannot be too confident with the interpretation of outcome as the effects of the 
mutated lysine cannot be certain if it is directly due to SUMOylation or any types of post-
translational modifications, such as ubiquitination. The single-point mutation experimental 
design can be time consuming and the interpretation of the data analysis has to be very 
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stringent based on the role of the crosstalk of the PTMs in the cells. As the bioinformatics 
data show that talin (K841, K2445) and vinculin (K731, K80) are SUMOylated at these lysine 
residues, firstly, experiments could be done to determine whether talin or vinculin can be 
ubiquitylated on these lysine residues in IP & WB experiments separately (acetylation, 
phosphorylation could also be tested), therefore, excluding the possibilities of the 
competitive lysine modification by different PTMs. Then, lysine-to-arginine mutagenesis 
could be done on these lysine residues in talin or vinculin and the interpretation can be 
confident that the modification is due to SUMOylation only. However, potential non-
consensus SUMO modification motifs still need to be considered. 
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Chapter 6 – The Regulation of SUMOylation in Focal Adhesions in 
Platelets and the Megakaryocyte-like CMK11-5 Cells  
 
6.1 Introduction and Hypothesis 
Platelets originate from the cytoplasm of megakaryocytes in the bone marrow, where they 
circulate and guard the integrity of the blood vascular system (Ruggeri, 2002). Integrin-
mediated platelet adhesion and aggregation are essential for shutting injured blood vessels 
and preventing excess blood loss. This process involves integrin activation or priming on the 
circulating platelets’ surfaces at the site of the wounded blood vessel; the molecular 
mechanism is triggered with the binding of talin to the integrin β subunit cytoplasmic tail 
(Moser et al., 2008). In resting platelets, the integrins exhibit a low affinity state for ligand 
binding and they shift to a high affinity state when the platelets encounter a vascular wound; 
in mice lacking talin-1 platelets are unable to activate integrins in response to major platelet 
agonists including fibrinogen, fibronectin and von Willebrand factor (VWF) and this leads to 
severe haemostatic effects and complete resistance to arterial thrombosis (Nieswandt et al., 
2007). In platelets, a process termed ‘inside-out’ signalling causes affinity alteration in 
integrin αIIbβ3 signalling (McDowall et al., 2003). RIAM, its overexpression together with 
talin recruitment to αIIbβ3 mediates agonist-induced αIIbβ3 activation (Watanabe et al., 
2008). Purified talin was found to directly bind to synthetic peptides corresponding to GPIIb 
(P2b) and GPIIIa (P3a) cytoplasmic sequences (cytoplasmic domains of αIIb and β3), 
suggesting that both GPIIb and GPIIIa directly mediated this interaction with talin (Knezevic 
et al., 1996). The integrin αIIbβ3 plays a central role in platelet aggregation, haemostasis 
and thrombosis and this response requires the capacity to bind soluble ligands (MA et al., 
2007).  
 
The activation or conformation change of integrin αIIbβ3 is tightly regulated through inside-
out signalling; vWF and fibrinogen binding can bridge the platelets together or vitronectin 
and fibronectin can modulate platelet aggregation; agonists such as ADP and thrombin 
which participate with G protein coupled receptors or with collagen or vWF, can involve 
GPIb-IX-V receptor complex or collagen receptors GPVI and all these lead to the activation 
of intracellular signalling events, such as reinforcement of adhesion and platelet activation, 
which feedback to the ligand binding competency and affinity to integrin αIIbβ3 extracellular 
domain (MA et al., 2007). At the vascular injury site, ADP, thrombin and TxA2 release act in 
an autocrine and paracrine manner to amplify the activation signal, attract and recruit 
circulating platelets to the thrombus site (Rivera et al., 2009). A simplified diagram is shown 
in Figure 67. 
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Figure 67. Signalling in platelet adhesion, activation and aggregation: platelets are adhered to 
collagen via GPIb-IX-V complex binding to vWF and GPVI collagen receptor signalling and platelets 
are activated by agonists such as thrombin, TxA2 (thromboxane A2) or ADP binding with their 
transmembrane receptors at the platelet membrane surface etc through inside-out signalling. 
Activation feeds back to activate platelet integrin αIIbβ3 which can bridge neighbouring platelets 
through fibrinogen binding leading to platelet aggregation 
 
A human megakaryocyte-like cell line, CMK11-5 cells, has been used in this study, which is 
found to release platelet-like particles that have some of the same functions as normal 
platelets, for example, these CMK11-5 cells express the platelet antigens GP Ib, GP IIb/IIIa, 
and GP IV, indicating similar receptor characteristics between CMK11-5 and platelets and it 
can be a useful model to study megakaryocyte function (Sato et al., 1989, Greco, 1997). 
Disruption of the talin 1 gene in mouse platelet precursor megakaryocytes produces 
circulating platelets which exhibit normal morphology, however, these mice show 
spontaneous haemorrhage and pathological bleeding; this resulted from the loss of talin 1, 
which led to the inhibition of the activation of platelet β1 and β3 integrin in response to 
platelet agonists and severe impaired integrin αIIbβ3-mediated platelet aggregation and β1-
mediated platelet adhesion (Petrich et al., 2007b). αIIbβ3 integrin activation is dependent on 
the talin association with the integrin β3 cytoplasmic tail in vivo, therefore, the modulation of 
β3 integrin and talin interactions could provide an attractive drug target for anti-thrombotics 
to achieve a reduced risk of pathological bleeding (Petrich et al., 2007a). Talin and kindlin-3 
are crucial for integrin αIIbβ3 activation in CMK11-5 cells (Nakazawa et al., 2013).  
 
Phorbol 12-myristate 13-acetate treatment (PMA) has been used in the experiments with the 
CMK11-5 cells. CMK11-5 cells are naturally grown in media suspension, the use of PMA 
helps the cells to adhere and spread on the plates to express their focal adhesions. Integrin 
αIIbβ3 expression in CMK cells with high GPIb expression can be activated by PMA 
(Kashiwagi et al., 2004). An acute treatment with PMA increases phosphorylation of focal 
adhesion kinase, paxillin, c-Src and cofillin and it could mediate cell spreading via the 
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(Inside-out 
signalling) 
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receptor complex 
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GPIIb/IIIa (αIIbβ3) 
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(TP) 
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activation of RhoA, which regulates actin reorganisation and FA formation (Lee et al., 2006). 
PMA has also been shown to modulate cell signalling through endogenous protein kinase C 
(PKC) and alternative fast diacylglycerol (DAG) signals could be transduced through the 
phorbol ester receptors, therefore affecting cell proliferation, differentiation, survival and 
transformation (Yang and Kazanietz, 2003). CMK11-5 cells are believed to have properties 
of megakaryocytic lineage including glycoprotein GPIIb / IIIa (integrin αIIbβ3) and platelets 
peroxidase activities and PMA treated CMK11-5 cells in conditioned medium could 
differentiate, stimulate and increase their GPIIb/IIIa antigen expressions but also PMA could 
induce the CMK11-5 cells to secrete hematopoietic growth factors including the GM-CSF 
(Komatsu et al., 1989). 
 
The role of focal adhesions in platelets and CMK11-5 cells are different to those in the 
cancer cells. Focal adhesions are important in megakaryopoiesis, including megakaryocyte 
differentiation, maturation and spreading and platelet function such as spreading upon 
fibrinogen binding (Hitchcock et al., 2008). However, focal adhesions are involved in cell 
migration and metastasis in cancer cells. Calpain-2 is important in adhesion turnover in a 
variety of cells including platelets: vinculin can be proteolyzed by calpain during platelet 
aggregation into at least three fragments with the major fragment being 95kDa within 5 
minutes upon platelets activation with thrombin or calcium ionophore; furthermore, the 
95kDa cleaved vinculin fragment translocated from the membrane fraction to the cytoskeletal 
platelets, which may be important in the cytoskeletal remodelling of aggregating platelets 
(Serrano and Devine, 2004).   
 
Hypothesis 
Focal adhesions can be SUMOylated in MDA-MB-231 cells, U2OS cells, CMK11-5 cells and 
platelets. SUMOylated proteins have been identified in this study in platelets and CMK11-5 
cells and in previous chapters SUMOylation has been shown to be involved in the regulation 
of FA dynamics and cell migration in the cancer cells. In platelets, SUMOylation could 
provide a novel mechanism for the integrin αIIbβ3-mediated activation of platelet adhesion 
and aggregation. In this study, the CMK11-5 cells and the platelets have been used to 
investigate whether inhibiting SUMOylation could affect the dynamic activities of the FAs. 
SUMOylation has been predicted to be involved in the regulation of FAs across different cell 
types; therefore, GA has been used in the experiments to determine its effects on the 
number and size of FAs in CMK11-5 cells and in platelet spreading. Cleavage of FA proteins 
resulted from the inhibition of SUMOylation.  
  
 
197 
6.2 Methods 
 
6.2. 1 Treating CMK11-5 Cells for Spreading and Immunostaining Experiments 
 
Fibrinogen Coating 
10mg of fibrinogen (FN) was weighed and 1ml PBS was added to dissolve it (10 mg/ml). 200 
µg/ml (1:50) was used as the working concentration. 130 µl FN was taken from the 10 mg/ml 
solution to mix with 6.5ml PBS. The glass coverslips were put into the 6-well plate and 
washed with methanol for 10 minutes. The methanol was removed and the coverslips were 
left to dry in the culture hood; 1ml FN (6.5ml) was added into each well and the coverslips 
were incubated with the FN for 1 hour at room temperature. Then the FN was removed and 
the coverslips washed with PBS once. The glass coverslips were blocked with 1% v/v BSA 
for 1 hour (0.1g BSA in 10ml PBS) at room temperature. After blocking, the BSA solution 
was removed; the CMK11-5 cells in RPMI media suspension were ready to be plated into 
the 6-well plate, 1 x 106 CMK11-5 cells were usually plated / well.  
 
PMA treatment (Phorbol 12-myristate 13-acetate) 
1 ml sterile DMSO was added to the PMA (Mass: 1mg, MW: 616.83, stock concentration: 1.6 
mM). 160nM PMA working concentration was used for the CMK cell adhering and spreading 
(1:10000). For each well, 0.2µl (1:10000) of PMA was added in 2ml RPMI media for the 
CMK11-5 cells. The antibiotics (20µl pen/strep) were also added into the 2ml RPMI media 
for CMK11-5 cell growth. CMK11-5 cells were grown in RPMI media supplemented with 10% 
FBS at 37º C/5% CO2 and passaged by dilution every 2-3 days at a density of 2 x 10
5 
cells/ml. Differentiation of CMK11-5 cells was advanced by a two-step process. The cells 
were plated at a density of 2 x 106 cells per well in 6-well plates in RPMI media plus 160 nM 
PMA for 48h. On the third day, non-adherent cells were removed by aspiration and growth 
media was changed to IMDM supplemented with 10% v/v FBS in the presence of 160 nM 
PMA up to 5 days. 
 
Immunostaining of CMK11-5 Cells 
The CMK11-5 cells were grown to 70% confluence and incubated with 160nM PMA for 2 
days. On the 3rd day the CMK11-5 cells were incubated with IMDM media (Gibco) containing 
160nM PMA up to 3 days. Then CMK11-5 cells were treated with 100µM GA for 15, 30 and 
60 minutes and were fixed and stained with antibodies (IHC: talin-1 antibody and Alexa 488 
goat anti-mouse secondary antibody). The IHC steps were the same as in the IHC section 
(2.8. 2).  
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6.2. 2 CMK11-5 Cells: siRNA Treatment  
CMK11-5 cells were treated with PMA as described previously and then treated with 0.2x 
Ubc9 siRNA (in Lipofectamine dilutions) for 48h. CMK11-5 whole cell lysates were made and 
labelled as negative control, scrambled siRNA and Ubc9 siRNA appropriately. The cell 
suspensions were centrifuged at 1500 rpm for 5 minutes. For each tube, the supernatant 
was removed and 200µl lysis buffer (1x RIPA, 1x PIC and 50mM NEM) was added to the 
cell pellet. The cells were resuspended in the lysis buffer immediately on ice. The cell lysates 
in each tube was transferred into eppendorf tubes and added with 1x SDS loading buffer. 
The samples were boiled at 95°C for 5 minutes and run on the gels afterwards.  
 
6.2. 3 Platelet Spreading Assays 
Platelets were previously taken from donors and the platelets were prepared according to 
the platelet isolation protocol (Professor Jon Gibbin’s lab protocol). 50ml tyrodes with 0.045g 
glucose, 15ml ACD (anticoagulant acid citrate dextrose solution), 4ml 4% v/v citrate and 10µl 
prostacyclin x2 were prepared. Water bath at 30°C was switched on half an hour before use. 
15ml ACD (against aggregation) was warmed up in water bath. Tyrodes with glucose was 
made up (Tyrode’s buffer used for washing and isolation of platelets), mixed gently and put 
in water bath. Rack LP4 tubes (18 tubes for 50ml blood) were prepared. A beaker of 
Klorsept disinfectant was prepared. 4ml 4% citrate was sucked up into a 50ml syringe. 50ml 
blood was taken. 7.5ml of ACD was added to each 50ml syringe. Blood was divided up in 
each of the 18 tubes. Tubes were put into the centrifuge; empty tubes were added with water 
for balancing. The tubes were centrifuged for 20 minutes at 700rpm (102g) at 21°C.  
 
New tubes, plastic pipettes and prostacyclin were prepared again. The contents were 
sucked off and the supernatant was kept (top layer of red blood was left = white blood cells) 
in one new 50ml falcon tube. 10µl prostacyclin was added and mixed carefully (inhibiting 
activation). The tubes were balanced and spun at 2600rpm (1413g) for 10 minutes at 24°C. 
After centrifugation the supernatant was discarded in Klorsept. The pellet was re-suspended 
with 25 ml tyrodes + glucose buffer; 3ml ACD was added. 10µl prostaglandin was added to 
platelets. Centrifugation was done at the 3rd time as before 2600rpm (1413g) for 10 minutes 
and supernatant was discarded. Platelets were re-suspended quickly in 5ml tyrodes and 
incubated at 31°C water bath for 30 minutes before starting experiment. 
 
2x108/ml washed platelets were left to adhere and spread on fibrinogen (100µg/ml) coated 
coverslips for 50 minutes at 37°C following three different treatments with or without 100µM 
GA. Non adherent platelets were removed and the coverslips were washed x3 with PBS, 
before fixing using 0.2% PFA for 10 minutes. The coverslips were then washed and treated 
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with 0.1% Triton-X100.  The coverslips were washed x3 before IHC staining with Alexa 488 
conjugated phalloidin for 1 hour at room temperature. The coverslips were then washed and 
mounted onto microscope slides. The adherent platelets were imaged with a 100x oil 
immersion lens on a Nikon A1-R confocal microscope.  
 
Treatment 1: the platelets were pre-incubated with the control or 100µM GA for 30 minutes 
prior to exposure to fibrinogen. Treatment 2: the platelets were treated with the control or 
100µM GA at the same time as they were added to fibrinogen coated coverslips. Treatment 
3: the platelets were allowed to adhere for 20 minutes prior to treatment with the control or 
100µM GA.  
 
6.2. 4 Immunoprecipitation and Western Blotting with Platelets  
The platelets were taken from different donors (different day/time, prepared in Jon’s lab 
previously) and the platelet samples were prepared previously. The platelets were then 
treated with 100µM GA for 15 minutes. 5µl 100mM GA was diluted with 45µl tyrodes (1:10). 
Then for the treatments, 5µl of the diluted 100mM GA (1:10) was added in 495µl and the 
platelets were incubated with the GA for 15 minutes. 100µM TRAP (Thrombin receptor 
activator peptide) treatment was done to activate the platelets for 30 seconds. The samples 
were prepared for the IP and WB experiments.  
 
6.2. 5 Platelets with the VIVAbindTM-SUMO Kit 
Platelets were taken from the donors and the platelet samples were prepared as described 
previously. The platelet samples were split into three samples: the control resting platelets, 
the GA 100µM treated samples and the TRAP 100µM activated samples. The platelets were 
treated with 100µM GA for 25 minutes. 5µl 100mM GA was diluted with 45µl tyrodes (1:10). 
Then for the treatment, 5µl of the diluted 100mM GA (1:10) was added in 495µl and the 
platelets were incubated with the GA for 25 minutes. For the TRAP activated platelets, the 
TRAP concentration was prepared the same as the GA, where 100µM TRAP was used. The 
TRAP was added nearly at the same time as the GA treatment was finished before loading 
the samples into the SUMO matrix columns. For the SUMO Kit, the concentration of the 
platelets was 0.6mg / 2ml. The cell lysates were made by adding the lysis buffer from the Kit 
provided. For each control, GA, and TRAP sample, 40µl SUMO matrix suspension was 
added and incubated overnight. The samples were prepared as the steps in the kit protocol 
described previously (Method 2.14 VIVAbindTM-SUMO Kit). Lastly, the samples were added 
with the RSTB loading buffer and heated for 5 minutes at 95°C and the samples were ready 
to run on 4-20% PAGE gels.   
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6.3 Inhibition of SUMOylation Causes Increased Number and Size of Talin Containing 
FAs in CMK11-5 Cells 
CMK11-5 cells were treated with 160nM PMA previously before they were treated with 
100µM GA for 15, 30 and 60 minutes. This was to enable the CMK11-5 cells to adhere and 
spread. The CMK11-5 cells were then immunostained for talin using the talin-1 antibody. 
The immunostaining shows that after GA treatments, there is increased number and size of 
talin containing FAs in the CMK11-5 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68. Immunostaining of talin in the CMK11-5 cells showing the talin containing FAs in the 
control compared to the 100µM GA treatments at 15, 30 or 60 minutes (n=3, individual replicates, 
representative images were shown, scale bar = 20µm).  
 
In Figure 68, PMA treatments and fibrinogen binding has made the CMK11-5 cells to 
express their focal adhesions in the control and GA treated samples. The results were 
quantified and presented in Figure 69 as a total number of 3 combined experiments.  
Control GA 15 minutes 
GA 30 minutes GA 60 minutes 
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Figure 69. Immunostaining of talin in CMK11-5 cells showing that compared to the untreated cells, 
after 100µM GA treatments at 15, 30 or 60 minutes, the mean number of the talin containing FAs 
were significantly increased; the mean size of the talin containing FAs was increased after 100 µM GA 
15 minutes treatment. The percentage of the CMK11-5 cells expressing talin containing FAs in the 
control compared to the 100µM GA treatments were also increased at 15, 30 or 60 minutes (data was 
presented as mean ± SEM, p<0.0001 ***, n=3).  
 
In Figure 69, compared to the untreated cells, after 15 minutes of 100µM GA treatments, the 
mean number of talin containing FAs was increased significantly from 27.9 ± 2.43 to 40.8 ± 
2.42 (*); after 30 minutes of 100µM GA treatments, the mean number of talin containing FAs 
was increased significantly from 27.9 ± 2.43 to 45.8 ± 3.14 (p<0.0001 ***); after 60 minutes 
of 100µM GA treatments, the mean number of talin containing FAs was increased 
significantly from 27.9 ± 2.43 to 44.7 ± 2.96 (p<0.0001 ***). (The control was run for the total 
period of 1 hour).  
 
Talin n=3 Control GA 15 minutes GA 30 minutes GA 60 minutes 
Mean ± SE 
Number 
27.9 ± 2.43 40.8 ± 2.42 45.8 ± 3.14 44.7 ± 2.96 
Mean ± SE 
Size µm
2
 
0.571 ± 0.026 0.712 ± 0.034 0.661± 0.022 0.661 ± 0.018 
Number of cells 
counted 
61 71 79 98 
The percentage of 
Cells Expressing 
FAs % 
35.9 ± 4.58 60.0 ± 5.68 59.3 ± 5.57 59.3 ± 5.12 
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Compared to the untreated cells, the mean size of talin containing FAs increased 
significantly after 15 minutes of 100µM GA treatments from 0.571 ± 0.026 to 0.712 ± 0.034 
(p=0.0029 **). 
 
Compared to the untreated cells, the percentage of the CMK11-5 cells expressing talin 
containing FAs after 15 minutes of 100 µM GA treatment was significantly increased from 
35.9 ± 4.58 % to 60.0 ± 5.68% (p=0.0055 *); after 30 minutes of 100 µM GA treatment, the 
percentage of the CMK11-5 cells expressing talin containing FAs was significantly increased 
from 35.9 ± 4.58 % to 59.3 ± 5.57 (p=0.0055 *); after 60 minutes of 100 µM GA treatment, 
the percentage of the CMK11-5 cells expressing talin containing FAs was significantly 
increased from 35.9 ± 4.58 % to 59.3 ± 5.12 (p=0.0055 *). 
 
6.4 Ubc9 siRNA Transfection Significantly Reduced the Ubc9 Enzyme Expression in 
CMK11-5 Cells  
CMK11-5 cells were treated with PMA as described previously and then treated with 0.2x 
diluted Ubc9 siRNA (25nM) for 48 hours. Whole cell lysates were prepared for each 
treatment. The samples were run on the gels and blotted with Ubc9 antibody to determine 
the Ubc9 enzyme expression after the treatments. The results were quantified and 
presented as Ubc9 / GAPDH ratio as a total number of 3 combined experiments in Figure 
70.  
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Figure 70. Western blot showing the negative control, scrambled siRNA and Ubc9 siRNA treatments 
for 48 hours in the CMK11-5 cells; the Ubc9 siRNA in 0.2x Lipofectamine diluted mixture treatment 
has caused the knockdown of Ubc9 E2 enzyme in the SUMOylation cycle.  The bar chart was 
presented as Ubc9 vs. GAPDH ratio (n=3, data was presented as mean ± SEM, p=0.011 *). 
 
In Figure 70, compared with the negative control, after 48 hours of 25nM Ubc9 siRNA 
treatments, the Ubc9 enzyme activity has decreased significantly as a ratio from 72.6 ± 3.67 
to 50.5 ± 3.54 (p=0.011 *).   
 
 
 
 
 
 
 
Negative 
control 
Scrambled 
siRNA 
Ubc9 siRNA 
Mean ± SE Mean ± SE Mean ± SE 
72.6 ± 3.67 75.4 ± 5.17 50.5 ± 3.54 
GAPDH 
Ubc9 
Negative ctrl  Scrambled ctrl  siRNA 
0.2x LIPO 
48h 
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6. 5 Ginkgolic Acid Reduces Platelet Adhesion and Spreading upon Fibrinogen 
Binding 
Platelets were previously taken from donors and prepared for isolation. 2x108/ml washed 
platelets were left to adhere and spread on fibrinogen (100µg/ml) coated coverslips for 50 
minutes at 37°C following three different treatments with or without 100µM GA. Platelets with 
100 µM GA treatments prior to fibrinogen binding or 100 µM GA treatments at the same time 
as the platelets were exposed to fibrinogen binding completely abolished platelet spreading, 
i.e. no platelets left could be adhered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 71. Platelets were left to pre-incubate with the control or 100µM GA for 30 minutes prior to 
exposure to fibrinogen for binding and incubated for a whole length of 50 minutes. Pre-treatments with 
100µM GA has completely abolished platelets spreading on fibrinogen binding. Non-adhered platelets 
were removed and adhered platelets were fixed and stained with Alexa 488 conjugated phalloidin. 
Adhered platelets were imaged with a 100x oil immersion lens on a Nikon A1-R confocal microscope. 
Three representative images were presented and experiments were done on the same day. 
 
In Figure 71, pre-treatment of platelets with 100µM GA for 30 minutes before being allowed 
to adhere and spread on fibrinogen for 50 minutes has completely ablated and prevented 
platelet adhesion to fibrinogen on the coverslips. 
 
 
Control 
GA 
5 µM 5 µM 5 µM 
5 µM 5 µM 5 µM 
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Figure 72. Platelets were treated with the control or 100µM GA at the same time as they were added 
to fibrinogen coated coverslips for binding for a whole incubation length of 50 minutes. Non-adhered 
platelets were removed and adhered platelets were fixed and stained with Alexa 488 conjugated 
phalloidin. Adhered platelets were imaged with a 100x oil immersion lens on a Nikon A1-R confocal 
microscope. Three representative images were presented and experiments were done on the same 
day. 
 
 
In Figure 72, no pre-treatment of platelets with 100µM GA was done, but the treatment was 
added at the same time as the platelets were exposed to fibrinogen coated coverslips and 
then left to adhere and spread for 50 minutes, it has also completely ablated and prevented 
platelet adhesion to fibrinogen binding on the coverslips. 
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Treatment 3: the platelets were allowed to adhere for 20 minutes first on the fibrinogen 
coated coverslips prior to treatment with control or 100µM GA and left for incubation for a 
total of 50 minutes, i.e. the treatment with 100µM GA was 30 minutes followed after the first 
20 minutes of platelets adhering to fibrinogen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 73. Platelets were left to adhere on fibrinogen for binding for 20 minutes first then followed by 
30 minutes treatment with the control or100µM GA; the total time for the platelets to fibrinogen binding 
was incubated for 50 minutes. Non-adhered platelets were removed and adhered platelets were fixed 
and stained with Alexa 488 conjugated phalloidin. Adhered platelets were imaged with a 100x oil 
immersion lens on a Nikon A1-R confocal microscope. Three representative images were presented 
and experiments were done on the same day. 
 
 
In Figure 73, the addition of 100µM GA treatment following 20 minutes of platelet adhesion 
and spreading appeared to prevent further platelet adhesion and it has inhibited the 
spreading of these platelets that were already adhered previously.  
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6.6 GA Treatment of Platelets Induces Cleavage of Talin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 74. IP and WB showing that endogenous talin can be SUMOylated in resting platelets. 
Platelets were activated by 100µM TRAP treatment for 30 seconds showing a cleavage pattern in the 
talin detected by the N-terminal c-9 talin antibody. 15 minutes of 100µM GA treatment has also 
caused the cleavage pattern in talin as the intact talin 250kDa and a smaller band at 47kDa  
 
The IP experiments with the platelets were done with Dr. Diana Barker alongside the IP 
experiments with MDA-MB-231 cells. Talin c-9 antibody detects the N-terminal end of the 
talin molecule. Talin can be SUMOylated in resting platelets and the intact talin was detected 
at 250kDa. In the TRAP (Thrombin receptor activator peptide) activated platelets, it has 
shown the 250kDa band as well as a smaller band at 47 kDa in Figure 74. This suggests 
that intact talin was SUMOylated and the cleaved talin was SUMOylated only at the smaller 
fragment (not in the resting platelets). 
 
Platelets incubated with 100uM GA for 15 minutes also show the same cleavage pattern of 
talin. The same experiments were also done without the addition of TRAP activation and the 
platelets were treated with 100uM GA for 15, 30 and 60 minutes and it also shows the 
cleaved products of talin. Later, the cleaved smaller band was confirmed in mass 
spectrometry that it was SUMOylated cleaved talin as the talin head (experiments conducted 
by Dr. Diana Barker).  
 
 
Resting   TRAP    GA  
                         15 mins       
                 
Talin 250kDa 
Cleaved talin 
head at 47kDa  
IP SUMO 2/3, IB: Talin (c-9, N-terminal ab) 
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6.7 SUMO VIVATM Binding Kit and Western Blotting Show SUMOylated Talin in 
Platelets  
The platelets samples were prepared as described previously. The platelets were treated 
with 100µM GA for 25 minutes and activated with 100µM TRAP at the same time as the GA 
treatment. The platelets whole cell lysates samples were then prepared and put through with 
the SUMO binding columns and incubated with the SUMO matrix overnight. The next day, 
the samples were washed, bound and eluted using the SUMO binding kit washing buffers. 
The eluted samples and the whole cell lysates samples were both run on the gels and 
probed on the membranes using talin or SUMO antibodies.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 75. The platelets whole cell lysates were 
activated with TRAP and treated with 100µM GA 
for 25 minutes before these samples were put 
through the SUMO binding columns and mixed 
with the SUMO matrix. The first IP supernatant 
were obtained as unbound samples and the eluted 
samples were obtained as the SUMO-captured IP 
samples. WB was performed to probe for talin 
showing that endogenous intact talin could be 
SUMOylated and the cleaved products of talin 
were also SUMOylated. WB was also done to 
probe for SUMO showing the SUMOylated proteins 
on the membrane. Overlay: Cy3=Talin / Green; 
Cy5 =SUMO-2 / Red.  
 
 
 
 
R Ctrl   Trap     GA      Ctrl       GA   
Wcl       Wcl     Wcl    Eluted   Eluted               
R Ctrl   Trap     GA     Ctrl      GA   
Wcl       Wcl     Wcl   Eluted  Eluted               
IP: SUMO, IB: Talin IP: SUMO, IB: SUMO 
R Ctrl   Trap     GA      Ctrl       GA   
Wcl       Wcl     Wcl    Eluted   Eluted               
Talin  
250kDa  
Cleaved 
talin  
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In Figure 75, in the IP SUMO and IB talin membrane, intact talin was SUMOylated at 
250kDa in both of the control eluted and 100µM GA eluted samples. In the 100µM GA 25 
minutes treated eluted sample, the cleaved smaller fragment of talin head was also seen at 
47kDa and this was SUMOylated.  
 
Summary of effect of SUMOylation inhibitors on FA dynamics 
 
Table 27. Summarising the effects of 100µM GA treatment in CMK11-5 cells and the platelets, the 
number and size of talin containing FAs were increased significantly and the percentage of the CMK 
cells expressing talin containing FAs was increased significantly; the platelet spreading was 
completely abolished after 100µM GA treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitors Number of focal 
adhesions increased 
/per cell 
Size of focal 
adhesions 
increased/µm
2
 
% 
Percentage 
expressing FAs 
Platelets 
spreading 
inhibited 
GA (E1) 
 
 
CMK+ 
15, 30, 60 minutes 
28 vs. 
41, 46, 45 
CMK+ 
15, 30, 60 minutes 
0.57 vs. 
0.71, 0.66, 0.66 
CMK+ 
15, 30, 60 minutes 
36% vs. 60% 
Platelets not 
adhered to 
fibrinogen 
binding- 
50 minutes 
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Discussion 
 
6.8 SUMOylation Plays an Important Role in the Regulation of Focal Adhesions and 
Cell Spreading in CMK11-5 cells and Platelets 
CMK11-5 cells express low levels of αllbβ3 integrin and are thought to be more differentiated 
than the parent CMK cells from which they were derived (Komatsu et al., 1989). Since the 
CMK11-5 cells were naturally grown in suspension culture, this created difficulties to 
naturally induce them to express focal adhesions while in suspension. PMA was used to 
induce the activation and spreading of CMK11-5 cells onto the fibrinogen-coated coverslips. 
PMA could stimulate cell differentiation, spreading and cell surface expression of integrin 
αllbβ3 during this time period (Kashiwagi et al., 2004). Also, non-adherent CMK11-5 cells 
were removed by aspiration and growth media was changed to IMDM containing PMA to 
achieve even higher levels of αllbβ3 on the cell surface. In this way, the talin containing FAs 
could be expressed and measured upon integrin αllbβ3 signalling. In the other cells, such as 
the human monocytic leukemia THP-1 cells, PMA induces the THP-1 cells to differentiate 
into macrophages and upregulate the p21WAF1/CIP1 promoter driven by a transcription factor 
Sp-1 (Traore et al., 2005). PMA was found to phosphorylate a number of cytosolic 
polypeptides, caused cell aggregations, lysosomal enzyme secretion and increased actin 
level associated with the cytoskeleton without the elevation of intracellular free Ca2+ in rabbit 
neutrophils (White et al., 1984). Short-term treatment with 100nM PMA activates PKC, ERK 
1/2 (5 minutes treatment) and p38 MAP kinases (mitogen activated protein kinases, 1 hour 
treatment) independently in differentiated parental human colonic adenocarcinoma cell line 
Caco-2 (Jiang and Fleet, 2012). Long-term treatment with PMA up to 12 continuous days 
without passage in human melanocytes caused changes in cell morphology, cell cycle, 
cytoskeleton and the higher the PMA concentration (up to 170nM) the higher differentiation 
percentage in the melanocytes (Chao-Hsing and Hsin-Su, 1991). PMA is therefore a co-
stimulator of cell differentiation. In this study, CMK11-5 cells not only were attached to the 
plastic coverslips from the suspension in the conditioned media but also were seen with 
irregular shaped morphology, indicating their differentiation.  
 
The inhibition of protein SUMOylation made the CMK11-5 cells increase the number and 
size of their talin containing FAs after the first 15 minutes of 100µM GA treatment. This effect 
was induced after the use of PMA as PMA caused FAs to form as the cells were adhered.  
 
The siRNA treatment reduced the Ubc9 expression after 48 hours in the CMK11-5 cells, 
indicating that the siRNA knockdown was effective. However, the knockdown was not 
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complete due to the length of the experiment and the nature of the cells and optimization 
needs further determination. CMK11-5 cells were grown in conditioned media and activated 
for 6-7 days before the siRNA knockdown effect was obtained. Therefore, siRNA was used 
to see if the Ubc9 expression was able to be reduced for the whole length of the 6 days 
experiments but it was not continuously used in the IHC experiments to count the FA 
number and size afterwards.   
 
For platelets, the inhibition of protein SUMOylation completely inhibited platelets from 
spreading prior to fibrinogen binding or after the platelets had been bound with fibrinogen for 
20 minutes. This suggests that SUMOylation was involved in integrin αIIbβ3-cell adhesion 
interactions and platelets spreading. Platelet membrane receptors function to mediate the 
initial tethering of platelets to the wounded blood vessel wall or a lesion and this process is in 
three successive steps: platelet adhesion, activation and aggregation (Ruggeri, 2002). There 
are many signalling factors associated with the activation of the integrin αIIbβ3 and platelet 
membrane surface receptors. Several mechanisms are involved namely the VWF- GPIbα 
mediated platelet adhesion and aggregation; platelet-collagen adhesion mediated by the 
immunoglobulin (Ig) superfamily member GPVI receptor and integrin α2β1 etc; the platelet 
adhesion to collagen requires the activation of integrin αIIbβ3 (GPIIb-IIIa) through inside-out 
signalling generated by GPVI and strengthened by the release of second mediators ADP 
(adenosine diphosphate) and thromboxane A2 (TxA2); platelets can adhere and aggregate 
to purified fibrinogen and fibrin under flow conditions, selectively mediated by αIIbβ3 
(Nieswandt and Watson, 2003, Ruggeri and Mendolicchio, 2007). Platelet aggregation is a 
more complex process: platelet aggregation at low hemodynamic conditions (blood flow, 
blood vessel wall shear rate < 1000 s-1)  is predominantly mediated by the integrin αIIbβ3 
interaction with fibrinogen and this is independent of the von Willebrand factor (VWF) and 
glycoprotein Ib (GPIb, a membrane-bound platelet receptor) interaction in promoting initial 
platelet tethering to the blood vessel wall; at shear rates between 1000-10,000 s-1, platelets 
tethering and the initial formation of discoid platelet aggregates is mediated by both GP 
Ib/V/IX and integrin αIIbβ3 and this becomes more VWF dependent progressively; at very 
high shear rates > 10,000 s-1, platelet aggregates does not require platelets activation and 
integrin αIIbβ3 however it is mostly mediated by VWF-GP Ib adhesive interactions (Jackson, 
2007).  
 
Talin can be SUMOylated in platelets. It indicates that the SUMOylation of talin in platelets 
may be involved in the activation of integrin αIIbβ3 signalling of the platelets leading to 
platelet spreading and aggregation. Inhibition of SUMOylation abolished the response of the 
integrin signalling therefore the platelets were completely incapable of fibrinogen binding.  
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6.9 Comparisons between Different Cell Types: the General Role of SUMOylation in 
the Regulation of Focal Adhesions  
The agonist TRAP at 5µM can activate the platelets as quickly as 30 seconds (García et al., 
2004). TRAP has been known as the thrombin receptor activating peptide, could mimic 
many effects of thrombin (McNicol and Robson, 1997) and once the platelets were activated, 
talin is cleaved with the talin head fragment being at 47kDa. Once talin is cleaved, it was the 
end-point of the activation of platelets.  
 
Various inhibitors including GA, 2-D08, gossypetin and Ubc9 siRNA have been used in 
MDA-MB-231 cells and U2OS cells, with the use of GA in the CMKs and the platelets. 
SUMOylation plays an important regulatory role in FA disassembly in MDA-MB-231 cells and 
U2OS cells, where various inhibitors’ treatments increased FA number and size. Similar 
effects were also seen in the CMK11-5 cells where 100µM GA treatment increased the 
number and size of talin containing FAs.  
 
Talin exists in two states as an auto-inhibited form and the activated form in conformational 
structural change which causes an increase in its affinity to integrin β3 binding and other 
ECM proteins during FA assembly (Ellis et al., 2013, Critchley and Gingras, 2008, Goult et 
al., 2013a). The binding of talin to the β3 integrin tail is critical for the agonist-induced 
integrin αIIbβ3 activation (Petrich et al., 2007a). Since inhibiting SUMOylation leads to the 
cleavage of talin, this suggests that SUMOylation could be playing a role in the integrin 
αIIbβ3 and talin binding signalling axis and in the activation of talin, hence in the platelet 
spreading.  
 
The regulatory mechanisms of SUMOylation of FAs in these cells were different. There were 
morphological changes regarding to the cell structure and alterations in the molecular 
integrin signalling pathway related in the talin functions. Talin was particularly investigated 
between the cancer cells and the platelets, where talin was obtained both of inactive non-
cleaved state and cleaved conformational change in the platelets. Meanwhile, in cancer cells 
overexpressed with SUMO-2, the cancer cells consistently expressed cleaved talin, probably 
due to the fast speed of turnover required in the cancer cells. In platelets, talin cleavage 
resulted from the inhibition of SUMOylation was an all-or-nothing effect and the talin 
cleavage effect in the cancer cells could be regarded as a manifest exaggeration for the 
cells’ functional requirement.  
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Figure 76. Talin is in its autoinhibition conformation in resting platelets. Upon agonist binding such as 
TRAP, platelets activation is through integrin αIIbβ3 signalling which causes talin conformational 
change. After GA treatment, cleavage of talin is seen and both intact talin and the cleaved fragment of 
talin are SUMOylated 
 
Talin was SUMOylated in both resting platelets and stimulated platelets. However, inhibiting 
SUMOylation after GA treatment caused cleavage of talin as the cleaved head domain as 
well as the intact talin. The N-terminal head of talin is ~47kDa and the C-terminal rod is 
~190kDa (or 200kDa) (Yan et al., 2001). This may suggest SUMOylation is protective 
against talin cleavage. Talin cleavage may be an important function of the platelet activation 
in platelet adhesion, spreading and aggregation as inhibiting SUMOylation inhibited platelet 
spreading upon fibrinogen binding. This regulation of SUMOylation in FA proteins is a 
different process compared to the cancer cells.  
 
The stimulation of platelets leads to the inside-out integrin αIIbβ3-FA signalling required for 
platelet aggregation with the neighbouring platelets to form a clot. This process is an all-or-
nothing effect: the effect of talin SUMOylation in the activated platelets can be seen as an 
amplified signalling: all the talin proteins recruited at the integrin-FA assembly site can be 
SUMOylated; in resting platelets, SUMOlyation protects against FA cleavage, however, talin 
can be cleaved by calpain-2 during platelet activation, since calpain activation is dependent 
on fibrinogen binding to integrin αIIbβ3 (Schoenwaelder et al., 1997) and calpain cleavage 
promotes talin binding to integrin β3 (Yan et al., 2001) and the cleaved talin is also 
SUMOylated. These cleaved SUMOylated talin are the endpoint of platelet activation which 
may contribute to the platelet adhesion and aggregation process. Inhibiting SUMOylation 
causes cleavage of talin and this effect is irreversible. Once the platelets were activated, the 
platelets could not be reverted back into their resting phase, i.e. once talin cleavage 
activation was stimulated, this was the endpoint of the inhibitory effects of the inhibitor.  
 
Cleaved head domain of talin: 47kDa 
Intact talin: 250kDa 
+ GA 
  
Agonist 
activation 
  
Talin autoinhibition 
  
Platelet activation: talin 
head binding to integrin β3 
Role of SUMOylation in Platelets 
Resting 
platelets 
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The FA proteins in the cancer cells are involved in fast cell migration and metastasis, 
therefore their turnover requires consistent assembly and disassembly. SUMO-2 conjugation 
may be required for the FA disassembly consistently in cancer cells. However, the 
mechanism in platelets is that they require FA proteins in spreading and aggregation during 
wound healing; therefore, it is not a constant process, since when platelets are activated 
they cannot be reverted back to resting stage. The cancer cells require fast cell migration 
and their FA proteins may also be constantly recycled from the cytosol to the membrane 
leading to the consistent fast turnover event. 
 
Talin, vinculin and filamin-1 have been identified as SUMOylation substrates in the MS 
analysis both in MDA-MB-231 and CMK11-5 cells. Talin and actin have been identified in 
MDA-MB-231 cells, CMK11-5 cells and platelets. Talin has been validated in the 
experiments to be a SUMOylation substrate. Interestingly, Integrin αIIbβ3 has been identified 
as a SUMOylation substrate in the MS analysis in both CMK11-5 cells and platelets. This 
suggests its overall role of integrin αIIbβ3 signalling in adhesion, activation and aggregation 
in megakaryocytes and platelets.  
 
Talin has two fractions: the membrane-associated and cytosolic fractions, the membrane-
associated talin was able to be cleaved into a 200kDa fragment similar to the calpain 
cleavage in CHO cells (Tranqui and Block, 1995). Talin was shown to be cleaved by calpain 
in skeletal muscle cells and released into the cytosol (Koh and Tidball, 2000). In resting 
platelets, talin was uniformly distributed throughout the cytoplasm; upon platelet activation, a 
significant amount of talin was rapidly redistributed to submembranous location (Bertagnolli 
et al., 1993). Talin and vinculin can both be cleaved by calpain (Franco et al., 2004). The 
membrane-associated talin and vinculin in the FAs in platelets are all SUMOylated at one 
time required for activation. Once stimulated, no cleaved fragments of talin can be obtained. 
Calpain activation, FA cleavage by calpain and the SUMOylation of talin may also be 
associated with the actin cytoskeleton rearrangement through integrin αIIbβ3 signalling 
during platelet aggregation process. However, the cleavage of talin is consistent and the 
cleaved talin fragments are SUMOylated and these may be important in actin-myosin 
network to achieve fast FA turnover e.g. FA disassembly in cancer cells during cancer cell 
migration.  
 
The FA complex required for the platelet spreading may also be different to that of the FA 
assembling in the cancer cells. FAK is a key regulator for the FA complex formation; the 
calcium and integrin binding protein could regulate platelet spreading through FAK activity 
but only on immobilized fibrinogen binding to the platelet fibrinogen receptor αIIbβ3 / GPIIb-
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IIIa (Naik and Naik, 2003). A megakaryocyte lineage-specific FAK-null mouse was 
generated, where FAK-null platelets exhibited diminished platelet spreading on immobilized 
fibrinogen indicating FAK role in megakaryocyte growth and platelet function in vivo 
(Hitchcock et al., 2008). Less was known about the role of vinculin in platelets; in one study, 
the vinculin gene was deleted in the megakaryocyte/platelet lineage in mice, in these 
vinculin-deficient platelets used from these mice, they displayed normal agonist-induced 
fibrinogen binding to αIIbβ3, normal platelet spreading and aggregation, actin 
polymerization, clot retraction and were capable of forming a pro-coagulant surface; they 
adhered to immobilized fibrinogen or collagen normally both under static and flow conditions, 
suggesting that vinculin may not be required for platelet αIIbβ3 function (Mitsios et al., 2010). 
However, vinculin was required for membrane cytoskeleton integrity: in thrombin-activated 
platelets vinculin was shown to be cleaved by calpain producing a major fragment at 95kDa 
with at least two other fragments during platelet aggregation, whereas in the resting platelets 
only full-length of vinculin was detectable; this 95kDa cleaved fragment was associated with 
the platelet cytoskeleton, where the cleaved vinculin fragments were transferred from the 
membrane to the cytoskeletal fractions in the aggregating platelets, suggesting that calpain 
cleavage of vinculin upon platelet stimulation may be involved in the actin cytoskeleton 
rearrangements important for platelet aggregation and motility; the calcium-dependent 
platelet protease, calpain was activated upon platelet activation and when the platelets were 
pre-incubated with its inhibitor calpeptin at 100µg/ml for 1 hour at 37°C then treated with 
1µM calcium ionophore abrogated vinculin cleavage to that level in the non-stimulated 
platelets (Serrano and Devine, 2004).  
 
SUMOylation is required for megakaryocytes and platelet adhesion and spreading. For 
future work, how SUMOylation of talin is directly implicated in platelet adhesion and 
spreading needs to be determined. Moreover, the role of these cleaved talin fragments (or 
vinculin fragments) in the FA turnover and their functions in relation to the platelet activation, 
adhesion and aggregation can be determined further. Firstly, calpain inhibitors in 
combination with GA need to be used to determine if talin can still be cleaved in the 
activated and aggregated platelets; antibodies or molecular tags against the fragmented talin 
(head domain or rod domain of talin) can be used to determine their localization during 
platelet activation.  
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Chapter 7 - Overall Discussion and Future Perspectives 
Metastasis contributes to high mortality rates of cancer which involves many highly regulated 
cell signalling processes. In this study, SUMOylation has been studied to look at its role in 
FAs and cancer cell migration. Talin, FAK and vinculin containing FAs have been shown to 
increase in number, size and turnover time after the SUMOylation inhibitor treatments, which 
has resulted in reduced speed of cell migration significantly. Inhibiting SUMOylation causes 
reduced FA turnover also indicating its role in FA disassembly. The SUMOylation of talin, 
vinculin and filamin-1 have been studied for the first time and validated in the MS studies. 
SUMOylation has been involved in the regulation of many FA proteins including talin, 
vinculin, filamin 1, actin and the integrin αIIbβ3 etc, which has suggested that SUMOylation 
has an overall diverse and crucial role in cell migration. Future experiments will be carried 
out to investigate closely how SUMOylation regulates FAs directly and its role in protein-
protein interactions within FAs.  
 
Site directed mutagenesis is the next step to determine if mutating lysines in part of the talin 
or vinculin molecule can directly impair cell migration; therefore, it can directly identify which 
lysines the talin molecule can be modified with SUMO 2/3. Since the bioinformatics tool are 
very stringent and reliable, it could suggest that what has been predicted to be the modified 
sites in the top list with the highest scores in the talin, vinculin or filamin-1 molecule could be 
genuine. This can also be used to determine whether mutating the predicted SUMOylated 
modified lysine residues in talin or vinculin could alter their localization in the cells, dynamics 
and turnover rates and their roles in adhesion signalling. However, IP & WB experiments 
also need to be done to investigate ubiquitination, phosphorylation or acetylation of FA 
proteins after mutagenesis of the speculated SUMO modified sites in FA proteins, since 
competition between PTMs could occur on the same lysine residue.  
 
7.1 De-SUMOylation and its Focus 
The SUMO de-conjugating enzymes are known as the Ulps and SENPs; in mammals, there 
are six SENPs: SENP1, SENP2, SENP3, SENP5, SENP6 and SENP7 (Wang and Dasso, 
2009). The human proteases SENP1, SENP2, SENP3 and SENP5 are most closely related 
to yeast Ulp1 in sequence; human SENP6 and SENP7 are related to yeast Ulp2 (Hay, 2007). 
Some examples have been listed to discuss the roles of the SENPs. The SUMO modification 
of transcription factors could lead to their transcriptional activation mainly related as 
transcriptional repression, i.e. SUMOylation of transcription factors correlates with the 
inhibition of transcription and SUMOylation promotes the transcription factors to interact with 
the co-repressors therefore regulating gene function (Gill, 2005). Furthermore, the SUMO 
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conjugation with transcription factor can be reversibly removed by the SENPs, which would 
de-repress the transcription action and therefore it also regulates the gene expression (Hay, 
2007). Ulps/SENPs are highly specified towards SUMO paralogs, but also other functions 
are discriminated between processing, chain-editing reactions and deconjugation 
(Mukhopadhyay and Dasso, 2007). SUMO processing and deconjugation are essential 
proteolytic activities for nuclear metabolism and cell cycle progress in both higher eukaryotes 
and yeast; mutational analysis and biochemistry revealed the mechanism for SENP2 
preferences to catalyze SUMO deconjugation over SUMO processing (Reverter and Lima, 
2006). RanGAP1 could be modified by SUMO-1 and SUMO-2 in vitro and selectively 
modified by SUMO-1 in vivo; the RanGAP1-SUMO-1 conjugates could also form a more 
stable high affinity complex with the nucleoporin Nup358 (also known as RanBP2) than 
RanGAP1-SUMO-2, which protects RanGAP1 from the isopeptidases preferentially even in 
the presence of these isopeptidases: SENP1, 2 and 5; additionally, SENP1, 2 and 5 could 
efficiently deconjugate both SUMO-1 - and SUMO-2 – conjugated RanGAP1 in the absence 
of Nup358 and Ubc9 (Zhu et al., 2009).  
 
SENP5 is required for cell division and mitochondrial function, previously, SENP5 has been 
reported to be present in the cytoplasm of oral squamous cell carcinoma (OSCC) 
predominantly, similarly, SENP3 was found to be overexpressed in OSCC (Sun et al., 2013, 
Ding et al., 2008); the inhibition of SENP5 could suppress cell growth, colony formation 
capacity and promote cell apoptosis i.e. an increase in caspase 3/7 activities and a decrease 
in cyclin B1 expression in serum-deprived osteosarcoma cells, U2OS cells and Saos-2 cells 
(Wang and Zhang, 2014). More specifically, knockdown of SENP5 using RNAi dramatically 
decreased proliferation in Hela cells and resulted in aberrant nuclei or multiple nuclei 
morphologies in many cells, especially multi-lobar nuclei indicating a defective mitosis or 
cytokinesis; whereas, the closet homolog SENP3 knockdown did not show this phenotype 
suggesting a unique role of SENP5 in the regulation of cell division (Di Bacco and Gill, 2006, 
Di Bacco et al., 2006). SENP1, 2, 3, 5 and 6 have SUMO-specific C-terminal hydrolase or 
isopeptidase activities; SENP5 was shown to remove SUMO-2 and SUMO-3 preferentially 
from SUMO-modified RanGAP1 in vitro; SENP5 RNAi led to an increase in SUMO-2 / 
SUMO-3 conjugated proteins than SUMO-1 conjugates (Di Bacco et al., 2006). 
 
In the previous discussion in Chapter 3, de-SUMOylation has been briefly mentioned as 
whether inhibiting de-SUMOylation on the effects of FA dynamic activities could be 
reversible or not can be investigated in the future experiments. SENP1 and SENP2 are 
concentrated at the nuclear envelope through interactions with components of the nuclear 
pore complex; SENP6 and SENP7 mainly exhibit nucleoplasmic distribution; SENP3 and 
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SENP5 are compartmentalized in the nucleolus, where they play roles in early stages of 
ribosome maturation, however, a subfraction of SENP3 and SENP5 are also resided in the 
nucleoplasm and the cytoplasm (Nayak and Müller, 2014, Hickey et al., 2012). Consequently, 
the effects of knocking down SENP5 in the cancer cells, i.e. in the U2OS cells could also be 
determined in relation to the FA dynamic activities. One experiment could be done in the 
future is to determine the co-localization of these SENPs with the FA proteins such as talin 
or vinculin in the cells, to determine where they are de-SUMOylated in the cells i.e. in the FA 
or in the cytosol where they can be turned over; whether talin or SENP5 are localized 
together in the FA so that the FA turnover is dynamic. The NEM (N-Ethylmaleimide) has 
been used together with the PIC (protease inhibitor cocktail) in the preparation of the IP 
samples in this study (although the use of NEM with PIC or PIC alone gave similar amount 
of proteins in the whole cell lysates protected from the proteases inhibitors). This was to 
ensure that no protein de-SUMOylation or degradation before the SUMOylated proteins 
could be immunoprecipitated, captured and identified on the WB scanning. Whether 
enhancing de-SUMOylation of a protein could be achievable experimentally or increasing the 
time for a protein to stay SUMOylated i.e. increasing SUMOylation level of a protein could 
affect its localization, regulation or protein-protein interaction and function can also be further 
investigated. Since the SUMOylation of the cytoplasmic proteins are less understood, the 
identification of the comodulator of these SENPs which can prevent de-SUMOylation can be 
further investigated. SUMOylation is a very dynamic process and conjugation or de-
conjugation of SUMO to the target proteins depends on the enzymatic and chemical 
conjugation steps. Therefore, the balance of SUMO conjugation and de-conjugation to the 
target proteins stays critical.  
  
7.2 SUMOylation and Ubiquitination 
Talin phosphorylation by Cdk5 regulates talin head ubiquitination, FA disassembly, 
lamellipodial dynamics and cell migration. The talin head can be cleaved by calpain-
mediated proteolysis and the talin head binds to smurf1, an E3 ubiquitin ligase more than the 
full length talin leading to talin head ubiquitination and degradation (Huang et al., 2009). 
Therefore, ubiquitination is a crosstalk PTM that can regulate the same substrate protein. 
The substrate protein can be conjugated to ubiquitin and ubiquitin-like protein (UBL), which 
regulates its physiological function; the bound UBLs regulate their protein interactions with 
the proteasome, which the ubiquitination (also termed ubiquitylation) pathway also uses 
enzymes like E1, E2 and E3 enzymes to attach specific ubiquitin to the substrate proteins 
(Hochstrasser, 2009). Ubiquitin and UBL have been classified as two classes, which the 
SUMO belongs to the UBL class (Müller et al., 2001, Melchior, 2000). The ubiquitin is also 
usually attached to lysine side chains of the substrate target protein resulting in branched 
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isopeptide-ubiquitin-target protein conjugate and targeting it to the 26S proteasome for 
degradation (Müller et al., 2001). The effects of ubiquitination and SUMOylation are resulted 
from the specific interactive domains of the binding proteins mostly; both modifications are 
reversible and these have been largely studied in the nucleus (Gill, 2004). Some proteins 
can be modified on the same lysine by SUMO or ubiquitin but with different functions, such 
as IkBα and yPCNA (Mabb and Miyamoto, 2007, Bergink and Jentsch, 2009). IkBα was 
primarily conjugated to SUMO-1 on K21, which was also utilized for ubiquitin modification, 
therefore, SUMO-1 conjugation to IkBα could not be ubiquitinated and was resistant to 
proteasome-mediated degradation (Desterro et al., 1998). The proliferating cell nuclear 
protein (PCNA) has been one of the most striking examples of the control switch between 
ubiquitin and SUMO; PCNA is a DNA polymerase which encircles DNA acting as a 
processing factor for DNA polymerisation and as a moving platform for factors involved in 
DNA replication, synthesis and repair; PCNA could be modified on the same conserved 
lysine 164 either by monoubiquitylation, lysine 63-linked polyubiquitin chains or SUMO 
(lysine 164 is a non-consensus SUMO-conjugating site), which has been involved in DNA 
damage response (Bergink and Jentsch, 2009, Hoege et al., 2002).  
 
In the previous discussion in Chapter 4, the total amount of protein stability has not been 
changed after the inhibition of protein SUMOylation globally suggesting that SUMOylation 
does not inhibit ubiquitination and therefore proteolysis of FA proteins. However, how 
ubiquitination of these FAs in cancer cells can have an impact on cell migration, parallel to 
their SUMOylation regulation have not been investigated yet. Since the talin head could be 
cleaved and can be regulated by SUMOylation and ubiquitination, this has raised interesting 
questions on how ubiquitin or SUMO could be regulating talin containing FA dynamic 
activities and therefore affecting cell migration. The ubiquitin C-terminal hydrolase-L1 
deubiquitinating enzyme (UCH-L1) has been found to colocalize with FAK, p120-catenin and 
vinculin at the motile edge of the Hela cell membrane during the first phases of adhesion, 
enhance FA formation and FAK activation; UCH-L1 could promote survival, proliferation and 
metastatic potential and is a key regulator of tumour invasion and metastasis (Frisan et al., 
2012, Kim et al., 2008).  
 
As this study shows fast FA turnover requires consistent SUMO-2 conjugation of talin and 
the talin-vinculin interaction protein complex; the ubiquitination pathway may not function 
effectively in the cancer cells, whether any dysfunctions of ubiquitin are involved in FA 
dynamic turnover and cell migration can be considered, i.e. the role of talin ubiquitination in 
relation to talin SUMOylation in the FA dynamic turnover and its regulation may not be in 
balance. These effects can be further examined including the mechanistically similar 
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crosstalk but with different functions for these two pathways. Ubiquitination inhibitors could 
be used in the focal adhesion turnover assays to determine FA protein dynamic activities 
and in cell migration study after inhibition of protein ubiquitination; antibodies against 
ubiquitin can be used in the IP & WB experiments to determine FA (talin and vinculin) 
ubiquitination.  
 
7.3. 1 Potential Drug Targets for Metastatic Cancers and Other Findings 
The six hallmarks of cancer have been elucidated with two additional hallmarks added to the 
hallmark system recently. The factors that contribute to the tumour development have been 
growing on the lists. SUMOylation as a type of PTMs which has been studied exclusively in 
the nucleus has recently attracted attention to its role outside the nucleus such as in the 
regulation of cytoplasmic proteins, including the focal adhesions.  
 
From this study, the pathway of SUMOylation in the regulation of FAs serves as a potential 
novel drug target for cancer treatments. There has only been one E2 enzyme in the 
SUMOylation conjugation pathway, interacting with nearly all the partners required for 
SUMOylation, which marks Ubc9 as a target for rational drug design (Duan et al., 2009). The 
cysteine 93 of Ubc9 serves as a covalent intermediate interaction; also, Ubc9 interacts with 
SUMO through non-covalent interaction but with high affinity, therefore, the virtual screening 
against the interface between the Ubc9 and SUMO, the covalent interactions between Ubc9 
and substrates and the non-covalent interface can be possible targets (Duan et al., 2009). 
 
Secondly, the activation of integrin requires talin phosphotyrosine-binding domain (PTB) 
binding to integrin β subunit cytoplasmic domains, knockdown of talin inhibited integrin 
activation; this serves as a therapeutic target to block talin from binding to integrin β subunit 
(Wegener et al., 2007, Tadokoro et al., 2003). Talin can be SUMOylated; from the previous 
experiments shown in this study, talin SUMOylation was consistently required in the cancer 
cells, i.e. talin was consistently in its conformational change and with SUMO-2 conjugation 
required for fast talin turnover.  
 
Thirdly, this SUMOylation regulatory mechanism of FA serves as a prospective molecular 
target, which small molecules can be developed to stop consistent talin SUMOylation, such 
as the ginkgolic acid used experimentally to inhibit talin / FA disassembly and prevent fast 
talin turnover in the cancer cells. Clinical trials have been carried out indicating the potential 
therapeutic roles of Ginkgo biloba extract in cardiovascular diseases, since it has been 
reported to produce antioxidant effects, stress-alleviating effects, modify vasomotor function, 
reduce blood cell adhesion to endothelium, inhibit activation of platelets and smooth muscle 
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cells and prevent thrombosis (Zhou et al., 2004). The designated Ginkgo biloba extract EGb 
761 is widely employed to treat cerebrovascular and peripheral vascular diseases and mild-
to-moderate dementia (DeFeudis and Drieu, 2004, Smith and Luo, 2004). Ginkgo biloba 
extract is also reported to have anticancer properties to exhibit chemopreventive reactions 
and antiangiogenic effects (Mahadevan and Park, 2008). Although the long-term therapeutic 
use still needs to be evaluated.  
 
From the literature, SUMOylation and anti-cancer drugs has become a more attractive area 
recently. Cancer treatment has included the anthracyclines and taxanes but the therapeutic 
efficacy has been a problem since DNA damage is associated with it, for example, the 
forkhead transcription factor (FoxM1) has been shown to have a critical role in resolving 
DNA damage response and genotoxic agents derived resistance (Khan et al., 2016). FoxM1 
expression has been associated with epirubicin sensitivity and DNA double-strand breaks 
repair; ectopic FoxM1 expression could abolish the double-strand breaks sustained in MCF-
7 breast cancer cells following epirubicin treatment and increase cell viability in response to 
enhanced DNA repair efficiency; however, FoxM1-null cells were hypersensitivity to DNA 
damage, epirubicin and γ-irradiation (Monteiro et al., 2013). In breast cancer, FoxM1 has 
been shown to be involved in endocrine, trastuzumab, cisplatin, paclitaxel, gefitinib and most 
recently in epirubicin resistance (Monteiro et al., 2013). FoxM1 inhibition could sensitize 
resistant glioblastoma cells to temozolomide by downregulating DNA repair response (Zhang 
et al., 2012). Recently, FoxM1 has been shown to be modified by SUMO-1 and FoxM1 
SUMOylation was enhanced in MCF-7 breast cancer cells following epirubicin treatment and 
SUMOylation could inhibit FoxM1 activity and delay cancer cell mitotic activity in response to 
cytotoxic drugs (Myatt et al., 2014). This is more to do with SUMO-1 than SUMO 2/3. 
 
Other studies have shown that increased Hsp90 (heat shock protein) SUMOylation could 
sensitize cancer cells to Hsp90 and therefore to Hsp90 inhibitors (Mollapour et al., 2014). 
Multiple myeloma patients have been found with decreased response to the proteasome 
inhibitor, bortezomib, which was found to specifically related to RNF4 belonging to the novel 
RING family Ub ligases, an E3 specific for poly-sumoylated proteins, which was induced in 
MM patients (Driscoll, 2012). The findings on SUMOylation of p53 oncogene can be 
important in the future p53 based anticancer therapies. Most cancer cells can activate 
telomerases to elongate telomeres and accomplish unlimited replicative potential, however, 
some cancer cells have to use telomere homologous recombination (HR) to elongate 
telomeres termed alternative lengthening of telomeres (ALT); the inhibition  of TRF1 or TRF2 
(telomere-binding protein) SUMOylation prevented APB formation (a hallmark of ALT cancer 
cells as the recruitment of telomeres to promyelocytic leukemia (PML) bodies, ALT-
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associated PML bodies, APBs) (Potts and Yu, 2007). These studies have made the role of 
SUMOylation with more understanding in the drug treatment development of cancer.  
From this study, therefore, SUMOylation of FA proteins can serve as novel drug target 
therapies as SUMOylation has been required for fast FA turnover, this mechanism can be 
served as a rational drug design i.e. to prevent consistent talin FA disassembly. 
 
7.3. 2 Potential Drug Targets for Anti-Platelets Therapy 
Platelets are key mediators of thrombosis and inflammation (Bhatt and Topol, 2003). The 
pathway of SUMOylation is also implicated in the potential drug target development for 
antiplatelet therapies to prevent thrombosis. The integrin β3 has been implicated in many 
physiological and pathological functions including platelets aggregation, thrombosis (αIIbβ3 
only expressed on platelets and megakaryocytes), implantation, placentation, angiogenesis, 
bone remodelling and tumour progression (αvβ3) (Hodivala-Dilke et al., 1999).  
Targeting FA SUMOylation may aid the development of prospective molecular drug targets 
in platelets with abnormal integrin signalling. Reduction in the talin-αIIbβ3 binding affinity 
could reduce integrin αIIbβ3 activation; this can be considered as a way for the protection 
from arterial thrombosis (Stefanini et al., 2014). Loss of talin-1 in mice has been shown to 
abrogate integrin activation (to all known major agonists), platelet aggregation and 
thrombosis formation in vitro and in vivo (Nieswandt et al., 2007).  
 
In platelet-mediated haemostasis and thrombosis, targeting talin SUMOylation may provide 
a mechanism in preventing the activation of platelets, i.e. targeting the talin cleavage and its 
downstream signalling pathway in platelets with upregulated integrin signalling, but the talin 
function is intact in the healthy resting platelets. Talin cleavage may be crucial for the FA 
turnover in the platelets. Inhibition of SUMOylation in platelets may assist in reducing platelet 
spreading; therefore it plays its role in the prevention of platelet adhesion and aggregation. 
In thrombosis, platelet aggregation is highly upregulated. Here, SUMOylation may serve as a 
novel drug target for the antiplatelet therapy.  
 
In conclusion, as many of the FA proteins have been identified as SUMOylation substrates 
and each of these proteins plays a critical role in the cell migration signalling pathway, this 
gives very useful information in the further investigation of the role of SUMOylation being 
involved in the cell migration and broadening the understanding of the function of 
SUMOylation in the regulation of not just one FA protein but a group of the other 
signalling/adaptor/FA proteins together.  
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